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V I I I 
'For the great enemy of the truth is very often not the lie - delib-
erate, contrived and dishonest - but the myth — persistent, 
persuasive and unrealistic. 
Too often we holdfast to the cliches of our forebears. We 
enjoy the comfort of opinion without the discomfort ofthought., 
President John F. Kennedy at 
the Yale Commencement Ceremony 
in July, 1962. 
CHAPTER I. INTRODUCTION 
§ 1. Why controlled clinical trials on mammary carcinoma? 
A survey of the literature shows that in spite of a great number of pertinent publica-
tions, uncertainty remains concerning the treatment of choice for a given patient with 
a given mammary carcinoma. There are numerous reports on very careful studies, 
but after 50 years no fundamental improvement of results has in fact been achieved. 
It can therefore be deduced that the retrospective methods of investigation so far 
practised have been insufficient to demonstrate possible differences in results of vari-
ous therapeutic regimens. 
Moreover these retrospective methods are open to serious criticism because the 
comparability of the groups of patients treated with different therapies cannot be 
guaranteed. 
There is obviously a need for investigations to evaluate various methods of treatment 
on the basis of statistically sound patterns. 
In The Netherlands, it was the late Professor Moeys who, some 20 years ago, recog-
nized the necessity of prospective studies on the treatment of mammary carcinoma, and 
instituted such a study. 
Moeys' initiative became the basis of the present study. However, as will appear, the 
material of Moeys does not completely meet modern requirements for prospective 
studies on mammary carcinoma. In the international literature (cf. Ch. V), the first 
advocates were such investigators as Kaae (in 1951), Paterson (in 1955), and Nissen-
Meyer (in 1957). 
Armitage ( 1968) wrote on this subject : 'The main requirement of a method for com-
paring the therapeutic effects of different treatments is that there must be no systematic 
bias tending to favour one or other treatment. If treatments are to be compared on 
different groups of patients we must try, as far as possible, to ensure that these groups 
are similar in all relevant respects, except in the treatments they receive.' 
For those familiar with statistical methods, it is a well established fact, that where 
statistical investigations are needed in evaluating the results of different treat-
ments, reliable conclusions can be obtained only by means of carefully performed 
clinical trials. 
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A controlled clinical trial here in brief to be called 'clinical trial' is an investigation in which 
two or more methods of treatment for a well-defined disease are compared on nmilarly composed 
groups of patients. The trial should aim at answering a definite question and meet the require-
ments f or a sound statistical analysis. 
As clinical trials yield results which warrant reliable conclusions, they can be com-
pared with other studies. Unlike other methods of investigation, these trials are designed 
on the lines of a laboratory experiment. Paterson ( 1962) wrote in this context : 'The 
term 'clinical trial', was advised by the Medical Research Council years ago to avoid 
the open use of the blunter term 'experiment'. This was wise ; but let us not forget among 
ourselves that clinical trials are true experiments, calling for just as rigid a discipline as 
the laboratory experiment'. 
To make a comparison possible between the results of different clinical trials, an 
exact description of the categories of patients and methods of treatment under investi-
gation must be available. For further details on clinical trials cf. Ch. I I I . At present, 
a large number of investigations are being carried out in the field of mammary carci-
noma, and these include a number of clinical trials. The World Health Organization 
(1968) has many studies on record. 
In an article by Flamant (1969) 161 clinical trials on cancer are noted, of which 34 
are on breast cancer. 
A number of clinical trials have already been completed, some of these concerned 
essentially curative therapies (Kaae 1965, 1968; Paterson 1959a, 1959b, 1962; 
Nissen-Meyer 1965, 1968), while others concerned metastatic carcinoma (Atkins 
1960). 
§ 2. The aims of the present study 
I t was our intention to collect a group of patients with mammary carcinoma who had 
been treated largely in accordance with a uniform plan and to evaluate retrospectively 
the various methods of treatment. 
With the collaboration of many colleagues, we succeeded in collecting 1500 patients 
of this type. This group of 1500 patients could be divided into several homogeneous sub-
groups. Since all the patients in each subgroup had been treated according to one fixed 
criterium it seemed possible, initially, to find a few comparable groups of patients in 
this material, treated with different therapies. Moreover we expected a part of the 
material, sampled by Moeys, would meet the requirements of a clinical trial. 
In processing our material we found that a considerable diversity of therapies had 
been used. Distinctions had to be made according to the usual surgical therapies such 
as simple mastectomy, simple mastectomy with axillary dissection, radical mastectomy 
and the techniques of irradiation. In a proportion of patients moreover, a radiological 
menopauze was prophylactically provoked, or hormones or cytostatic drugs were 
prophylactically given. Both surgeons and radiologists had accepted their own fixed 
plan of therapy. Except in the series of Moeys, we do not know, however, which indi-
cations may have caused them to deviate from this plan. When evaluating treat-
ments, only definite combinations of surgical, radiological and drug treatments can be 
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regarded as a unity, and a variety of combinations has to be considered. Exact differ­
entiation of all variations of therapy in our material would cause such fragmentation 
of the material that a statistically sound investigation of the results of various therapies 
would be impracticable because of insufficient numbers of patients in each therapy-
group. 
In solving this problem it seemed rational to sample even more patients with 
mammary cancer treated according to particular schemes until a sufficient number in 
each subgroup was reached. 
Many examples can be found in the literature which show the possibility of 
sampling large series of patients with mammary cancer (cf. table 1-1 Berniczei, 1962). 
TABLE i-1. The number of patients included in retrospective studies on mammary cancer. 
A survey of the literature (from Berniczei M. 1962, table I). 
Author 
Berven 
Kaae, E 
Haagensen 
( Presby tenan-Hospi tal ) 
Taylor 
Sedgwick and St. Ville 
Shimkin 
Nohnnan 
Adair 
Wanke 
Diethelm 
Berkson 
(Mayo-CUnics) 
Lewison 
(J Hopkins-Hospital) 
Robbins 
(Memorial Center Hospital) 
McWhirler 
Harrington, W. 
(Material of the Мауо-СІшкз) 
Warren and Tompkins 
Year 
1908-45 
1915-19 
1920-24 
1925-29 
1930-34 
1935-39 
1940-42 
1894 
until 1904 
1911-14 
1918-20 
1921-23 
1924-26 
1927-29 
1930-32 
1933-35 
1936-40 
1941-50 
1918-44 
1936-41 
1935-42 
1908-52 
1913-45 
1910-14 
1950-54 
1935-40 
1941-45 
1940-43 
1950-55 
1941^17 
1910-44 
Number 
of 
patients 
25 000 
189 
128 
127 
160 
225 
314 
181 
468 
103 
134 
183 
208 
220 
231 
328 
600 
292 
899 
1042 
3836 
1098 
698 
2363 
1416 
220 
259 
1281 
2168 
1882 
8224 
769 
Author 
Badesse 
Williams 
Watson 
Zaunbauer 
(Wiener I Chir Klinik) 
Urban 
Kohier 
Kirsch 
Ryan 
Gray and Anglen 
Sicard 
Abramaon, Clifton, Slagle 
Koulumies 
Widow and Huber 
Hickey, R С 
Treves and Holleb 
(Memorial Cent for Cancer) 
Antonellis (Myers Clin ) 
Miller and Fendergrass 
Ravnihar 
Alnch, Liddle, Morton 
Gould, E A , and H H Kerr 
Arner 
Hendnck, J W. 
Edward, M L. 
Year 
1935-46 
1958 
-
1932-43 
1944-52 
1949-53 
1959 
1958 
1935-41 
1 9 4 2 ^ 8 
1939-53 
1931-39 
1940-51 
1936-47 
1949-54 
1926-49 
1956 
— 
1939-49 
— 
1959 
1923-43 
1945-54 
1929-51 
1955 
1955 
1933-51 
1958 
Number 
of 
patients 
77 
310 
100 
645 
1055 
244 
76 
290 
347 
1399 
2123 
278 
192 
98 
189 
544 
360 
229 
1661 
913 
444 
431 
182 
149 
219 
121 
1029 
641 
448 
241 
1652 
562 
253 
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From our study, however, it appears that unselected sampling of patients will not 
help to solve existing problems of treatment (cf. Ch. II). Indeed, it seems im-
possible to come to reliable conclusions concerning different therapies, using our 
material, even if it was possible to extend it considerably. 
Margaret Merrell (Bradford Hill, 1967) has wisely observed: 'large numbers in 
themselves are worse than useless if the groups are not comparable, since they encourage 
confidence in an erroneous opinion'. 
Meanwhile, because of the diversity in therapeutic conceptions existing in The 
Netherlands, The Netherlands' Cancer Organization decided to found a committee to 
discuss the treatment of mammary carcinoma (van Slooten, Breur, Hampe, Nelemans, 
Rümke, Schwarz, Thomas, Zwaveling, Beerepoot, 1968). It is the aim of this committee 
to lay down guidelines concerning the treatment of mammary carcinoma and to study 
the possibilities of executing a clinical trial in The Netherlands. 
Partly as a result of discussions in this committee the Author concluded that, when 
planning a clinical trial it is important first to have some idea of the number of patients 
required. 
After having made a computation of the number of patients required for a definite 
clinical trial, we concluded that it is upon this number that the practicability of a 
clinical trial concerning mammary carcinoma largely depends. 
Some people are still very vague about this problem. 
Truelovc (1964) states: 'In general it is worth working with fairly large numbers 
although there are special circumstances where the results should be obtained with the 
maximum economy'. 
Bradford Hill (1967) wrote on this subject: 'The well-controlled and well-reported 
experiment docs not, as is sometimes thought, demand vast numbers. 
If the groups are strictly comparable, then often a total of 50 to 100 cases, and some-
times very much less, will provide sufficient evidence. The actual numbers must, of 
course, depend upon the problem at stake and upon the magnitude of difference be-
tween the treatment and control groups that is to be expected or is actually observed'. 
In this study we want to get an impression of the real numbers of patients required 
on statistical grounds in executing a clinical trial and how these numbers can be in-
fluenced by variations of design of the trial (cf. Ch. I l l §3, §6). Apart from these statis-
tical considerations it was our aim to underline any other difliculties, arising in the 
study of the treatment of mammary carcinoma. 
As we already mentioned, it may be necessary not to study the different treatments 
on all patients with mammary carcinoma as a whole, but on homogeneous subgroups. 
These are drawn up according to such characteristics of the tumor or the host, as may 
influence the course of the disease. The number of these characteristics is so great, that 
it must be realized, that it is possible the disease will be influenced far more by them 
than by therapy. Even when the patients involved in a trial constitute a homogeneous 
subgroup of the mammary carcinoma patients, there is always some variety left. 
It is therefore necessary to assign the different therapies by randomization. If 
randomization is performed over the total group of patients available, it is possible, 
that within several subgroups the numbers of patients with definite characteristics 
allocated to the therapies compared differ considerably. For this reason Armitage 
(1968) recommends using a separate randomization list for each subgroup. From these 
considerations our approach will become much clearer as we study the number of 
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patients required to get statistically reliable conclusions concerning each subgroup. 
In considering the extent of our material, it became clear to us that although the data 
drawn from it were inadequate for a comparison of treatments yet it could be used in 
planning a clinical trial, particularly in estimating the number of patients required. 
The reliability of these estimates, of course, depends on the representativeness of this 
material for mammary carcinoma patients in general (cf. Ch. I I §4). In this study a 
survey is given of the factors determining the number of patients required in executing 
a clinical trial to evaluate different treatments for mammary carcinoma (cf. Ch. I I I ) . 
In addition, a method is described of estimating the requisite number of patients. 
This method is applied to our collection of 1500 patients with mammary tumors to 
get an impression of the number of patients required to solve particular problems 
concerning the treatment of mammary carcinoma. For this purpose nearly all the 
data considered in our series have been recorded in frequency tables. 
In an at tempt to gain an impression of the influence of coincidences between several 
characteristics of the tumor or the host on our computation, contingency tables have 
been worked out for 15 frequently appearing characteristics (cf. Appendix Part I ) . 
However, anybody who is interested in planning a controlled clinical trial on 
mammary carcinoma should use preferably the figures of his own series of patients, in 
applying our computation. 
To illustrate our approach, a number of completed clinical trials concerning mam-
mary carcinoma are analysed according to our criteria (cf. Ch. V) . An evaluation 
is given of the possibility of solving particular problems with the help of the clinical 
trials concerned. Because in the clinical trials executed so far the only criteria used are 
those that can be expressed in absolute or relative figures, our examples are worked out 
on the basis of such criteria i.e. 5 years mortality, 5 years recurrence rate. 
General aspects of the organization as well as the ethical problems of a clinical trial 
are not considered to be within the scope of this study. Considerations about the 
organization of clinical trials can be found in the booklet of Flamant (1970). Ethical 
guidelines are laid down in a Statement of the Medical Research Council (1962—63) 
and in the Declaration of Helsinki (1964). 
We investigated the possibility of obtaining from our data an impression of the 
course of mammary carcinoma. 
Although we realize the great importance of records on this subject in the evaluation 
of methods of treatment it is not considered to be within the scope of this study. 
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'/η the evaluation of a given procedure it becomes apparent 
only too often that, in recording some obvious and fundamental 
data, no provision has been made to establish the starting-point. 
Many statistics become non-comparable, and therefore often 
useless, because different criteria are applied'. 
Schmidt (1967), in his inaugural address. 
CHAPTER II MATERIAL AND METHODS 
§ 1. Introduction 
The collaboration of many colleagues made it possible to pool documented material of 
about 1500 patients with malignant disease of the breast in The Netherlands. The mate­
rial was obtained from centres in Tilburg (including Moeys' series), Arnhem and 
Leeuwarden (cf. table II-I). The patients received their first therapy during the 
period 1947-1966. 
§ 2 . The trial of Moeys 
Moeys' trial was so arranged that therapy in his own clinic consisted exclusively of 
simple mastectomy with postoperative irradiation according to McWhirtcr's method, 
while the other clinic in Tilburg used only radical mastectomy with postoperative 
irradiation. In keeping with this design however, the possibility of preselection is left 
open, as general practioners familiar with the organization of Moeys' trial may well 
have selected patients according to their opinion about the most suitable therapy. 
For these reasons we abandoned our previous plan to draw conclusions from the 
results of Moeys' trial. 
§ 3. Survey of the entire material 
After Moeys' departure from Tilburg in 1958 the trial was not continued. The 
manner of registration was not changed, however. 
To get a suitable group of patients, the whole series from Tilburg, and thereafter all 
the patients at the centres in Arnhem and Leeuwarden were included in our series. 
(Specifications cf. tables II-l and II-2). 
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TABLE il-1. The distribution of the patients over the three centres. 
C E N T R E 
Tilburg 
Arnhem 
Leeuwarden 
Totals 
Numbers of 
patients 
643 
314 
460 
1417 
% 
45.5 
22.2 
32.3 
100.0 
An additional 89 cases of malignant disease of the breast are registered but were not 
included in the material, while their inclusion would disturb the uniformity of the 
series (cf. table II-2) . 
TABLE II-2. Survey of cases not included in the material {percentages on total number of entire 
material: 1506 cases). 
0.5 
2.3 
1.2 
0.5 
1.3 
Totals 89 5.8 
* Patients noted as having metastases in the contralateral breast are not included. 
DIAGNOSIS 
Breast carcinoma in males 
Bilateral breast cancer* 
Simultaneous breast carcinoma and other carcinoma 
(except skin carcinoma) 
Distant metastases of carcinoma other than mammary, 
located in the breast 
Sarcoma 
Numbers of 
patients 
7 
36 
19 
7 
20 
§ 4. Methods of recording and manipulating data 
T o record the data of our series of patients we used the form 'Insertion (Mamma) ' , 
introduced by the Clinical Stage Grouping (1960-1964) of the Union Internationale 
contre le Cancer (cf. Appendix Part V). This form is based on the International T N M 
classification, in which the clinical stages of mammary carcinoma have been placed on 
record (cf. Ch. I l l §8). 
Of the data on these patients we recorded as follows those characteristics that could 
have influenced the course of the disease : 
1. The data of Moeys' trial were first recorded partly on a form designed by Moeys 
and partly on clinical records. All these data have been taken over by the author 
on the 'Insertion (Mamma) ' form. 
2. The remaining data of Tilburg and the data of Arnhem and Leeuwarden were for 
the most part directly recorded on the aforementioned 'Insertion (Mamma) ' form. 
A number of data were recorded on clinical records and have been taken over by 
the author on the 'Insertion (Mamma) ' form. In total, 119 data per patient were 
encoded and punched into 80 columns-punch cards, which were further processed 
with the computer IBM 360/50 of the University Computer Centre at Nijmegen. 
4 punch cards were used per patient. 
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Using the Cross-tab 2 program the data were tabulated in frequency tables 
(table fl-f50) and two-way contingency tables (table f
c
l - f
c
99). 
In these tables the frequencies are supplied in absolute figures of totals whole series 
and in absolute figures and percentages of row and of column totals of totals noticed 
data. Finally per d a t u m percentages are supplied of the noticed data. (cf. explanation 
f
c
 tables, Appendix Part 1). 
The data of our material considered usable for our purpose are arranged in such a 
way as to be suitable in determining the number of patients required for a clinical 
trial. Except for data indicating the 'curative operability' of the patient, data on the 
course of the disease after starting treatment are not included as they are not neces­
sary for determining the required number of patients. 
§ 5. Uncertainties in the material 
In using our data for a determination of the requisite number of patients in a 
clinical trial, one must remember the uncertainties as to whether our material was 
representative of m a m m a r y carcinoma in general. 
Some known uncertainties are described below : 
a. The material was obtained by pooling the groups of patients of three centres (Tilburg, 
Arnhem and Leeuwarden). T h e geographical situations of these centres do not 
ensure that all the patients with mammary carcinoma in the respective districts are 
in fact treated at the centres. Some patients may have received their treatments at 
University Clinics. This means no assurance can be given that the material gives an 
exact picture of the whole population of patients in the catchment areas of the centres 
concerned. As a result, a selection-factor of unknown magnitude has been introduced. 
b. Scores of physicians recorded data on patients, including evaluation of the tumor 
stage. As these records were not verified by a coordinating committee, Observer 
variation' must be assumed to have had a powerful influence. 
с A proportion of data was first recorded on a form designed by Moeys or on the 
clinical record-cards (cf. Ch. I I §4). These data have been taken over on the 'Inser­
tion ( M a m m a ) ' form by the author and thus misinterpretations of the original 
records might be introduced. 
d. O u r data were taken from the clinical records of surgeons and radiologists. It is 
possible that a patient could have been seen only at the out-patient clinic, in which 
case she would of course be absent from our material. 
e. We obtained our series by pooling the material of several centres in order to obtain 
larger numbers of patients. An unknown number of uncertainties regarding the 
composition of each of these series had to be accepted. 
f. Although the recording of data always gave an impression of accuracy, a consid­
erable number of data were found to be lacking. I t is understandable that this 
introduces a source of uncertainty of incalculable magnitude. Thus, for a proportion 
of the absent data one might assume that the symptom under consideration was 
absent. 
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I t is for instance understandable that a clinician examining a tumor classified as 
stage I , docs not record the fact that the supraclavicular glands are not affected. In that 
case, this symptom would be recorded as 'unknown' in this study. On the other hand, 
in examining a tumor classified as stage IV, it may well be that slight adhesions to the 
skin or the substratum are not recorded. One may tend to remove the cases with 'un-
known' data from the material in order to enhance the reliability of the study. We 
decided not to do so, as this possibly implies also the introduction of a selection factor, 
the magnitude of which cannot be estimated. For example: if all cases in which affec-
tion of the supraclavicular glands was not recorded were removed from the material, 
this would involve far more stage I cases than stage I I I cases. Consequently, a bias 
would be introduced in the frequency distribution of the stages. 
For this reason we preferred to state the number of 'unknowns' * with each datum, 
calculating the relative frequencies only for the 'knowns'. Proceeding in this way the 
investigator hopes that the relative frequencies in the group of unknowns will equal 
that in the group of knowns. 
Nevertheless, a number of about 150 patients has not been included in our 1500 
patients because the available data were too incomplete on essential points to be pro-
cessed. The fact that no complete record was made of a patient may mean that this was 
not considered important for that particular case because of an expectedly benign 
lesion or by reason of the extent of the disease or bad general condition. New forms of 
selection may thus have been introduced. 
noted as 'other' in the tables of the appendix. 
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C H A P T E R III. ESTIMATING THE NUMBERS OF PATIENTS REQUIRED 
FOR A CLINICAL TRIAL 
§ 1. Introduction 
A controlled clinical trial must fulfil a number of conditions to allow of objective and 
reliable comparison. Every clinical trial needs careful preparation, of which only a 
general description can be given within the scope of this paper. As a rule, the basic 
question will be an incompletely specified medical problem, e.g. whether ovariectomy 
is useful in the treatment of mammary carcinoma patients who have not yet or who 
have only recently entered the menopause. 
The problem will first have to be described more accurately. The criterion 'not yet or 
only recently entered menopause' must be defined. One must further define the way in 
which the ovariectomy is to be performed and the additional methods of treatment to 
be administered. Once the problem has been defined accurately sufficiently from the 
medical point of view, a more detailed statistical specification will generally be neces-
sary as well. For instance, in regard to ovariectomy the physician will require a decision 
valid for menstruating women suffering from a mammary carcinoma in a particular 
stage of development. The statistician can approach this problem only if the population 
of women among whom the investigation is to be carried out is determined more 
precisely from the geographical and chronological points of view, e.g.: patients with 
mammary carcinoma living in The Netherlands on January 1st, 1970, who fulfil the 
conditions stated. 
The population about whom a decision is required may consist of far more patients 
than are necessary for an adequate trial. In that case the trial will have to be carried out 
with a representative sample from the patient population. This sample must be selected 
in such a way as to have a composition similar to the population in certain general 
characteristics, but otherwise to be at random. If the sample is composed in this man-
ner, the conclusions drawn from the clinical trial will in principle be valid for the 
population as a whole. 
However, in respect of mammary carcinoma the number of patients available at a 
given time will generally be insufficient for the organization of a trial. If so, all suitable 
patients applying for treatment successively during a given period will have to be 
included in the trial. The possibility must then be borne in mind that the patients 
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available for a trial constitute a select group in regard to the reaction to one or more of 
the methods of treatment to be compared. Once it has been decided which patients will 
be included in the clinical trial and what methods of treatment will be compared, the 
methods of treatment must be so assigned to the patients that no single therapy is 
systematically 'favored' or 'neglected'. This means that we must prevent the group of 
patients to be subjected to a particular method of treatment differing systematically 
from other patients in the trial in regard to factors which may affect the success of 
treatment. This can be achieved by random assignment of methods of treatment ; in 
principle, by drawing lots. 
The method of drawing lots depends on still other factors, e.g. whether all patients 
are available at the same time or will become available successively. For further details 
cf. Appendix Part V I . 
In order for the results of the various methods of treatment to be compared, criteria 
permitting useful comparison of the results must be defined before the experiment 
starts. In principle, these criteria consist of data concerning the groups of patients, for 
instance : mean survival time, or mean percentage of patients in whom a certain phenom-
enon (death, recurrence) occurs within a certain period. More than one criterion 
may be involved in the discussion. Since the results, though not differing in one aspect, 
may nevertheless differ in another, a more differentiated conclusion concerning the 
methods of treatment compared can be achieved in this way. 
§ 2. Statistical tests 
When the groups of patients used to compare the methods of treatment are selected 
at random from the available patient population, these groups may show 'coincidental' 
differences of factors which may influence the treatment. A decision that the methods 
of treatment (in regard to a certain criterion) are not equivalent may then be made on 
the basis of differences in results actually due to differences occurring 'coincidentally' 
during the drawing of lots, e.g. differences in the general conditions of the groups of 
patients treated. In Statistics, a false conclusion of this nature is called an error of the first 
order. 
By subjecting the finding to an adequate statistical test, dependent on the criterion 
of comparison applied, and by basing the conclusions on the result of this test, the 
probability of an error of the first order being made can be kept within previously 
defined limits, the level of significance. This is always possible, irrespective of the 
number of patients available. 
A statistical test in regard to a particular criterion can, in principle, only lead to one 
of two conclusions : either 
I . The methods of treatment compared are not equivalent. In this case, a difference 
has been demonstrated between the methods. The probability that this conclusion 
is false is less than the level of significance selected. 
I I . No difference can be demonstrated between the methods of treatment. 
Conclusion I. is not synonymous with the conclusion that the methods of treatment 
are equivalent. It is possible for the effect of a small difference between the therapeutic 
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methods to be masked by the effect of a 'coincidental' difference in compositions 
between the two groups of patients. 
Every test with a defined level of significance has its power. This power is the 
probability of an existing difference actually being detected. In this connection we call 
a difference detected if the null hypothesis that no difference exists after testing is 
rejected. T h e power depends o n : 
a. the test applied, 
b. the level of significance (the higher the level of significance, the greater the power), 
с the number of patients in the trial and their distribution between the various methods 
of treatment, and 
d. the degree of actual difference in effect between the methods of treatment compared. 
The difference in effect under d. concerns the difference in parameter applied as a 
criterion (e.g. relative frequency of survival, or mean survival time) in the entire 
patient population considered. When the experiment is being planned, this difference 
is always unknown. T h e power must be interpreted as a function of this unknown 
difference. Knowledge of the power of the test to be applied is essential for the design 
of a clinical trial and in particular for estimating the number of patients required. 
This knowledge can be applied in various ways : 
a. We can determine the degree of difference in effect which we want to demonstrate by 
the experiment to a reasonable certainty, e.g. a probability of 9 5 % . Once the test and 
the level of significance to be applied are defined, this results in a minimum number 
of patients required per method of treatment. This minimum is henceforth called the 
statistically required number of patients. It depends on the test used, the level of 
significance, the difference in effect to be detected, and the desired probability that 
this difference will be detected. 
b. If method a. requires prohibitively large numbers, we may also base our trial on the 
number of patients becoming available within a reasonable period of time. T h e 
power of the test then indicates the degree of minimal difference in effect one is able to 
demonstrate with a probability of e.g. 9 5 % . When in this connection we speak of 
detecting a particular difference in effect, this only means that we have demonstrated 
that the difference in the population is not = 0. It does not mean, therefore, that the 
difference is of a particular degree. 
In the following paragraphs we shall discuss three statistical tests applicable for the 
analysis of clinical trials. We shall limit ourselves to descriptions of the principles of the 
tests and to tables of the numbers of patients required. For further details concerning 
the tests and the theoretical backgrounds to the tables, cf. Appendix Part VI. 
Apart from the number of patients required the expected duration is also significant 
in planning for a trial. A particular test may be efficient in regard to the number of 
patients required but may take much longer to reach a decision than some other test 
requiring more patients. A discussion of the duration of trials can also be found in 
Part VI of the Appendix. 
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§ 3. The χ*- Usi for a 2 У. 2 table 
A certain population of patients suffers from a particular disease. For this disease two 
methods of treatment, A and B, may be considered. T h e result of the treatment is 
evaluated on the basis of a criterion such as death, recurrence or the development of 
metastases within a certain period after commencement of treatment. For the sake of 
clarity we shall for the moment assume that the criteria are, that the treatment has been 
'successful' if the patient survives and 'unsuccessful' if he dies within 5 years after 
commencement of treatment. Let us call P A % and Р в % the unknown proportions of 
patients in the population considered in whom method A and method В are successful. 
We regard the methods of treatment as equivalent if P A = Р в and unequivalent if 
P A # Рв· T O check this we take two random samples from the population, both 
consisting of the same number S. The patients in one sample are treated by method A 
and those in the other sample by method B. If ПА patients in the first sample and п в 
patients in the second sample show a certain effect within the period defined, the 
hypothesis P A = Р в will be rejected if — ^— is 'sufficiently large'. This 'suffi-
O ¡J 
ciently large' depends on the desired level of significance a. For further particulars, 
and a detailed example, cf. Appendix Part V I . If we also demand that the hypothesis 
P A = Р в should be rejected with reasonable certainty, for instance at least ( 100 — β%)> 
if P A and Р в have different, known values, this leads to a certain minimal value of S. 
This value S is listed in table SI, for α = 5 % and β = 5%, for the values of P A and Рв 
which are multiples of 10%. In order to give an impression of the value of S if a power 
of 9 0 % is required, table S2 was calculated for α = 5 % and β = 10%. 
In the appendix we have also calculated the factor for a number of values of α and β 
by which the necessary number of observations from table SI must be multiplied if a 
power other than 9 5 % and/or different level of significance is desired. For α = β = 5%, 
we find that the S necessary with 5 year survival probabilities of 40 and 5 0 % for meth­
ods A and В amounts to 642. If β = 10% were acceptable, this number would become 
0.809 X 642 = 519 (cf. table S2) and if only a β = 1 % were accepted, S would become 
1.849 X 642 = 1,187 (cf. Appendix Part VI) . 
T o limit the number of tables in our further discussion, we apply a level of signifi­
cance α = 5 % and a power of (100 — β) = 9 5 % , the values usually accepted in 
statistical testing. Obviously the possible applications of these tables are limited to 
clinical trials in which the criterion of comparison is the proportion of patients who 
present a certain reaction within a certain period. Even within this design, the table 
does not supply complete information : it is only valid for experiments in which but two 
methods of treatment are compared. T h e eventuality of comparison of more than two 
methods of treatment, where the procedure is much more complicated, is not ex­
pounded in this study. 
Another limitation of the table is that it is assumed that the two samples to be com­
pared are of the same size. An experiment with equal numbers of patients in both 
treatment groups is admittedly more efficient than an experiment with unequal 
numbers but in practice it is possible that one of the two therapeutical methods can 
only be applied to a limited number (less than 50%) of the patients available, for 
instance due to lack of technical facilities. Strictly speaking, the table only applies 
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where the groups to be compared may be regarded as random samples from a pop­
ulation. T h e parameters P A and Рв are defined in relation to this population. For 
instance, when all the patients available in a given area are included in the experiment, 
the group will have to be regarded as a sample of an imaginary population or it will have 
to be assumed that in every case there is the same probability P A ( P B ) that the patient 
will present the reaction within the period defined under treatment by method A (B). 
At the beginning of this section we mentioned a criterion for evaluation of the results 
of therapy. This criterion must be defined primarily on medical grounds. If from the 
medical point of view several criteria are equally useful for deciding whether there is 
any difference between two methods of treatment, we may consider a choice on the 
basis of the numbers of patients required. If 5 year survival is selected as the criterion, 
the probabilities that patients survive for 5 years after treatment by methods A and В 
might be, say, 4 0 % and 5 0 % respectively. T h e number of patients required to detect 
this difterence is 642 per treatment group. If the probability of local recurrence within 
5 years is selected as the criterion, these probabilities may be 10% and 2 0 % respectively 
and the number of patients then necessary to detect this difference amounts to 323 per 
treatment group. 
Greater selectivity resulting in formation of more homogeneous patient groups may 
also lead to a reduction in the number of patients required (as explained at the end of 
Part VI of the Appendix) while the chances that the trial will supply answers to specific 
questions are even better with greater selectivity (cf. Ch. I l l § 6). In choosing the 
criterion we must further consider the fact that effectively different methods of treat­
ment may differ not only in the chances of 5 year survival achieved, but also in the 
entire survival curve. Suppose the curve after treatment A is exponential (cf. Appendix 
Part VI) , while after treatment В it remains practically horizontal for 3 years because 
metastasization is delayed by hormonal treatment. 
FIGURE in-1. The consequence of a difference in survival curve between treatment A and B. 
Survival rate 
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T h e difference in 3 year survival rates will then be considerable. If we further sup­
pose that the sensitivity of the tumor to hormone treatment rapidly decreases after 
3 years, the survival curve for treatment В would become exponential after this period 
and the two curves would rapidly approach each other. H a d the 7 year survival rate 
been selected as criterion, it is probable that no distinct difference would have been 
detected, despite the fact that method В has marked advantages (cf. Figure I I I - l ) . 
In planning a trial, a choice must ultimately be made. When the investigation in­
volves an entirely new method of treatment, with no clear expectations concerning 
chances of survival, we may at the most consider a pilot trial with a small number of 
patients, e.g. only sufficient to allow detection of a difference of 3 0 % in the chance of 
survival. 
However, when the effect of an entirely new therapy is to be studied, a pilot trial of 
limited extent may be very useful because it obviates the danger of any important ad­
vantage of the new method escaping notice. If the new therapy proves greatly inferior, 
the number of patients treated by it is only small. If we can assess the difference in 
chance of survival which is maximally possible, if necessary after a pilot trial, we must 
determine the number of patients required by means of table S1. If this number is found 
to be too large, it would hardly be advisable to organize a trial. If the number is 
feasible, we are confronted with a dilemma. T h e larger the number of patients included 
in the therapeutic experiment, the smaller the difference in chance of survival detec­
table by the investigation and the clearer the conclusion that can be drawn. 
If the number of observations is sufficient to detect a difference of e.g. 10% in survival 
chance, we may, if the trial does not yield a significant result, conclude that the differ­
ence in survival chance is 10% at the most. This maximum possible difference may be 
so small that no further study can be considered. O n the other hand, a new trial may be 
started with a sufficient number of patients to detect the difference. This possibility 
makes it advisable when planning a trial to pay special attention to its practical 
feasibility. If a trial is on too large a scale, coordination between the participating 
centers may become a problem, it may be difficult to follow all patients, to establish 
cause of death in sufficient detail, etc. O n the other hand trials with large numbers of 
patients do have the advantage of keeping us better informed concerning the effect of 
treatment on the course of the disease and giving us an impression of the complications 
likely to occur (Witts, 1964). 
O n e must also remember that a trial not offering a 9 5 % probability of detection of a 
particular difference in the 5 year survival rate may nevertheless have a fairly good 
power in regard to this difference (cf. Appendix Part VI table A l ) . 
T h e examples worked out in this thesis are based on the assumption that differences 
in probability of survival of 10% or multiples thereof had to be detected. For this 
purpose, table SI has generally been used (cf. Ch. IV). 
For P A and Р в we chose values approximating to the relative survival rates found in 
our material or in the reports of other investigators. 
Table SI is based on the χ 2 test for a 2 X 2 table. 
I n § 4 and § 5 we described two other test methods (for detailed descriptions cf. 
Appendix Part V I ) . With comparable alternatives these methods may require 
fewer patients than the χ2 test. They may also lead to a conclusion in a shorter 
time. 
Nevertheless in trials concerning mammary carcinoma, the χ2 test was applied 
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as a general rule, its principal advantage being that it is less complicated, especially 
on the following points: 
1. T h e criterion is simple : all that needs recording concerning the patients involved 
being whether they have died within a certain period and whether the m a m m a r y 
carcinoma may be regarded as the direct or indirect cause of death. The administrative 
work is therefore relatively light. 
2. T h e number of patients required depends exclusively on the chances of surviving 
the period defined. No further assumptions concerning the distribution of the survival 
times need be made. 
3. T h e duration of the trial can be estimated beforehand and with reasonable 
accuracy. I t is the length of time required to collect the required number of patients 
(which can be estimated if the annual intake is known) plus the length of time until the 
result of the treatment is evaluated. 
In contrast to the sequential methods, valid evaluation of the results is only possible 
once the entire trial has been completed. This constitutes an advantage in as much as it 
keeps the administration of the trial simple. It has the disadvantage that a statistically 
justified conclusion is difficult to draw if an interim comparison of survival rates shows 
that the results differ greatly. T h e sequential methods lead automatically to a rapid 
decision in such situations. 
With the χ 2 test one is only justified in discontinuing the trial when the number 
of deaths under one treatment (A) is already so much larger than that under the 
other method (B) that even when the results still to come would be as favourable as 
possible for A, the conclusion would still have to be that В was significantly better than 
A. Naturally, such a situation will only occur rarely. It is only possible once the results 
are known for the vast majority of patients included in the trial. 
TABLE S1. The requisite number of patients f or each of the two therapies according to the χ 2 test for 
a 2x2 table (two-sided test; level of significance : α = 5 % ; minimum power: 100 — β = 95% ) * 
Probability of 
success after 
В (in % ) 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 
63 
31 
20 
14 
11 
10 
63 
323 
98 
50 
31 
21 
15 
11 
20 
31 
323 
483 
133 
63 
37 
24 
16 
11 
Probability of 
30 
20 
98 
483 
589 
154 
70 
39 
24 
15 
40 
14 
50 
133 
589 
642 
161 
70 
37 
21 
success 
50 
11 
31 
63 
154 
642 
642 
154 
63 
31 
11 
after A (in % 
60 
21 
37 
70 
161 
642 
589 
133 
50 
14 
70 
15 
24 
39 
70 
154 
589 
483 
98 
20 
) 
80 
11 
16 
24 
37 
63 
133 
483 
323 
31 
90 
11 
15 
21 
31 
40 
98 
323 
63 
100 
11 
14 
20 
31 
63 
• Based on an article by Paulson (1947), but adjusted to 2-sided testing (cf. Appendix Part VI). 
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TABLE S2. The requisite number of patients f or each of the two therapies according to the χΐ lest 
for a 2 X 2 table (two-sided test; level of significance : α = 5% ; minimum power : 100 — β = 
90%). Figures obtained by multiplying the numbers of table SI by 0.809 (cf. Appendix Part VI, 
pag. 184). 
Probability of 
success after 
B ( i n % ) 
Probability of success after A (in % ) 
10 20 30 40 50 60 70 80 90 100 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
51 
25 
16 
11 
9 
51 
261 
79 
40 
25 
17 
12 
9 
25 
261 
391 
108 
51 
30 
19 
13 
9 
16 
79 
391 
477 
125 
57 
32 
19 
12 
11 
40 
108 
477 
519 
130 
57 
30 
17 
9 
25 
51 
125 
519 
519 
125 
51 
25 
9 
17 
30 
57 
130 
519 
477 
108 
40 
11 
12 
19 
32 
57 
125 
477 
391 
79 
16 
9 
13 
19 
30 
51 
108 
391 
261 
25 
9 
12 
17 
25 
40 
79 
261 
51 
9 
11 
16 
25 
51 
§ 4. Wilcoxon's test for two samples 
Wilcoxon's test is a statistical method which uses survival time since commence­
ment of treatment as the criterion of the results. It leads to the conclusion that therapy 
A is better than therapy В when the patients treated by method Л survive for 
significantly longer after commencement of treatment than those treated by method 
B. A high intake of patients per unit of time is favorable because it reduces the 
starting-up period of the trial to a minimum. 
For calculating the numbers of patients required for the Wilcoxon test, we must not 
only specify the diiTerence in result we want to demonstrate, as in the χ 2 test, but we 
must also specify the survival curve after the two methods of treatment. For a more 
detailed discussion of Wilcoxon's test the reader is referred to Part VI of the Appendix. 
§ 5. Sequential Analysis 
A different possibility is represented by the sequential methods analysis. For one of 
the sequential techniques considered, patients are divided into pairs. This may be 
done by constantly forming pairs of two successively admitted patients. I t is, however, 
preferable if possible to pair every patient with another patient who resembles her in 
certain characteristics important to the result of treatment. This may mean that a 
pair of patients can only be completed after some time. 
Therapy A is then assigned to one member of each pair and therapy В to the other, 
always at random ; lots must be drawn as soon as the first patient of the pair starts 
treatment (cf. Appendix Part V I ) . 
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§ 6. The constitution of homogeneous groups
Vil diseases, in our case mammary carcinoma, have their natural course. There are 
many possible variations in biological characteristics such as rate of growth?; iiorm one- 
dependence, sex chromatin and the manner and rate of metastatic growtK. The in- 
fluence which these characteristics exert on the course of the disease is insufficiently 
known if at all. Instituting a therapy means that a characteristic is added to the 
natural course, with the intention of influencing it favorably. The influence of this 
added characteristic on the course can be evaluated only in its relation to as many as 
possible of the natural characteristics considered capable of influencing the course.
I f the individual characteristics of the patients are not taken into account, the same 
therapy can be expected to yield considerably different results.
If a trial is limited exclusively to patients possessing those characteristics that will 
be influenced precisely by the methods of treatment to be studied, a maximal effect 
may be expected from this trial. Accordingly, strict criteria will have to be defined 
to be fulfilled by the patiënt and the tumor before the patiënt can be included in the 
trial; the criteria must be adequate for the investigation to be carried out.
These criteria must be defined in such a way that no doubt is possible concerning 
their interpretation. Thus homogeneous groups of patients are formed which allow of 
«pecific analysis. Only then will it be possible accurately to determine in what way and 
10 what degree the therapy has affected the course of the disease. I t will be obvious, 
for instance, that when a local treatment with a curative intention is to be evaluated, 
no patients will be included in the trial whose pathological process has already spread 
beyond the area to be treated. This reasoning does not imply that a trial with a 
heterogeneous patiënt material is impossible.
If we were to include all available patients into a trial intended to evaluafc: the effect 
of a certain therapy on the local process, the treatment would have little or no in­
fluence on the evolution of the disease in a considerable number because the patho­
logical process would already have spread beyond the area to be treated. This renders 
analysis of the trial very difficult and it is even doubtful whether valid conclusions 
could be reached at all. Owing to the inclusion of a group of irrelevant patients, a 
possible favorable effect of a therapy might well not manifest itself clearly. As appears 
from the design of numerous current trials investigators are thoroughly aware of 
ihe favorable effect of maximum homogeneity of the patiënt groups where the 
investigation in question is concerned (Flamant, 1969).
In this context Bradford Hill (1960) wrote: ‘thebasic principles are randomization, 
replication and unbiased observation. In  a simple experiment in the laboratory the 
scientific worker wishes to see what happens to A if he manipulates B. He tries to keep 
constant all other factors that may upset or influence the relationship. Similarly in the 
controlled trial we endeavour to keep constant the characteristics of our patients that 
may influence the comparisons of those on treatment A and those on treatm ent B. 
Some of those characteristics we can keep constant by stratification -  by keeping equal 
in the two groups such obvious features as age and sex. O ther characteristics we cannot 
deliberately equalize, and our aim is to achieve it by the random allocation which, in 
in the long run, offers no favour to one or other group’.
As argued above, it is important for homogeneous groups to be formed from the 
patient material. These groups are selected on the basis of factors able to influence the 
result of a treatment, e.g. clinical stage, patient's age, localization of tumor, etc. 
T h e possibility may then be taken into account that two methods of treatment are 
equivalent for one group but not for another. T h e number of patients available per 
group must be as large as possible in order that the statistical test applied may have 
sufficient power. Let us suppose that in view of the desired power per method of 
treatment, S patients are required per group when two therapies (t) are compared and 
both are applied to the same number of patients, the number of patients actually included 
in the trial e.g. the statistically required minimum number 
Xclinical trial (Xot) = t X S = 2S. 
Suppose the group concerned consists of F of the total number of patients who suffer 
from the disease. 
The total number of patients with mammary carcinoma that must be available if the trial is to 
be possible Xmaterlal (Xm) must now fulfil 
F 
100 
χ X
m
 > t x S 
or 
^ ^ 100 
Xm > -^- X t X S 
T h e least number of patients X
m
 required in order for a justified conclusion still to be 
possible in the subgroup is then 
(1) X
m
 = ^ χ t χ S 
in which F is the percentage corresponding to the subgroup to be examined and t the 
number of therapies compared. 
In order to facilitate the calculation of X
m
 we have introduced the multiplication-
100 100 
f a c t o r - - = — - . 
/ o
 100 
If the subgroup concerned makes F% of the material available, indicates the factor by 
F 
which the number of patients required on statistical grounds (S) must be multiplied if all 
patients included in the trial are to meet the criteria. 
Conversely we can deduce from equation ( 1 ) the relative size F
m
in. of the smallest 
subgroup within which the methods of treatment can still be compared if the total 
number η of patients available is known. This number must be substituted for X
m
 in 
( 1 ) and F solved : 
100 χ t χ S 
{¿j Γ min. = 
η 
Accordingly when planning a clinical trial we must know the number of patients who 
are or will become available, but we must also know how these patients are divided 
between the relevant subgroups. I n practice it is often impossible to obtain exact data 
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on these points. Every reasonably reliable, if general, information on this point is of 
importance, however. At first we only need to know the order of magnitude of the 
number of patients required to decide whether a particular clinical trial will be feasible 
or not with the available patient material. If in the course of the experiment it appears 
that the required number of patients is not reached in certain subgroups, we can always 
decide to continue the experiment longer or refrain from drawing conclusions where 
these subgroups are concerned. We must also consider the calculations carried out in 
this thesis. O n the basis of the available material of mammary carcinoma in T h e 
Netherlands we have attempted to deduce the percentages of subgroups of interest for 
comparing therapies. We are aware that these patients do not constitute a sample from 
a well-defined patient material obtained according to recognized techniques of random 
selection. Nevertheless, we consider the sample sufficiently representative of the 
population of Dutch women suffering from m a m m a r y carcinoma to substitute the 
percentages calculated from this group into one of our equations (1) and (2) so as to 
obtain an impression of the size of an adequate clinical trial concerning mammary 
carcinoma. 
Possibly superfluously, we would point out in this connection that this does not run 
counter to our decision not to use the data for a retrospective comparison. Even though 
it is a reasonable assumption that the clinics involved will not have applied any radical 
selection in accepting patients with mammary carcinoma for treatment (or at any rate 
none other than is usually applied in this respect), this does not guarantee that no 
selection was applied in selection of treatment. And such a guarantee would be 
necessary for a retrospective comparison of therapies. 
Still, our calculations are only orientative in character. Even if the patient material 
had been a random sample from the population of mammary carcinoma patients in T h e 
Netherlands during the period of the trial, we still have to take into account the normal 
random sample variation in the percentages calculated as well as the fact that the 
composition of the population may change with the passage of time. In regard to the 
random sample variation, suppose a particular percentage is estimated as F % and the 
total material contains η patients. The relative error in the percentage found and 
accordingly in the minimum number of patients required according to equation (1), 
will, with a margin of error of 5 to 10% (F not too near 0 or 100%) not exceed 
'ЩИ
1 
From this we can conclude that if for η = 1,417 patients for the subgroup, we estimate 
a percentage of 10 on the basis of the random sample variation, we may expect a 
relative error exceeding 16% in the calculated number of patients required for a 
clinical trial. This relative error is listed for different values of F and η = 1,417 in 
table S3. 
This table shows that the relative errors which may occur do not necessarily consti­
tute an objection since it is only our intention to make a general estimate of the number 
of patients required. I t should, however, be remembered that other (systematic) errors 
may also play a part in the estimation of percentages of patients in the various sub­
groups, since our material is not necessarily representative of all characteristics. 
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TABLE S3. Table of two times the relative standard error e in the required number of patients as a 
function of the selection percentage F. The sampling error will usually not exceed e. 
F(0/„) e(%) 
5 23 2 
10 15 9 
15 12 6 
20 10 6 
25 9 2 
30 В 1 
35 7 2 
40 6.5 
45 5 9 
50 53 
55 4 8 
60 4 3 
65 3 9 
70 3 5 
75 3 1 
BO 2 7 
85 2 2 
90 18 
95 1 3 
T h e factors which may affect the treatment of m a m m a r y carcinoma are e.g. special 
characteristics of the tumor or of the patient, such as the extension of the pathological 
process expressed as the stage according to one of the international standard classifi­
cations, the site of the tumor, the age of the patient and her curative operability. Two 
of these characteristics, the stage classification (§ 8) and the curative operability (§ 7) 
are discussed later in greater detail. 
In order to determine their influence on the number of patients required for a 
clinical trial for this purpose, the characteristics determining the natural course of the 
disease must first be listed. It will thus be found that in an average series of patients 
some characteristics are very frequent while others occur more sporadically. Particu­
larly when we combine sporadic characteristics, this combination will occur only 
rarely. 
In order to show how to calculate the percentage of a subgroup selected on the basis 
of various criteria, we give a concrete example. Suppose these criteria imply that the 
patients concerned have a stage I tumor at an age under 70 years, with a tumor with 
lateral localization which in retrospect might be regarded as suitable for curative 
surgery. In that case the percentage F of the patients in this subgroup may be calculated 
by means of the following equation : 
гзі J J L = J L χ J L
 x Jl_ χ
 f
°* 
\0> inn inn л inn A inn A 100 100 100 100 100 
In this equation: 
fi = the percentage of patients available with a stage I tumor 
f2 = the percentage of patients available with a tumor in stage I and aged under 
70 years 
* The symbol О is used here to indicate the curative operability. 
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ί3 = the percentage of patients available under 70 with stage I tumors with a lateral 
localization, and 
f0 = the percentage of patients available under 70 with laterally localized tumors in 
stage I, who in retrospect were found to have been suitable for curative operation. 
In this formulation, the possibility is left open that the various factors by which the 
patients are subdivided depend on each other. T h e percentages fj, fj and f0 do not 
stand in relation to the entire group of available patients who have the properties 
mentioned in the categories above. If instead we substitute percentages of the entire 
group of patients into equation (3), it must be assumed that the factors in the various 
categories are independent. If independence is assumed, use can be made of the data 
for the calculation of F from the single tables (f 1 — f50, cf. Appendix Part I ) . 
However, it is possible that two characteristics to be considered in the study are 
dependent (e.g. age and menopause). I n that case F can be computed only if the 
combined frequency (fc) of two characteristics is known. Should this dependence be 
neglected, then the number of patients will be over- or underestimated. When two 
characteristics are dependent, use must be made of the contingency tables and the 
combined frequency fc must replace the product of the individual frequencies. 
T h e contingency tables have been worked out for 15 characteristics in an attempt to 
gain an impression of the influence of eventual dependencies on our computation. 
Elaboration of the combined frequencies between other, less frequent characteristics 
seemed less meaningful, because our calculation only aims at a global estimate. 
No combinations of more than two characteristics have been worked out in the f
c 
tables. O n page 55, however, we present an example in which F is calculated from our 
fc tables. In addition we show the result of the same calculation carried out by computer, 
in which all possible dependencies have been taken into account. In this example the 
ultimate outcomes are highly similar. 
If a parallel examination of different subgroups is desired, we must calculate the 
number X
m
 on the basis of the frequency F of the smallest subgroup. However, this ha s 
the consequence that more patients possessing the less rare characteristics will be 
available than are strictly necessary for the trial. 
It will be clear from the above that the more wc select in the two therapy groups, the 
greater the total number of patients required (Xm) will become, because this number 
depends on the percentage of incidence of the select group in the patient material. 
As table SI shows, the number of patients S required depends not only on differences in 
the 'success' percentages in the population but also on their average values. If this lies 
close to nil or 100%, the required number S grows smaller for the same difference. In 
this connection we may attempt to apply such a selection that a large difference may 
appear in 'success percentages', which means we want a subgroup of patients in which 
it may be expected that one of the two methods of treatment compared will be specifi­
cally more suitable than the other, while at the same time in the selection of the success 
criteria we strive for a high, or conversely, a low, mean percentage of success in the two 
groups (for a detailed calculation cf. Ch. V §2 p . 65). 
However, the problem here lies in the fact that as soon as there are grounds for 
expecting a considerable difference in success percentages, the ethical permissibility 
of the trial becomes doubtful. Presumably the best we may expect from a selection in 
subgroups is that somewhere a large, unexpected difference in success percentages will 
occur, with relatively high or relatively low percentages of success. 
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§ 7. Factors whose influence upon the number of patients required appears retrospectively 
This chapter deals with the at tempt to get an idea of the numbers of patients suitable 
for inclusion in the material to be studied after completion of a clinical trial. One of the 
factors that may influence this number is the curative operability. We regard as 
curatively operable those patients who in principle might be cured completely by 
means of a particular therapy. Patients in whom the pathological process has already 
spread outside the region to be treated are regarded as curatively inoperable. When we 
intend to study in principle curative local treatments, we only can use real stage I or 
stage I I patients. When afterwards it appears that a number of these patients must be 
classified as stage IV, this group of patients must be excluded from the trial. In the 
headings of the tables concerning curative operability (cf. Appendix Part I I ) , we shall 
use the letter O. 
Patients dying of causes other than tumor must also be excluded from the trial. Even 
if we wish to exclude all patients with a double carcinoma or with carcinoma other than 
a mammary carcinoma, the precise number of these patients can only be determined 
after the end of the trial, unless it is decided to exclude only those patients that fulfil this 
condition at the beginning of the trial. One of the data that can only be known after the 
trial is the number of patients who for some reason cannot be followed up until the end 
of the trial. 
If it is found in retrospect that a number of patients have been classified incorrectly, 
and consequently have been included incorrectly in the trial, it is permissible to exclude 
these patients from the trial if the phenomenon can be expected to an equal extent in 
the two groups to be compared. 
In calculating the number of patients necessary, it is desirable to take this factor into 
account if the number of patients concerned are considerable. Owing to coincidence, 
the distribution over the patient groups may show great differences. However, the 
groups remain comparable in spite of this difference, because they were composed by 
lots, and statistical analysis remains possible although the optimal fifty-fifty division is 
now lost. 
The success of a clinical trial may depend on the inclusion or exclusion of the 
curatively inoperable patients. The presence of a large number of patients whose 
prognosis cannot be expected to be influenced by the treatment may render the 
ultimate differences in the results so small that the superiority of any form of treatment 
can no longer be determined. 
This problem will be particularly in evidence with local therapies, aimed at the 
curative treatment of the local process, and less clearly with general therapies that may 
influence the time of appearance of distant metastases (e.g. ovariectomy cf. clinical 
trial Paterson Ch. V § 3, or treatment with cytostatic agents). 
If only the effects of general therapies on the frequency of local and regional recur-
rence are to be studied, irrespective of the development of distant metastases, it is better 
not to select cases on the basis of curative operability. 
The consequences of the 'curative operability' for a clinical trial are as follows : 
Given a population of patients in whom the effect of treatment A is to be compared with 
that of treatment B, it is to be expected that for a part of this population, to be estab-
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lished beforehand or in retrospect, the effect of both methods of treatment will be the 
same (mostly nil). These patients we shall call the irrelevant cases (irrelevant as regards 
the methods of treatment to be compared) or 'curatively inoperable' patients. 
T h e presence of irrelevant patients in a clinical trial may exert an unfavorable in­
fluence on the discriminative qualities of the tests to be applied, so that the number of 
patients necessary may be relatively larger than when the irrelevant patients are left 
out of the trial. Both the effect on the difference in result and the effect on the number 
of patients necessary will be demonstrated by the following example. 
If we assume that two therapies A and В are compared in a clinical trial with patients 
in stage I, I I and I I I , then the patients who die within 3 years after the beginning of 
the therapy are regarded as irrelevant. O n the basis of the data listed in table О 8, we 
expect that this will be the case in 40 % of the patients. Therefore, if we commence the tes t 
by applying therapies A and В in equal groups of patients, both of which have been 
composed at random, the chance that a person will prove to be irrelevant is 40 % in both 
groups. Now let us assume that the irrelevant patients are not included. This means 
that our therapy groups actually consist of patients who are still alive at least 3 years 
after the beginning of the therapy and that we evaluate the result of the trial on the basis 
of the numbers of these patients who are dead 7 years later. Let us further assume that 
the 10 year mortality chances are 6 0 % and 70%, and the 3 year mortality chance in 
both groups, 40%. T h e chance that a patient will survive for longer than 3 years but for 
shorter than 10 years then amounts in group A to 60 — 40 = 2 0 % and in group В to 
70 — 40 = 30%. I n r c l a t i o n t o the group of the relevant patients (100 — 40 = 6 0 % of 
all patients), therefore, there is a 10 year mortality chance of 2 0 / 6 0 = 3 3 . 3 % in group A, 
and of 30/60 = 5 0 % in group B; this difference in mortality chance of 16.7% in the 
relevant patients is equivalent to the difference between 60 and 70% in all patients. 
Now let us assume that the irrelevant patients are counted in. In both therapy groups 
we include 589 patients. According to tabic SI , there will then be a 9 5 % chance that a 
significant difference between the therapies will be found, when the 10 year mortality 
chances P A and Pjj are 6 0 % and 70%, respectively. 
Now if the irrelevant patients are left out and Рд = 33.3% and Р в = 50%, we find 
that per therapy 154* patients are necessary for these differences to be demonstrable; 
predictably, therefore, per therapy group - — . 154 = 256 patients in all. This is only 
43.5 % of the 589 patients who are thought to be necessary when the irrelevant patients 
are not concerned beforehand. Accordingly, exclusion of the irrelevant patients in this 
case means a considerable decrease in the number of patients necessary for a partic­
ular difference in the 10 year mortality rate to be demonstrable. 
Why the curative operability is considered as important 
A study of the figures in our material concerning the course of the disease raised the 
question of the validity of an evaluation of the results of therapies intended as curative 
* In view of the construction of table SI, a value of 30% has been chosen for Рд and value 
of 50% for Рв. 
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FIGURE iii-l. The 'curative operability' on the basis of'death from tumor within 3 years after the 
beginning of the treatment' ( 10 years follow up, cf. Appendix table 04) ; each clinical stage 
considered as 700%. 
Entire material 
57.4% 
Stage I 
73.6% 
in a group of this kind. A considerable number of patients with stage I, II or I I I tumors 
showed obvious distant metastases shortly after institution of treatment (of. tables 
O I - 0 2 ) , and many patients died shortly after (cf. tables 0 5 - 0 6 , figures I I I - l and 
III-4) . It seems highly likely that the distant metastases were already present in 
these patients when treatment was started. It is unlikely that in these cases the course 
can have been influenced by a therapy meant only to cure the local and regional 
disease process. 
Moeys (1953) wrote in this context: 'When a cancerous growth has been removed 
in toto and no metastases have been found during the operation, the conclusion 
that the patient has been cured is unfortunately unjustified. Cancer is not a local 
abnormality but a systemic disease. T o my mind, a mammary carcinoma has 
already produced disseminations outside the field of operation of even the most radical 
surgeon'. 
McDonald (1958) and McWhirter (1955) have also presented arguments in favor 
of a limited curative operability. O n the basis of data from the literature, McDonald 
(1958) presented a study of m a m m a r y carcinoma according to their biological char­
acter. H e studied groups of untreated and treated patients and concluded that therapy 
Stage П Stage III 
63.2% 53.6% 
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cannot influence an unfavourable course in 4 0 % of patients with mammary carcinoma ; 
in another 4 0 % the course is favourable and likewise uninfluenced by therapy. In only 
20% of patients can early effective therapy be expected to influence the disease process. 
If our multiplication factor (cf. Ch. I l l §6) regarding the operability was com-
puted on the basis of the number of patients suitable for an at tempt to establish the 
value of therapy in mammary carcinoma, then according to McDonald, the multi-
plication factor would amount to = - ¡r-r- = 5. 
/o 20 
McWhirter (1955) likewise made an estimate of the percentage of inoperable pa-
tients on the basis of data from the literature. He did so in view of the rate of occurrence 
of pathological glands in the various glandular regions, the local dissemination and 
distant metastases. Pathological axillary glands were found in 34% of cases ; of this 
group, 60% showed supraclavicular or parasternal metastases. These patients can be 
considered as curatively inoperable. 
FIGURE Ш-2. Specification of the inoperable patients according to McWhirter 
64 
50% 
29 
20 
15 
Glands outside 
the region of 
operation 
Extensive 
local 
growth 
Venfied 
distant 
metastases 
Total percentage 
of curative 
inoperabihty 
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This gives us (cf. Figure 111-2) : 
Glands outside the region of operation 
Extensive local growth 
Verified distant metastases 
Total percentage of curative inoperability 
2 0 % 
2 9 % 
1 5 % 
6 4 % 
T h e remaining 'curat ive operability' is therefore 3 6 % . Using these data, our multi-
100 100 
plication factor would amount to =
 Q C - = 2.8 according to McWhirter. % 36 
I n a recent article by Bruce et al. (1970) we have found additional arguments in 
favor of our views on curative operability. O n the basis of the patterns of recurrent 
disease in 876 patients, 6 5 % of which had been treated according to the method of 
McWhirter (follow up 10 years or more), the authors conclude ' O u r experience has 
made it abundantly clear that distant recurrence is the essential feature of therapeutic 
failure, and, when there is both local and distant recrudescence, the local and the 
remote lesions are virtually synchronous'. Stages I and I I (Manchester classification) 
were regarded as 'potentially curable'. Local recurrence is encountered in 31 % of this 
group of patients and distant metastases in 4 9 % (cf. tabic I I I - l and table III-2) . 
TABLE iii-l. Іжаі recurrence in 'potentially curable' patients* 
Clinical 
stage 
I 
II 
'Potentially 
curable' 
No. of 
patients 
238 
185 
423 
Site of local recurrence 
Axilla 
33 (14%) 
54 (29%) 
87 (21%) 
Chest 
wall 
35 (15%) 
48 (26%) 
83 (20%) 
Supracla­
vicular 
26(11%) 
33 (18%) 
59 (14%) 
No. of patients 
with local 
recurrence 
58 
73 
131 
% incidence of 
24 
40 
31 
TABLE ni-2. Distant metastases in 'potentially curable' patients* 
Clinical 
stage 
I 
II 
Potentially 
curable' 
No. of 
patients 
238 
185 
423 
No. with distant 
metastases 
104 
104 
208 
No. with skeletal 
metastases 
60 
55 
115 
% incidence of distant 
metastases 
44 
56 
49 
I t further appears from this study that the largest number of recurrences are seen 
during the first 3 years after the beginning of the treatment (cf. Figure 111-3 from Bruce). 
* Table from Bruce (1970). 
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FIGURE іп-З. Time-intervals between primary treatment and the detection of recurrent disease in 
112 potentially curable patients showing evidence of local and distant recurrence (from Bruce, 
1970). 
IZ 3 0 6 0 9 0 120 150 180 
Interval between treatment and distant metastases 
( mo ) 
The degree of 'curative operability' of mammary carcinoma was also estimated on 
the basis of data from our own material. A patient was regarded as 'curatively 
inoperable' by the author when occult distant metastases were present at onset of 
treatment. Two criteria were applied in this estimate, viz: 
1. Manifestation of distant metastases within 3 years of starting treatment. 
2. Death as a result of tumor growth within 3 years of starting treatment. 
According to this assessment the remaining part of the series was regarded as 
'curatively operable'. For computation we must define a period within which 
metastases must be demonstrable to warrant a conclusion of curative inoperability. 
However, since the rate of metastatic growth is uncertain, such a definition is im­
possible. Nevertheless, in order to gain an impression of the rate of metastatic growth 
and related 'curative operability', we computed for both criteria the figures over a 
3 year period from starting treatment. The 3 year period was chosen because our 
material indicates that some 4 0 % of distant metastases become manifest within 
3 years and some 4 0 % of the patients of our series died of tumor within 3 years. 
An additional argument in favor of a term of 3 years as a criterium of the curative 
operability is the length of time that elapses between the first occurrence of distant 
metastases and the time of death of the patients in our series. The duration of this 
period gives an impression of the growth rate of metastases. In order to demonstrate 
this, an analysis was made of data concerning the 357 patients who were followed up 
for 10 years ; no stage-classification was made. The metastases were classified according 
2'i 
§ 6. The constitution of homogeneous groups 
All diseases, in our case mammary carcinoma, have their natural course. There are 
many possible variations in biological characteristics such as rate of growth, hormone-
dependence, sex chromatin and the manner and rate of metastatic growth. The in-
fluence which these characteristics exert on the course of the disease is insufficiently 
known, if at all. Instituting a therapy means that a characteristic is added to the 
natural course, with the intention of influencing it favorably. The influence of this 
added characteristic on the course can be evaluated only in its relation to as many as 
possible of the natural characteristics considered capable of influencing the course. 
If the individual characteristics of the patients are not taken into account, the same 
therapy can be expected to yield considerably different results. 
If a trial is limited exclusively to patients possessing those characteristics that will 
be influenced precisely by the methods of treatment to be studied, a maximal effect 
may be expected from this trial. Accordingly, strict criteria will have to be defined 
to be fulfilled by the patient and the tumor before the patient can be included in the 
trial; the criteria must be adequate for the investigation to be carried out. 
These criteria must be defined in such a way that no doubt is possible concerning 
their interpretation. Thus homogeneous groups of patients arc formed which allow of 
specific analysis. Only then will it be possible accurately to determine in what way and 
to what degree the therapy has affected the course of the disease. It will be obvious, 
for instance, that when a local treatment with a curative intention is to be evaluated, 
no patients will be included in the trial whose pathological process has already spread 
beyond the area to be treated. This reasoning does not imply that a trial with a 
heterogeneous patient material is impossible. 
If we were to include all available patients into a trial intended to evaluate the elTect 
of a certain therapy on the local process, the treatment would have little or no in-
fluence on the evolution of the disease in a considerable number because the patho-
logical process would already have spread beyond the area to be treated. This renders 
analysis of the trial very difficult and it is even doubtful whether valid conclusions 
could be reached at all. Owing to the inclusion of a group of irrelevant patients, a 
possible favorable effect of a therapy might well not manifest itself clearly. As appears 
from the design of numerous current trials investigators are thoroughly aware of 
the favorable effect of maximum homogeneity of the patient groups where the 
investigation in question is concerned (Flamant, 1969). 
In this context Bradford Hill ( 1960) wrote : ' the basic principles are randomization, 
replication and unbiased observation. In a simple experiment in the laboratory the 
scientific worker wishes to see what happens to A if he manipulates B. He tries to keep 
constant all other factors that may upset or influence the relationship. Similarly in the 
controlled trial we endeavour to keep constant the characteristics of our patients that 
may influence the comparisons of those on treatment A and those on treatment B. 
Some of those characteristics we can keep constant by stratification - by keeping equal 
in the two groups such obvious features as age and sex. Other characteristics we cannot 
deliberately equalize, and our aim is to achieve it by the random allocation which, in 
in the long run, offers no favour to one or other group' . 
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FIGURE ш-4. The number of patients (in percentages) 'died of tumor within 3 years after 
starting treatment' by stages (International TN M classification). 
The whole series 10 years follow up is 100 percent. 
Broken lines: number of patients (in percentages) of whole series 10 years follow up, 
by stage. 
50% 
27.2 
6.7 i ! 
! 3 · 9 ! 
4.8 
I I I I I I 
* New manHcstatton of distant metastases within 3 yean. 
I V * clinical stage 
to localization, viz. local and/or regional recurrence and metastases in lungs, bones, 
liver, skin, brain or contralateral breast. T h e registration was based on one particular 
localization, with determination of the duration of survival after this metastasis had 
manifested itself, alone or in combination with metastases in some other localization. 
I n every group of metastases, the total number of patients who exhibited metastases in 
that particular localization was regarded as 100%. In case of combination of two or 
more localizations, the course was registered for both cases. Patients with metastases in 
more than one localization were counted in anew for every localization. 
As can be seen in table III-3 and table III-4, it is only patients with local and/or 
regional recurrences and patients with bone metastases who survive for longer than 3 
years. This is the case only if there is no combination with other localizations. 
T h e evolution is then as follows (cf. table 111-3) : 
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TABLE ш-З. The period that elapses between the first occurrence of local and)'or regional re­
currence and bone metastases respectively and the moment of death. The percentages indicate what 
portion of the total number of patients in each groups has died. 
Localization without 
combination with 
other metastases 
Local and/or regional 
Bone 
total number 
of patients 
( = 100°/) 
37 
31 
0 
18 9 
22 6 
1 
29 7 
25 8 
% of deaths 
2 
8 1 
1 9 4 
per year* 
3 
8 1 
9.7 
4 - 5 
24 3 
19.4 
> 5 
1 0 8 
3.2 
If combinations with other localizations are counted in, the course is as follows: 
TABLE III-4. The period that elapses between the first occurrence of metastases and the moment 
of death. In every metastatic group, all the metastases that occurred in combination with this 
localization were always included. The percentages indicate what portion of the total number 
of patients in every group of metastases has died. 
Locahz ;ation 
local and/or 
lungs 
bone 
liver 
skin 
brani 
contralateral 
regional 
total number 
of patients 
( = 100%) 
75 
58 
63 
24 
8 
16 
7 
0 
41 3 
62 1 
4 8 0 
03 3 
75.0 
81.3 
42 9 
1 
32 0 
34 5 
32 0 
16 7 
1 2 5 
12 5 
28 6 
% of deaths 
2 
8 0 
3 4 
12 7 
-
— 
6 3 
143 
per year* 
3 
6 6 
— 
4 8 
-
12 5 
— 
14 3 
4 - 5 
5 3 
— 
1 6 
— 
— 
-
-
> 5 
6 6 
-
1 6 
-
-
-
-
We have arbitrarily selected a duration of 3 years as the criterium of curative opera-
bility. We are fully aware that after 3 years a manifestation of tumor growth outside the 
area treated may equally well indicate the presence of these metastases at the time of the 
treatment. Nevertheless we regard this period of 3 years as important because a 
development of metastases after its end rather tends to indicate a lack of radicality of 
the local or regional treatment, resulting in a new spread of tumor cells. However, the 
above considerations tend to show that the application of clinical classifications can 
never have more than very limited value in the definition of the prognosis. Accurate 
determination of the stage of clinical spread will only become possible with an im­
provement in the early diagnosis of distant metastasis. 
T h e estimation of the curative operability was made from our material, which had 
been followed up for 5 years or more and 10 years or more. Wc also made a division 
according to clinical stages (International T N M classification) : stage I through stage 
IV. T h e data concerning the curative operability are recorded in absolute figures, in 
percentages per stage and in percentages per combination of stages (cf. tables 0 1 , 2, 
* The figure 0 indicates 0 - 1 year after the beginning of the treatment. 
The figure 1 , 1 - 2 years etc. 
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FIGURE ш-5. End results of treatment of mammary carcinoma. 10 years follow up. Different 
treatment modalities not considered, all stages included (cf. Appendix Part II table 06). 
65.0 
50% 
a Alive without signs of 
tumor. 
b Alive with signs of 
tumor. 
с Died of tumor within 
3 years after starting 
t reatment. 
d Died of tumor 4 years 
or later after starting 
treatment. 
c + d Totals died of tumor. 
f Died of other cause 
than tumor. 
42.6 
26.9 
0.8 
л 1 
22.4 
7,3 
c+d 
5, 6, Appendix Part I I ) . From these figures the multiplicationfactor was computed 
100 
using table (of. Appendix Part IV), and recorded in table O S , 4, 7, 8 (cf. Αρ­
χο 
pendix Part I I ) . 
We must point out that the different methods of treatment in our series, are not 
considered in the assumption that they are not essential in this respect. The number 
of patients required for a definite clinical trial must be multiplied by the computed 
multiplicationfactor (from О tables) if the percentage 'curative operability' is taken 
into account. 
Another characteristic influencing the number of patients suitable for follow up is 
mortality from disease other than that under investigation. In our material the mor­
tality from other causes was 9.0% (whole series 5 year follow up) and 7 .3% (whole 
series 10 year follow up). This means that respectively 100-9.0 = 91 % and 100-7.3 = 
9 2 . 7 % of the whole series have not died from other causes than tumor. T h e multi-
100 100 
plicationfactors are = 1.10 and -^r^~ = 1.08 respectively. In our computation 
regarding some imaginary trials (cf. Ch. IV) this factor is accounted for on the basis 
of the number of patients who died from other causes within 3 years ('high risk 
patients' 3.5%). 
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''Differences in staging have more influence upon the statistical 
results than differences in treatment.' 
McWhirter 1956. 
§ 8. Clinical classifications 
In the attempt to obtain some impression of the prognosis on the basis of the clinical 
symptoms, a number of clinical classifications have been introduced. In these classifi­
cations the severity of the disease is expressed by 4 stages. Stage I indicates a limited 
spread of the disease, and the higher stages (IT, I I I and/or IV) a greater spread. 
Such classifications should make it possible, during examination and definition of the 
indications of treatment, to define accurately what categories of patients are considered. 
In clinical trials, it is important to form groups of patients with identical charac­
teristics, because in this way the efficacy of the various methods of treatment can be 
better defined (cf. Ch. I l l § 6). 
In regard to carcinoma of the breast, numerous classifications are in use and not 
always with identical criteria. With the aid of such data a scheme of treatment may 
be devised and the value of the therapeutic schemes later analysed. T h e question of 
whether it is indeed possible and useful to draw up a classification as to prognosis on 
the basis of the clinical symptoms will not be considered in this chapter (for curative 
operability cf. Ch. I l l § 7). 
T h e discussions in this chapter are helpful in demonstrating the necessity of the use 
of comparable groups of patients in investigations concerning carcinoma of the breast. 
As can be seen in table I I I - 5 , where a number of series of patients are compared that 
have been subdivided according to different classifications, the staging differs so much 
that it is unlikely that these differences are to be attributed to population differences 
exclusively. 
TABLE ш-5. A survey of the absolute and relative numbers of patients per stage, according to 
several clinical classifications for mammary carcinoma (a report of the literature). 
Clinical classification 
International T N M 
Lucassen (1964) 
International T N M 
Present series 
American T N M 
MacKay (1966) 
Steinthal 
Richards (1948) 
Columbia' 
Butcher (1961) 
Manchester 
McWhirter (1955) 
Stage I 
_ 
23 4 
414 
29 4 
549 
45 0 
147 
16 0 
216 
50 8 
582 
3 1 0 
Stage II 
_ 
2 1 5 
183 
13 1 
156 
12 8 
591 
6 4 0 
135 
31.8 
481 
26 0 
Stage III 
_ 
4 1 5 
743 
52 7 
375 
30 8 
183 
20 0 
48 
1 1 3 
250 
1 3 0 
Stage IV 
_ 
1 3 6 
69 
4 8 
139 
1 1 4 
_ 
-
26 
6 1 
569 
30 0 
Totals 
_ 
100.0 
1409 
100.0 
1219 
100.0 
921 
100.0 
425 
100.0 
1882 
100.0 
* Columbia classification stage А, В, С and D, 
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Not all investigators consider the differences between the classifications as important. 
Handley (1967) for instance regards as equivalent stage I I I of the International T N M 
Classification, stage I I I of the modification of the T N M system proposed by the 
American Joint Committee on Cancer Staging and End Results reporting of the 
American College of Surgeons, and stage С of the Columbia Clinical System. Zippin 
( 1966), on the other hand, has pointed out the differences between the American T N M 
Classification and the International T N M Classification. His findings are listed in 
table III-6. 
Numbtrs TAHLE πι-6. International TNM classification versus American TNM classification {from 
ν
 o r
'
z o
°
t a
 pippin 1966), modification to our tables. 
American T N M classification 
Slage IV 
Stage І П 
Stage II 
Stage I 
Totals 
Stage IV 
195 
86 7 
100 0 
— 
— 
195 
110 
100.0 
International T N M classification 
Stage III 
30 
13 3 
5.0 
381 
100.0 
63 6 
73 
23 6 
12 2 
115 
13.5 
19 2 
599 
34 0 
100.0 
Stage II 
— 
— 
236 
76.4 
100 0 
— 
236 
13.4 
100.0 
Stage I 
— 
— 
— 
734 
86 5 
100 0 
734 
4 1 6 
100.0 
Totals 
225 
100.0 
12.7 
381 
100.0 
21.6 
JOS 
100.0 
1 7 6 
849 
loo.o 
48 1 
1764 
loo.o 
100.0 
In order to gain an impression of the degree of comparability of various classifications we 
compared on our own material several commonly-used classifications with the Interna­
tional T N M classification we used (uicc 1968). This comparison is highly artificial and 
gives only a general impression.* The chief problem in this respect was that the Inter­
national T N M classification entirely ignores certain symptoms considered essential in 
another classification, e.g. ' the size of axillary glands' or ' the occurrence of carcino­
matous mastitis' in the Columbia classification. Efforts were made to establish which 
of the T N M categories determine the stage of tumor growth in the International T N M 
classification. This is elucidated in a diagram. As regards other classifications, the T N M 
categories essential to each stage were likewise charted, always on the basis of the 
highest stage (legend cf. p . 36). With every diagram, the conditions of the classifi­
cation in question are stated. 
For this comparison, the 8 patients whose classification was unknown were included in stage III . 
34 
T h e following clinical classifications are considered : 
a. T h e Classification of the Joint Committee on Cancer Staging and End Results 
Reporting of the American College of Surgeons (American T N M ) (Spratt 1967). 
b . Steinthal Classification (Steinthal 1905). 
c. Columbia Classification (Spratt 1967). 
d. Manchester Classification (Windeyer 1949). 
O n the basis of the foregoing data we computed the stage distribution in our material 
in the terms of the other classifications. For this purpose a computer program was 
designed to determine in each classification the T N M categories corresponding with 
the highest stage, to count the number of patients meeting these criteria. This number 
was subtracted from the material. T h e lower stages were successively counted and 
subtracted from the remaining material. T h e figures thus obtained were used in 
compiling the contingency tables of the T N M classification versus each of the other 
classifications. 
T h e relative frequency distribution of the various stages is shown in the following 
tables I I I - 7 — I I I - 1 0 a n d Figures I I I - 6 — I I I - 9 , which reveal considerable differences. 
T h e degree of consistency of the various stages between the International T N M 
system and the other classifications was computed from the number of patients who 
came under the same stage heading in the various classifications (cf. table I I I - l l ) . 
T h e diagrams clearly reveal the difference in structure of the stages, on comparison 
of the different classifications. Comparison of the figures from our material also reveals 
considerable differences. In our opinion therefore, a comparison of different methods 
of treatment in groups of patients who have been classified according to different 
systems is not very useful, and will give rise to numerous misunderstandings, to the 
detriment of the patients. 
The International TNM classification 
Τ — P r i m a r y t u m o u r 
TO N o evidence of primary tumour. 
T l T u m o u r 2 cm or lesa in greatest dimension; 
Skin not involved, except in the case of Paget's disease confined to nipple ; 
N o retraction of nipple ; 
N o pectoral muscle fixation; 
N o chest wall fixation. 
T 2 T u m o u r more than 2 cm but not more than 5 cm in greatest dimension, от 
incomplete skin fixation (tethered or dimpled), or 
nipple retraction (in subareolar tumours), or 
Paget's disease extending beyond the nipple; 
N o pectoral muscle fixation ; 
N o chest wall fixation. 
T 3 T u m o u r more than 5 cm but not more than 10 cm in greatest dimension, or 
skin fixation complete (infiltrated or ulcerated), or 
peau d'orange in tumour area, or 
pectoral muscle fixation 1 (incomplete or complete). N o chest wall fixation. 
1 Incomplete pectoral muscle fixation indicates that contraction of the muscle limits tumour mobility. 
Complete pectoral muscle fixation indicates that contraction of the muscle abolishes tumour mobility. 
T 4 T u m o u r more t h a n 10 cm in greatest dimension, or 
skin involvement or peau d 'orange wide of tumour but not beyond breast area, or 
chest wall fixation.2 
2 T h e chest wall includes the nbs , intercostal muscles and serratus anterior muscle but not the pectoral muscle. 
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Ν — Reg iona l l y m p h n o d e s 
T h e clinician may record whether palpable nodes are considered to contain growth or not 
NO N o palpable homolateral axillary nodes. 
N1 Movable homolateral axillary nodes 
N i d Nodes not considered to contain growth. 
N16 Nodes considered to contain growth 
N2 Homolateral axillary nodes fixed to one another or to other structures. 
N 3 Homolateral supra· or infra-clavicular nodes movable or fixed or oedema of the a r m 3 
3 O e d e m a of the a r m may be caused by lymphatic obstruction, lymph nodes may not then be palpable. 
M — D i s t a n t m e t a s t a s e s 
MO N o evidence of distant metastases. 
M l Distant metastases present 
Μ ί α Skin involvement wide of breast 
M l ¿ Involvement of contralateral nodes or contralateral breast 
M l с Clinical or radiographic evidence of metastases to lungs, pleural cavity, skeleton, liver, etc* 
Stage-group ing 
With MO, classification by Τ and N gives stages as follows 
Stage I 
Stage II 
Stage III 
TINO 
TINI 
T1N2 
T1N3 
T3N0 
T3N1 
T3N2 
T3N3 
T2N0 
T2N1 
T2N2 
T2N3 
T4N0 
T4N1 
T4N2 
T4N3 
With M l stage must be I V . 
EXPLANATION OF THE DIAGRAMS 
ι i 
I I 
! 1 
T h e categories which determine the same stage in both systems were boxed in 
with a continuous line 
Categories included in the International T N M but not in the classification 
considered were boxed in with a n interrupted line and cancelled. 
T h e categories classified in a different stage in the classification considered were 
boxed in with a continuous h o c , boxes with an interrupted line were used to 
indicate where these categories were placed ш the T N M system. T h e arrow 
indicates the direction of the category-displacement. 
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The International TNM classification* 
Stage I Suge II Stage III Stage IV 
Size 
Skin 
Pirçct s discise 
Nipple rcinction 
Fettoni muselé utichmcnt 
Chest will attdchmenl 
Homolateral аміі ir\ Kmph 
nodes 
Homolatcr il supraclavicular 
or infraclavicular lymph nodes 
Arm edema 
Distant metastases 
Ti 
Лі. 
T4 
T i 
Ύ2 
Т3 
Г4 
Ti 
T2 
Г-> 
l i 
l 3 i 
J j b 
i i 
No 
N i l 
N [ b 
N i x 
N2b 
N3 
N3 
Mo 
M 
Γι 
'il 
ІЗ 
H 
li 
i 2 
'i 
U 
li 
I2 
Γι 
l-> 
ij 
Η 
li 
lì 
ij 
І4 
Γι 
Ti 
Τι 
ГІ 
Γ J 
U 
Τι 
TÍ 
гз 
η 
Τι 
Ta 
l ì 
Γι 
I^h 
Γι 
Τ4 
N3 
Кз 
Mo 
M 
г> 
l i 
' J ' 
ТзЬ 
l i 
T4 
No 
Гма 
N i b 
N i x 
N i y 
Nja 
N2b 
N3 
N3 
Mo 
M 
l i 
T3-1 
Tgb 
l i 
T4 
No 
Ni a 
N i b 
Nix 
Niy 
N2 a 
Nab 
N3 
N3 
Mo 
M 
* The TNM categories which deternune the Stages aie boxed in. 
The American TNM classification, proposed by the American Joint Committee on Cancer 
Staging and End Results reporting of the American College of Surgeons 
T: Primary Tumor 
T l Tumor of 2 cm. or less in its greatest dimensión; skin not involved, or involved locally with Pagel's disease 
T2 Tumor over 2 cm. in size or with skin attachment (dimpling of skin) or nipple retraction (in subareolar tumors) ; no 
pectoral muscle or chest wall attachment 
T3 Tumor of any size with any of the following: skin infiltration, ulceration, peau d'orange, skin edema, pectoral muscle or 
chest wall attachment 
J/ ; Regional Lymph Nodes 
NO N o clinically palpable axillary lymph nodes (metastasis not suspected) 
N1 Clinically palpable axillary lymph nodes that are not fixed (metastasis suspected) 
N2 Clinically palpable homolateral axillary or infraclavicular lymph nodes that are fixed to one another or to other structures 
(metastasis suspected) 
M; Distant Metastasis 
MO N o distant metastasis 
M l Clinical and radiographic evidence of metastasis except those to homolateral axillary or infraclavicular lymph nodes 
These descriptions are then combined to define four stages. 
Stage I: T1 /N0 /M0; T2/N0/M0 
Stage II : T1 /N1/M0; T2/N1/M0 
Stage III : T 3 / N 0 / M 0 ; T 3 / N 1 / M 0 ; T 3 / N 1 / M 0 ; T 3 / N 2 / M 0 ; T l / N 2 / M O ; T 2 / N 2 / M O ; and includes any combination 
of T l , T2 or T3 with N2 and MO 
Stage I V : Any clinical stage of disease with distant metastasis ( M l ) . 
Numbers TABLE ιπ-7. American TNM classification versus International TNM classification. 
% Horizontal 
American T N M 
Stage I V 
Stage III 
Stage II 
Stage I 
Totab 
SUge IV 
69 
52.7 
100.0 
S9 
4.8 
100.0 
International T N M classification 
Stage III 
62 
47.3 
8.2 
468 
97.3 
62.3 
84 
63.7 
11.1 
133 
24.0 
18.4 
752 
53.1 
100.0 
Stage II 
13 
2.7 
6.9 
133 
58.1 
70.8 
42 
7.3 
22.3 
188 
13.2 
100.0 
Stage I 
12 
5.2 
2.9 
396 
68.7 
97.1 
408 
28.9 
100.0 
Totals 
131 
100.0 
9.3 
481 
100.0 
33.9 
229 
100.0 
16.1 
576 
100.0 
40.7 
1417 
100.0 
100.0 
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The American TNM classification projected on to the International TNM classification*) * * ) 
Stage I Stage II Stage III Stage IV 
Size 
Skin 
Pagct's disease 
Nipple retraction 
Pectoral muscle attachment 
Chest wall attachment 
Homolateral axillary lymph 
nodes 
Homolateral supraclavicular 
or infraclavicular lymph nodes 
Arm edema 
Distant metastases 
Ti 
1 > 
'•S 
l i 
'l-i 
' J 
T4 
' ^ T i 
1 2 ^ 
T 2 
'Ι ι 
Гза 
ізь 
Τ ι 
Г4 
No 
N i a 
Τι 
Ta 
T4 
Τι 
l a 
! 3 
Ti 
'l'a 
Г3 
T4 
Τ ι 
T 4 
Τι 
l a 
' 3 
Τι 
Ta 
тз 
Т4 
Ti T I T I 
Та '1 a Ta 
Ta Ta '12 
l i 
T j b 
Τ ι 
T 4 
Ί ι 
І З Ь 
l i 
η 
l i 
13а 
'ІЗЬ 
T i 
'Ч 
No No No 
Nib 
Nix 
Niy 
Naa 
Nab 
^"""Т?™-^ 
Nib 
Nix 
Niy 
Naa 
Nab 
Nia Nia 
N3 Щ 
N 3 
Mo 
M 
N 3 
Nib 
Nix 
Naa 
Nab 
L s ! _ ^ - j 
Nib 
Nix 
Niy 
Naa 
Nab 
N3 
N 3 
Mo Mo 
M M 
Mo 
M 
*) Skin edema not considered, 
·*) Infraclavicular lymph nodes headed under N2. 
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The Steinthal classification 
S T A G E I Cancers limited to the breast so far as can be determined by palpation and clinical study 
S T A G E I I C a n e e n in which the axillary lymph nodes are palpable, and clinically suspected of harbouring neoplastic 
deposits 
I n this stage there is no evidence of implication of any other neighbouring organ or tissue 
S T A G L I I I Cancers ш which adjacent organs or tissues are involved by the neoplasm e g the pectoral muscles, the skin when 
ulcerated, the opposite breast, cervical lymph nodes, the skeletal tissues, etc 
Numbers TABLE Ш-8. Steinthal classification versus International TN M classification. 
y
o
 Horizontal 
Stemlhal classification 
Stage III 
Stage I I 
Stage I 
Totals 
Stage I V 
69 
35 0 
100 0 
69 
4 8 
100.0 
International T N M classification 
Stage I I I 
129 
5 6 0 
17 1 
270 
63 7 
36 0 
353 
4 4 3 
4 6 9 
752 
53 1 
100 0 
Stage I I 
145 
3 4 2 
77 1 
43 
5 4 
22 9 
188 
132 
100.0 
Stage I 
9 
2 1 
2 2 
399 
50 3 
97 8 
408 
28 9 
100.0 
Totals 
198 
100 0 
14 0 
424 
100 0 
29 8 
795 
100.0 
56 2 
1417 
100.0 
100.0 
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The Steinthal classification projected on to the International TNM classification 
Suge II 
l i 
І 2 
тз 
T4 
Τι 
Та 
ТЗ 
Т4 
T i 
Та 
Та 
T i 
І 3 а 
ТзЬ 
Stage III 
Τι 
I 4 -
I 
L. 
1 
1 
1 
Та 
4 J 
T + \ I 
l i 
Та 
T i 
Та 
Та 
Γι 
I ja 
Tjb 
Τ ι 
Та 
тз 
Т4 
l i 
Га 
тз 
Т4 
l i 
Та 
Та 
T i 
І 3 а 
ТзЬ 
Chest wall attachment 
Homohteral axillary lymph 
nodes 
Ti 
Homolateral supraclavicular 
or infraclavicular lymph nodes 
Arm edema 
Distant metastases 
Г4 
N i 
N 3 
Mo 
M 
Ί ι 
Γ4 
N3 
N 3 
Mo 
M 
T4 
N0 
N i a 
N i b 
N i x 
N i y 
Naa 
Nab 
... 
N3 
^ " ~ ~ М ^ 
Mo 
M 
T i 
T 4 
N 0 
N i a 
N i b 
N i x 
N i y 
Naa 
Nab 
N3 
N3 
_Mo 
" M" 
The Columbia classification 
STAGE Λ : No skin edema, ulceration or solid fixation of tumor to chest wall; axillary oodes not cluucally involved. 
STAGE В * No skin edema, ulceration or solid fixation of tumor to chest wall, clinically involved axillary nodes, but less than 
2 5 cm. ш transverse diameter and not fixed to overlying skin or deeper structure of axilla. 
STAGE С : Any one of five grave signs of comparatively advanced carcinoma: 
1. Edema of skin of limited extent (less than one third of the skin over the breast). 
2 Skin ulceration 
3. Solid fixation of tumor to chest wall. 
4. Massive involvement of axillary lymph nodes (2 5 cm or more in transverse diameter) 
5. Fixation of the axillary nodes to overlying skin or deeper structures of the axilla. 
STAGE D * All other patients with more advanced breast carcinoma including: 
1 A combination of any two or more of the five grave signs listed in Stage C. 
2. Extensive edema of skin (involving more than one third of the skin over the breast). 
3. Satellite akin nodulo. 
4. The inflammatory type of carcinoma 
5 Supraclavicular metastases, clinically 
6. Parasternal metastases, clinically. 
7. Edema of the ipsilateral arm. 
Θ. Distant metastases. 
Numbers TABLE ш-9. Columbia classification versus International TNM classification. 
% Horizontal 
Columbia daaification 
Stage D 
Stage С 
Stage В 
Stage A 
Total» 
Stage IV 
es 
34.0 
100.0 
69 
4.8 
100.0 
International TNM classification 
Stage III 
Ш 
660 
17.8 
295 
100.0 
39.1 
130 
45.9 
17.3 
193 
30.4 
25.8 
752 
53.1 
100.0 
Suge II 
145 
51.2 
77.1 
43 
6.7 
22.9 
188 
13 2 
100.0 
Stage I 
8 
2.9 
2.0 
400 
62.9 
98.0 
408 
28.9 
100.0 
Totals 
203 
100.0 
14 3 
295 
100.0 
20 8 
283 
100.0 
20.1 
€36 
100.0 
448 
1417 
100.0 
100.0 
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The Columbia classification projected on to the International TNM classification *) * *) 
Stage A Stage В Stage С Stage D 
Size 
Skin 
Paget's disease 
Nipple retraction 
Pectoral muscle attachment 
Chest wall attachment 
Homolateral axillary lymph 
nodes 
Homolateral supraclavicular 
or infraclavicular lymph nodes 
Arm edema 
Distant metastases 
ГЧ^і "Ι Τι 
і З ^ ¡ T2 
Т4 
Τι 
Tz 
тз 
тз 
T4 
Τι 
Т2 
тз 
Т4 Т4 
т$\, 
Тза 
ТзЬ 
Ti 
Т4 
No 
Nia 
Nib 
Nix 
Niy 
Τι 
Т2 
Т2 
τ" 
1 за 
ТзЬ 
Τι 
Т4 
N2a 
N0 
Nia 
Nib 
Nix 
Niy 
Naa 
Ti 
T2 
^ ^ 3 
Ti 
T2 
1 
1 
1 
Т3 
L ' Г * 
Τι 
T2 
T2 
Τι 
L т ^ 
Τι 
— * • 
^ 
Т4 
N0 
Nia 
N2b N2b 
N 3 N3 
N3 N3 
Mo 
M 
Nib 
Nix 
N.y 
N¿a 
N2b 
L
 N3 
N3 
Mo Mo 
M M 
"1 
Ti 
T2 
ТЗ 
T4 
Ti 
T2 
ТЗ 
T4 
Ti 
T2 
T2 
Ti 
Тза 
ТзЬ 
Τι 
T4 
No 
Nía 
Nib 
Nix 
Niy 
N2a 
N2b 
N3 
N3 
Mo 
M 
* Where two boxed-in categories arc connected with one another by a Ime, these categories count only where they are pre 
in combination. 
** Size of the axillary lymph nodes, skin edema, satellite skin nodules, the inflammatory type of carcinoma, parasternal mc 
taso (clinically), not considered. 
The Manchester ( Windeyer) Classification 
STAGE ι The growth is confined to the breast Involvement of the skin directly over and in continuity with the tumor does 
not affect staging provided that the area involved is small in relation to the size of the breast. 
STAGE II As Stage I but there are palpable mobile lymph nodes in the axilla. 
STAGE III The growth is extending beyond the corpus mammae as shown by: 
a The skin is invaded or fixed over an area large in relation to the size of the breast 
b. The tumor is fixed to underlying muscle Axillary glands may or may not be palpable but if glands are present 
they must be mobile 
STAGE IV The growth has spread beyond the breast area as shown by 
a Fixation of axillary nodes indicating extension outside the capsule 
b. The tumor is completely fixed to the chest wall 
с Secondary lymph nodes in supraclavicular region. 
d Secondary deposits in skin- wide of tumor 
e. Secondary deposits in the opposite breast 
Г Distant metastases, e g bone, liver, lung, etc 
Numbers TABLE Ш-10. Manchester classification versus International TNM classification 
% Horizontal 
% Vertical Manchester classification 
Stage IV 
Stage III 
Stage II 
Stage I 
Totals 
Stage IV 
ÍS 
29 2 
100 0 
69 
48 
100 0 
International TNM classification 
Stage III 
167 
70 8 
22 2 
363 
965 
48 2 
108 
36 5 
14 4 
114 
22 4 
15 2 
752 
53 1 
100.0 
Stage II 
13 
35 
69 
163 
55 1 
867 
12 
24 
64 
IBB 
132 
100.0 
Stage I 
25 
84 
6 1 
3B3 
75 2 
93 9 
tos 
28 9 
100.0 
Totals 
236 
100.0 
16 7 
376 
100.0 
26 6 
296 
100 0 
20 9 
509 
100.0 
35 8 
1417 
100.0 
100.0 
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The Manchester classification projected on to the International TNM classification 
Stage I Stage II Stage III Stage IV 
Size 
Skin 
Pagct's disease 
Nipple retraction 
Pectoral muscle attachment 
Chest wall attachment 
Homolateral axillary lymph 
nodes 
Homolateral supraclavicular 
or infraclavicular lymph nodes 
Arm edema 
Distant metastases 
T S \ 
Τι 
Ta 
тз
 т
з 
Т4 Т4 
Τι 
Та 
Тч 
Τι 
Ta 
тз 
Т4 Т4 
4 N § V 4 
'^~-
<
і^^] 
Τ ι 
Тза 
ТчЬ 
Ti 
Ta 
*\Тз 
Τι 
Та 
тз 
t — I * — , 
T i 
Та 
тз 
T4 
Τι 
Та 
— • 
тз 
Т 4 
Ti T I T I 
Та Та Та 
Та Та Та 
T i 
Тза 
ТзЬ 
Ti T I 
Τ ι 
Тза 
ТзЬ 
Τ ι 
Τι 
Тза 
ТзЬ 
Ï 4 T4 T4 
No 
Nia 
Nib 
Nix 
Ν ι ν 
Naa 
Nab 
N o 
Nia 
N i b 
Nix 
Niy 
Naa 
Nah 
T i 
'l 't 
No No 
Nia 
Nib 
Nix 
Niy 
Naa 
Nab — 
N3 N 3 I N3 j — • 
N 3 
Mo 
M 
N 3 
N i a 
N i b 
Nix 
Niy 
Naa 
Nab 
N 3 
N 3 
Mo Mo 
M M 
M o 
M 
TABLE ш - П . The number of patients in the various classifications (in absolute and relative 
frequencies) under the same stage-heading as the International TNM Classification. 
(The series of 1417patients is 100%) 
Clinical Classification Numbers Percentage 
American T N M 
Stein thai 
Columbia 
Manchester 
1066 
673 
909 
978 
75.3 
47.5 
64.1 
69.0 
A survey of the relative numbers of patients per stage, according to several clinical classifications 
for mammary carcinoma (cf. tables JII-7—III-10). 
% Stage I (Fig. III-6) + % Stage II (Fig. III-7) + % Stage III (Fig. III-8) + 
% Stage IV (Fig. III-9) = 100%. 
FIGURE ra-6 STAGE ι (Columbia classification stage A) 
56.2 
50% 
40.7 
28.9 
44.8 
35.8 
Int. TNM. Am. TNM. Sfeinthal Columbia Manchester 
46 
FIGURE ιπ-7 STAGE π (Columbia classification stage В) 
50% 
29,8 
16,1 
13.2 
20.1 
20.9 
Int. TNM. Am.TNM. Steinthal Columbia Manchester 
FIGURE ш-8 STAGE m (Columbia classification stage C) 
53.1 
50% 
33.9 
26.6 
20.8 
14.0 
Int.TNM. Am.TNM. Steinthal Columbia Manchester 
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FIGURE III-9 STAGE iv (Columbia classification stage D) 
50% 
16.7 
14.3 
9.3 
4.8 
Int.TNM. Am.TNM. Columbia Manchester 
§ 9. The requisite number of members of the general female population 
O u r computation may enable the investigator to estimate the number of patients 
required for a clinical trial in accordance with individual criteria. The only remaining 
question concerns the number of patients with mammary carcinoma available in a 
general population. I n order to be able to calculate the size of the female population 
(Xpopuiation) necessary for a particular clinical trial, the multiplicationfactor 
has been introduced. Factor is based on the annual number of female deaths from 
malignant conditions of the mammary gland in the general population as recorded in 
tables concerning the Cancer Mortality in 24 countries (cf. table P, Appendix Part I I I ) . 
T h e assumption in using this figure is that all patients dying of mammary carcinoma 
are recorded, the annual mortality is not variable and the annual morbidity corre­
sponds to the annual mortality. 
T h e introduction of factor q, which indicates the number of years during which the 
patients will be included in the trial, gives an impression of the number of members 
of the female population who must be available per year. O u r computation of Xp gives 
an impression of the geographical extent of the organization that is required if a 
clinical trial is to be carried out. 
Л.П -Λ.Π1 X 
(T) 
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An investigator is not likely to wish to collect his entire material within one year. 
For the estimate, therefore, factor — — should be divided by the number of years (q) 
during which the patients are included in the trial. If the collecting period of the trial is 
10 years (q = 10) then the required size of the female population is to be estimated 
with the aid of factor 
10 
For example, if factor Ρ is found to equal 3.3 X 103 (cf. table P, Appendix Part Til) then 
mammary carcinoma occurs annually in 1 out of 3300 women. Computed for the 10 
3*300 
year period this makes —i.e. 1 patient out of 330 women. I t must be remembered 
that it will be impossible to include all cases with m a m m a r y carcinoma in the trial. The 
figures supplied by the Central Cancer Registration Office in The Netherlands give an 
indication of the number of patients potentially available (cf. table III-12). 
TABLE III-12. The number of patients recorded by the Metherlands Central Cancer Registration 
(from Meinsma 1963 and 1965) 
Period Total number of patients Number of patients 
per annum 
1953-1955 2181 717 
1956-1958 3689 1229 
An inquiry made in T h e Netherlands by Zwaveling (1966) has shown that far larger 
figures can be obtained with the collaboration of many surgeons. Zwaveling received 
notification of some 1494 patients per annum, i.e. the majority of some 2000 annual 
patients in T h e Netherlands. 
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CHAPTER IV. ESTIMATING THE NUMBER OF PATIENTS REQUIRED 
FOR SOME IMAGINARY CLINICAL TRIALS TO COM­
PARE THE RESULTS OF SEVERAL THERAPIES FOR 
MAMMARY CARCINOMA 
In this chapter the numbers of patients required are calculated for some imaginary 
trials, with reference to examples. Our main intention is to give an impression with the 
aid of data from our patient material of the influence of progressively increased 
selectivity on the total number of patients required (Хщ)· For the number required on 
statistical grounds, we used table SI of the χ2 test for a 2 X 2 table. If Fn is the 
percentage of the entire population of patients with mammary carcinoma fulfilling η 
selection criteria, and fi, fj, f3, etc. the percentages of incidence of every single selection 
criterion, F
n
 is calculated as follows : 
F
n
 fj fz f3
 t 
z_
 =
 î у = у - etc 
100 100 100 100 
Since the dependence, if any, is not known for all the selection factors, they are 
assumed to be independent in these cases. In order to gain an impression of the magni­
tude of error resulting from this assumption we have established with the aid of a 
computer how many patients in our material fulfilled all the requirements of the first 
trial (cf. note 6, p. 56). In order to indicate the influence of each selection factor, anew 
selection factor was added each time in the calculation and X
m
 was calculated succes­
sively. Consequently the numbers listed for a given selection factor are valid when the 
factors in question and/or listed previously are accepted as conditions for admission of 
patients to the trial. The necessary data were borrowed from the f tables (cf. Appen­
dix)*. The required number S was always based on the condition that a difference 
between a probability of success Рд = 60% with treatment A and Рв = 70% with 
treatment В should be detectable with a probability of 95%; and for the case when 
PA = 60% but Рв = 80%. This condition has been selected because these figures 
correspond to the percentages of 5 year results in large series in the literature con­
cerning the early stages of mammary carcinoma (cf. table IV-1). Naturally, on the 
basis of table SI the calculation can also be made for other values of PA and Рв. 
* For further details concerning the calculation of Хщ, cf. Ch. Ill § 6. 
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TABLE iv-1. Results oj Treatment of mammary carcinoma. Five year survival in stage Α ι pa­
tients. (Columbia Clinical Classification). 
Author 
Kennedy and Miller2 
Handley 3 
Butcher2 
Therapy 
Simple 
Mastectomy 
Modified 
Radical 
Mastectomy 
Radical 
Mastectomy 
Number of 
pattens 
115 
117 
216 
% survival 
62 
76 
76 
Haagensen and Cooley* 
Dahl-Iversen and Tobiassen2 
Williams and Curwen* 
Radical 
Mastectomy 
Super-Radical 
Total 
Mastectomy 
•f axillary 
dissection 
+ irradiation 
344 
277 
68 
77 
72 
Kaae and Johausen 2 McWhirter's 
method 
159 
Baclesse4 Prolonged 
Roentgen 
Therapy 
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1 For comparability of stage A Columbia Clinical Classification and Stage I International T N M Classification cf Ch III §8 
2 Haagensen et al. 1963. 
3 Handley 1965. 
4 Badesse 1965. 
As mentioned previously, S may vary widely if other criteria for success of the treat­
ment are set. In all cases, two methods of treatment were compared (t = 2). 
The calculation then goes as follows : 
100 X , 2S χ 
T h e multiplicationfactor 
F
n 
100 (cf. t a b l e — - , Appendix Part IV), which indi-
x
'n /o 
cates the factor by which the number of patients required on statistical grounds must 
be multiplied if all patients included in the trial are to meet the criteria set, is listed for 
each selection factor. 
Finally we determined the minimum number of women Xp which a population 
must contain in order for a period of q years to yield a sufficient number of mammary 
carcinoma patients to permit a trial with X
m
 patients. Suppose Ρ is the incidence of 
m a m m a r y carcinoma among the population, i.e. the number of women who develop 
m a m m a r y carcinoma per 100 women per year, then : 
X X p X q therefore: X p = X,, Xm = 
100 χ P.q 
Ρ is unknown, but we do know the number of women per 100 women per year who die 
from m a m m a r y carcinoma. If we assume that in nearly all women who develop this 
disease, the diagnosis will ultimately also be registered as the cause of death, we may 
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Substitute for Ρ the annual percentage mortality from m a m m a r y carcinoma in T h e 
Netherlands (cf. table P, Appendix Part I I I ) . 
(3.3 X 103) 
When q = 5 : Xp = Хщ· г 
Xp = Xm· (0 66 X 103) 
Xp = 660 Хщ· 
Therefore if the 5 year survival rate is selected as the criterion, the trial will last 
10 years. 
For the 4 examples worked out, we have presupposed a selection based on the 
following criteria : 
1. T h e patients must be females. 
2. Mammary carcinoma to be verified histologically. 
3. T h e mammary carcinoma not to be bilateral. 
4. The patient not to suffer from carcinomata other than the mammary one, with the 
exception of cutaneous carcinoma. 
5. T h e excision biopsy for mammary carcinoma to be performed no earlier than two 
weeks prior to admission to the trial. 
6. T h e patient not to have died within 3 years of admission to the trial from any other 
disease than mammary carcinoma (only to be established during the trial). 
7. T h e patient to be less than 70 years old. 
O u r calculation will show (cf. table IV-2) that according to our estimate only 69 .5% 
of the patient material fulfils these conditions. O n e should note that the number of 
high-risk patients (point 6 above) cannot be known at the beginning of the trial, so that 
these patients have to be preliminarily included into the trial. We have not taken into 
account the loss of patients due to lack of follow up. I n our series, this was of the order 
of 1%. For registration we must therefore reckon on a larger number of patients than 
the statistically required minimum 2S (Xct, cf. p . 20). 
TABLE rv-2. Relative frequency in our material of criteria for inclusion of patients in the imagi­
nary clinical trials considered m tables IV-3 and IV-4. 
100 3) 
Criteria f , 1 ) F, î ) 
Fi 
1 Female patients only 
2. Tumor venfìed histologically 
3. Only unilateral mammary carcinoma 
4. No other carcinoma (except skin carcinoma) present 
5. Excision biopsy for verification no longer than 2 weeks ago 
6. No high nsk patients 4) 
7 Age up to 70 (cf table Π 6) 
All criteria for inclusion - 69 5 % 1 44 
1 ) fj = relative frequency ш material of criterion considered 
2) F l •* (Γ,.Γ,.^/ΙΟΟ = remaining part (percentage) of material meeting criteria considered and foregoing entena. 
3) Factor for computation of Х
ш
 (cf. Appendix Part IV) 
4) The value of f, stated here is the relative frequency of patienta ш our material who died from other diseases within 3 yean 
of commencement of therapy. 
100% 
100% 
97 7% 
98 8% 
944% 
96 5% 
79 0% 
100% 
100% 
97 7% 
96 5% 
91 1% 
87 9% 
69 5% 
100 
100 
102 
1 04 
1 10 
1 14 
144 
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FIRST DESIGN (cf. table IV-3) : 
Since the effect to be investigated is what may be expected from therapies aimed at 
the local process with its regional spread, the patient material must fulfil the following 
conditions. 
1. The tumor must be stage I on the International TNM Classification. With the aid 
of our data, the size of the group of patients fulfilling these conditions can be 
approximated as follows. Table fc 24 shows that 337 patients in stage I were younger 
than 70. The total number of patients aged up to 70 years is 1110. Of these 1110 
patients, 337 (or 30.4 %) were in stage I. 
2. The tumor to be localized in the lateral half of the breast (46.1 % cf. table fc 64). 
3. The patient may be regarded as suitable for curative surgery (78.8% cf. table 07) . 
This means that the patient must not die from tumor growth within 3 years of 
beginning the treatment. 
Since we cannot know at the beginning of the trial which patients will die from tumor 
growth within 3 years, observation of the last condition means that a number of extra 
patients will have to be treated, in order to leave a sufficient number at the end of the 
trial. This first design is based on comparison of the results of two surgical methods of 
treatment A and B. The design may also be used for comparing non-surgical methods 
of treatment. We have, however, made this selection since the conditions for this 
design also apply to the designs mentioned below, where the histology of the axillary 
glands is of importance. 
SECOND DESIGN (cf. table IV-3): 
In patients who fulfil the conditions mentioned above and who have been submitted 
to some form of surgical treatment, we now make a distinction between histological pos-
itivity and negativity of the axillary glands (37.0 % cf. table fc 98). The group of patients 
with histologically positive axillary glands is divided at random into two equal groups : 
one group treated by X-ray and a control group. Since randomization is applied to the 
surgical therapy as well, any possible systematic effect of the nature of the surgical 
treatment is excluded. If a group of patients were available for this trial who had been 
treated by a uniform surgical method, more homogeneous groups might be formed 
which would be very favorable for demonstrating a possible systematic effect of the 
radiological treatment. 
THIRD DESIGN (cf. table IV-3) : 
With a clinical trial according to this design we can study the value of prophylactic 
ovariectomy in non-menopausal women. For this purpose, subdivision according 
to menopause is made in a group of patients who fulfil the conditions of the first 
design. Since ovariectomy may be expected to have some influence on the devel-
opment of distant metastases, the condition of'curative operability' (78.8% of Stage I 
patients cf. table 07) was not applied to this design, so that the ultimate numbers of 
78.8 
the first design must be multiplied by —™-. The group of non-menopausal women 
was divided at random into equal ovariectomy and control groups. In order to exclude 
any systematic effect of previous surgery and/or radiotherapy, randomization was 
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applied to the previous treatment as well. Of this design, as of the second design, it 
would be more favorable if patients were available for this trial who had previously 
been subjected to uniform surgical and radiological therapy. 
With the aid of our data, the size of the group of patients fulfilling the conditions for 
non-menopausal women under 70 in stage I can be approximated as follows. 
The total number of patients in stage I is 413 (cf. table fc 24). According to table 
fc 56, 27.6% of all patients in stage I are not menopausal; 27.6%of the total of 413 
patients is 114. Table fc 24 shows that 337 patients in stage I were younger than 70. 
Of these 337 patients, 114 (or 33.8%) were non-menopausal. 
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TABLE г -З. Estimation of number of patients required for an imaginary clinical trial in order 
to compare two therapies A and B. 
It is assumed that a difference of x-year population survival rates PA and Ρ в has to be detected 
with a probability of 95% by the χ* test for a 2 X 2 table (at the 5% level of significance) 
applied on observed x-year survival rates. The value of x can be chosen arbitrarily (greater than 
3 for all trials where the curative operability is taken into account). It is assumed that all 
patients have to meet of criteria 1—7 of table IV-2 ; for each trial some additional conditions (con­
nected to the types of therapies considered) are imposed subsequently. Mutual dependencies 
between these conditions are not taken into account, except for those mentioned in the tables. The 
values of PA and PB rnay depend on these conditions, but the computation is always carried 
out for the same two cases PA = 60%, PB = 80% and PA = 60%, Рв = 70%. 
Conditions 
C a s e P A = 6 0 % 
PB - 8 0 % 
2S = 266 
r.
1) F i 2 ) 100' ) 
"F. 
ХпИ) X n ' ) 
(millions) 
C a « P A = 6 0 % 
Рв - 'о% 
2S = 1178 
X m 4 ) X p ' ) 
(milliona) 
Trial I for comparing two surgical therapies A and В 
1. All entena of tabic IV-2 
2. Tumor ol stage I (International T N M 
classifica lion) in patienU aged up to 
70 years 
3. Curative operable patients, in patients 
with tumor of stage I (5 years less 
follow up) 
4. '1 umor localized laterally, in patients 
with tumor of stage I 
_ 
3 0 . 4 % 
78 8 % 
4 6 1 % 
69 5 % 
2 1 . 1 % 
1 6 6 % 
7 6 5 % 6 ) 
1 4 4 
4.74 
6.02 
13.1 
383 
1,260 
1,600 
3,480 
0.25 
0 83 
1.1 
2.3 
1,700 
5,580 
7,090 
15,400 
1.1 
3.7 
4.7 
10. 
Trial II for comparing patients treated by radiotherapv (A) to a control group (B) 
I. All conditions of tnal I 
2. Patients with positive axillary glands 
ш patients with tumor of stage I 
_ 
3 7 . 0 % 
7 6 5 % 
2 8 3 % 
13 1 
35 3 
3,480 
9,390 
2 3 
6.2 
15,400 
41,600 
10. 
27. 
Tnal III for comparing patients subjected to ovariectomy (A) to a control group (B) 
1. All conditions of trial I except for 
curative operability (condition 3) 
2. Non-mcnopausal patients in patients 
of stage I 
_ 
3 3 . 8 % 
9 7 3 % 
3 2 9 % 
10.3 
30.4 
2,730 
8,100 
1.8 
5.3 
12,100 
35,800 
8. 
24. 
1) fj = relative frequency in our material of patients with the condition considered (percentage). 
2) Fj = (fj.F^iJ/lOO = remaining part oi material after imposing condition considered. 
3) 100/Fj = factor with which the number 2S has to be multiplied in order to obtain X
m
. 
4) X
m
 = estimated number of patients required for a trial if they have to meet the condition considered and the preceding 
ones (to 3 sigmâcant figures). 
5) X p = estimated size of female population in which X r n patients are expected per year; X p « 660 X m is stated in millions 
(to 2 sigmûcant figures). 
6) This percentage calculated directly from the number of patients fulfilling all conditions 1 through 4 in our data and the total 
number of patients involved (nol assuming independence of conditions cf p. 51) was 7.40. 
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F O U R T H D E S I G N (cf. table IV-4) : 
The purpose of this trial design was to study in one series of patients the value of two 
methods of surgical treatment A and В combined with radiological treatment and 
ovariectomy. T h e aim was not solely to determine the effect of surgical therapy A or В 
and of postoperative irradiation or ovariectomy by themselves, but to gain an impres­
sion of the effect of these methods of treatment when applied to the same patient. In this 
respect, this design differs from earlier ones which were aimed at evaluation of one 
therapy only and the nature of previous therapies was not taken into account. I n order 
to exclude a systematic effect of previous therapies, the randomization of the previous 
designs was applied to these therapies as well. 
For this fourth design (parts II and I I I ) use was made of more homogeneous groups 
of patients, since the effect of previous treatments is part of the investigation. An objec­
tion to this design is, however, that for part I I (radiological treatment) and part I I I 
(ovariectomy), larger numbers of patients are required than for analogous trials as 
described under the second and third designs. 
T h e fourth design consists of three parts (cf. Figure IV-1). 
P A R T I : T h e patient material fulfilling the conditions of the first design is divided at 
random into two equal groups. One group is treated by surgical therapy A, the other 
by therapy B. Accordingly, part I of the fourth design is identical to the first design 
(cf. p. 54). 
P A R T I I : Surgical therapy groups A and В are both subdivided into groups with 
histologically positive axillary glands (P) and groups with histologically negative 
axillary glands (N). We thus have groups AP, AN, BP and BN. Groups AP and BP are 
once more divided at random into equal groups, of which only one group is irradiated 
(irradiation, A P R and BPR; irradiation controls APC and BPC). Patients with 
histologically negative axillary glands (AN and BN) are not submitted to additional 
treatment. 
P A R T I I I : T h e irradiation and irradiation control groups are divided into meno­
pausal patients (M) and non-menopausal patients (M). Thus the following groups of 
patients are formed: A P R M , A P R M , B P R M , B P R M , A P C M , A P C M , B P C M and 
BPCM. The groups of non-menopausal patients in whom the presence of positive 
axillary glands was established during the examination for part II are now divided at 
random, dependent on the menopausal condition, into two equal groups of which one 
is subjected to ovariectomy ( 0 ) while the other serves as control ( 0 ) * . 
Thus, the following therapy groups are formed : 
A P R M 0 , A P R M 0 , А Р С М 0 , А Р С М 0 
B P R M 0 , B P R M 0 , В Р С М 0 , В Р С М 0 . 
* If in the comparison of ovariectomy groups the curative operability is not to be taken into 
account, the numbers found must be divided by -„
 0 , or multiplied by ' , as in the third 
/o.o 1UU 
design (cf. page 54). 
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FIGURE iv-1. Schematic presentation of the fourth design (cf. p. 57). 
P A R T I 
APRM APRM ЛРСМ ЛРСМ BPRNI BPRM BPCM BPCM 
P A R T I I 
A P R M 0 / \ A P R M 0 A P C M 0 / \ A P C M 0 BPRM0/\BPRM0 BPCM0/\BPCM0 
P A R T I I I 
T h e groups of menopausal patients A P R M , B P R M , A P C M and BPCM are given no 
further treatment. If desired, part H I might be extended to study the effect of irradia­
tion in patients with negative axillary glands, groups AN and BN. In this case, therapy 
groups ANR, ANC, BNR and BNC would be formed. If desired, the non-menopausal 
patients in these groups might be subjected to a study of the effect of ovariectomy, in 
accordance with part I I I . However, the inclusion of patients with histologically 
negative axillary glands in the trial is of little importance for the calculation of the 
required number of patients X
m
, since X
m
 is computed on the basis of the least frequent 
characteristic, i.e. histologically positive axillary glands. If Xm includes a sufficiently 
large number of patients with histologically positive axillary glands, there will un­
doubtedly be enough patients with histologically negative axillary glands. 
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TABLE iv-4. Estimation of number of patients required for an imaginary clinical trial for com­
paring results of different types of therapies simultaneously. 
PART I· Both groups of patients for a trial to compare two surgical therapies (cf table IV- 3, 
trial I) are divided into a Radiation group and a Radiation Control group 
PAR Til · The total number of patients meeting the additional conditions of trial II (cf table IV-3J 
required for testing the effect of radiotherapy within each of the surgery groups is estimated. 
PART III: Each of the four groups of Part II are divided into an Ovariectomy group and an 
Ovariectomy Control group The total number of patients meeting the additional conditions of trial HI 
(cf table IV-3) required for testing the effect of ovariectomy within each of the four groups is 
estimated For assumptions and key, cf table IV-3. 
Conditions 
Case P A = 6 0 % 
Рц = 8 0 % 
2S » 266 
r. F, 
100 
Fi 
x
m 
Xp 
(millions) 
C a s e P A = 6 0 % 
Рц = 7 0 % 
2S = 1178 
Xm 
(millions) 
Part I Comparing two surgical therapies A and В 
All conditions of trial I, table IV-3 
-
7 6 5 % 13 1 3,480 2 3 15,400 10 
Part II Testing effect of radiotherapy within each surgery group 
Number of patients required for part I 
multiplied by 2 4 
Patients with positive axillary glands 
in patients with tumor of stage I 
-
37 0 % ' ) 
3 5 7 % 
1 4 2 % 
26 2 
70 4 
6,970 
18,700 
4 6 
12 
30,900 
82,900 
20 
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Part III Testing effect of ovariectomy within each of the four groups of part II 
Number of patients required for part II 
multiplied by 2 2 ) 
Non menopausal patients m patients 
of stage I 
-
33 8 % 3 ) 
0 7 1 % 
0 2 4 % 
141 
417 
37,500 
111,000 
25 
73 
166,000 
490,000 
110 
320 
1) For division into Radiation and Radiation Control groups 
2) For division into Ovariectomy and Ovariectomy Control groups 
The numbers 100/ F | v X m and X p may differ slightly from twice the foregoing values since all results are rounded off after 
computation 
3) Cf First and second designs respectively 
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C H A P T E R V. O U R APPROACH APPLIED T O A NUMBER OF CLINICAL 
TRIALS FROM THE LITERATURE 
§ 1. Introduction 
In this chapter, our approach is applied to the data of some previously completed 
clinical trials. For this purpose we selected the studies of Kaae (1965, 1968), Paterson 
( 1959a, 1959b, 1962) and Nissen-Meyer ( 1965, 1968). Clinical evaluation of the results 
of these trials lies outside the scope of this study. 
We estimated the number of patients required for trials, assuming that the estimated 
population result rates were approximately the same as those actually found experi­
mentally. This was done for differences between the population result rates from 10% 
up to the minimum difference detectable with a probability of 9 5 % with the same 
number of patients as that considered in the trial. We based our estimates on the actual 
selection percentages found by the investigators and not on those in our material. These 
percentages were calculated from the number of patients possessing some (combined) 
characteristics and the total number of patients available, so no assumptions of 
independence of characteristics had to be made. None of the investigators mentioned 
took the factor 'curative operability' (cf. Ch. I l l §7) into account, so the required 
numbers of patients estimated in accordance with our approach are not corrected for 
curative operability. We will thus demonstrate with a few examples the extent to which 
tabulation of the curative operability influences the numbers of patients required.In 
our tables on these investigators, we first give a survey of their results. In this respect 
the following data are tabulated : 
I Total number of patients included in trial. 
II Absolute numbers and percentages of patients meeting requirements laid down 
by investigator. 
I I I An indication of the therapies compared and the absolute number of patients to 
whom these therapies were allocated. 
IV T h e result rates found in each of the treatment groups 5, 7 or 10 years after 
treatment. 
V The result of the statistical test for the difference of these result rates. 
If not recorded by the author, the p-value of the χ2 test for a 2 X 2 table, 
with Yates correction, is given. 
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We then give our approach to the minimal detectable difference in population 
survival rates, obtainable from the number of patients in the trial under consid­
eration. 
VI From the percentage F of the entire series meeting the requirements (cf. II) the 
multiplication factor 2 X is computed (cf. I X ) . 
V I I Different values of the population survival rates P A and Р в are chosen, approx­
imating to the (sample) result rates actually found. T h e values Рд and Р в are 
always multiples of 10%, so that table SI can be used. 
V I I I From table SI we find the number S (the number of patients required in each 
therapy group to detect the difference between P A and Рв with a probability 
of 9 5 % ) . 
I X Applying the multiplication factor to S, the total number of patients 
X
m
 = S X 2 X —=— required according to our criteria is found (cf. Ch. I l l §6). 
г 
Operations V I - I X are carried out for differences 10%, 2 0 % , etc. between PA and 
Р в until the number X
m
 exceeds the number of patients actually included in the trial. 
I n this way, the order of magnitude of the minimal detectable difference is obtained. 
§ 2. Каае'з Clinical Trial 
T h e clinical trial carried out by Kaae and Johansen (1965, 1968) compared two 
random series : 
a. simple mastectomy with postoperative irradiation (McWhirter group), and 
b. extended radical mastectomy by the Dahl-Iversen method. This operation is a 
classical radical mastectomy, extended by the inclusion of dissection of the supra­
clavicular and internal mammary lymph nodes. T h e internal mammary chain is 
removed from the first to fourth intercostal spaces. No supplementary irradiation 
was administered. 
T h e study covered the period 1951-1957, comprising 331 cases (operable and in­
operable) in the McWhirter group and 335 in the extended radical mastectomy group. 
Staging was partly done in accordance with the International Clinical Classification 
(Copcland 1959-'60) and partly according to the criteria of Haagensen (1943). T h e 
5 year results were known for all cases, and the 10 year results were known for 234 and 
250 cases respectively. A subdivision is made into stage I cases and operable minus 
stage I cases. 
T h e age distribution was approximately the same in both groups, so no correction 
was applied in analysis. The results were analysed as crude survival rates, crude 
recurrence-free survival rates without correction for death, without signs of recurrence 
and manifestation of distant metastases. In our considerations, the figures for crude 
survival rates are used. In table K a a e IV the influence of the use of different criteria on 
the number of patients required is evaluated. Not all the patients with operable cancer 
admitted into the trial received the treatment scheduled for their group. 
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The McWhirter technique was carried out on only 76%. No operation was per-
formed in 14% of cases on account of biological inoperability (advanced age, concom-
itant disease)· or refusal of treatment. The remaining 10% of patients wished to be 
treated at other hospitals. Similarly, in the extended radical mastectomy group, all 
operable cases should have had extended radical mastectomy. 76% were admitted to 
this operation, which was carried out in all but 25 cases or 12% of the 206 patients. 
Fifteen proved technically inoperable at operation, and 8 were in too poor a condition 
for extended radical mastectomy and 2 refused to have extended radical mastectomy. 
They were given simple mastectomy, in some cases with partial excision of the lymph 
nodes and postoperative X-ray irradiation. 1 3 % were not operated on because of 
biological inoperability and 1 % refused. Again, 10% of the patients desired treatment 
at other hospitals. 
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TABLE KAAE I. McWhirter's method and Extended radical mastectomy compared in operable 
patients, 5 and 10 years crude survival rates considered. No division into subgroups. 
5 yean follow up 10 yean follow up 
Numbers of patients included in KAAF.'S climcal trial 
Numbers of patients meeting Only "operable" patients 
requirements considered. 
Exceptions: 
Biologically inoperable 
Refused operation 
Other exceptions 
Clinical classification 
Therapies considered 
Numbers of patients per therapy group 
Results of percentages 
(crude survival rate) 
Statistical significance (not recorded by KAAE) 
X 2 teat: ρ value 
666 
100% 
Operable 
425 
6 3 . 8 % 
Stage not considered 
McWhirter's 
method 
219 
6 6 % 
Extended 
radical 
mastectomy 
206 
6 7 % 
ρ = 0.94 
666 
100% 
Operable 
302 
4 5 . 3 % 
Stage not considered 
McWhirter's 
method 
149 
4 6 % 
Extended 
radical 
mastectomy 
153 
4 9 % 
ρ = 0.72 
Numbers of patients required according to our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplicationfactor 2 χ - -
F 
63 8 % 
100 
2 χ = 3.1 
63.8 
4 5 . 3 % 
100 
2 χ - _ = 4 . 4 
45.3 
ΙΓ a 1 0 % di (Terence in population survival rate has Lo be detccled 
Values of P A and Pß assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required .«« 
on the basis of our criteria X™ ™ S χ 2 X 
m
 F 
PA = 6 0 % 
PB = 7 0 % 
589 
3 1 χ 589 - 1,800 ± 
PA = 4U% 
Pß = 50% 
642 
4 4 χ 642 = 2,800 ± 
If a 2 0 % dilTereiice in population survival rate has to be delected 
Values of P A and Рв assumed 
(round result percentages) lor entering table Si 
Number of S 
(cf table S.) 
Numbers ol patients required jpp 
on the basis of our criteria Χ™ = S χ 2 χ --
К 
Р л - 6 0 % 
Pß - 80% 
133 
3 1 λ 133 = 400 i 
Ρ Α - 4 0 % 
Pß - 6 0 % 
161 
4 4 < 161 = 700 ± 
' Р д and Pg indicdie ihe assumed population survival rales from McWhirter's method and extended radical masteciomy 
respectively. 
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TABLE KAAE II. McWkirter''s method and Extendedradical mastectomy compared (Syears crude 
survival rate). Operable patients divided into Clinical Stage I and Operable minus Stage I cases. 
5 yean follow up 
Numbers of patients included in KAAE'S clinical trial 
Numbers of patients meeting Only "operable" patients 
requirements considered. 
Exceptions : 
Biologically inoperable 
Refused operation 
Other exceptions 
Clinical classification 
Therapies considered 
Numbers of patients per therapy group 
Results in percentages 
(crude survival rate) 
Statistical significance (not recorded by KAAE) 
X 2 test : ρ value 
666 
100% 
Operable 
425 
6 3 . 8 % 
Clinical stage I 
290 
43 5 % 
McWhirter's 
method 
149 
7 5 % 
Extended 
radical 
mastectomy 
141 
7 7 % 
ρ = 0.78 
Operable minus stage I 
135 
2 0 . 3 % 
McWhirter's 
method 
70 
4 6 % 
Extended 
radical 
mastectomy 
65 
4 8 % 
ρ = 0.96 
Numbers of patients required according to our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplicationfactor 2 x 
43 5 % 
100 
2 X = 4 . 6 
43.5 
2 0 . 3 % 
100 
2 χ = 9 9 
20.3 
If a 1 0 % difference in population survival rate has to be detected 
Values of Р д and Pß assumed 
(round result percentages) for entering table S| 
Number of S 
(cf. lableS,) 
Numbers of patients required .QQ 
on the basis of our criteria X m = S x 2 x 
m
 F 
Рл - 7 0 % 
PB = 8 0 % 
4B3 
4.6 χ 483 = 2,200 ± 
PA = 4 0 % 
Pß - 50% 
642 
9.9 χ 642 = 6,400 ± 
If a 2 0 % difference in population survival rale has to be detected 
Values of Р д and Pg assumed 
(round result percentages) for entering table Si 
Number of S 
(cf. table S,) 
Numbers of patients required .QQ 
on the basis of our criteria X
m
 = S x 2 χ 
P A = 6 0 % 
Pß = 80% 
133 
4.6 χ 133 - 600 ± 
PA = 4 0 % 
PB - ьо% 
161 
9.9 χ 161 = 1,600 ± 
If a 3 0 % difference in population survival rale has to be detected 
Values of Р д and Pß assumed 
(round result percentages) for entering table Si 
Number of S 
(cf. table S,) 
Numbers of patients required JQQ 
on the basis of our criteria Xm = S χ 2 χ ^ 
-
-
-
Ρ Α - з о % 
Рв = 6 0 % 
70 
9.9 χ 70 = 700 i . 
Р д and P Q indicale the assumed population survival rates from McWhirter's method and Extended radical mastectomy 
respectively. 
TABLE KAAE III. McWhirter's method and Extended radical mastectomy compared ( 10 years 
crude survival rate)
 t Operable patients dividedinto ChnicalStage land Operable minus Stage leases. 
Numbcn of patients included in KAAE'S clinical tnal 
I 
Numben of patients meeting Only "operable" patients 
requirements considered 
£xcepuoiu· 
II Biologically inoperable 
Refused operation 
Other exceptions 
Clinical classification 
Therapies considered 
H I Numbcn of patients per therapy group 
Results m percentages 
I V (crude survival rate) 
Statistical significance (not recoraed by KAA£) 
X2 test · ρ value 
10 years follow up 
666 
100% 
Operable 
302 
45 3 % 
Clinical stage I 
202 
30 3 % 
McWhirter's 
method 
97 
5 4 % 
Extended 
radical 
mastectomy 
105 
5 8 % 
ρ » 0 62 
Operable minus stage I 
100 
15 0 % 
McWhirter's 
method 
52 
2 8 % 
Extended 
radical 
mastectomy 
48 
2 9 % 
Ρ - 1 
Numbers of patients required according to our entena 
V I Percentage of entire scries meeting the requirements 
100 
Multiphcauonfactor 2 χ — 
30 3 % 
2 χ 1 0 0 = 6 6 
30 3 
1 5 0 % 
100 
2 χ - 13 3 
15 0 
VII 
νια 
I X 
If a 1 0 % difference in population survival rate has to be detected 
Values of Р д and Ρβ assumed 
(round result percentages) for entenng table Sj 
Number of S 
(cf table S,) 
Numbcn of patients required «QQ 
on the basis of our entena X
m
 — S X 2 X 
P A - 5 0 % 
PB = 6 0 % 
642 
6 6 X 642 = 4,200 ± 
PA - 2 0 % 
Pfl = 3 0 % 
483 
13 3 χ 483 = 6,400 ± 
If a 20 % difference in population survival rate has to be detected 
П 
VIII 
Values of P A and Рв assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table Si) 
Numbers of patients required . - Q 
on the basis of our entena X
m
 = S χ 2 X 
P A - 5 0 % 
PB = 7 0 % 
154 
6 6 χ 154 = 1,000 ± 
PA = 2 0 % 
Pfl - 4 0 % 
133 
13 3 χ 133 - 1,800 ± 
VII 
n u 
I X 
If a 30 % difference in population survival rate has to be detected 
Values of P A and Рв assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table Si) 
Numbers of patients required ,ΛΛ 
on the basis of our entena X
m
 = S X 2 X 
PA - 4 0 % 
Pfl - 7 0 % 
70 
6 6 X 70 = 450 ± 
P A - 1 0 % 
Pfl - 4 0 % 
50 
13 3 χ 50 - 650 ± 
Рд and Pj) indicate the assumed population survival rates from McWhirter's method and Extended radical mastectomy 
respectively. 
In Kaae's trial, no difference in probability of survival could be demonstrated 
between McWhirter 's method and extended radical mastectomy. This does not 
justify the conclusion that the two surgical methods are equivalent. The number of 
patients who could be followed up for 5 years was large enough according to our 
calculations to demonstrate a 2 0 % difference in probability of survival with 9 5 % 
probability. From this it may be concluded that if there is a difference between the 
chances of survival between the two methods, it is probably less than 20%. The possi-
bility remains, therefore, that there is a difference of less than 20% between the chances 
of survival, but Kaae does not demonstrate this. 
Similar considerations apply to the group of patients followed up for 10 years. The 
number of these patients, on the other hand, was only large enough to demonstrate a 
difference of 30% in the survival chances with 9 5 % probability. It is therefore possible 
that there is a difference of less than 30% between the two chances of survival. Conse-
quently, if it is believed possible that the chances of survival are not the same but differ 
by less than 20% and 30% respectively, Kaae's trial should be repealed with more 
patients in order that these differences may be demonstrated with reasonable 
certainty. 
It should be noted that a repetition of Kaae's trial would give rise to problems in 
collecting an identical group of patients, since the composition of Kaae's material 
was not entirely clear because he applied two different clinical classifications to his 
group (cf. p. 62). From tables Kaae I, II and I I I we can deduce how many patients 
would be required to demonstrate maximum differences of 10% in survival chances. 
Although Kaae's publications contain no data useful in the calculation of our factor 
of 'curative operability', we consider it interesting to give an impression of the in-
fluence this factor may exert on the number of patients required for the design of a 
trial as organized by Kaae. Let us therefore suppose that the group of patients examined 
by Kaae and the patients classified by us at stage I + II have similar characteristics. 
The 'curative operability' would then amount to 70.5% (cf. table OS) and the 
100 
multiplicationfactor would increase by - = 1.42. 
It is to be expected, however, that the percentages of results will be closer to 0% or 
100% than the percentages of results found by Kaae and that for this reason the number 
S will grow smaller, so that fewer, rather than more patients will be required (cf. 
Ch. I l l § 7, p. 25). 
From our study it is clear that the requisite number of patients depends amongst 
other things on the criteria chosen in marking the results (cf. Ch. I l l § 3 p. 14). As an 
example, an attempt is made to demonstrate this on the basis of Kaae's trial. From 
Kaae's results we calculated the numbers of patients required according to various 
criteria. Kaae's table IV shows the consequences of applying different criteria of 
success most clearly in the group of'operable cases' in which for the demonstration of a 
difference in results of 10% with a probability of 9 5 % , for the criteria 'crude survival 
rate' and 'distant metastases', a total of 1,800 patients was found, whereas for the 
criterion 'local/regional recurrence' only 1,000 patients are sufficient. 
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TABLE KAAE IV. Requisite number of patients according to different criteria of succes (5 years 
follow up). Operable cases, Clinical Stage I and Operable minus Stage I patients considered. 
Cntena 
(5 yean 
follow-up) 
McWlurter's 
method1) 
Extended radical 
mastectomy1) 
Results of 
treatment 
P A and P B 
assumed2) 
Number of 
S assumed 
(cf. table S,) 
Multiplication-
factor cf 
Kaae I, II and III 
Number* of 
patients required 
Operable cases, cf Kaae I 
Crude 
survival 
rate 
cf. table 
K a a e l 
6 6 % 
6 7 % 
P A = 6 0 % 
589 
1,800 ± 
bical/ 
regional 
recurrence 
1 8 % 
2 2 % 
PA = i o % 
P B = 2 0 % 
323 
3 1 
1,000 ± 
Distant 
metastases 
3 8 % 
3 7 % 
P A = « % 
Рв=зо% 
589 
1,800 ± 
Clinical stage I, cf Kaae II 
Crude 
urvival 
rate 
cf table 
Kaae II 
7 5 % 
7 7 % 
PA = 7 0 % 
Рв=во% 
483 
2,200 ± 
Local/ 
regional 
recurrence 
1 5 % 
1 6 % 
P A = i o % 
P B = 2 0 % 
323 
4 6 
1,500 ± 
Distant 
metastases 
2 8 % 
2 7 % 
P A = 3 0 % 
Р В = 2 0 % 
483 
2.200 ± 
Operable minus stage I, cf Kaae II 
Crude 
survival 
rate 
cf table 
Kaae II 
4 6 % 
4 8 % 
PA = 4 0 % 
Р В = 5 0 % 
642 
6,400 ± 
Local/ 
regional 
recurrence 
2 6 % 
3 7 % 
P A - 3 0 % 
P B = « % 
589 
9 9 
5,800 ± 
Distant 
metastases 
5 9 % 
5 8 % 
P A = 6 0 % 
P B - 5 0 % 
642 
6,400 ± 
1) Results in percentages actually found 
2) P A and Pß indicate assumed population survival rates from McWhirter's method and Extended radical mastectomy respectively. 
§ 3. Paterson's Ovarían Radiation Trial 
Paterson's first trial (1959a, 1962), was designed to evaluate the contribution made by 
castration in a menopausal* group of women with cancer of the breast. The problem 
he set himself was to establish whether X-ray sterilization of the ovaries at the earliest 
possible moment in menopausal women could materially affect the course of the 
disease. 
All breast cancer cases presenting at the Christie Hospital, Manchester, meno-
pausal, and under 55 years of age were considered admissible to the trial, provided 
there were neither contra-indications to ovarian castration nor any special reason why 
it should be advised as a treatment of choice. The experimental sample for analysis 
consists of a varied selection of appropriate patients referred to the hospital for consid-
eration for radiotherapy and allocated on a purely random basis either to have imme-
diate ovarian irradiation (radiated group), or not to be so irradiated (control group). 
Either of these policies was quite independent of whatever other procedures were called 
* For the purposes of Paterson's study menopausal women were defined as those before or 
at the menopause, or within 2 years thereafter. 
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for. A substantial proportion of the cases presenting postoperatively had, prior to 
operation presumptive stage I or stage II cancers of the breast (Manchester staging). 
These, as will be seen later, form the most important group in the study. T h e re­
mainder included new but inoperable cases (stages I I I and IV, Manchester staging) 
and those recurrent either in the breast, axilla, or supraclavicular region, following an 
operation some time previously. The sample is not therefore a representative cross-
section of all stages of breast cancer and in particular it should be appreciated that 
both early cases prior to operation and late cases for which hormone treatment was the 
only procedure possible are absent from the sample. 
The study covered the period 1948-1955 and at completion the total sample consisted 
of 747 patients (10 year follow u p : 744 patients) with breast cancer at various states of 
advancement but predominantly in a postoperative state when first seen and consid­
ered for ovarian radiation. 
Paterson made a division of his series into the following subgroups : 
a. Two major subgroups according to the status of the patient when first reviewed for 
possible ovarian radiation : -
1. postoperative cases - patients admitted to the trial shortly after mastectomy and 
clinically free from demonstrable disease, and, 
2. inoperable or late cases - patients unsuitable for operation when first seen or with 
recurrent or residual disease. 
b . Two age groups ( < 45 years and 45-54 years). 
с The postoperative group was divided into two subgroups according to whether 
malignant invasion was or was not found in the axillary nodes after operation, i.e. 
the contrast separately for proved surgical stage I and other cases. 
Paterson used three criteria to state the results of the postoperative group. These 
criteria are Crude survival rate, Recurrence rate breast area (including axillary and 
supraclavicular nodes) and Manifestation of distant metastases. 
The 10 year results ofPaterson's ovarian radiation trial are recorded by Cole (1968). 
Cole's figures were used in our approach, except for table Paterson IV, where Paterson's 
5 year figures are employed. In the tables referring to both trials of Paterson, the 
symbol X
m
 has a different notation than in the other trials considered in this chapter. 
Paterson worked with selected groups of patients and does not state the percentage of 
all available mammary carcinoma patients which these groups comprised. Therefore 
we can only calculate the number of patients of the selected group which according to 
our criteria is required for a trial as intended by Paterson. For the sake of uniformity, 
this number is indicated by X
m
. 
In the other tables, X
m
 stands for the number of unsclcctcd m a m m a r y carcinoma 
patients required, which is naturally larger. 
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TABLE P A T E R S O N I. Ovarian radiation and Control groups compared ( 10years crude survival 
rate). No divinan into subgroups. 
I 
II 
III 
I V 
V 
Numbera of patients included in PATERSON'S clinical trial 
Numbcn of patients meeting requirements 
Therapies considered 
Numbers of patients per therapy group 
Results m percentages 
(10 years crude survival rate) 
Statistical significance (COLE) 
744 
100% 
Type of case not considered 
Age not considered 
Axillary involvement not considered 
Radiated 
369 
46 6 % 
Control 
375 
41.6% 
ρ - 0 1 7 
Numbers of patients required according to our entena 
V I Percentage of entire series meeting the requirements 100% 
Mul tipi icationfac tor 2 x 
100 100 
2 χ 2.0 
100 
If a 1 0 % difference in population survival rate has to be detected 
__ Values of Р д and Pg assumed 
(round result percentages) for entering table Si 
P A = 5 0 % 
PB - 4 0 % 
VIII 
Number of S 
(cf. table S,) 64Z 
Numbers of patients required 
I X on the basis of our criteria Xfr ' S χ 2 χ 2 χ 642 = 1,300 ± 
If a 20 % difference in population 
VII Values of Р д and Ρβ assumed 
(round result percentages) for entering table Si 
у ™ Number of S 
(cf table S,) 
Numbers of patients required JQQ 
I X on the basis of our criteria X
m
 = S x 2 X 
survival rate has to be detected 
P A = 6 0 % 
PB - 4 0 % 
161 
2 χ 161 - 320 ± 
Р д and Р д indicate the assumed population survival rates of Radiation and Control groups respectively, 
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TABLE P A T E R S O N I I . Ovarian radiation and Control groups compared (10 years crude 
survival rate). Subdivision into Direct postoperative and Late Postoperative groups. 
II 
III 
IV 
ν 
VI 
Numbcn of paticoU included in PATERSON'S clinical trial 
Numbera of patients meeting requirements 
Therapies considered 
Numbers of patients per therapy group 
Results in percentages 
(10 years crude survival rate) 
Statistical significance (COLE) 
744 
100% 
Direct postoperative 
596 
8 0 . 2 % 
Late postoperative 
148 
1 9 . 8 % 
Age not considered 
Axillary involvement not considered 
Radiated 
293 
54 .9% 
Control 
303 
4 7 . 5 % 
ρ = 0.07 
Radiated 
76 
14.5% 
Control 
72 
16.7% 
ρ = 0.89 
(not recorded by Cole) 
Numbers of patients required according to our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplicationfactor 2 X 
8 0 . 2 % 
100 
2 χ 2.5 
80.2 
19.8% 
100 
2 X = 10.1 
19.8 
VII 
VIII 
IX 
VII 
Vil i 
IX 
VII 
Vili 
IX 
If a 1 0 % difference in population 
Values of Р д and P Q assumed 
(round result percentages) for entering table S | 
Number of S 
(cf. table S,) 
Numbers of patients required .QQ 
on the basis of our criteria X
m
 = S χ 2 x 
survival rate has to be detected 
PA = 5 0 % 
Pfl = 4 0 % 
642 
2.5 χ 642 - 1,600 ± 
P A = 1 0 % 
Pfl = 2 0 % 
323 
10.1 χ 323 - 3,000 ± 
If a 20% difference in population survival rate has to be detected 
Values of Р д and Рц assumed 
(round result percentages) for entering table Si 
Number of S 
(cf. table S,) 
Numbers of patients required 
on the basis of our criteria X
m
 = S X 2 X 
100 
P A = 6 0 % 
Pfl = 4 0 % 
161 
2.5 χ 161 = 400 ± 
P A = 1 0 % 
Pfl = 3 0 % 
98 
10.1 χ 98 = 1,000 ± 
If a 3 0 % dilTerencc in population 
Values of Р д and Ρβ assumed 
(round result percentages) for entering table Si 
Number of S 
(cf. table S,) 
Numbers of patients required JQQ 
on the basis of our criteria X
m
 = S X 2 X 
survival rate has to be detected 
— 
— 
-
PA = io% 
PB = 4 0 % 
50 
10.1 X 50 = 500 ± 
Р д and Рд indicate the assumed population survival rates of Radiation and Control groups respectively. 
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TABLE P A T E R S O N I I I . Ovarian radiation and Control groups compared ( 10years recurrence 
rate breast area and 10years manifestation of distant metastases). Only Direct postoperative 
patients considered. 
I 
II 
III 
IV 
V 
Numbers of patients included in PATERSON'S clinical trial 
Numbers of patients meeting requirements 
Therapies considered 
Numbers of patients per therapy group 
Results m percentages 
Statistical significance (COLE) 
744 
100% 
Direct 
Age not 
post-operative 
596 
80 2 % 
considered 
Axillary involvement not considered 
Radiated 
293 
Control 
303 
10 years recurrence rate 
breast area 
(including axillary and 
supraclavicular nodes) 
23 2 % 29 7 % 
ρ = 0 0 7 
Radiated 
293 
Control 
303 
Manifestation of 
distant metastases 
(10 years follow up) 
4 6 1 % 54 5 % 
ρ = 0 0 4 
Numbers of patienta required according to our entena 
Percentage of entire scries meeting the requirements 
100 
Multiplicationfactor 2 X 
F 
80 2 % 
100 
2 χ - - = 2 5 
80 2 
VII 
vin 
I X 
If a 1 0 % diflerence in population result rate has to be detected 
Values of Р д and Pjj assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table SO 
Numbers of patients required . - Q 
on the basis of our criteria Xm « S X 2 X -
- m
 F 
PA = 2 0 % 
PB - 3 0 % 
483 
2 5 χ 483 - 1,200 ± 
PA = « % 
PB - 5 0 % 
642 
2 5 χ 642 - 1,600 ± 
If a 20% difference in population result rate has to be detected 
VIII 
Values of P A and Pg assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required 
on the basis of our criteria X
m
 •• S X 2 X 
100 
"F 
P A - 2 0 % 
Р в - « % 
133 
2 5 χ 133 - 350 ± 
PA = «% 
Р в » 6 0 % 
161 
2.5 χ 161 - 400 ± 
Рд and P3 indicate the assumed population result percentages by Radiation and Control groups respectively. 
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TABLE P A T E R S O N IV. Ovarian radiation and Control groups compared (5years mortality). 
Subdivision according to age. 
Numbers of patients included in PATERSON'S clinical trial 
Numbers of patients meeting requirements 
Therapies considered 
Numbers of patients per therapy group 
Results in percentages (5 years mortality) 
Statistical significance (PA I LRbON) 
747 
100% 
Type of case not considered 
< 45 years 
444 
59 5 % 
45-54 years 
303 
40 5 % 
АкіІІагу involvement not considered 
Radiated 
226 
4 6 % 
Control 
218 
5 2 % 
ρ = 0 3 
Radiated 
143 
3 5 % 
Control 
160 
4 2 % 
ρ = 0 2 
Numbers of patients required according to our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplirationfactor 2 X 
59 5 % 
100 
2 χ - - - 3 4 
59 5 
4 0 5 % 
100 
2 X - - 4 9 
4 0 5 
If a 1 0 % difference in population mortality rale has to be detected 
Values of P A and Pg assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required JQQ 
on the basis of our criteria X
m
 = S χ 2 χ 
P/V - 4 0 % 
Pfi = 5 0 % 
642 
3 4 χ 642 - 2,200 ± 
P A = 3 0 % 
P B = 4 0 % 
589 
4 9 χ 589 = 2,900 ± 
If a 2 0 % difference in population mortality rate has to be detected 
Values of Р д and Pjj assumed 
(round result percentages) for entering table S | 
Number of S 
(cf table S|) 
Numbere of patients required JQQ 
on the basis of our criteria Xjn = S X 2 X 
PA = 4 0 % 
P B = 6 0 % 
161 
3 4 χ 161 - 550 ± 
P A = 3 0 % 
Pfl = 5 0 % 
154 
4 9 χ 154 - 750 ± 
Р д and Pg indicate the assumed population mortality rates of Radiation and Control groups respectively 
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TABLE PATERSON V. Ovarían radiation and Control groups compared (10 years crude 
survival rate). Only Direct postoperative patients considered. Subdivision according to axillary 
involvement. 
I l l 
I V 
V 
Numbers of patients included in P A T E R S O N ' S clinical trial 
Numbers of patients meeting requirements 
Therapies considered 
Numbers of patients per therapy group 
Results in percentages 
(10 years crude survival rate) 
Statistical significance (COLE) 
744 
100% 
Direct postoperative 
Age not considered 
Axilla not involved 
193 
32 4 % 
Radia ted 
90 
8 0 % 
Control 
103 
6 8 % 
ρ - 0.06 
Axilla involved 
403 
67 7 % 
Radiated 
203 
4 3 . 8 % 
Control 
200 
3 7 % 
ρ = 0 1 6 
VI 
Numbers of patients required according to our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplicationfactor 2 X — 
F 
32.4 
100 
2 x = 6 2 
32 4 
67 6 
100 
2 χ - -
67.6 
3.0 
VII 
Vil i 
I X 
VII 
Vili 
I X 
If a 1 0 % difference in population 
Values of Р д and Pjj assumed 
(round result percentages) for entering table S | 
Number of S 
(cf. table SO 
Numbers of patients required .QQ 
on the basis of our e n t e n a X
m
 = S X 2 X 
survival rate has to be detected 
P A - 8 0 % 
Pfl = 7 0 % 
483 
6 2 χ 483 = 3,000 ± 
P * = 4 0 % 
Pfl - 3 0 % 
589 
3.0 χ 589 = 1,800 ± 
If a 2 0 % différence in population survival rate has to be detected 
Values of Р д and Pjj assumed 
(round result percentages) for entering table Sj 
N u m b e r of S 
(cf table SO 
Numbers of patients required . « Q 
on the basis of our e n t e n a X
m
 = S x 2 x 
PA - 8 0 % 
Pfl = 6 0 % 
133 
6 2 X 133 - 800 ± 
PA = 5 0 % 
Pfl = 3 0 % 
154 
3.0 X 154 - 450 ± 
Р д a n d P g indicate the assumed population survival rates of Radiat ion and Control groups respectively. 
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In studying the results of Paterson's ovariectomy trial, it appears that reliable general 
conclusions can be drawn from the direct postoperative series (cf. Paterson's tables I 
and I I I ) . The reader will have noted that for this group, Paterson finds significant or 
nearly significant figures from his total of 744 patients, whereas the numbers calcu­
lated by us are higher (cf table V-1 ). 
TABLE V - l . 
Cntenon Difference 
in results 
Statistical X
m
 as calculated 
significance by us 
Crude survival rate 
cf. table Paterson II 
Recurrence rate breast area 
cf. table Paterson III 
Mamrestation of distant metastases 
cf. table Paterson III 
7.4% 
6 . 5 % 
8 . 4 % 
ρ = 0.07 
ρ = 0.07 
ρ = 0.04 
1600 
950 
1300 
Suppose the 5 year survival chances are P A = 4 0 % , Р в = 6 0 % . In this case, according 
to table Paterson I, we require 161 patients per treatment group to demonstrate this 
difference with 9 5 % probability. This means : in 9 5 % of the cases in which, with Р л = 
40%, Р в = 6 0 % we carry out a trial with 161 patients per treatment group, weshall 
find two percentages of survival, Рд and Рв which differ significantly according to the 
^
2
-test for a 2 X 2 table. In 5 % of the cases the values found for Рд and Рв will not 
differ significantly. This is due to the fact that Рд and Pu depend on chance; they may 
assume different values in the vicinity of survival probabilities Рд and Р в ; sometimes 
these values will not differ sufficiently to justify the conclusion that Рд < Рв-
Now suppose we take only 100 patients per treatment group, which according to our 
criterion is 'insufficient'. Nevertheless (according to table Al in the Appendix), there 
is still more than an 81 % probability that a significant result will be obtained, in other 
words, this is still quite possible. Calculation according to our criteria shows that with 
the patient material available, differences can be demonstrated between the irradiated 
and the control group of 2 0 % or more. This also applies when we classify according to 
age and to pathology of the axillary glands. It is regrettable that Paterson did not study 
a subdivision on the basis of a combination of these characteristics. When two charac­
teristics, either singly or in combination, exert a slight favorable effect on the prognosis, 
it is possible that this favorable influence will only manifest itself with significant 
figures when these characteristics are studied in combination. However, owing to the 
size of this series of Paterson, further subdivision leads to too small subgroups. If we 
suppose that in Paterson's patient material the occurrence of axillary involvement and 
the age are independent selection criteria, we can calculate the size of the smallest sub­
group formed by patients with the characteristics 'axilla not involved' and 'age 45-54 
years'. The frequencies of these characteristics are 40 .5% and 32.4% respectively (cf. 
Paterson IV and V). Accordingly we may estimate that a combination of these charac-
40.5 32.4 
teristics will occur in —— -^ . " = 13.1% of cases, or about 100 patients. With a 
subdivision into treatment groups of equal size, this would still make it possible to 
demonstrate a difference of 30 to 4 0 % between the chances of results (cf. table SI) . 
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In Ch. H I §3 p . 14, a possible difference in survival curves between two groups is 
considered. 
Cole (1968) describes such a phenomenon: 
'By the end of the 1st year 12.6 per cent of the irradiated group had developed signs 
of recurrence or metastases, while 24.4 per cent of the control group had evidence of 
disease. This difference is highly significant (p = 0.0002). 
Year by year the incidence of recurrence or metastases in the irradiated group is 
less than in the control group. It is interesting to note that by the end of 10 years 
47.4 per cent of the irradiated group showed evidence of active disease or had died 
while the comparable figure of 48.2 per cent was reached in the control group 6 years 
earlier, i.e. at the end of the 4th year. 
T h e cumulative incidence of recurrent disease in the group who had negative axillary 
nodes is given in table V-2. In the first year there is little difference between the irradi­
ated and the control groups (4.4 per cent compared with 6.8 per cent) but this is to be 
expected as all these patients had early disease when included in the trial. However, 
year by year through the table there is a postponement of the development of active 
disease in the irradiated group. By the end of the 7th year 21.1 per cent of the treated 
group had active disease, a figure similar to that already reached at the end of 3 years 
for the control group (21.4%). 
TABLE v-2. Relative incidence of recurrence of malignancy to 10th anniversary or to death 
within that period for group with negative axillary nodes. 
Number of cases Cumulative incidence % 
Years after treatment Irradiated Control 
Within 1 yr. 90 103 
„ 2 „ 
» 3 „ 
.. 4 „ 
„ 5 „ 
,. 7 .. 
„ 10 „ 
T h e results for the patients with positive axillary nodes are presented in table V-3, 
from which it is seen that at 1 year there is a highly significant difference between the 
recurrence rates in the irradiated and control groups (p = 0.00006). The same delay 
in the onset of active disease is seen year by year as in the previous tables. At 10 years 
57.6 per cent of the irradiated group had active disease, a figure comparable to that 
of 57 per cent for the control group, reached at the end of 3 years. 
TABLE v-3. Relative incidence of recurrence of malignancy to lOlh anniversary or to death within 
that period for group with positive axillary nodes. 
Irradiated 
4.4 
8.9 
14.4 
17.8 
16.7 
21.1 
24.4 
Control 
6.8 
14.6 
21.4 
25.2 
27.2 
33.0 
35.9 
Years afte 
Within 1 
„ 2 
.. 3 
„ 4 
„ 5 
., 7 
„ 10 
г treatment 
yr. 
„ 
„ 
f, 
Jt 
„ 
Jf 
Number of cases 
Irradiated Control 
203 200 
Cumulative 
Irradiated 
1Ü.3 
33.0 
41.9 
44.8 
50.7 
53.7 
57.6 
incidence % 
Control 
33.5 
51.0 
57.0 
60.0 
61.5 
63.0 
67.0 
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From these results it would appear that ovarian irradiation prolongs the time between 
the treatment of primary disease and the later development of recurrence' . 
§ 4. Paterson's Postoperative Radiotherapy Trial 
Paterson's second trial attempted to evaluate routine postoperative radiotherapy 
(1959b). 
The criteria for acceptance of patients into the trial were: 
1. Female patients with histologically verified mammary carcinoma. 
2. Under 70 years of age. 
3. All patients without exception had undergone a standard radical mastectomy of the 
Halsted type for stage I or stage II mammary carcinoma, with possibly a small 
minority of early stage I I I cases (Manchester staging). 
4. Having had no other treatment. 
5. Being clinically free of demonstrable residue or distant metastases. 
6. Having no evidence in the surgical description of the operation to suggest that the 
operation was thought to have been incomplete. 
7. Having no reason for the adoption of a 'watch' policy as a treatment of choice, for 
example on account of concomitant disease. 
Paterson compared prophylactic irradiation in one group shortly after operation 
with a careful watch policy in another group, with irradiation only on the first actual 
evidence of relapse. Two different but both radical X-ray techniques were used. One 
primarily involved irradiation of the breast flap and axilla (quadrate technique), and 
the other primarily involved irradiation of the axillary, supraclavicular and paraster-
nal lymph node drainage areas (peripheral technique). The study covered the period 
1949-1955 and included 709 patients treated and 752 watched. Paterson made a sub-
division of the series according to age and axillary involvement. As a measure of results 
of therapy the 7 years crude survival rate was used. 
I n a l O year analysis, Easson ( 1968) makes a division into stage I and stage I I cases in 
evaluating recurrence rates. Although Paterson, as in his ovariectomy trial, used a se-
lected group of patients, we for the sake of uniformity use the symbol X m (cf. Ch. V, p . 69). 
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TABLE P A T E R S O N VI. Treated and Watched groups compared (7years mortality rate and 
10years local recurrence rate). Technique not considered. No division into subgroups. 
Numbera of patients included in PATERSON'S clinical trial 
Postoperative radiotherapy 
Numbers of patients meeting 
requirements 
(Data on clinical 
classification not recorded 
by PATERSON) 
Therapies considered 
Numbers of patients per therapy group 
Results in percentages 
Statistical significance 
(not recorded by PATERSON and EASSON) 
X2 test : ρ value 
1,461 
1 0 0 % 
Technique not considered 
Age not considered 
Axillary involvement not considered 
Treated 
709 
Watched 
752 
7 vean mortality rate 
5 3 % 5 1 % 
ρ = 0.47 
Treated 
709 
Watched 
752 
10 years local recurrence rate 
19% 3 2 % 
Ρ < і ^ 
Numbers of patients required according to our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplicationfactor 2 X -
100% 
100 
2 χ — = 2.0 
100 
If a 1 0 % diflerence in population result rate has to be delected 
Values of Р д and Pg assumed 
(round result percentages) for entering table Si 
Number of S 
(cf. table SO 
Numbers of patients required .Q» 
on the basis of our criteria X
m
 ^ S X 2 x 
P A = 6 0 % 
PB = 5 0 % 
642 
2.0 χ 642 = 1,300 ± 
P A - 2 0 % 
PB = 3 0 % 
483 
2.0 X 483 = 950 ± 
Р д and PJJ indicate the assumed population mortality or local recurrence rates of Treated and Watched groups respectively. 
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TABLE P A T E R S O N V I I . Treated and Watched groups compared (10years local recurrence 
rate). Technique not considered. Subdivision into Stage I and Stage II cases. 
Numbers of patients included in PATERSON'S clinical trial 
Postoperative radiotherapy 
Numbers of patients meeting requirements 
Therapies considered 
Numbers οΓ patients per therapy group 
Results in percentages 
(10 years local recurrence rate) 
Statistical significance 
(not recorded by bASSON) 
X2 test ρ value 
1,461 
1 0 0 % 
Technique not considered 
Stage I 
527 
36 1 % 
Stage II 
934 
63 9 % 
Age not considered 
Axillary involvement not considered 
Treated Watched 
not recorded 
9 5 % 16 0 % 
ρ = 0 0 3 5 
Treated Watched 
not recorded 
25 0 % 41 5 % 
Ρ < 10-» 
Numbers of patients requirrd according to our criteria 
Percentage of entire series meeting the requirements 
100 
Mulliplicationfactor 2 X 
36 1% 
100 
2 x
- 3 6 , = 5 5 
63 9 % 
100 
2 X - = 3 1 
63 9 
If a 1 0 % difference in population local recurrence rate has to be detected 
Values of Р д and Pg assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required ,QQ 
on the basis of our entena X
m
 = S X 2 X — 
P A = io% 
PB = 2 0 % 
323 
5 5 χ 323 = 1,750 ± 
PA = 2 0 % 
PB = 3 0 % 
483 
3.1 X 483 = 1,500 ± 
If a 2 0 % difference in population local recurrence rate has to be detected 
Values of Р д and P g assumed 
(round result percentages) for entering table S | 
Number of S 
(cf table S,) 
Numbers of patients required .QQ 
on the basis of our entena X
m
 = S χ 2 χ -
PA = " 0 % 
Pfl - 3 0 % 
98 
5 5 χ 98 = 550 τ 
PA = 2 0 % 
Pfl = 4 0 % 
133 
3 1 χ 133 = 400 ± 
Р д and Pg indicate the assumed population local recurrence rates for Treated and Watched groups respectively. 
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TABLE P A T E R S O N V I I I . Treated and Watched groups compared (7years crude survival 
rate). Technique not considered. Subdivision according to age. 
Numbers of patients included in P A T T R S O V S clinical trial 
Postoperative radiotherapy 
Numbers of patients meeting (Data on clinical 
requirements classification are not 
recorded by ΡΑΊ LRSON) 
Therapies considered 
Numbers of patients per therapy group 
Results in percent ages 
(7 years crude survival rate) 
Statistical significance 
(not recorded by PA Π RSON) 
X 2 test ρ value (therapy groups assumed to be equal) 
1,461 
100% 
Technique not considered 
< 50 years 
623 
42 7 % 
> 50 yean 
838 
57 3 % 
Axillary involvement not considered 
Treated 
Not recorded 
54 0 % 
Watched 
Not recorded 
45 0 % 
ρ = 0 03 
Treated 
Not recorded 
53 0 % 
Watched 
Not recorded 
55 0 % 
ρ = 0 6 4 
Numbers of patients required according lo our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplicattonfactor 2 χ - — 
42 7 % 
100 
2 X - = 4 7 
42 7 
57 3 % 
100 
2 χ = 3 5 
57 3 
If a 1 0 % diíTerence in population survival rate has to be detected 
Values of P A and Ρβ assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required .QQ 
on the basis of our criteria X
m
 = S X 2 X — 
PA = 5 0 % 
PB - 4 0 % 
642 
4 7 χ 642 = 3,000 ± 
PA = 5 0 % 
Pu 6 0 % 
642 
3 5 χ 642 = 2,200 ± 
If a 2 0 % dilTerencc in population survival rate has to be detected 
Values of Р д and Pg assumed 
round result percentages) for entering table Sj 
Number of S 
cf table Si) 
Numbers of patients required .QQ 
on the basis of our criteria Х
т
 = S X 2 X 
P A - 6 0 % 
PB = 4 0 % 
161 
4 7 χ 161 = 750 ± 
PA = 5 0 % 
Рв - Ό % 
154 
3 5 X 154 - 550 ± 
Р д and Pjj indicate the assumed population survival rales of Treated and Watched groups respectively 
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TABLE P A T E R S O N I X . Radiation (Quadrate technique) and Control groups compared 
(7years crude survival rate) Subdivision according to axillary involvement. 
Numbers of patients included in P A T E R S O N ' S clinical trial 
Postoperative radiotherapy 
Λ Quadrate technique 
В Peripheral technique 
Numbers of patients meeting 
requirements 
(Data on clinical 
classification are not 
recorded by P A T T R S O N ) 
Therapies considered 
Numbers of patients per therapy grour 
Results in percentages 
(7 years crude survival rate) 
Statistical significance 
(not recorded by P A T T R S O N ) 
χ
2
 test ρ value 
1,461 
100% 
Quadrate technique 
720 
49 3 % 
Age not considered 
Axilla not involved 
247 
1 6 8 % 
Treated 
105 
36 2 % 
Watched 
142 
27 3 % 
ρ = 0 1 9 
Axilla involved 
473 
32 4 % 
Treated 
222 
63 5 % 
Watched 
251 
65 5 % 
ρ = 0 7 3 
Numbers of patients required according to our criteria 
Percentage of entire series meeting the requirements 
100 
Multiplicationlaetor 2 ж 
1 6 8 % 
100 
2 X - 119 
16 8 
32 4 % 
100 
2 χ = 6 2 
32 4 
If a 10% difference in population survival rate has to be detected 
Values of Р д and P R assumed 
(round result percentages) for entering table Sj 
Number of S 
(сГ table SO 
Numbera of patients required JQQ 
on the basis of our criteria X
m
 =• S X 2 x 
P л зо% 
Р в = 2 0 % 
48J 
119 χ 483 = 5,700 i 
l'A - ' 0 % 
Ρ β = 6 0 % 
589 
6 2 χ 589 = 3,600 ί 
If a 2 0 % diflerence in population survival rate has to be detected 
Values of Р д and Ρ β assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required ,Λ« 
on the basis of our criteria X
m
 = S X 2 X -
HA - «% 
Ρ β = 2 0 % 
133 
11 9 X 133 = 1,600 1 
PA = 7 0 % 
Ρ β - 5 0 % 
154 
6 2 χ 154 - 950 ± 
Р д and Ρ β indicate the assumed population survival rates of Treated and Watched groups respectively 
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TABLE P A T E R S O N X. Radiated (Peripheral technique) and Control groups compared 
(7years crude survival rate). Subdivision according to axillary involvement. 
Numben of patients included in PATERSON'S clinical tnal 
Postoperative radiotherapy 
A. Quadrate technique 
В Peripheral technique 
Number· of patient· meeting 
requirements 
(Data on clinical 
classification are not 
recorded by PATERSON) 
Therapies considered 
N u m b e n of patients per therapy group 
Results in percentages 
(7 yeara crude survival rate) 
Statistical significance 
(not recorded by PATERSON) 
χ
2
 test ρ value 
1,461 
100% 
Peripheral technique 
741 
50 7 % 
Age not considered 
Axilla not involved 
281 
19 2 % 
Treated 
139 
37 0 % 
Watched 
142 
36 0 % 
ρ - 1 0 
Axilla involved 
460 
3 1 5 % 
Treated 
243 
58 0 % 
Watched 
217 
56 0 % 
ρ = 0 6 9 
Numben of patients required according to our criteria 
Percentage of entire senes meeting the requirements 
100 
Multiphcationfactor 2 χ 
1 9 2 % 
100 
2
 x -т^; - 1 0 4 
19 2 
3 1 5 % 
100 
2 χ = 6 3 
31 5 
If a 10% difference m population survival rate has to be detected 
Values of P A anf Рд assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required «QQ 
on the basis of our entena X
m
 - S χ 2 χ — 
PA = « κ 
Рв - зо% 
589 
10 4 χ 589 = 6,000 ± 
ΡΑ = 6 0 % 
PB - 5 0 % 
642 
6 3 χ 642 - 4,000 ± 
If a 20% difference in population survival rate has to be detected 
Values of Р д and Ρβ assumed 
(round result percentage*) for entering table Si 
Number of S 
(cf table S,) 
Numben of patients required JQQ 
on the basis of our entena X
m
 » S X 2 X 
F 
PA - 5 0 % 
Рв = зо% 
154 
10 4 χ 154 = 1,600 ± 
P A = 6 0 % 
PB = 4 0 % 
161 
6 3 χ 161 - 1,000 ± 
Ρ A and Рд indicate the assumed population survival rates of Treated and Watched groups respectively. 
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According to our criteria, the number of patients in Paterson's postoperative irra­
diation trial would be sufficient to demonstrate a possible difference of 10% between 
the population result rates P A and Р в with a probability of 95 % (cf. table Paterson 
VI) if no subdivisions were made according to selection criteria (age, stage of pathol­
ogy of the axillary glands). 
If a subdivision is made on the basis of one of these criteria, it will in general only be 
possible to demonstrate differences of the order of 20 % between P A and Р в with a 
probability of 9 5 % . As noted in connection with Paterson's ovariectomy trial, one 
might consider organizing a trial with subgroups corresponding to a combination of 
two or more of the selection criteria. For instance, if Paterson had combined the criteria 
age < 50 years (42.7% cf. table Paterson V I I I ) and 'axilla not involved' (19.2% cf. 
table Paterson X) into one subgroup, and these selection criteria had been regarded 
42.7 19.2 
as independent of one another, it may be estimated that o n l y — — X = 8 . 2 % 
of the patient material would have fulfilled the conditions. This amounts to about 100 
patients. With a subdivision into treatment groups of equal size, this would still have 
permitted demonstration of a difference of 30 to 4 0 % between the population result 
rates. Paterson's trial (cf. table Paterson VI) clearly shows how, when two methods of 
treatment are compared, no difference may be found for one criterion, while there is a 
difference for a different criterion. While the 7 year mortality rates of the treated and 
watched groups amount to 5 3 % and 51 % respectively (the 10 year mortality rate in 
the two groups together is 5 5 % ) , we find there is a significant difference in the 10 year 
local recurrence rates (19.0% and 32.0% respectively). 
We can also see from Paterson's table VI that the numbers of patients required for the 
various success criteria differ, because the value of S is influenced by the percentage of 
results ('7 years mortality ra te ' : 1300 ± patients. '10 years local recurrence r a t e ' : 
950 i patients). In this trial, significant differences continue to occur even after sub­
division into stages I and I I . According to our criteria, there were almost enough 
patients to demonstrate a difference of 10% in result with a probability of 9 5 % , and 
ample to demonstrate a difference of 20%. If in this trial the factor 'curative opera-
bility' is taken into account, a slight decrease in X
m
 results. 
If in this trial the factor 'curative operability' is taken into account a considerable 
decrease in X
m
 is possible. 
Paterson's data showed that the 3 year mortality was about 3 0 % . If in the final 
analysis this group would be excluded from the trial, only 70 out of every 100 patients 
remain for investigation. We considered the case P A = 6 0 % and Р в = 5 0 % , 7 year 
population mortality rate; therefore the value of S is S = 642 and X
m
 is 2 X 642, or 
about 1300. 
If the 3 year mortality is the same in both therapygroups, the mortality between 
3 and 7 years was 3 0 % and 2 0 % respectively, with respect to number of operable 
0.3 0.2 
patients -jr-=- — 42 .9% and ——— = 28.6%. T h e number S for the operable patients 
according to formula (2) of the Appendix now is equal to 290. And thus Xm = 2 X 
Д52. χ 290 = 830 ±. 
70 
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This is a reduction of about 6 5 % with respect to the number X m = 1300 required 
if the inoperable patients are not excluded. 
§ 5. Nissen-Meyer's Ovariectomy Trial 
Nissen-Meyer (1965; 1968) describes his trial as follows: 
'Between 22nd November 1957 and 31st December 1963, 932 women under the age 
of 70 years were admitted as in-patients for the initial treatment of histologically proved 
operable cancer of the breast. Following histological examination of the axillary nodes, 
455 patients were classified as stage 1 and 447 as stage 2. The histology of the axillary 
nodes was not known in thirty patients, who were classified as stage 1 or 2. 
All patients were included in a prospective study of 'prophylactic' versus ' thera-
peutic' castration. Six hundred and sixty-four had suppression of ovarian function (74 
by surgical oophorectomy, 590 by ovarian irradiation) as part of the primary treat-
ment. The remaining 268 cases did not have immediate castration, but it was planned 
that this should be performed as soon as recurrence was diagnosed. All other forms of 
therapy were kept as standardized as possible. Inclusion in a controlled clinical trial 
with random allocation was considered ethically justified in 448 of these patients. Full 
details of the methods of allocation to different groups, treatment, and analysis of 
results have been given previously (Nissen-Meyer, 1965). 
In this paper an attempt has been made to ascertain whether castration performed 
as an adjuvant to radical mastectomy, ( 1 ) increases the symptom-free interval in those 
patients destined to develop recurrence, (2) prolongs survival to a greater extent than 
if postponed until recurrence occurs, (3) is beneficial to postmenopausal patients, and 
(4) gives equal results when performed surgically or by radiation.' 
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TABLE N I S S E N - M E Y E R I. (according to original subdivision of series, but not used by 
NISSEN-MEYER in his trial). 
Ovariectomy and Control groups compared (3 yr. and 5 yr. crude survival rates). Only pre­
menopausal patients considered. 
Subdivision into subgroups according to age, clinical stage, malignancy grade and localization 
of tumor. 
Number» of patienta available in 1,442 
NISSEN-MEYER'S study 100% 
N u m b e n of pauents meeting 
requirementa 
Included only 
stages I and II 
under 70 
Premenopausal 
Clinical stage 
Malignancy 
grade 
(histologically) 
Localization 
Therapies considered 
Numben of patients per therapy group 
Yean' follow up 
Results in percentages 
(crude survival rate) 
Statistical significance 
(not recorded by NISSEN-MEYER) 
χ » test : ρ value 
902 
62 4 % 
418 
29 2 % 
I 
217 
15 3 % 
I + II 
141 
9 7 % 
Lateral 
BO 
5 6 % 
Cas­
tra­
tion 
42 
Con­
trol 
38 
5 
92 3 
% 
94.6 
% 
ρ = 1 0 
Medial 
61 
4 2 % 
Cas­
tra­
tion 
29 
Con­
trol 
32 
3 
82 8 
% 
9 6 5 
% 
ρ = 0 1 1 
II 
201 
13 9 % 
III + IV 
76 
5 3 % 
-
Cas­
tra­
tion 
Con­
trol 
41 35 
5 
36.0 
% 
100 0 
% 
ρ = 0 0 3 
I + I I 
45 
3 1% 
-
Cas­
tra­
tion 
39 
Con­
trol 
6 
5 
85 4 
% 
-
-
III + IV 
15 
10 8 % 
Cas­
tra­
tion 
154 
Con­
trol 
2 
5 
68 1 
% 
-
-
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Numbers of patients required according to our entena 
Percentage of entire series meeting the 
requirements 
100 
Multiplicationfactor 2 X -
5 6 % 
100 
2 χ — — 
5 6 
- 35 7 
4 2 % 
100 
2 χ — -
4 2 
- 4 7 6 
5 3 % 
100 
2 X = 
5 3 
- 37 7 
If a 1 0 % difference in population survival rate has to be detected 
Values of Р д and Рц assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table SO 
Numbers of patients required 
on the basis of our criteria JQQ 
Xm = S x 2 x — 
P A - 9 0 % 
P B = 100% 
63 
35 7 X 63 -
= 2,250 ± 
PA - 8 0 % 
PB = 9 0 % 
323 
47 6 X 323 = 
= 15,500 ± 
PA - 9 0 % 
P B = 100% 
63 
37 7 X 63 = 
= 2,350 ± 
If a 2 0 % difference in population survival rate has to be detected 
Values of Р д and Рц assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table SO 
Numbers of patients required 
on the basis of our criteria ілл 
X
m
- S x 2 x
 F 
PA = 8 0 % 
Pfl = 100% 
31 
35 7 χ 31 -
= 1,100 ± 
PA = 8 0 % 
Pfi - ioo% 
31 
47 6 X 31 = 
- 1,500 ± 
PA = 8 0 % 
PB = ioo% 
31 
37 7 X 31 = 
= 1,150 ± 
If a 3 0 % difference in population survival rate has to be detected 
Values of Р д and Рц assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table SO 
Numbers of patients required 
on the basis of our entena .до 
X
m
 = S x 2 x T 
_ 
-
-
P A = 7 0 % 
Pfl = 100% 
20 
47 6 χ 20 -
- 950 ± 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
_ 
-
-
Рд and PQ indicate the assumed population survival rates of Castration and Control groups respectively 
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TABLE NISSEN-MEYER II (according to original subdivision of series, but not used by 
NISSEN-MEYER in his trial). 
Ovariectomy and Control groups compared (3yr. and 5yr. crude survival rate). Only postmeno­
pausal patients considered. 
Subdivision into subgroups according to age, clinical stage, malignancy grade and localization of 
tumor. 
Numbers of patients available for 1,442 
NISSEN-MEYER'S study 100% 
Numbers of patients meeting 
requirements 
Included only 
stages I and II 
under 70 
Postmeno­
pausal 
CI ілісаі stage 
Malignancy 
grade 
(histologically) 
Localization 
Therapies considered 
Numbers of patients per therapy group 
Years' follow'up 
Results in percentages 
(crude survival rate) 
Statistical significance 
(not recorded by NISSEN-MEYER) 
χ
2
 test : ρ value 
902 
6 2 . 4 % 
484 
33.6% 
I II 
238 246 
16.5% 17.1% 
i+ii ш ι iv i+ii iii+iv 
141 97 49 197 
9.8% 6 7 % 3 4 % 13.7% 
Lateral 
74 
5 . 1 % 
Cas­
tra­
tion 
53 
Con­
trol 
21 
4 
92.4 
% 
77.0 
ρ - 0.13 
Medial 
67 
4 .6% 
Cas­
tra­
tion 
47 
Con­
trol 
20 
4 
9 4 0 
% 
79.1 
% 
ρ = 0.21 
-
Cas­
tra­
tion 
68 
Con­
trol 
29 
5 
87 4 
% 
80 6 
% 
ρ = 0.10 
-
Cas­
tra­
tion 
34 
Con­
trol 
15 
2 
79.7 
% 
71.8 
ρ = 0.72 
-
Cas­
tra­
tion 
140 
Con­
trol 
57 
6 
51.4 
% 
4 0 8 
% 
ρ - 0.21 
88 
Numbcn of patients required according to our entena 
VI 
Percentage of enure велся meeting the 
requi remenu 
Multiplication factor JQQ 
2 x T 
5 1% 
100 
2 χ = 
5 1 
- 39 2 
• 6 % 
100 
2 X 
4 6 
- 43 5 
6 7 % 
100 
2 χ 
6.7 
- 29 9 
3 4 % 
100 
2
* 3 4 -
- see 
13 7 % 
100 
2 χ « 
13 7 
- 14 6 
If a 1 0 % difference in population survival rate has to be detected 
Values of Р д and Pg assumed 
V I 1
 (round remit percentages) for entering table Si 
Number of S 
І П
 (cf table SO 
Numbers of patients required 
¡ χ on the basis of our entena JQQ 
Xm - S x 2 χ - -
PA - 9 0 % 
Pfl = 8 0 % 
323 
39 2 χ 323 -
= 12,500 ± 
PA - 9 0 % 
Pfl - 8 0 % 
323 
43 5 χ 323 -
- 14,000 ± 
PA - 9 0 % 
Pfl - 8 0 % 
323 
29 9 χ 323 -
- 9,500 ± 
PA - 8 0 % 
Pfl " 7 0 % 
483 
58 8 χ 483 = 
- 28,500 ± 
PA = 5 0 % 
Pfl - « % 
642 
14 6 χ 642 -
= 9,500 ± 
If a 20 % dtflerence in population survival rate hai to be detect« 
Value« of P A and Pg ajsumed 
^
1
 (round result percentages) for entering table Si 
Number of S 
V " 1 (cf table S,) 
Numbers of patients required 
¡ χ on the basis of our criteria JQQ 
X
m
 - S χ 2 χ — 
PA - 9 0 % 
Pfl - 7 0 % 
98 
39 2 χ 98 -
- 3,800 ± 
PA = 9 0 % 
Pfl - 7 0 % 
98 
43 5 X 98 -
- 4,300 ± 
P A - 9 0 % 
Pfl - 7 0 % 
98 
29 9 X 98 -
- 2.900 ± 
•d 
PA = 8 0 % 
Pfl " 6 0 % 
133 
58 8 X 133 -
= 7,800 ± 
PA = 60% 
Pß - « % 
161 
146 χ 161 -
- 2,350 ± 
If a 30 % diflerence ш population survival rate has to be detected 
VII 
VIII 
Values of Р д and Гц assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required 
on the basis of our entena , QQ 
Xo, - S χ 2 χ - -
PA = 9 0 % 
Pß - 6 0 % 
50 
39 2 χ 50 -
- 1,950 ± 
PA - 9 0 % 
Pfl = 6 0 % 
50 
43 5 χ 50 = 
- 2,200 ± 
PA - 9 0 % 
Pfl - 6 0 % 
50 
29 9 χ 50 -
. 1,500 ± 
PA = 9 0 % 
Рв - 6 0 % 
50 
5 8 8 χ 50 -
- 3,000 ± 
P A - 6 0 % 
Pfl - 3 0 % 
70 
14.6 χ 70 -
= 1,000 ± 
If a 4 0 % difference in population survival rate has to be detected 
Values of Р д and Pg assumed 
Number of S 
V m
 (cf tab les, ) 
Numben of pauents required 
I X on the basis of our entena JQQ 
X
m
 - S χ 2 χ - F 
PA - 9 0 % 
Pfl - 5 0 % 
31 
39 3 χ 31 -
= 1,200 ± 
PA - 9 0 % 
Pfl - 5 0 % 
31 
43 5 χ 31 -
- 1.300 ± 
-
-
-
PA - 9 0 % 
Pß - 50% 
31 
5 8 8 X 31 -
- 1,750 ± 
_ 
-
-
Рд and Pß indicate the assumed population survival rata of Castration and Control groups respectively. 
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TABLE NISSEN M E Y E R I I I . Ovariectomy and Control groups compared in premenopausal 
patients (8 years % free from disease and % crude survival) in stage I cases. 
Surgical and Radiological ovariectomy groups compared ( 7years % free of disease and 8years % 
crude survival) in stage H cases. No further division into subgroups. 
Numbers of patients available for 
NISSEN-MEYER'S study 
Numbers of patients meeting requirements 
Including only stages I and II under 70 
Premenopausal 
Included in clinical trial according to prognostic signs 
and ethically acceptable 
Therapies considered 
Numbers of patients per therapy group 
Years* follow up 
Results in percentages 
(taken from MSSEN-MEYER'S graphs) 
Statistical significance 
(not recorded by NISSCN-MbYtR) 
χ
2
 test ρ value 
1.442 
100% 
902 
6 2 . 4 % 
418 
2 9 2 % 
Stage I 
161 
11.2% 
Castration and Control 
Allocated at random 
8 
% free from 
disease 
Cas­
tra­
tion 
8 0 % 
± 
Con­
trol 
9 0 % 
± 
ρ = 0.12 
8 
% crude 
survival 
Cas­
tra­
tion 
8 0 % 
i 
Con­
trol 
9 0 % 
± 
ρ - 0.12 
Stage II 
112 
7 8 % 
Surgical and Radiological 
castration 
Allocated at random 
7 
% free from 
disease 
Sur­
gical 
cas­
tra­
tion 
5 0 % 
± 
Radio­
logical 
cas­
tra­
tion 
6 0 % 
Í 
ρ = 0.34 
8 
% crude 
survival 
Sur­
gical 
cas­
tra­
tion 
5 0 % 
± 
Radio­
logical 
cas­
tra­
tion 
5 0 % 
± 
Ρ = ι 
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Numbers of patients required according to our entena 
Percentage of entire series meeting the requirements 
100 
Mulliplicalionfactor 2 χ 
1 1 2 % 
100 
2 x 179 
1 1 2 
7 8 % 
100 
If a 1 0 % difference in population result rate has to be detected 
Values of P A a n d Ρβ assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table Si) 
Numbers of patients required .QQ 
on the basis of our entena X
m
 - S χ 2 X 
ΡΑ = 8 0 % 
PB = 9 0 % 
323 
17 9 χ 3 2 3 -
= 5,800 ± 
PA - β ο % 
PB -90% 
323 
17 9 χ 323 = 
= 5,800 ± 
PA - 5 0 % 
P B = 6 0 % 
642 
25 6 χ 642 = 
- 16,500 ± 
PA - 5 0 % 
P B = 6 0 % 
642 
25 6 χ 642 -
= 16,500 ± 
If a 2 0 % difference ία population TTSUU rate has to be detected 
Values of Р д and Pjj assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table Si) 
Numbers of patients required . Q -
on the basis of our entena X
m
 — S X 2 x -
PA = 7 0 % 
Pfl - 9 0 % 
98 
17 9 χ 98 = 
= 1,750 ± 
PA = 7 0 % 
PB = 9 0 % 
98 
17 9 χ 98 = 
- 1,750 ± 
PA = « % 
PB = 6 0 % 
161 
25 6 χ 161 -
- 4 , 0 0 0 ± 
P A = « 0 % 
PB - 6 0 % 
161 
25 6 χ 161 -
- 4 , 0 0 0 ± 
If a 3 0 % diiTerencc in population result rate has to be detected 
Values of V\ and Pg assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required
 | ( ) 0 
on the basis of our criteria X,,! = S χ 2 X — 
Ρ Α = 6 0 % 
PB = 9 0 % 
50 
17 9 χ 50 -
= 9 0 0 ± 
PA = 6 0 % 
PB - 9 0 % 
50 
17 9 X 50 = 
- 9 0 0 ± 
PA = « % 
P B - 7 0 % 
70 
25 6 χ 70 = 
= 1,800 ± 
PA - «·/. 
PB - 7 0 % 
70 
25 6 χ 70 » 
- 1,800 ± 
In stage I cases, Р д and Pj} indicate assumed population " % free from disease" and " % crude survival" Primary 
castration and Control groups respectively, and m stage II cases Surgical castration and Radiological castration groupi 
respectively. 
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TABLE NISSEN-MEYER IV. Ovariectomy and Control groups compared in postmenopausal 
patients. (7 or 8years % fiee from disease and 8years % crude survival rates). 
Subdivision into stage I and stage II cases. 
Numbere of patients available for 
NISSEN-MEYER'S study 
Numben of patients meeting requirements 
Including only stages I and II under 70 
Postmenopausal 
Clinical stage 
Included in clinical trial 
Therapies considered 
Numben of patients per therapy group 
Years' follow up 
Results m percentages (from NISSEN-MbYER'S graphs) 
Statistical significance 
(not recorded by NISSbN-MbYER) · 
χ 2 test ρ value 
1,442 
100% 
902 
62 4 % 
484 
33 6 % 
I 
238 
16 5 % 
80 
5 6 % 
Castration and Control 
Allocated at random 
θ 
% free from 
disease 
Cas­
tra­
tion 
7 5 % 
± 
Con­
trol 
6 5 % 
± 
ρ = 0 4 6 
В 
% crude 
survival 
Cas­
tra­
tion 
7 0 % 
± 
Con­
trol 
7 5 % 
± 
ρ = 0 8 0 
II 
246 
17 1% 
95 
6 6 % 
Castration and Control 
Allocated at random 
7 
% free from 
disease 
Cas­
tra­
tion 
4 0 % 
± 
Con­
trol 
2 0 % 
± 
ρ - 0 0 6 
В 
% crude 
survival 
Cas­
tra­
tion 
4 0 % 
± 
Con­
trol 
3 0 % 
± 
ρ = 0 3 5 
'Nissen-Meyer notes that the differences had reached statistical ngnificance 4 yean after commencement of study. 
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Numbers of patients required according to our entena 
Percentage of entire series meeting the requirements 
Multiphcationfactor ,QQ 
2
*Ύ 
5 6 % 
100 
2 X - 35 7 
5 6 
6 6 % 
100 
2 x = 3 0 3 
6 6 
If a 10% difference ш population result rate has to be detected 
Values of F A and Рц assumed 
(round result percentages) for entering table Si 
Number of S 
(сГ table S,) 
Numbers of patients required ,QQ 
on the basis of our criteria X
m
 — S χ 2 χ 
ΡΑ - 8 0 % 
PB = 7 0 % 
483 
35 7 χ 483 = 
= 17,000 ± 
Ρ Α - Ό % 
Ρβ - 8 0 % 
483 
35 7 χ 483 = 
- 17,000 ± 
ΡΑ - 30%Ί 
Ρ β - 2 0 % 
483 
30 3 χ 483 -
= 14,500 ± 
ΡΑ = « % 
Ρ Β = 3 0 % 
483 
30 3 χ 483 -
- 14,500 ± 
If a 20% difference ш population result rete has to be detected 
Values of Р д and Pjj assumed 
(round result percentages) for entering table Si 
Number of S 
(cf table S,) 
Numbers of patients required IQQ 
on the basis of our criteria X
m
 = S X 2 X 
PA - eo% 
Ρβ = 6 0 % 
133 
35 7 χ 1 3 3 -
- 4,800 ± 
P A = 6 0 % 
Pfl - 8 0 % 
133 
35 7 X 133 = 
= 4,800 ± 
P A - « % 
Pfl - 2 0 % 
133 
30 3 χ 133 -
- 4,000 ± 
P A - « % 
Ρβ = 2 0 % 
133 
30 3 χ 133 -
= 4,000 ± 
If a 30% difference in population result rate has tp be detected 
Values of Р д and Pjj assumed 
(round result percentages) for entenng table Si 
Number of S 
(cf table SO 
Numbers of patients required ,«« 
on the basis of our entena X
m
 = S χ 2 χ 
PA = 9 0 % 
Рв - 6 0 % 
50 
35 7 χ 50 = 
- 1,800 ± 
P A = 6 0 % 
Ρβ - 9 0 % 
50 
35 7 χ 50 = 
- 1,800 ± 
Р д = « % 
Ρ β - ' 0 % 
50 
30 3 χ 50 = 
= 1,500 ± 
ΡΑ = 4 0 % 
Ρβ - 1 0 % 
50 
30 3 χ 50 -
- 1,500 ± 
Рд and Ρβ indicate the assumed (»pulation " % free from disease" and "% crude survival" of Primary castration and 
Control groupa respectively 
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Nissen-Meyer's material consisted of 1,442 women admitted for primary treatment 
of histologically verified carcinoma of the breast between 1957 and 1963. 
The design of Nissen-Meyer's clinical trial is a good example of the consequences of 
variegated division into subgroups according to prognostic factors (cf. tables Nissen-
Meyer l a n d I I ) . 
In our tables we followed the subdivision suggested by Nissen-Meyer and 
computed the numbers of patients required on the basis of our criteria. 
Since according to the author 902 patients could be regarded as suitable for inclusion 
in the trial on clinical grounds, and since he gives the division into subgroups of these 
902 patients, we started our approximation with this number and calculated the 
percentage difference between castration and control groups that might be demon-
strated by the Nissen-Meyer patient material (cf. tables Nissen-Meyer I and II) if all 
subgroups were considered separately. These examples have been worked out primar-
ily to demonstrate the effects of subdivision carried to great lengths on the total num-
ber of patients required. 
However, since Nissen-Meyer applied radical pre-selection on ethical grounds, the 
number of patients actually included in the trial was much smaller, and the sub-
division based on prognostic factors was not carried out completely. This raises the 
question of the extent to which this intensive pre-selection affected the composition 
of the material, and even whether one is justified in calling this experiment a clinical 
trial at all (cf. Moeys' trial, Ch. I I § 2). 
In the premenopausal group, only 161 patients in stage I were randomly divided into 
a primary castration group and a control group. 112 premenopausal stage I I patients 
were all subjected to primary castration and were divided at random into two groups 
in order to compare surgical and radiological ovariectomy (cf. table Nissen-Meyer 
I I I ) . In the postmenopausal group, 80 patients in stage I and 95 stage II cases were 
divided at random into a primary castration group and a control group (cf. table 
Nissen-Meyer IV) . 
As can be concluded from Nissen-Meyer's tables, his division into subgroups, however 
interesting in itself, produces so much fragmentation of the material that the numbers 
of patients per subgroup only would permit investigation on the basis of a difference 
of 4 0 % in result rate between the two therapy groups. 
If in this design of Nissen-Meyer's, every subgroup would have to be checked 
separately for the difference between radiological and surgical ovariectomy, every 
castration group would have to be subdivided again into two equal therapy groups, 
and X m would have to be multiplied by a factor of 2. It is doubtful whether such an 
extensive trial would be worth while for mammary carcinoma, a condition in which no 
great differences in result are to be expected. It is possible, however, that a selection 
carried to greater lengths might in itself yield certain data, for instance if it appeared 
that in one particular subgroup the treatment administered gave a particularly good 
result. However, the planning of such a trial would give rise to considerable organi-
zatory problems in view of the large number of patients required. Cooperation be-
tween numerous centers would then be necessary. 
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As regards the trial actually conducted by Nissen-Meyer (cf. tables Nissen-Meyer I I I 
and IV) , we see that the series was nearly large enough to demonstrate a difference of 
2 0 % in population result rates in the pre-menopausal group. The post-menopausal 
group contained a sufficient number of patients to demonstrate a difference of 3 0 % in 
population result rates. A publication by Nissen-Meyer (1968) shows that he found a 
significant difference between the two therapies after a follow up of 4 years. He also 
found significant differences in the 2nd and 3rd years of follow up of postmenopausal 
patients in stage I I I cases for the criterion ' % free of disease'. For the criterion ' % 
crude survival' he found significant differences in stage I cases in the 2nd year and in 
stage I I cases in the 1st year. If only one significant difference is found for a single 
criterion, not too much significance should be attached to such an isolated event. 
It is of course true that an occasional significant difference may still be encountered 
when the methods of treatment are actually equivalent (this probability is less than 
the level of significance, in our case 5%) . 
Matters are different when, as Nissen-Meyer reports in postmenopausal patients 
over 60 years of age for criterion ' % free of disease', differences of the order of 2 0 % 
are encountered in the 1st, 2nd, 3rd and 6th years of follow up. 
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SUMMARY AND CONCLUSIONS 
Chapter I discusses the importance of controlled clinical trials in establishing the treat-
ment that produces the best results in mammary carcinoma. 
From the data at present available concerning the course and treatment of mamma-
ry carcinoma, it is not possible to indicate with any certainty what treatment would 
be best for a given patient with a given mammary carcinoma. 
In our opinion the results so far obtained in retrospective studies of the results of 
various treatments include too many uncertainties to provide valid clinical guide-
lines, and our own series of 1500 patients with malignant disease of the breast illus-
trates this. 
Our findings make clear that the mere preparation of a large and well documented 
series of patients is no guarantee that valid conclusions can be drawn from it. Neither 
will the inclusion of new groups of patients in the series solve the problem, for each 
subsequent group of patients has its own uncertainties, so that including new groups 
of patients in the material only adds new uncertainties. Investigations to solve this 
problem are an urgent necessity, and controlled clinical trials seem to be the only 
method for such investigations. 
A controlled clinical trial is an investigation in which two or more methods of 
treatment for a well defined disease are compared on similarly composed groups of 
patients. The trial should aim at answering a definite question, and meet the require-
ments of sound statistical analysis. The design of such trials will have to be similar to 
that of a laboratory experiment. 
Both during discussions in the Committee on the Treatment of Mammary Carci-
noma in The Netherlands, and while considering our own findings, we came to the 
conclusion that it is important to establish the number of patients required for a clinical 
trial. 
In Chapter II a survey is given of our material and of the manner in which it was 
recorded and processed, while the problems encountered in statistical analysis are 
discussed. 
The uncertainties caused by the introduction of possibly false data, and the possi-
bility of selection caused by the inclusion or exclusion of not entirely exact recorded 
data is considered. 
It appeared that our series of 1500 patients with mammary tumors could not be 
used in obtaining statistically reliable conclusions as to the value of different methods 
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of treatment, at which we had originally aimed, but however it appeared to be useful 
in estimating the number of patients required for a clinical trial. 
Chapter H I describes our approach in estimating the number of patients required 
for a clinical trial. 
By using this approach it will be possible to compute : 
X
c
t : T h e number of patients actually included in the trial, and 
X
m
: T h e total number of patients with mammary carcinoma that must be available 
if the trial is to be possible. 
Xp : The number of members of general female population required for it. 
From these figures an investigator can also decide the possibilities of designing a 
clinical trial with a given series of patients. Some statistical tests are described. For 
a more detailed discussion of these tests the reader is referred to Part VI of the Appen­
dix. Since the χ2 test is generally used in trials concerning mammary carcinoma, we 
also used this test in our study. The examples worked out are based on the assumption 
that differences in result rates between two thereapies of 10 % , or multiples thereof, had 
to be detected, and for this purpose, table SI has been used. 
Problems concerning the constitution of homogeneous groups of patients are 
discussed. 
In our opinion it is pointless to ressort to mass registration of patients with a given 
disease for inclusion in a clinical trial. Only by finding the answer to clearly stated 
questions will it be possible to obtain data of clinical validity, and if these questions 
are to be answered, the material will have to meet certain requirements. Only a small 
proportion of the total number of patients mostly will be suitable for a study of these 
questions. 
In the Appendix Part I, frequency tables (fn) are given about the noticed data from 
our series of 1500 patients. As a clinical trial aims at forming comparable groups, 
these tables can be used in computing the number of patients required if all patients 
concerned are to meet the proposed requirements. 
In using the contingency tables (Γ0) for 15 characteristics of the tumor and the host, 
possible dependencies can be taken into account. T h e conceptions of McDonald, 
McWhirter, and Bruce on 'curative operability' are described. Further, we deter­
mined the 'curative operability' according to our criteria. 
From О tables (Appendix Part II) an impression can be gained of the timing of local 
and/or regional recurrences and of distant metastases as recorded in our series, and a 
survey is also given of the time and cause of death. From these data 'the curative 
operability' by clinical stage is computed. 
Clinical staging is stated whenever it appeared that commonly used clinical classifi­
cations show considerable differences. In order to show the degree of these differences, 
the classifications concerned are projected on to the International T N M classification, 
while at the same time we computed the stage distribution in our material in the 
terms of the other classification. 
This comparison between clinical classifications is used as an argument against in­
tensifying the problems of mammary carcinoma research by using noncomparable 
classifications. Data concerning clinical staging, needed in the formation of homo­
geneous groups, can be obtained from tables fn an fc. 
Chapter IV presents the computations in the context of the organization of several 
imaginary clinical trials. 
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Our study has shown that , even with a nation-wide organization of such trials in 
our country, the material will not yield sufficiently large categories of patients to carry 
out one of these studies. 
Chapter V relates our approach to a number of clinical trials already completed. 
The clinical trials considered almost only allow general conclusions. The division into 
subgroups according to characteristics that affect the prognosis gives rise to marked 
fragmentation of the material, and this fragmentation only permits investigations on 
the basis of a relatively big difference in result rates to be expected between the two 
therapy groups. 
In case such a big difference in result rates could not be demonstrated, however, the 
possibility remains that there actually is a difference, but this difference will be smaller 
than the expected bigger difference in result rates on the basis of which the investiga-
tions concerned have been designed. 
These trials should be repeated with larger numbers of patients in order to demon-
strate such smaller differences. 
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'CONTROLLED CLINICAL TRIALS' 
E E N B E S C H O U W I N G O V E R H E T B E N O D I G D E A A N T A L P A T I E N T E N . 
EEN STUDIE GEBASEERD OP MAMMACARCINOOM. 
SAMENVATTING EN CONCLUSIES 
In hoofdstuk I wordt de belangrijke plaats, die 'controlled clinical trials' innemen 
bij het onderzoek naar de beste therapie voor de behandeling van het mamma-
carcinoom, beschreven. 
Uit wat momenteel bekend is betreffende het verloop en de behandeling van 
mammacarcinoom, is niet met enige zekerheid na te gaan welke speciale therapie 
"dient te worden gekozen voor de behandeling van een bepaalde patiënt met ccn be-
paald mammacarcinoom. Naar onze mening geven de gevolgtrekkingen, welke kun-
nen worden gemaakt uit de gegevens van tot dusver uitgevoerde retrospectieve onder-
zoekingen betreffende de resultaten van verschillende therapieën, onvoldoende zeker-
heid om volledig betrouwbare richtlijnen voor de kliniek op te stellen. 
Het eigen materiaal van 1500 patiënten met kwaadaardige nieuwvormingen van de 
borstklier is hier een voorbeeld van. Onze bevindingen maken duidelijk, dat het ver-
zamelen van grote en goed gedocumenteerde series patiënten nog niet garandeert, dat 
er met behulp van dit materiaal betrouwbare conclusies kunnen worden getrokken. 
Het opnemen van nieuwe groepen patiënten in de serie zal dit probleem niet oplossen, 
want de diverse ongesclcctcerde groepen patiënten zullen onderlinge, moeilijk te 
definiëren verschillen vertonen, zodat door het toevoegen van nieuwe groepen 
patiënten aan het materiaal slechts nieuwe onzekerheden worden toegevoegd. 
Onderzoekingen die dit probleem oplossen zijn noodzakelijk en 'controlled clinical 
trials' lijken de aangewezen methode te zijn. 
Een 'controlled clinical trial ' is een onderzoek, waarbij twee of meer behandelings-
methoden voor een nauwkeurig omschreven ziektebeeld, worden vergeleken bij 
identieke groepen patiënten. 
Het onderzoek is gericht op de beantwoording van een concrete vraag, en dient te 
voldoen aan de eisen die men stelt aan een goede statistische analyse. 
Men moet zulke trials op dezelfde wijze opzetten als een laboratorium experiment. 
Zowel naar aanleiding van de discussies in de Commissie Mammacarcinoom vanhet 
L O K als naar aanleiding van eigen bevindingen kwamen wij tot de overtuiging, dat het 
belangrijk is om vast te stellen hoeveel patiënten men nodig zal hebben om een 'clini-
cal trial' uit te kunnen voeren. 
In Hoofdstuk I I wordt een overzicht gegeven van het eigen materiaal en de wijze 
waarop dit materiaal werd geregistreerd en bewerkt, terwijl tevens de problemen die 
zich voordeden bij de statistische analyse worden beschreven. Ook wordt beschreven, 
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op welke wijze mogelijk foutieve gegevens in het geregistreerde patiëntenmateriaal 
terecht zijn gekomen. Daarnaast wordt de mogelijke praeselectie, veroorzaakt door het 
invoegen of weglaten van gegevens die niet geheel exact werden geregistreerd, be-
schouwd. 
Hoewel het oorspronkelijk in de bedoeling lag ons materiaal van 1500 patiënten 
met mammatumoren te gebruiken voor een onderzoek naar het resultaat van ver-
schillende behandelingswijzen bleek nu, dat het niet mogelijk was statistisch verant-
woorde conclusies te trekken. Daarentegen bleek het wel mogelijk ons patiënten-
materiaal te gebruiken voor een schatting van het aantal patiënten dat nodig zal zijn 
om een 'clinical trial ' uit te voeren. 
In Hoofdstuk I I I wordt beschreven op welke wijze men het benodigde aantal 
patiënten voor een 'clinical trial' kan schatten. 
Het is mogelijk de volgende factoren te berekenen : 
Xct: Het aantal patiënten dat in feite in de 'clinical trial ' wordt opgenomen, 
X m : Het totale aantal patiënten met mammacarcinoom dat beschikbaar moet zijn 
om een 'clinical trial ' mogelijk te maken, en 
Xp : Het aantal leden van de gehele vrouwelijke bevolking dat beschikbaar moet zijn 
om de 'clinical trial ' mogelijk te maken. 
Wanneer een onderzoeker een bepaalde groep patiënten wil gebruiken voor ccn 
'clinical tr ial ' ,kan hij zich met behulp van de berekening oriënteren over de aard van 
het onderzoek, dat mogelijk is met behulp van deze groep patiënten. 
Enige statistische toetsen worden beschreven. Voor een meer gedetailleerde be-
schrijving van deze toetsen wordt de lezer verwezen naar Deel VI van de Appendix. 
Daar de χ2 toets meestal wordt gebruikt bij trials betreffende mammacarcinoom 
werd deze toets ook in onze studie toegepast. De voorbeelden die werden uitgewerkt 
zijn er op gebaseerd dat verschillen in resultaat tussen twee therapieën van 10% of 
veelvouden daarvan kunnen worden ontdekt. Hiertoe werd tabel SI gebruikt. De 
problemen bij het samenstellen van homogene patiëntengroepen worden besproken. 
Naar onze mening is het niet zinvol om bij de opzet van een 'clinical trial' over te gaan 
tot massale registratie van patiënten die aan een bepaalde ziekte lijden. Slechts wan-
neer men het antwoord op duidelijk omschreven vragen vindt, zal het mogelijk zijn 
bruikbare klinische gegevens te verkrijgen. 
O m dergelijke vragen te kunnen beantwoorden moet het patiëntenmateriaal aan 
bepaalde eisen voldoen. Meestal zal slechts een klein omschreven deel van de gehele 
serie patiënten te gebruiken zijn voor een dergelijk onderzoek. In de Appendix Deel I 
worden frequentietabellen (fn) gegeven betreffende alle exact geregistreerde gegevens 
uit onze serie van 1500 patiënten. 
Bij het vormen van vergelijkbare patiëntengroepen voor een 'clinical trial', waarbij 
alle patiënten dezelfde karakteristieke eigenschappen dienen te hebben, zijn deze 
tabellen te gebruiken om het voor de 'trial' benodigde aantal patiënten te berekenen. 
Door de 'contingency' tabellen (fc) te gebuiken, die 15 karakteristieke eigenschappen 
van de tumor en de gastheer betreffen, kan men mogelijke onderlinge afhankelijkheid 
van deze eigenschappen in de berekening betrekken. 
De opvattingen van McDonald, McWhirter en Bruce betreffende de curatieve 
operabiliteit worden beschreven. Tevens wordt aan de hand van eigen criteria de 
curatieve operabiliteit bepaald. Uit de O tabellen (Appendix Deel II) kan een indruk 
worden verkregen over het tijdstip waarop locale en/of regionale recidieven en me-
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tastasen op afstand zich manifesteren bij de patiënten van onze serie; ook wordt een 
overzicht gegeven betreffende tijdstip en oorzaak van overlijden. Met behulp van deze 
gegevens wordt de curatieve operabiliteit voor elk klinisch stadium berekend. 
In §8 wordt de klinische klassificatie beschreven, omdat blijkt dat algemeen ge-
bruikte klinische klassificaties onderling grote verschillen vertonen. O m een indruk te 
geven van de aard van deze verschillen worden de betreffende klassificaties geprojec-
teerd op de Internationale T N M klassificatie, terwijl met behulp van de computer de 
indeling naar stadium in het eigen materiaal werd omgewerkt volgens de eisen van de 
andere klassificaties. Deze vergelijking tussen enkele klinische klassificaties wordt 
gebruikt als argument tegen het intensiveren van de problemen rondom de research 
op het gebied van mammacarcinoom, veroorzaakt door het gebruik van niet vergelijk-
bare klassificaties. Gegevens betreffende de klinische klassificaties, die nodig zijn om 
homogene patiëntengroepen te vormen, kunnen worden gevonden in de fn en fc 
tabellen. 
In Hoofdstuk IV wordt aan de hand van enkele denkbeeldige 'clinical trials' het 
daartoe benodigde aantal patiënten berekend. Uit deze berekeningen blijkt, dat 
zelfs een organisatie, die ons gehele land zou omvatten onvoldoende aantallen pa-
tiënten op zou leveren om een van deze 'trials' werkelijk uit te voeren. 
In Hoofdstuk V wordt onze benadering toegepast op een aantal reeds voltooide 
'trials'. Deze 'clinical trials' staan vrijwel alleen algemene conclusies toe. De verde-
ling in subgroepen, bij deze trials toegepast aan de hand van karakteristieke eigen-
schappen die de prognose kunnen beïnvloeden, geeft aanleiding tot een sterke op-
splitsing van het patiëntenmateriaal. Deze opsplitsing laat slechts onderzoekingen toe 
op basis van een te verwachten relatief groot verschil in resultatenpercentages tussen 
de twee therapiegroepen. De mogelijkheid blijft bestaan dat, wanneer dit relatief 
grote verschil in resultatenpercentages niet kon worden aangetoond, er in werkelijk-
heid toch een verschil bestaat, maar dit verschil zal kleiner zijn dan het grotere ver-
schil in resultatenpercentages dat werd verwacht, en op basis waarvan deze onder-
zoekingen werden opgezet. Men zou deze 'trials' moeten herhalen met een groter aan-
tal patiënten, om dergelijke kleinere verschillen aan te kunnen tonen. 
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APPENDIX 
P A R T I FIGURES T O BE USED IN FORMING HOMOGENEOUS SUB­
GROUPS 
§ 1 Frequency tables 
CONTENTS 
Π Center. 
f 2 Date of admission. 
f3 Marital status. 
f4 Duration of symptoms before start­
ing treatment (Information obtained 
from patient). 
(5 First consultation of family doctor 
( Time until onset of clinical treat­
ment). 
f6 First consultation of surgeon (Time 
until onset of clinical treatment). 
f 7 Manifestation of tumor. 
f 8 Age at menarche. 
f 9 Duration of menstrual cycle. 
ПО Frequency of menstrual cycle. 
f 11 Regularity of menstrual cycle. 
f 12 Occurrence of maslopathia (Anam­
nesis). 
f 13 Inciderne of carcinoma in the family. 
f 14 Numbers of marriages. 
f 15 Age ( 10year periods). 
Π 6 Age (3 age groups). 
f 17 Puerperal mastitis. 
f 18 Numbers of abortions. 
f 19 Age at onset of menopause (5 year 
periods). 
f20 Age at onset of menopause (3 age 
groups). 
f 21 Cause of menopause. 
f 22 Clinical manifestation of tumor. 
f 23 Site of tumor. 
f 24 Location of tumor (in detail). 
f 25 Location of tumor (medial, lateral). 
f 26 Size of tumor. 
f27 Fixation to skin. 
f 28 Paget's disease of the nipple. 
f29 Nipple retraction. 
f 30 Pectoral muscle fixation. 
f31 Cfust wall attachment. 
f32 Status of the homolateral axillary 
lymph nodes. 
f33 Status of the supra- and infraclavi­
cular lymph nodes. 
f34 Arm edema. 
f35 Clinical stage. 
(International TNM classification). 
f36 Clinical stage. 
(International TNM clasnfication). 
Stage in is divided into two groups, 
a: large tumor only, no other symp­
toms; b: also other symptoms. 
f37 Interval between biopsy and surgical 
treatment. 
f38 Contents of tumor in cm? 
(Pathological report). 
f 39 Largest diameter of tumor 
(Pathological report). 
f40 Microscopic infiltration of skin 
(Pathological report). 
f41 Microscopic infiltration of mammary 
tissue. (Pathological report). 
f42 Microscopic infiltration of fatty tissue 
(Pathological report). 
f43 Microscopic infiltration of muscle 
(Pathological report). 
f44 Microscopic infiltration of blood 
vessels (Pathological report). 
f45 Microscopic structure of tumor 
(Pathological report). 
f46 Ducts (Pathological report). 
f47 Characteristics of the nucleus 
(Pathological report). 
f48 Fibrous stroma formation 
(Pathological report). 
f49 Histology of the axillary lymph 
nodes (Pathological report). 
f50 Pathological Diagnosis 
(Pathological report). 
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TABLE f 1 Center. 
Tilburg 
No. 643 
% 45 4 
Arnhem 
314 
22 2 
Leeuwarden 
460 
32 4 
Totals whole senes 
1417 
Totals noticed data 
1417 
100.0 
TABLE f 2 Date of admission. 
1947-1949 1950-1954 1955-1959 1960-1964 1965-1967 Other 
Totals Totals 
whole series noticed data 
No 
7. 
41 
29 
161 
114 
372 
26 3 
684 
483 
157 
11 1 
1417 1415 
loo.o 
TABLE f 3 Marital status. 
Unmamed Married Religious Other Totals whole series Totals noticed data 
No 
% 
204 
144 
117S 
83 4 
30 
2 1 
1412 
100 0 
TABLE f 4 Duration of symptoms before starting treatment (Information obtained from patient). 
Totals Totals 
0-13 14-30 1-2 3-5 6-11 1-2 3-4 5-9 > 10 whole noticed 
days days months months months years years years years Other series data 
No. 
% 
194 
14 4 
25« 
19 6 
230 
17 1 
210 
159 
158 
1 1 4 
188 
14 1 
53 
3 9 
26 
2 1 
19 
1 5 
81 1417 1336 
100.0 
TABLE f 5 First consultation of family doctor (Time until onset of clinical treatment). 
Totals Totals 
0-13 14-30 1-2 3-5 6-11 1-2 3-4 5-9 5= 10 whole noticed 
days days months months months years years yean years Other senes dala 
No 
v. 
631 
65 6 
126 
13 1 
77 
8 0 
J5 
3 6 
34 
3 5 
35 
3 6 
9 
0 9 
9 
0 9 
6 
0 6 
455 1417 962 
100 0 
TABLE f 6 First consultation of surgeon ( Time until onset of clinical treatment). 
No 
% 
0-13 
days 
827 
85 5 
14-30 
days 
64 
6 6 
1-2 
months 
35 
3 6 
3-5 
months 
8 
0 8 
6-11 
months 
10 
1 0 
1-2 
years 
10 
1 0 
3-4 
yean 
4 
0 4 
5-9 
yean 
5 
0 5 
3= 10 
yean 
4 
0 4 
Other 
450 
Totals 
whole 
series 
1417 
Totals 
noticed 
data 
967 
100 0 
TABLE f 7 Manifestation of tumor. 
With With 
Accidental By periodic Accidental reference reference 
discovery Deliberate medical discovery to breast to other Totab Totals 
by patient self examination examination by physician complaints complaints Other whole series noticed data 
No. 1161 24 2 94 38 22 76 1417 ¡341 
% 8 6 5 18 01 70 28 16 100.0 
TABLE f 8 Age at menarche. 
< 11 yean 11-16 years > 16 years Other Totals whole series Totals noticed data 
No. 9 
1.0 
784 
90.4 
74 
8.5 
1417 S67 
100.0 
TABLE f 9 Duration of menstrual cycle. 
< 3 days S-5 days > 5 days Other Totals whole series Totals Doticed data 
No. 
% 
15 
2.6 
449 
79.2 
¡03 
18.2 
567 
100.0 
TABLE f lO Frequency of menstrual cycle. 
< 21 days 21-25 days 26-30 days > 30 days 
Totals 
whole series 
Totals 
noticed data 
No. 
% 
5 
0.8 
62 
10.5 
504 
85.6 
IS 
3.1 
агв 
589 
100.0 
TABLE f 11 Regularity of menstrual cycle. 
Regular Irregular Other Totals whole series Totals noticed data 
No. 506 
83.8 
97 
162 
1417 603 
100.0 
TABLE f 12 Occurrence of mastopathia {Anamnesis). 
No mastopathia Mastopathia Other Totals whole scries Totals noticed data 
No. 
% 
348 
90.4 
37 
9.6 
1032 385 
100.0 
TABLE f 13 Incidence of carcinoma in the family. 
One case 
of breast 
cancer in 
the family 
More than 
one case 
of breast 
cancer in 
the family 
One case 
of other 
carcinoma 
in the fainili 
More than 
one case Breast cancer 
of other and other 
carcinoma carcinoma Nocarcinoma Totals Totals 
No. 43 
% 7.2 
6 
1.0 
m y 
95 
15.9 
in the family 
26 
4.4 
in the family 
16 
2.7 
in the family 
410 
68.8 
Other 
821 
whole series 
1417 
noticed data 
596 
100.0 
TABLE f 14 Numbers of marriages. 
1 marriage 2 marriages 3 marriages Unmarried Other 
Totals 
whole scries 
Totals 
noticed data 
No. 
7. 
1149 
81.4 
27 
1.9 
2 
0.1 
234 
16.5 
1417 1412 
100.0 
TABLE f 15 Age (10year periods). 
< 2 0 
years 
20-29 
years 
30-39 
years 
40-49 
years 
50-59 
years 
60-69 
years 
70-79 
years 
80-89 
years Other 
Totals 
whole 
series 
Totals 
noticed 
data 
No. 4 13 92 327 360 322 223 74 2 1417 1415 
1 0 6 % 0.3 0.9 6.5 23.1 24.5 22.8 15.8 5.2 100.0 
TABLE f 16 Age (3 age groups). 
T o t a b 
< 35 yean 
No 42 
% 3 0 
35-49 yeara 
394 
27 8 
50-69 y t a n 
6S2 
4 8 2 
> 69 y e a n 
297 
2 1 0 
Other 
2 
whole senes 
1417 
noticed data 
1415 
100 0 
TABLE f 17 Puerperal mastitis. 
Left side Right side Both sides 
No puerperal 
mastitis O the r 
Totals 
whole series 
Totals 
noticed data 
No 
% 
32 
3 2 
17 
1 7 
6 
0 6 
951 
94 5 
411 1417 1006 
100.0 
TABLE f 18 Numbers of abortions. 
1 abortion 2 abortions ^ 3 abortions No abortion Other 
Totals 
whole series 
Totals 
noticed data 
No 
% 
134 
12 4 
56 
5 2 
35 
3 2 
852 
79 2 
/077 
100 0 
TABLE f 19 Age at onset of menopause (5 year periods). 
< 3 5 
years 
No 6 
% 0 7 
35 39 
years 
25 
2 8 
40-44 
years 
84 
9 3 
4 5 ^ 9 
years 
206 
22 7 
50-54 
years 
323 
35 7 
55-59 
years 
35 
3 9 
> 60 
years 
2 
0 2 
No 
menopause Other 
225 511 
24 8 
Totals 
whole 
series 
1417 
Totals 
noticed 
data 
906 
100.0 
TABLE f 20 Age at onset of menopause (3 age groups). 
< 45 years 45-55 years ^ 55 years No menopause Other 
Totals 
whole series 
Totals 
noticed data 
No 
% 
115 
12 7 
529 
5 8 4 
37 
4 1 
225 
24 8 
511 1417 906 
100 0 
TABLE f 21 Cause of menopause. 
Spontaneous 
Surgical or 
radiological 
castration No menopause Other Totals whole senes Totals noticed data 
No 
% 
616 
67 7 
69 
7 6 
225 
24 7 
910 
100 0 
TABLE f 22 Clinical manifestation of tumor. 
Occult tumor T u m o r manifest Other Totals whole senes Totals noticed data 
No 19 
14 
1326 
98 6 
1345 
100 0 
TABLE f 23 Site of tumor. 
Right Left Other Totals whole senes Totals noticed data 
No 686 717 14 1417 1403 
% 489 51 1 1000 107 
TABLE f 24 Location of tumor (in detail). 
α a 
S « S -
•2 9 -Si 
о 'С 
No. / і в 
% 12.0 
5? 
3.9 
48 
3.6 
/55 
11.7 
373 
27.8 
72 
5.4 
/27 
9.5 
43 
3.3 
257 
17.7 
69 
5.1 
Ш 7 7J35 
100.0 
TABLE f 2 5 Location of tumor (medial, lateral). 
Medial, subareolar or 
whole breast Lateral Other Totals whole series Totals noticed data 
No. 734 
55.0 
601 
45.0 
82 1335 
100.0 
TABLE f 26 Size of tumor. 
Symbols 
Internat ional 
T N M 
classification 
Symptoms 
N o . 
% 
Т 1 
Not more 
than 2 cm 
200 
15.1 
Т2 
2-5 cm 
591 
44.1 
Т З 
5-10 c m 
445 
33.3 
Т 4 
More t h a n 
10 c m 
100 
7.5 
O t h e r 
81 
Totals 
whole series 
1417 
Total« 
noticed data 
1338 
100.0 
TABLE f 27 Fixation to skin. 
Symbols 
International 
T N M 
classification T I T2 ТЗ T4 
Skin 
not Incomplete 
Skin fixation 
wide of tumor 
Complete but not beyond Totals Totals 
Symptoms 
No. 
% 
involved 
581 
42.7 
skin fixation 
349 
25.7 
skin fixation 
344 
25.4 
breast area 
84 
6.2 
Other 
59 
whole series 
1417 
noticed data 
/35« 
100.0 
TABLE f 28 Paget*s disease of the nipple. 
Symbols 
International 
T N M classification Tl T2 
Symptoms 
N o Paget's 
disease 
Limited to 
the nipple 
Outside 
the nipple Other 
Totals 
whole series 
Totals 
noticed data 
No. 1299 20 14 84 1417 1333 
% 97 A 1.5 1.1 100.0 
TABLE f 29 Nipple retraction. 
Symbols 
International 
Ί Ν Μ classification T2 
Symptoms 
No. 
7. 
No nipple 
retraction 
933 
70 1 
Nipple 
retraction 
398 
29 9 
Other 
86 
Totals whole series 
1417 
Totals noticed data 
1331 
100.0 
TABLE f 30 Pectoral muscle fixation. 
Symbols 
International 
T N M classification T l ТЗа ТЗЬ 
Symptoms 
N o 
No fixation 
1058 
80 3 
Incomplete 
fixation 
168 
12 7 
Complete 
fixation 
92 
7.0 
Other 
99 
Totals 
whole series 
1417 
Totals 
noticed data 
1318 
100.0 
TABLE f 31 Chest wall attachment. 
Symbols 
International 
T N M classification T l T4 
Symptoms 
No 
"λ 
Not fixed 
1297 
98 S 
Fixed 
19 
1 4 
Other 
101 
Totals whole series 
1417 
Totals noticed data 
1316 
100.0 
TABLE f 32 Status of the homolateral axillary lymph nodes. 
Symbols 
International 
T N M classification N0 N l a N i x N l y N2a N2b 
Symptoms 
No 
% 
N o lymph 
nodes 
palpable 
744 
541 
Considered 
to contain 
no growth 
89 
6 1 5 
Single 
242 
1 7 6 
Multiple 
208 
15.1 
Fixed to 
one 
another 
35 
2 5 
Fixed to 
other 
structures 
58 
4 2 
Other 
41 
Totals 
whole 
series 
1417 
Totals 
noticed 
data 
1376 
100.0 
In Jetables N 0 and N l a are headed under 'considered to contain no growth' f N2a and N2b under 'fixed to one another or 
to other structures' 
TABLE f 33 Status of the supra- and infraclavicular lymph nodes. * 
Symbols 
International 
T N M classification N3 N 0 
Symptoms 
No. 
·/. 
Considered to 
contain growth 
80 
100 0 
Other 
1337 
Totals whole series 
1417 
Totals noticed data 
80 
100.0 
'Considered to contain no growth' and 'unknown' both are headed under Other' . 
TABLE f 34 Arm edema. 
Symbols International 
T N M classification 
Symptoms 
No. 
% 
N3 
Arm edema 
44 
100.0 
N0 
Other 
1373 
Totals whole series 
1417 
Totals noticed data 
44 
100.0 
TABLE f 35 Clinical stage (International TNM classification). 
Stage I Stage II Stage III Stage I V Other 
Тоіаіз 
whole series 
Totals 
noticed data 
No. 
% 
414 
29.4 
183 
13.0 
743 
52.8 
69 
4.9 
1409 
100.0 
TABLE f 36 Clinical stage (International TNM classification). 
Stage in is divided into two groups, a : large tumor only, no other symptoms* ; b : also other 
symptoms. 
Stage III, large Stage III, also 
tumor only, no otber 
Stage I Stage II other symptoms symptoms Stage IV Other 
Totals Totals 
whole series noticed data 
No. 414 
29.4 
183 
13.0 
184 
13.1 
555 
39.7 
69 
4.9 
1417 1409 
loo.o 
Stage I l i a including: 
T l or T2 (Skin, Paget*9 disease. Nipple retraction, Pectoral muscle fixation, Chest wall attachment) 
T 3 (Size) N0 M0 
T 3 (Size) NI M0 
TABLE f 37 Interval between biopsy and surgical treatment. 
0-1 day 2-14 days 15 days or more Other Totals whole series Totals noticed data 
No. 444 
32.4 
659 
48.0 
268 
196 
46 1417 1371 
100.0 
TABLE f 38 Contents of tumor in cm* (Pathological report). 
•s ε 
•s 
о 
Η Sä 
Η -σ 
No. 
% 
20 
2.5 
106 
13.2 
209 
26.0 10.9 
146 
18.2 
54 
6.7 
73 
9.3 
47 34 
4.2 1.3 
15 
1.9 
614 1417 803 
100.0 
* Calculated from reported diameters. 
TABLE f 39 Largest diameter of tumor (Pathological report). 
< 1 cm 1 cm 2 cm 8 cm Other 
Totals Totals 
whole noticed 
series data 
No. 23 44 252 248 93 80 44 47 46 540 ¡417 877 
% 2 6 5.0 28.7 28.3 10.6 9.1 5.0 5.4 5.2 100.0 
TABLE f40 Microscopic infiltration of skin (Pathological report). 
Scanty 
infiltration 
No. 17 
% 2 5 
Extensive 
infiltration 
170 
24 7 
Ulceration 
26 
3 8 
No infiltration 
476 
69 1 
Other 
728 
Totals 
whole series 
1417 
Totals 
noticed data 
689 
100.0 
TABLE f 41 Microscopic infiltration of mammary tissue (Pathological report). 
Scanty 
infìltration 
Extensive 
infiltration N o infiltration Totals whole series Total noticed data 
No 
% 
29 
5 7 
282 
55 7 
195 
38 5 
911 506 
100.0 
TABLE f 42 Microscopic infiltration of fatty tissue (Pathological report). 
Scanty 
inñltration 
Extensive 
infiltration N o infiltration Totals whole scries Totals noticed data 
No 
% 
51 
10 9 
276 
59 1 
140 
30 0 
1417 467 
100.0 
TABLE f 43 Microscopic infiltration of muscle (Pathological report). 
Scanty 
infiltration 
Extensive 
infiltration No infiltration Other Totals whole series Totals noticed data 
No 
% 
67 
10 2 
583 
88 6 
658 
100 0 
TABLE f 44 Microscopic infiltration of blood vessels (Pathological report). 
Scanty 
infiltration 
Extensive 
infiltration N o infiltration Olher Totals whole series Totals noticed data 
No 
% 
19 
5 3 
68 
1 9 0 
270 
75 6 
1060 1417 357 
100.0 
TABLE f 45 Microscopic structure of tumor (Pathological report). 
υ S 
-5 0 
• = 3 Œ 3 
» -a 
"S ·Ό 
с ¿ζ 
g t 
ο Ό e « Ό 
E « 
= ε 
No í 2S3 141 1 3 1 1 56 3 27 890 1417 527 
% 0 2 55 6 26 8 0 2 0 6 0 2 0 2 10 6 0 6 5 1 100.0 
TABLE f 46 Ducts (Pathological report). 
Tumor-
growth ш ducts 
Duct 
papilloma Invasive growth Other Totals whole чепея TotaU noticed data 
No. 
% 
166 
77 9 
27 
12 7 
20 
9 4 
1204 1417 213 
100.0 
TABLE f 47 Characteristics of the nucleus (Pathological report). 
JS ζ 
s 
No 
% 
1 
05 
Ή 
3 3 
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16 
•d у 
1 
05 
R
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v
a
c
u
o
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05 
3 
1 
33 
179 
I 
Í 
118 
643 
S J 
2 ? 
4 
22 
X 
17 
92 
1233 1417 184 
100 0 
TABLE f 48 Fibrous stroma formation (Pathological report). 
Scarce fìbrous stroma 
infiltration 
Abundant fìbrous 
stroma infiltration Other Totals whole series Totals noticed data 
No 
% 
34 
7 8 
404 
92 2 
438 
100.0 
TABLE f 49 Histology of the axillary lymph nodes (Pathological report). 
Histologically 
negative 
Histologically 
positive Other Totals whole senes Totals noticed data 
No. 
% 
402 
38 1 
652 
6 1 9 
1054 
100 0 
TABLE f 50 Pathological Diagnosis. 
1 1 
9 
К 
(4 
υ 
fr 
g 
α 
О 
л 
υ 
fr 
з 
•i 
No. 826 38 38 258 11 16 5 225 — 1417 1417 
% 58 5 2.7 2 7 18 4 0 7 11 0.4 15.5 100.0 

§ 2 Contingency tables 
CONTENTS 
Mantal status 
Age 
Duration of symptoms 
Age at onset of menopause 
Cause of menopause 
Location of tumor 
Size of tumor 
Fixation to skin 
Nipple retraction 
Pectoral muscle fixation 
Status of the homolateral axillary 
lymph nodes 
Status of the supra- and infraclavicular 
lymph nodes 
Clinical staging (International TNM 
classification) 
Clinical staging (International TNM 
classification) Stage III is divided 
Histology of the axillary lymph nodes 
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Size of tumor 
bucation to skin 
Nipple retraction 
Pectoral muscle fixation 
Status of the homolateral axillary 
lymph nodes 
Status of the supra- and infraclavicular 
lymph nodes 
Clinical staging (International T N M 
classification) 
Clinical staging (International T N M 
classification) Stage III is divided 
Histology of the axillary lymph nodes 
Marital status 
Jiumbers Unmarried 
< 35 years 
^ S -
2 6 
14 3 
0 4 
35-49 years 
Numbers Married 
Numbers Totals noticed data 
-- 3S 
3 1 
8 5 7 
2 6 
— + 
r- 60 
25 6 
1 5 2 
4 3 
— + 
Age 
50-69 years 
^ 105 -
4 4 9 
15 5 
7 4 
> 69 ycara 
Totals 
noticed data 
^334 
28 4 
8 4 8 
23 7 
— + 
-u 
^ , 42 
3 0 
100.0 
3 0 
— 27 9 
100 0 
27 9 
— + 
^ 5 7 3 
4 8 7 
845 
4 0 6 
-^678 
48 1 
100.0 
4 8 1 
— + 
^63 
26 9 
21 2 
4 5 
—^234 
1 9 9 
78 8 
16 6 
^297 
2 1 0 
100 0 
210 
- im 
100.0 
83 4 
83 4 
Ί411 
100.0 
100.0 
100.0 
Age 
Marital status < 35 yearn 35^19 years 50-69 years > 69 yeais 
Totals 
noticed data 
% Horizontal 
% Vertical 
% Horizontal 
% Vertical 
Unmarried 
Married 
Totals noticed data 
% Honzontal 
% Vertical 
6 
2 6 — 
14 3 
0 4 
60 
+ _ 25 6 — 
152 
4 3 r 
105 
+ _ 4 4 9 — 
— 1 5 5 
7 4 
36 
3 1 
85 7 
2 6 
42 
3 0 
-100.0 
3 0 
394 
- 2 7 9 — 
100.0 
27 9 
573 
— 487 — 
— 845 
4 0 6 
63 
- 26 9 
• 2 1 2 
4 5 
234 
— 19 9 
— 78 8 
16 6 
678 
- 48 1 — 
100.0 
4 8 1 
297 
— 2 1 0 
— 100.0 
21 0 
234 
= 100.0 
^ — 16 6 
16 6 
1177 
= 100.0 
— 83 4 
83 4 
1411 
100 0 
100 0 
100 0 
116 
Marital status < 35 yean 35-49 yean 
Age 
50-69 years > 69 years 
Totals 
noticed data 
Unmarried 
Married 
Totab noticed data 
fi 
2.6 
14.3 
0.4 -
36 
3.1 
85.7 
2.6 -
42 
3.0 
100.0 
3.0 
- + 
- + 
60 
25.6 
15.2 
— 4.3 -
334 
28.4 
84.8 
— 23.7 -
394 
27.9 
100.0 
27.9 
- +. 
- -4-
¡05 
44.9 
15.5 
— 7.4 -
573 
48.7 
84.5 
— 40.6 -
678 
48.1 
100.0 
48.1 
- + 
- + 
63 
26.9 
21.2 
— 4.5 
234 
19.9 
78.8 
— 16.6 —• 
297 \ 
21.0 I 
100.0 ' 
21.0 
234 
100.0 
16.6 
16.6 
1177 
100.0 
83.4 
83.4 
1411 
100.0 
I 100.0 
V_ = 100.0 % Totals noticed data 
EXPLANATION OF TWO-WAY CONTINGENCY TABLES (fc) 
Totals whole series = Absolute figures including 'knowns 'and 'unknowns' of whole 
series. 
Totals noticed data = Absolute figures of the number of 'knowns', the relative 
frequencies are calculated only for the 'knowns'. 
Other = Absolute figures of the number of'unknowns'. 
Per datum four figures are given : 
First figure= the absolute figure (italics). 
Second figure = Percentage of row totals (% Horizontal); totab noticed data of 
row concerned considered as 100%. 
Third figure = Percentage of column totals (% Vertical); totals noticed data of 
column concerned considered as 100%. 
Fourth figure = Percentage of table totals ( % Totals noticed data) ; totals noticed 
data of whole material considered as 100%. 
117 
NwnbtTS 
% Honzontal 
% Vertical 
% Totals noticed data 
TABLE f
c
 1 Marital status versus Age. 
Age 
Marital status 
Unmarried 
Married 
Other 
< 35 years 
в 
2 6 
14 3 
0 4 
36 
3 1 
85 7 
2 6 
-
35-49 years 
60 
25 6 
15 2 
4 3 
334 
28 4 
8 4 8 
23 7 
-
50-69 years 
105 
4 4 9 
155 
7 4 
573 
48 7 
8 4 5 
4 0 6 
4 
> 69 years 
63 
26 9 
21 2 
4 5 
234 
19 9 
78 8 
1 6 6 
-
Other 
_ 
; 
; 
Totals 
whole series 
234 
та 
5 
Totals 
noticed data 
234 
100.0 
166 
16 6 
1177 
100 0 
83 4 
83 4 
-
Totals whole series 42 2 1417 1415 
Totals noticed data 42 
3 0 
Ю0 
3 0 
394 
27 9 
100 0 
27 9 
678 
4 8 1 
100 0 
48 1 
297 
2 1 0 
100.0 
2 1 0 
1412 1411 
100 0 
100.0 
100 0 
TABLE f
c
 2 Marital status versus Duration of symptoms. 
Totals whole series 
Duration of symptoms before starting treatment 
Marital status 
Unmarried 
Married 
Other 
O-30 days 
77 
35 5 
17 1 
5 8 
374 
33 5 
82 9 
28 1 
1 
1-6 months 
66 
30 4 
15 0 
5 0 
373 
33 5 
85 0 
28 0 
1 
> 6 months 
74 
34 1 
16 7 
5 6 
363 
33 0 
83 3 
27 6 
2 
Other 
17 
63 
1 
Totals 
whole series 
234 
1178 
5 
Totals 
noticed data 
217 
100.0 
16 3 
16 3 
1115 
100.0 
83 7 
83 7 
-
452 440 81 1417 
Totals noticed data 451 
33 9 
100.0 
33 9 
439 
33 0 
100 0 
33 0 
442 
33 2 
100 0 
33 2 
1332 
100.0 
100.0 
100 0 
118 
TABLE fe 3 Marital status versus Age at onset of menopause. 
Age at onset of menopause 
Marital status 
Unmarried 
Mamed 
Other 
Totals whole scries 
< 45 years 
16 
117 
139 
1 8 
99 
12 9 
86 1 
1 1 0 
-
115 
45-55 years 
88 
Ь42 
16 7 
9 7 
439 
57 2 
83 3 
4 8 6 
2 
529 
> 55 years 
J 
3 6 
13 5 
0 6 
32 
4 2 
86 5 
3 5 
-
37 
No 
menopause 
M 
20 4 
12 4 
3 1 
197 
25 7 
87 6 
2 1 8 
-
225 
Other 
97 
411 
3 
511 
Totals 
whole series 
234 
1178 
5 
1417 
Total« 
noticed data 
137 
100 0 
15 2 
15 2 
767 
100.0 
8 4 8 
8 4 8 
-
906 
Numbers 
% Horizontal 
% Vertical 
% Ί otals noticed data 
Totals noticed data 115 
12 7 
100 0 
12 7 
527 
58 3 
100.0 
58 3 
37 
4 1 
100 0 
4 1 
225 
24 9 
100.0 
24 9 
1412 904 
100 0 
100.0 
100.0 
TABLE f
c
 4 Montai status versus Cause of menopause. 
Cause of menopause 
Marital status 
Unmarried 
Married 
Other 
Totals whole senes 
Spontaneous 
101 
73 2 
16 5 
11 1 
512 
66 6 
83 5 
56 4 
3 
616 
Surgical or 
radiological 
castration 
9 
6 5 
13 0 
1 0 
60 
7 8 
87 0 
6 6 
-
69 
No menopause 
28 
20 3 
12 4 
3 1 
197 
25 6 
87 6 
2 1 7 
-
225 
Other 
96 
409 
2 
507 
Totals 
whole senes 
234 
1178 
5 
1417 
Totals 
noticed data 
138 
100 0 
15 2 
152 
769 
100 0 
84 8 
8 4 8 
-
910 
Totab noticed data 613 
67 6 
100.0 
67 6 
69 
7 6 
100.0 
7 6 
225 
24 В 
100.0 
24 8 
¡412 907 
100 0 
looo 
100.0 
119 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fc 5 Marital status versus Location of tumor. 
Location of tumor 
Marital status 
Medial, 
subareolar, 
or whole breast Lateral Other 
Totals 
whole series 
Unmarried 
Married 
Other 
Totals whole series 
¡22 
56.7 
16.7 
9.2 
610 
54.7 
83.3 
45.8 
93 
43.3 
15.5 
7.0 
19 234 
50S 
45.3 
84.5 
38.0 
62 1173 
82 
Totals 
noticed data 
215 
100.0 
16.2 
16.2 
1116 
100.0 
83.8 
83.8 
1335 
Totals noticed data 732 
55.0 
100.0 
55.0 
599 
45.0 
100.0 
45.0 
1412 1331 
100.0 
100.0 
100.0 
TABLE fc 6 Marital status versus Size of tumor. 
Totals whole series 
Size of tumor 
Marital status 
Unmarried 
Married 
Other 
Not more 
than 2 cm 
25 
11.5 
12.5 
1.9 
175 
15.7 
87.5 
13.1 
-
2-5 cm 
94 
43.1 
15.9 
7.0 
497 
44.6 
84.1 
37.3 
-
5-10 cm 
74 
33.9 
16.8 
5.6 
367 
32.9 
83.2 
27.6 
4 
More than 
10 cm 
25 
11.5 
25.0 
1.9 
75 
6.7 
75.0 
5.6 
-
Other 
16 
64 
1 
Totals 
whole series 
234 
1178 
5 
Totals 
noticed data 
218 
100.0 
16.4 
16.4 
1114 
100.0 
83.6 
83.6 
-
200 100 81 1417 1336 
Totals noticed data 200 
15.0 
00.0 
15.0 
591 
44.4 
100.0 
44.4 
441 
33.1 
100.0 
33.1 
100 
7.5 
100.0 
7.5 
1332 
100.0 
100.0 
100.0 
120 
TABLE fe 7 Maritai status versus Fixation to skin. 
Fixation to skin 
Marital status 
Unmarried 
Married 
Other 
locomplete 
skin fixation 
« 
28.7 
18.4 
4.7 
284 
25.1 
81.6 
21.0 
J 
Complete 
skin fixation 
61 
27.4 
17.9 
4.5 
279 
24.7 
82.1 
20.6 
4 
Skin fixation 
wide of tumor 
but not 
beyond 
breast area 
IS 
8.1 
21.4 
1.3 
SS 
5.8 
78.6 
4.9 
-
Skin not 
involved 
SO 
35.8 
13.4 
6.0 
SOI 
44.3 
86.6 
37.0 
-
Other 
и 
48 
-
Total» 
whole scries 
234 
1178 
5 
Totals 
noticed data 
223 
100.0 
16.5 
16.5 
изо 
100.0 
83.5 
83.5 
-
Numbers 
% Horizontal 
% Vertical 
% Totals noticed daat 
Totals whole series 59 1417 
Totals Doticed data 348 
25.7 
100.0 
25.7 
340 
25.1 
100.0 
25.1 
84 
6.2 
100.0 
6.2 
581 
43.0 
100.0 
43.0 
1412 1353 
100.0 
loo.o 
100.0 
TABLE f
c
 8 Marital status versus NippL· retraction. 
Marital status 
Nipple retraction 
Nipple 
retraction 
7S 
34.5 
19.3 
5.7 
318 
28.8 
80.7 
24.0 
No nipple 
retraction 
144 
65.5 
15.5 
10.9 
738 
71.2 
84.5 
59.4 
Other 
Totals 
whole series 
Totals 
noticed data 
Unmarried 220 
100.0 
16.6 
16.6 
Married 72 1178 HOS 
100.0 
83.4 
83.4 
Other 
Totals whole series 398 933 86 1417 
Totals noticed data 394 
29.7 
100.0 
29.7 
932 
70.3 
100.0 
70.3 
132S 
100.0 
100.0 
100.0 
121 
Numbers 
% Honzontal 
% Vertical 
% Total» noticed data 
TABLE fc 9 Marital status versus Pectoral muscle fixation. 
Marital status 
U o m a m e d 
Mamed 
Other 
Totals whole senes 
Pectoral muscle fixation 
No fixation 
Incomplete 
fixation 
Complete 
fixation Other 
Totals 
whole series 
172 
8 0 4 
16 3 
13 1 
ааз 
80.3 
83 7 
67 3 
iosa 
27 
12 6 
16 2 
2 1 
15 
7 0 
16 5 
1 1 
20 234 
140 
12 7 
83 8 
10 7 
76 
6 9 
83 5 
5 8 
79 1178 
168 92 99 ¡417 
Totals 
noticed data 
214 
100 0 
16 3 
16 3 
1099 
100 0 
83 7 
83 7 
Totals noticed data 1055 
80 4 
100.0 
80 4 
¡67 
12 7 
100.0 
12 7 
91 
6 9 
100.0 
6 9 
1313 
100 0 
100.0 
100 0 
TABLE fc 10 Marital status versus Status of the homolateral axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Marital status 
Unmarried 
M a m e d 
Other 
Totals whole senes 
Single 
4β 
20 9 
19 9 
3 5 
193 
16 9 
BOI 
14 1 
/ 
242 
Multiple 
40 
1 7 4 
19 3 
2 9 
167 
14 6 
80 7 
12 2 
1 
208 
Fixed to one 
another or to 
other structures 
13 
5 7 
14 1 
0 9 
79 
6 9 
85 9 
5 8 
; 
93 
Considered 
to contain 
no growth 
129 
56 0 
1 5 4 
9 4 
702 
6 1 5 
8 4 6 
5 1 2 
2 
833 
Other 
4 
37 
-
41 
Totals 
whole series 
234 
1178 
5 
1417 
Totals 
noticed data 
230 
100 0 
16 8 
168 
1¡4¡ 
100.0 
83 2 
83 2 
-
1376 
Totals noticed data 241 
176 
100.0 
176 
207 
15 1 
100.0 
15 1 
92 
6 7 
100.0 
6 7 
831 
6 0 6 
100 0 
6 0 6 
1412 1371 
100.0 
100.0 
100 0 
122 
TABLE f
c
 и Marital status versus Status of the supra- and infraclavicular lymph nodes. 
Status of the supra- and infraclavicular lymph nodes 
Considered to 
Marital status contain growth Other Totals whole senes Total·: noticed data 
Unmarried 12 222 234 12 
100.0 100.0 
15.0 15.0 
15.0 15.0 
Married 
Other 
Totals w hole series 
Totals noticed data 
68 
100.0 
85.0 
85 0 
-
SO 
во 
100.0 
100.0 
100.0 
ino 
s 
1337 
1178 
5 
1417 
1412 
68 
100.0 
85.0 
85.0 
-
80 
80 
100.0 
100.0 
100.0 
TABLE Г
с
 12 Marital status versus Clinical stage (International TNM classification). 
Cluneal stage (lotemational T N M classifícatioa) 
Totals Totals 
Marital status Stage I Stage II Stage III Stage IV Other whole series noticed data 
Unmarried 
M a m e d 
Other 
Totals whole series 
Totals noticed data 
61 
26.3 
14.7 
4.2 
353 
30.2 
85.3 
25.1 
-
414 
414 
29.3 
100.0 
29.3 
33 
14.2 
18.1 
2.4 
149 
12.6 
81.9 
10.8 
1 
183 
182 
13.2 
100.0 
13.2 
120 
51.7 
16.2 
8.5 
620 
52.9 
83.8 
43 9 
3 
743 
740 
52.4 
100.0 
52.4 
18 
7.8 
26.5 
1.5 
59 
4.3 
73.5 
3 6 
1 
69 
68 
5.1 
100.0 
5.1 
2 
6 
-
8 
_ 
234 
1178 
5 
1417 
1412 
232 
100.0 
16.6 
16.6 
1172 
100.0 
83.4 
83.4 
-
1409 
1404 
100.0 
100.0 
100.0 
Jvumbers 
% Horizontal 
% Vertical 
% Totals noticed data 
123 
Numbers 
% Honzontal 
% Vertical 
% Totals noticed t 
TABLE fc 13 Marital status versus Histology of the axillary lymph nodes. 
Marital status 
Unmarried 
Other 
Totals whole series 
Histology of the axillary lymph nodes 
Histologically 
negative 
65 
39 6 
16 3 
6 2 
334 
37 7 
83 7 
3 1 8 
Histologically 
positive 
99 
6 0 4 
15 2 
9 4 
552 
62 3 
8 4 8 
52 6 
402 
Totals 
whole senes 
70 234 
292 im 
652 
Totals 
noticed data 
164 
100.0 
15 6 
15 6 
886 
100.0 
84 4 
84 4 
1054 
Totals noticed data 399 
38 0 
loo.o 
38 0 
651 
62 0 
100.0 
62 0 
1412 1050 
100 0 
loo.o 
100.0 
TABLE fc 14 Age versus Duration of symptoms before starting treatment. 
Duration of symptoms before starting treatment 
Age 
< 35 years 
35-49 yean 
50-69 yean 
> 69 yean 
Other 
0-30 days 
10 
25 6 
2 2 
0 7 
132 
34 6 
29 2 
9 9 
227 
35 0 
5 0 2 
1 7 0 
S3 
3 1 2 
18 4 
6 2 
-
1-6 months 
17 
43 6 
3 9 
1 3 
137 
36 0 
31 1 
10 3 
213 
32 8 
4 8 4 
16 0 
73 
27.4 
16 6 
5 5 
-
> · 6 months 
12 
30 8 
2 7 
0 9 
112 
29 4 
25 3 
8 4 
209 
32 2 
47 2 
15 7 
110 
4 1 4 
24 8 
8 2 
1 
Other 
3 
13 
33 
31 
1 
Totals 
whole series 
42 
394 
682 
297 
2 
Totals 
noticed data 
39 
100.0 
2 9 
2 9 
381 
100.0 
28 5 
28 5 
649 
100.0 
4 8 6 
48 6 
266 
100.0 
199 
19 9 
-
Totals whole senes 452 440 444 
Totals noticed data 452 
33.9 
100.0 
33 9 
440 
33 0 
100.0 
33 0 
443 
33 2 
100.0 
33 2 
1415 1335 
100.0 
100.0 
100 0 
124 
TABLE fe 15 Age versus Age at onset of menopause. 
Age at onset of menopause 
Age 
< 35 yean 
35-49 years 
50-69 years 
> 69 yeara 
Other 
< 45 years 
17 
8.1 
14.8 
1.9 
70 
14.4 
60.9 
7.7 
28 
14.9 
24.3 
3.1 
-
45-55 years 
23 
11.0 
4.4 
2.5 
35» 
71.9 
66.6 
38.7 
153 
81.4 
29.0 
16.9 
2 
> 55 years 
_ 
31 
6.4 
83.8 
3.4 
7 
3.8 
16.2 
0.7 
-
No 
menopause 
19 
100.0 
8.4 
2.1 
170 
8.0 
75.6 
18.7 
36 
7.4 
16.0 
4.0 
_ 
-
Other 
23 
184 
195 
109 
-
Totals 
whole series 
42 
394 
682 
297 
2 
Totals 
noticed data 
19 
100.0 
2.1 
2.1 
210 
100.0 
23.2 
23.2 
487 
100.0 
53.9 
53.9 
188 
100.0 
20.8 
20.8 
-
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole senes 523 225 1417 906 
Totals noticed data ¡IS 
12.7 
100.0 
12.7 
526 
58.3 
100.0 
58.3 
38 
4.1 
100.0 
4.1 
225 
24.9 
100.0 
24.9 
904 
100.0 
100.0 
100.0 
TABLE fc 16 Age versus Cause of menopause. 
Age 
Cause of menopause 
Surgical or 
radiological 
Spontaneous castration No menopause Other 
Totals 
whole series 
Totals 
noticed data 
< 35 years 20 
100.0 
8.0 
2.2 
22 42 20 
100.0 
2.2 
2.2 
35-49 years 32 
14.9 
5.2 
3.5 
15 
7.0 
21.7 
1.7 
163 
78.1 
76.0 
18.5 
394 215 
100.0 
23.7 
23.7 
50-69 years 396 
82.8 
64.7 
43.7 
46 
9.6 
66.7 
5.1 
36 
7.5 
16.0 
4.0 
682 478 
100.0 
52.6 
52.6 
> 69 years 184 
94.4 
30.0 
20.3 
11 
5.6 
11.6 
0.9 
102 297 195 
100.0 
21.5 
21.5 
Totals whole series 224 507 1417 910 
Totals noticed data 612 
67.6 
100.0 
67.6 
72 
7.6 
100.0 
7.6 
224 
24.8 
100.0 
24.8 
¡415 908 
100.0 
100.0 
100.0 
125 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fc 17 Age versus Location of tumor. 
Location of tumor 
Age 
Medial, 
subareolar, 
or whole breast Lateral Other 
Totals 
whole series 
< 35 years 
35-49 years 
50-69 years 
> 69 years 
Other 
Totals whole series 
19 
47.5 
2.6 
1.4 
192 
52.5 
26.2 
14.4 
348 
53 9 
47.4 
26.1 
175 
62.3 
23.8 
13.1 
734 
21 
52 5 
3.5 
1.6 
174 
47.5 
29.0 
13.1 
28 
298 
46.1 
49.7 
22.4 
36 
106 
37.7 
17.7 
8.0 
16 
682 
297 
601 1417 
Totals 
noticed data 
40 
100.0 
3.0 
3.0 
366 
100.0 
27.5 
27.5 
646 
100.0 
48.5 
48.5 
281 
100.0 
21.1 
21.1 
Totals noticed data 734 
55.1 
100.0 
55.1 
599 
44.9 
100.0 
4 4 9 
1415 1333 
100.0 
100.0 
100.0 
TABLE fc 18 Age versus Size of tumor. 
Size of tumor 
Age 
< 35 years 
35-49 years 
50-69 years 
> 69 years 
Other 
Not more 
than 2 cm 
9 
22.0 
4.5 
0.7 
71 
19.3 
35.7 
5.3 
83 
13.0 
41.7 
6.2 
36 
12.6 
18.1 
2.7 
1 
2-5 cm 
10 
24.4 
1.7 
0.7 
156 
42.4 
26.4 
11.7 
295 
46.2 
49.9 
22.1 
130 
45.5 
22.0 
9.7 
-
5-10 cm 
19 
46.3 
4.3 
1.4 
117 
31.8 
26.4 
8.8 
216 
33.8 
48.6 
16.2 
92 
32.2 
20.7 
6.9 
/ 
More than 
10 cm 
3 
7.3 
3.0 
0.2 
24 
6.5 
24.0 
1.8 
45 
7.0 
45.0 
3.4 
28 
9.8 
28.0 
2.1 
-
Other 
; 
26 
43 
11 
-
Totals 
whole series 
42 
394 
682 
297 
2 
Totals 
noticed data 
41 
100.0 
3.1 
3.1 
368 
100.0 
27.6 
27.6 
639 
100.0 
47.9 
47.9 
286 
100.0 
21.4 
21.4 
-
Totals whole series 200 591 100 1417 1336 
Totals noticed data 
126 
199 
14.9 
00.0 
14.9 
591 
44.3 
100.0 
44.3 
444 
33.3 
100.0 
33.3 
100 
7.5 
100.0 
7.5 
1415 1334 
100.0 
100.0 
100.0 
TABLE fc 19 
Age 
< 35 years 
35-^9 years 
50-69 years 
> 69 years 
Other 
Age versus Fixation to skin. 
Incnmplete 
skin fixation 
7 
18 9 
2 0 
0 5 
82 
22 2 
23 5 
6 0 
171 
26 0 
49 0 
12 6 
89 
30.6 
25 5 
6 6 
-
Complete 
skin fixation 
7 
18 9 
2 0 
0 5 
70 
189 
20 4 
5 2 
164 
24 9 
47 8 
12.1 
102 
35 1 
29 7 
7 5 
1 
Fixation to skin 
Skin fixation 
wide of tumor 
but not 
beyond 
breast area 
2 7 
12 
0 1 
12 
3 2 
14 3 
0 9 
47 
7 1 
56 0 
3 5 
24 
8 2 
28 6 
1 8 
-
Skm not 
involved 
22 
59 4 
3 6 
1 7 
206 
55 7 
3 1 6 
15 2 
276 
42 0 
49 9 
20 4 
76 
26 2 
14 9 
5 6 
1 
Other 
5 
24 
24 
6 
-
Totals 
whole scries 
42 
394 
682 
297 
2 
Totals 
noticed data 
37 
100.0 
2 7 
2 7 
370 
100.0 
27 3 
27 3 
658 
100 0 
48 5 
48 5 
291 
100.0 
2 1 5 
2 1 5 
-
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole series 349 344 1417 1358 
Totals noticed data 349 
25 7 
100.0 
25 7 
343 
25 3 
100.0 
25 3 
84 
6 2 
100.0 
6 2 
580 
42 8 
100 0 
42 8 
1356 
100 0 
100.0 
loo.o 
TABLE fc 20 Age versus Nipple retraction. 
Nipple retraction 
Nipple 
retraction 
No nipple 
retraction Other 
Totals 
whole series 
Totals 
noticed data 
< 35 years 6 
16 7 
1 5 
0 5 
30 
83 3 
32 
2 3 
42 36 
100.0 
2 7 
2 7 
35-49 years 82 
22 6 
20 6 
6 2 
281 
77 4 
30 2 
21 1 
394 363 
100 0 
27 3 
27 3 
50-69 years 209 
32 5 
52 5 
157 
435 
67 5 
4 6 7 
32 7 
644 
100 0 
48 5 
48.5 
> 69 years 101 
35 3 
25 4 
7 6 
185 
6 4 7 
199 
139 
286 
100.0 
2 1 5 
2 1 5 
Other 
Totals whole ernes 
Totals noticed data 398 
29 9 
100.0 
29 9 
931 
70 1 
100.0 
70 1 
1415 1329 
100.0 
100.0 
100.0 127 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed 
TABLE fc 21 Age versus Pectoral muscle fixation. 
dala 
Age 
•< 35 years 
35-49 yeara 
50-69 yean 
> 69 years 
Other 
Totals whole яегіеэ 
Pectoral muscle fixation 
No fixation 
Incomplete 
fixation 
Complete 
fixation Other 
Totals 
whole series 
32 
86.5 
3.0 
2.4 
301 
83.1 
28.5 
22.9 
509 
80.2 
48.2 
38.7 
214 
75.9 
20.3 
16.3 
1058 
4 
10.8 
2.4 
0.3 
/ 
2.7 
1.1 
0.1 
42 
39 
10.8 
23.2 
3.0 
22 
6.1 
23.9 
1.7 
32 394 
32 
12.9 
48.8 
6.2 
44 
6.9 
47.8 
3.3 
682 
43 
15.2 
25.6 
3.3 
25 
8.9 
27.2 
1.9 
297 
168 99 1417 
Totals 
noticed data 
37 
100.0 
2.8 
2.8 
362 
100.0 
27.5 
27.5 
«35 
100.0 
48.3 
48.3 
282 
100.0 
21.4 
21.4 
Totals noticed data 1056 
80.2 
100.0 
80.2 
168 
12.8 
100.0 
12.8 
92 
7.0 
100.0 
7.0 
1415 1316 
100.0 
100.0 
loo.o 
TABLE f
c
 22 Age versus Status of the homolateral axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Age 
< 35 years 
35-49 yean 
50-69 years 
> 69 years 
Other 
Totals whole series 
Single 
9 
22.5 
3.7 
0.7 
67 
17.4 
27.7 
4.9 
108 
16.3 
44.6 
7.9 
58 
20.2 
24.0 
4.2 
-
242 
Multiple 
6 
15.0 
2.9 
0.4 
64 
16.7 
30.8 
4.7 
95 
14.3 
45.7 
6.9 
43 
15.0 
20.7 
3.1 
-
208 
Fixed to one 
another or to 
other structures 
2 
5.0 
2.2 
0.1 
15 
3.9 
16.3 
1.1 
51 
7.7 
55.4 
3.7 
24 
8.4 
26.1 
1.7 
; 
93 
Considered 
to contain 
no growth 
23 
57.5 
2.9 
1.7 
238 
62.0 
28 6 
17.3 
409 
61.7 
49.0 
29.8 
162 
56.5 
19.5 
11.8 
/ 
833 
Other 
2 
10 
19 
10 
-
41 
Totals 
whole scries 
42 
394 
682 
297 
2 
1417 
Totals 
noticed data 
40 
100.0 
2.9 
2.9 
384 
100.0 
27.9 
27.9 
663 
100.0 
48.3 
48.3 
287 
100.0 
20.9 
20.9 
-
1376 
Totals noticed data 
128 
242 
17.6 
100.0 
17.6 
208 
15.1 
100.0 
15.1 
92 
6.7 
100.0 
6.7 
832 
60.6 
100.0 
60.6 
1415 1374 
100.0 
100.0 
100.0 
TABLE fe 23 Age versus Status of the supra- and infraclavicular lymph nodes. 
Ag<= 
<C 3 5 y e a r s 
35-^9 years 
50-69 years 
> 69 years 
Other 
Totals whole series 
Status of the supra- and infraclavicular lymph nodes 
Considered to 
contain growth Totals whole series Totals noticed data 
4 
100.0 
5.0 
5.0 
22 
100.0 
27.5 
27.5 
37 
100.0 
46.3 
46.3 
17 
100.0 
21.3 
21.3 
372 394 
280 
1337 
4 
loo.o 
5.0 
5.0 
22 
100.0 
27.5 
27.5 
37 
100.0 
46.3 
46.3 
17 
100.0 
21.3 
21.3 
SO 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals noticed data SO 
100.0 
100.0 
100.0 
1411 80 
100.0 
100.0 
100.0 
TABLE fc 24 Age versus Clinical stage (International TNM classification). 
Age 
Clinical stage (International T N M classification) 
Stage I Stage II Stage III 
Totals Totals 
Stage I V Other whole series noticed data 
•< 35 years 14 
33.3 
3.4 
1.0 
J 
11.9 
2.7 
0.4 
22 
52.4 
3.0 
1.6 
1 
2.4 
1.4 
0.1 
42 42 
100.0 
3.0 
3.0 
35-49 years 127 
32.4 
30.8 
9.0 
66 
16.8 
36.1 
4.7 
187 
47.7 
25.2 
13.2 
12 
3.1 
17.4 
0.8 
394 392 
100.0 
27.8 
27.8 
50-69 years 196 
29.0 
47.5 
14.0 
13.0 
48.1 
6.2 
350 
51.8 
47.2 
24.9 
42 
6.2 
60.9 
3.0 
682 676 
100.0 
48.2 
48.2 
> 69 years 76 
25.6 
18.4 
5.4 
24 
8.1 
13.1 
1.7 
183 
61.6 
24.7 
12.9 
14 
4.7 
20.3 
1.0 
297 297 
100.0 
21.0 
21.0 
Other 1 
T o t a b whole series 414 183 743 1417 1409 
Totals noticed data 413 
29.4 
100.0 
29.4 
183 
13.1 
100.0 
13.1 
742 
52.6 
100.0 
52.6 
69 
4.9 
100.0 
4.9 
1407 
100.0 
100.0 
100.0 
129 
TABLE fe 25 Age versus Clinical stage (International TNM classification). 
Stage in is divided into two groups\ a: large tumor опіу^ no other symptoms; b: also other 
symptoms 
Clinical stage (International T N M classification) 
Stage III 
large tumor 
only, no Stage III 
other also other Totals Totals 
Age Stage I Stage II symptoms symptoms Stage IV Other whole series noticed data 
< 35 i c a n 
35-49 years 
50-69 years 
> 69 years 
Other 
Totals whole senes 
Totals noticed data 
14 
33 3 
3 4 
1 0 
127 
32 4 
30 8 
9 0 
196 
29 0 
47 5 
1 3 9 
76 
25 6 
1 8 4 
5 4 
1 
414 
413 
29 4 
100 0 
29 4 
5 
1 1 9 
2 7 
0 4 
66 
1 6 0 
36 1 
4 7 
88 
1 3 0 
48 1 
6 3 
24 
8 1 
13 1 
1 7 
-
183 
183 
1 3 0 
100.0 
1 3 0 
12 
28 6 
6 5 
0 9 
61 
15 6 
33 2 
4 3 
85 
12 6 
46 2 
6 0 
26 
8 8 
14 1 
1 8 
-
184 
184 
13 1 
100.0 
13 1 
10 
23 8 
1 8 
0 7 
126 
32 1 
22 6 
9 0 
26S 
39 2 
47 5 
18 8 
157 
52 9 
28 1 
1 1 2 
1 
559 
558 
39 7 
100.0 
39 7 
/ 
2 4 
1 4 
0 1 
12 
3 1 
1 7 4 
0 9 
42 
6 2 
60 9 
3 0 
14 
4 7 
20 3 
1 0 
-
69 
69 
4 9 
100.0 
4 9 
_ 
2 
6 
-
8 
_ 
42 
394 
682 
297 
2 
1417 
1415 
42 
100 0 
3 0 
3 0 
392 
100 0 
27 9 
27 9 
676 
100 0 
4 8 0 
48 0 
297 
100.0 
21 1 
21 1 
-
1409 
1407 
100 0 
100.0 
100 0 
TABLE fc 26 Age versus Histology of the axillary lymph nodes. 
Histology of the axillary lymph nodes 
Histologically Histologically Totals Totals 
Age negative positive Other whole series noticed data 
< 35 years 
35-49 yean 
50-69 yean 
> 69 years 
Other 
Totals whole senes 
8 
25 0 
2 0 
0 8 
114 
36 2 
28 4 
10 8 
209 
39 0 
52 0 
19 8 
71 
4 1 8 
17 7 
6 7 
-
402 
24 
75 0 
3 7 
2 3 
201 
63 8 
30 9 
19 1 
327 
6 1 0 
50 2 
31 1 
99 
58 2 
152 
9 4 
/ 
652 
10 
79 
146 
127 
1 
363 
42 
394 
682 
297 
2 
1417 
32 
100.0 
3 0 
3 0 
315 
100 0 
29 9 
29 9 
536 
100.0 
5 0 9 
5 0 9 
170 
100.0 
16 1 
16 1 
-
1054 
Totab noticed data 402 651 - 1415 1053 
38 2 61 8 100.0 
100 0 100.0 100.0 
130 38 2 618 100.0 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fe 27 Duration of symptoms before starting treatment versus Age at onset of menopause. 
Age at onset of menopause 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
< 45 yean 
36 
11.3 
32.4 
4.1 
33 
12.0 
29.7 
3.8 
42 
15.0 
37.8 
4.8 
4 
45 55 years 
J90 
59.4 
37.4 
21.7 
/57 
57.3 
30.9 
18.0 
161 
57.5 
31.7 
18.4 
21 
> 55 years 
14 
4.4 
40.0 
1.6 
// 
4.0 
31.4 
1.3 
10 
3.6 
28.6 
1.1 
2 
N o 
menopause 
80 
25.0 
36.4 
9.2 
73 
26.6 
33.2 
8.4 
67 
23.9 
30.5 
7.7 
J 
Other 
132 
166 
164 
49 
Totals 
whole series 
452 
440 
444 
81 
Totals 
noticed data 
320 
100.0 
36.6 
36.6 
274 
100.0 
31.4 
31.4 
280 
100.0 
32.0 
32.0 
-
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole series ¡15 529 37 1417 906 
Totals noticed data 111 
12.7 
100.0 
12.7 
508 
58.1 
100.0 
58.1 
35 
4.0 
100.0 
4.0 
220 
25.2 
100.0 
25.2 
1336 874 
100.0 
loo.o 
100.0 
TABLE fc 28 Duration of symptoms before starting treatment versus Cause of menopause. 
Cause of menopause 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
Spontaneous 
212 
67.1 
36.1 
24.3 
178 
64.3 
30.3 
20.4 
197 
70.4 
33.6 
22.6 
29 
Surgical or 
radiological 
castration 
24 
7.6 
36.4 
2.7 
25 
9.0 
37.9 
2.9 
17 
6.1 
25.8 
1.9 
3 
No menopause 
80 
25.3 
36.4 
9.2 
74 
26.7 
33.6 
8.5 
66 
23.6 
30.0 
7.6 
5 
Other 
136 
163 
164 
44 
Totals 
whole series 
452 
440 
444 
81 
Totals 
noticed data 
316 
100.0 
36.2 
36.2 
277 
100.0 
31.7 
31.7 
280 
100.0 
32.1 
32.1 
-
Totals whole series 
Totals noticed data 587 
67.2 
100.0 
67.2 
5« 
7.6 
100.0 
7.6 
220 
25.2 
100.0 
25.2 
1336 873 
100.0 
100.0 
100.0 
131 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed с 
TABLE fc 29 Duration of symptoms be/ore starting treatment versus Location of tumor. 
Location of tumor 
Duration of 
symptoms before 
starting treatment 
Medial, 
subareolar, 
or whole breast Lateral O t h e r 
Totals 
whole series 
0-30 days 
1-6 months 
! > 6 months 
Other 
Totals whole series 
213 
49 2 
30 4 
16 9 
224 
5 4 1 
32 0 
177 
264 
63 3 
37 7 
20 9 
33 
734 
220 
50 8 
39 1 
174 
¡9 
190 
45 9 
33 7 
15 0 
26 
153 
36 7 
27 2 
12 1 
27 
38 10 
452 
440 
444 
81 
601 82 1417 
Totals 
noticed da ta 
433 
100.0 
34 3 
34 3 
414 
100.0 
32 7 
32 7 
417 
100.0 
33 0 
33 0 
1335 
Totals noticed data 701 
55 5 
100.0 
55 5 
563 
4 4 5 
100.0 
4 4 5 
1336 1264 
100.0 
100.0 
100.0 
TABLE fc 30 Duration of symptoms before starting treatment versus Size of tumor. 
Size of tumor 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
Not more 
than 2 cm 
71 
16 3 
38 4 
5 6 
65 
15 8 
35 1 
5 2 
49 
1 1 9 
26 5 
3 9 
15 
2-5 cm 
235 
53 9 
4 1 9 
187 
187 
45 5 
33 3 
14 9 
139 
33 7 
24 8 
110 
30 
5-10 cm 
119 
27 3 
28 3 
9 5 
132 
32 1 
3 1 4 
106 
169 
4 1 0 
4 0 2 
134 
25 
More than 
10 cm 
и 
2 5 
1 1 8 
0 9 
27 
6 6 
29 0 
2 1 
J J 
13 3 
59 1 
4 4 
7 
Other 
16 
29 
32 
4 
Totals 
whole series 
452 
440 
444 
81 
Totals 
noticed d a t a 
436 
100.0 
3 4 6 
34 6 
411 
100.0 
32 7 
32 7 
412 
100.0 
32 7 
32 7 
-
Totals whole series 200 591 100 81 1417 1336 
Totals noticed data 185 
14 7 
100.0 
14 7 
561 
4 4 6 
100.0 
4 4 6 
420 
33 4 
100.0 
33 4 
93 
7 4 
100 0 
7 4 
1259 
100 0 
100.0 
100.0 
132 
TABLE fe 31 Duration of symptoms before starting treatment versus Fixation to skin. 
Fixation to skin 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
Incomplete 
skin fixation 
124 
28 5 
37 5 
9 7 
119 
28 5 
36 0 
9 3 
88 
20 5 
26 6 
6 9 
18 
Complete 
skin fixation 
61 
14 0 
19 1 
4 8 
98 
23 5 
30 6 
7 6 
161 
37 4 
50 3 
12 6 
24 
Skin fixation 
wide of tumor 
but not 
beyond 
breast area 
13 
3 0 
16 0 
1 0 
22 
5 3 
27 2 
1 7 
46 
10 7 
56 8 
3 6 
3 
Skin not 
involved 
237 
5 4 4 
4 4 2 
18 5 
178 
42 6 
31 1 
1 3 9 
135 
3 1 4 
24 7 
10 4 
31 
Other 
17 
23 
14 
5 
Totals 
whole series 
452 
440 
444 
81 
Totals 
noticed data 
435 
100 0 
34 0 
34 0 
417 
100 0 
32 5 
32 5 
430 
100 0 
33 5 
33 5 
-
Numbers 
% Horizontal 
'A, Vertical 
% Totals noticed data 
Totals whole senes 349 344 59 1417 1358 
Ί otals noticed data 331 
25 8 
100.0 
25 8 
320 
25 0 
100 0 
25 0 
81 
6 3 
100 0 
6 3 
550 
42 9 
100 0 
42 9 
1282 
100 0 
100.0 
100 0 
TABLE f
c
 32 Duration of symptoms before starting treatment versus Nipple retraction. 
Nipple retraction 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
Nipple 
retraction 
85 
20 0 
22 5 
6 8 
118 
28 8 
3 1 3 
9 4 
¡74 
41 1 
4 6 2 
13 8 
21 
No nipple 
retraction 
341 
80 0 
38 7 
27 1 
292 
7 1 2 
33 1 
23 2 
249 
58 9 
28 2 
19 8 
51 
Other 
26 
30 
21 
9 
Totals 
whole series 
452 
440 
444 
81 
Totals 
noticed data 
426 
100 0 
33 8 
33 8 
410 
100 0 
32 6 
32 6 
423 
looo 
33 6 
33 6 
-
Totals whole senes 398 933 86 1417 1331 
Totals noticed data 377 
29 9 
100.0 
29 9 
««2 
70 1 
100 0 
70 1 
1336 1259 
100.0 
100.0 
100.0 
133 
Numbers 
% Honzonta 
% Vertical 
% Totals noticed data 
TABLE fc 33 Duration of symptoms be/ore starting treatment versus Pectoral muscle fixation. 
Pectoral muscle fixation 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
No fixation 
363 
87 2 
36 4 
29 5 
325 
80 2 
32 2 
26 1 
317 
75 5 
3 1 4 
25 4 
48 
Incomplete 
fixation 
46 
10 9 
29 7 
3 7 
53 
13 1 
34 2 
4 3 
56 
13 3 
36 1 
4 5 
¡3 
Complete 
fixation 
в 
1 9 
9 8 
0 6 
27 
6 7 
32 9 
2 2 
47 
112 
57 3 
3 8 
JO 
Other 
30 
35 
24 
10 
Totals 
whole senes 
452 
440 
444 
81 
Totals 
noticed data 
422 
100 0 
33 8 
33 8 
405 
100 0 
32 5 
32 5 
420 
100.0 
33 7 
33 7 
-
Totals whole scries 92 1318 
Totals noticed data 1010 
8 1 0 
100 0 
8 1 0 
/55 
12 4 
100 0 
1 2 4 
82 
6 6 
100.0 
6 6 
1247 
100.0 
100 0 
100.0 
TABLE fc 34 Duration of symptoms before starting treatment versus Status of the homolateral 
axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
Totals whole series 
Single 
73 
1 6 4 
32 2 
5 6 
81 
19 1 
35 7 
6 2 
73 
16 9 
32 2 
5 6 
15 
242 
Multiple 
54 
12 1 
28 0 
4 1 
62 
14 6 
32 1 
4 8 
77 
1 7 8 
39 9 
6 0 
15 
208 
Fixed to one 
another or to 
other structures 
28 
6 3 
30 8 
2 1 
22 
5 2 
24 2 
1 7 
41 
9 5 
45 1 
3 1 
2 
93 
Considered 
to contain 
no growth 
290 
65 2 
36 6 
22 3 
260 
6 1 0 
32 8 
20 0 
242 
55 8 
30 6 
185 
41 
833 
Other 
; 
15 
и 
8 
41 
Totals 
whole series 
452 
440 
444 
81 
1417 
Totals 
noticed data 
445 
100 0 
3 4 2 
34 2 
425 
100 0 
32 6 
32 6 
433 
100.0 
33 2 
33 2 
-
1376 
Totals noticed data 227 
1 7 4 
100 0 
17 4 
193 
14 8 
100 0 
14 8 
91 
7 0 
100 0 
7 0 
792 
6 0 8 
100.0 
6 0 8 
1336 1303 
100 0 
100 0 
100.0 
134 
TABLE fe 35 Duration of symptoms before starting treatment versus Status of the supra- and ambers 
infraclavicular lymph nodes. 
Duration of symptoms before 
starting treatment 
0-30 days 
1-6 months 
> 6 months 
Status of the supra- and infraclavicular lymph nodes 
Considered to 
contain growth Other Totals whole series Totals noticed data 
15 
100.0 
19.7 
19.7 
26 
100.0 
34.2 
34.2 
35 
100.0 
46.1 
46.1 
409 444 
15 
100.0 
19.7 
19.7 
26 
100.0 
34.2 
34.2 
35 
100.0 
46.1 
46.1 
% Vertical 
% Totals noticed data 
Totals whole series ¡337 
Totals noticed data 76 
100.0 
100.0 
100.0 
1336 76 
100.0 
100.0 
100.0 
TABLE fc 36 Duration of symptoms before starting treatment versus Clinical stage (Interna-
tional TNM classification). 
Clinical stage (International T N M classification) 
Duration of 
symptoms before 
starting treatment 
0-30 days 
1-6 montlis 
> 6 months 
Other 
Stage I 
172 
38.2 
43.8 
12.9 
131 
29.8 
33.3 
9.8 
90 
20.4 
22.9 
6.7 
21 
Stage I I 
70 
15.6 
4 0 2 
5.2 
64 
14.5 
36.8 
4.8 
40 
9.1 
23.0 
3.0 
9 
Stage I I I 
197 
43.8 
28.1 
14.9 
232 
52.7 
33.1 
17.4 
272 
61.7 
38.8 
20.4 
42 
Stage I V 
и 
2.4 
17.5 
0.8 
13 
3.0 
20.6 
1.0 
39 
8.8 
61.9 
3.1 
ff 
Other 
2 
-
3 
3 
Totals 
whole series 
452 
440 
444 
81 
Totals 
noticed data 
450 
100.0 
33.8 
33.8 
440 
100.0 
33.0 
33.0 
441 
100.0 
33.2 
33.2 
-
Totals whole series 69 1417 1409 
Totals noticed data 393 
29.4 
100.0 
29.4 
174 
13.0 
100.0 
13.0 
701 
52.7 
100.0 
52.7 
63 
4.9 
100.0 
4.9 
1336 1331 
100.0 
100.0 
100.0 
135 
Numbers 
% Horizontal 
% Vertical 
'/, Totals noticed data 
TABLE f
c
 37 Duration of symptoms before starting treatment versus Clinical stage 
(International TNM classification). Stage m is divided into two groups, a : large tumor only, no 
other symptoms; b: abo other symptoms. 
Clinical stage (International T N M classification) 
Duration οΓ 
symptoms 
before 
starting 
treatment 
0-30 days 
1-6 months 
> 6 months 
Other 
Totals whole series 
Totals noticed data 
Stage I 
172 
38 2 
« 8 
12 9 
131 
29 8 
3 1 3 
9 8 
90 
20 4 
22 9 
6 8 
21 
414 
393 
29 5 
100.0 
29 5 
Stage II 
70 
156 
40 2 
5 3 
64 
145 
36 8 
4 8 
40 
9 1 
23 0 
3 0 
9 
183 
174 
13 1 
100.0 
131 
Stage III 
large tumor 
only, no 
other 
symptoms 
Í7 
14 9 
37 9 
5 0 
eo 
136 
33 9 
4 5 
50 
113 
28 2 
3 8 
7 
184 
177 
133 
100.0 
133 
Stage III 
also other 
symptoms 
130 
28 9 
24 8 
9 8 
172 
39 1 
32 8 
12 9 
222 
50 3 
42 4 
167 
35 
559 
524 
39 4 
100.0 
39 4 
Stage IV 
11 
2 4 
175 
0Я 
13 
3 0 
20 6 
1 0 
39 
8 8 
6 1 9 
2 9 
6 
69 
63 
4 7 
100.0 
4 7 
Other 
2 
-
3 
3 
8 
_ 
Totals 
whole series 
452 
440 
444 
81 
1417 
1336 
Totals 
noticed data 
450 
100.0 
33 8 
33 8 
440 
100.0 
33 0 
33 0 
441 
100.0 
33 2 
33 2 
-
1409 
1331 
100.0 
looo 
100.0 
TABLE f
c
 38 Duration of symptoms before starting treatment versus Histology of the axillary 
lymph nodes. 
Duration of 
symptoms before 
starting treatment 
Histology of the axillary lymph nodes 
Histologically 
negative 
Histologically 
positive 
Totals 
whole series 
Totals 
noticed data 
0-30 days ¡64 
45 3 
42 9 
16 4 
198 
5 4 7 
32 0 
19 8 
90 452 362 
100.0 
36 2 
36 2 
1-6 months 119 
35 3 
3 1 2 
1 1 9 
218 
6 4 7 
35 2 
21 β 
103 440 337 
100.0 
33 7 
33 7 
^> 6 months 99 
32.8 
25.9 
9 9 
203 
67 2 
32 8 
20 3 
142 302 
100 0 
30 2 
30 2 
Other 20 33 28 81 
Totals whole s 652 363 1054 
Totals noticed data 382 
38.2 
100.0 
38 2 
619 
6 1 8 
100.0 
6 1 8 
1336 ¡001 
100.0 
100.0 
100.0 
136 
TABLE fe 39 Age at onset of menopause versus Cause of menopause. 
Age at onset of 
menopause 
<C 45 years 
45-55 years 
! > 55 y e a n 
N o menopause 
O t h e r 
TotaJs whole series 
Cause οΓ menopause 
Surgical 
or radiological 
Spontaneous castration N o menopause O t h e r 
Totals 
whole series 
SO 
74.1 
13.6 
9.1 
474 
93.3 
80.5 
54.0 
35 
97.2 
5.9 
4.0 
27 
616 
28 
25.9 
44.4 
3.2 
34 
6.7 
54.0 
3.9 
21 
I 
2.8 
1.6 
0.1 
22S 
100.0 
100.0 
25.7 
478 
69 225 1417 
Totals 
noticed d a t a 
108 
100.0 
12.3 
12.3 
508 
100.0 
57.9 
57.9 
36 
100.0 
4.1 
4.1 
225 
100.0 
25.7 
25.7 
Numbrrs 
% Horizontal 
% Vertical 
% Totals noticed d a t a 
Totals noticed data 589 
67.2 
100.0 
67.2 
63 
7.2 
100.0 
7.2 
225 
25.7 
100.0 
25.7 
«77 
100.0 
100.0 
100.0 
TABLE fc 40 Age at onset of menopause versus Location of tumor. 
Age at onset of 
menopause 
Location of tumor 
Medial, 
subareolar 
or whole breast Lateral Other 
Totals 
whole series 
Total« 
noticed data 
<C 45 years ff5 
59.6 
13.0 
7.6 
44 
40.4 
12.4 
5.1 
109 
100.0 
12.7 
12.7 
45-55 years 290 
57.7 
58.1 
33.9 
213 
42.3 
59.8 
24.9 
529 503 
100.0 
58.8 
58.8 
> 55 y e a n 21 
60.0 
4.2 
2.5 
14 
40.0 
3.9 
1.6 
37 35 
100.0 
4.1 
4.1 
N o menopause 123 
59.1 
24.6 
14.4 
85 
40.9 
23.9 
9.9 
17 208 
100.0 
24.3 
24.3 
O t h e r 235 245 31 
Totals whole series 734 82 1335 
Totals noticed data 499 
58.4 
100.0 
58.4 
356 
41.6 
100.0 
41.6 
906 855 
100.0 
100.0 
100.0 137 
lumbers 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fc 41 Age at onset of menopause versus Size of tumor. 
Size of tumor 
Age at onset of 
menopause 
< 45 yean 
45-55 years 
> 55 yean 
N o menopause 
Other 
Not more 
than 2 cm 
13 
12 4 
9 7 
1 6 
74 
14 7 
55 2 
8 7 
4 
108 
3 0 
0 5 
43 
199 
32 1 
5 0 
66 
2-5 cm 
58 
55 2 
13 9 
6 8 
239 
47 6 
57 2 
27 7 
23 
62 2 
5 5 
2 7 
98 
45 4 
23 4 
113 
173 
5-10 cm 
31 
29 5 
12 1 
3 7 
154 
30 7 
60 2 
178 
8 
2 1 6 
3 1 
0 9 
63 
29 2 
24 6 
7 3 
189 
More than 
10 cm 
3 
2 9 
5 8 
0 4 
35 
7 0 
67 3 
4 1 
2 
5 4 
3 8 
0 2 
12 
5 6 
23 1 
1 4 
48 
Other 
10 
27 
-
9 
35 
Totals 
whole scries 
115 
529 
37 
225 
511 
Totals 
noticed data 
105 
100 0 
12 5 
1 2 5 
502 
100 0 
58 3 
58 3 
37 
100.0 
4 3 
4 3 
216 
100 0 
25 0 
25 0 
-
Totals whole senes 591 81 
Totals noticed data 134 
15 7 
00.0 
157 
418 
4 8 5 
100.0 
4 8 5 
256 
29 7 
100 0 
29 7 
52 
6 1 
100.0 
6 1 
906 860 
100.0 
100.0 
100.0 
TABLE fc 42 Age at onset of menopause versus Fixation to skin. 
Fixation to skin 
Age at onset of 
menopause 
< 45 yean 
45-55 yean 
> 55 yean 
No menopause 
Other 
Incomplete 
skin fixation 
39 
35 5 
1 5 4 
4 4 
164 
3 1 4 
65 1 
18 6 
/; 
3 1 4 
4 4 
1 2 
38 
176 
15 1 
4 3 
97 
Complete 
skin fixation 
26 
23 6 
13 5 
2 9 
121 
23 2 
63 0 
13 7 
9 
25 7 
4 7 
1 0 
36 
16 7 
18 8 
4 1 
152 
Skin fixation 
wide of tumor 
but not 
beyond 
breast area 
4 
3 6 
7 8 
0 5 
35 
6 7 
6 8 6 
4 0 
2 
5 7 
3 9 
0 2 
10 
4 6 
19 6 
1 1 
33 
Skin not 
involved 
41 
37 3 
10 6 
4 8 
202 
38 7 
52 1 
22 8 
13 
37 2 
3 3 
1 5 
132 
61 1 
34 0 
14 9 
193 
Other 
J 
7 
2 
9 
36 
Totals 
whole series 
115 
529 
37 
225 
511 
Totals 
noticed data 
no 
loo.o 
1 2 5 
12 5 
522 
looo 
59 1 
59 1 
35 
100.0 
4 0 
4 0 
216 
loo.o 
24 5 
24 5 
-
Totals whole senes 349 344 84 59 1417 1358 
Totals noticed data 
138 
252 
28 5 
100 0 
28 5 
192 
2 1 7 
100 0 
2 1 7 
51 
5 8 
100.0 
SB 
388 
4 4 0 
100.0 
4 4 0 
906 883 
100.0 
100.0 
100.0 
TABLE fe 43 Age at onset of menopause versus Nipple retraction 
Nipple retraction 
Age at onset of 
menopause 
< 45 years 
45-55 year» 
< 55 yean 
No menopause 
Other 
Nipple 
retraction 
30 
27 0 
1 1 4 
3 4 
178 
34 6 
67 7 
20 3 
12 
34 3 
4 6 
1 4 
43 
20 1 
16 3 
4 9 
135 
No nipple 
retraction 
81 
73 0 
13 2 
9 3 
337 
65 4 
55 1 
38 5 
23 
65 7 
3 8 
2 6 
171 
79 9 
27 9 
1 9 5 
321 
Other 
4 
14 
2 
11 
55 
Totals 
whole series 
115 
529 
37 
225 
511 
Totals 
noticed data 
//; 
100.0 
12 7 
12 7 
515 
100.0 
58 9 
58 9 
35 
100 0 
4 0 
4 0 
214 
100.0 
24 5 
24 5 
-
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole series 398 1417 ¡331 
Totals noticed data 263 
30 1 
100 0 
30 1 
612 
69 9 
100 0 
69 9 
50« 875 
loo.o 
100 0 
100.0 
TABLE fc 44 Age at onset of menopause versus Pectoral muscle fixation. 
Age at onset of 
menopause 
Pectoral muscle fixation 
Incomplete 
fixation 
Complete 
fixation 
Totals 
whole scries 
Totals 
noticed data 
< 45 years 86 
78 2 
12 4 
9 9 
¡4 
12 7 
11 7 
1 6 
10 
9 1 
179 
12 
110 
100.0 
12 7 
12 7 
45-55 yean 407 
79 3 
5 8 7 
4 6 8 
76 
14 8 
63 3 
87 
30 
5 8 
53 6 
3 5 
529 513 
100 0 
59 0 
59 0 
> 55 years 27 
79 4 
3 9 
3 1 
3 
88 
25 
03 
4 
118 
7 1 
0 5 
37 34 
100.0 
3 9 
3 9 
No menopause 173 
8 1 6 
25 0 
19 9 
27 
12 7 
22 5 
3 1 
12 
5 7 
2 1 4 
1 4 
225 212 
100 0 
24 4 
24 4 
Other 365 48 36 62 511 
Totals whole senes 1058 168 92 99 1318 
Totals noticed data 693 
79 7 
100.0 
79.7 
120 
1 3 8 
100.0 
13 8 
56 
6 4 
100.0 
6 4 
906 869 
100.0 
100 0 
100.0 
139 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fe 45 Age at onset of menopause versus Status of the homolateral axillary lymph 
nodes. 
Status of the homolateral axillary lymph nodes 
Age at onset of 
menopause 
< 45 years 
45-55 years 
> 55 years 
No menopause 
Other 
Single 
21 
18.9 
13.0 
2.4 
90 
17.3 
55.6 
10.1 
а 
21.6 
4.9 
0.9 
43 
19.5 
26.5 
4.8 
80 
Multiple 
9 
8.1 
8.0 
1.0 
76 
14.6 
67.3 
8.5 
3 
8.1 
2.7 
0.3 
25 
11.3 
22.1 
2.8 
95 
Fixed to one 
another or to 
other structures 
¡0 
9.0 
15.2 
1.1 
42 
8.1 
63.6 
4.7 
5 
13.5 
7.6 
0.6 
9 
4.1 
13.6 
1.0 
27 
Considered 
to contain 
no growth 
71 
64.0 
13.0 
7.9 
312 
60.0 
56.П 
35.2 
21 
56.8 
3.8 
2.4 
144 
65.2 
26.4 
16.3 
285 
Other 
4 
9 
-
4 
24 
Total» 
whole series 
115 
529 
37 
225 
511 
Totals 
noticed data 
111 
100.0 
12.5 
12.5 
520 
100.0 
58.5 
58.5 
37 
100.0 
4.2 
4.2 
221 
100.0 
24.9 
24.9 
-
Totals whole series 242 208 93 1417 1376 
Totals noticed data 162 
18.2 
100.0 
18.2 
113 
12.7 
100.0 
12.7 
66 
7.4 
100.0 
7.4 
548 
61.8 
100.0 
61.8 
906 889 
100.0 
100.0 
100.0 
TABLE fc 46 Age at onset of menopause versus Status of the supra- and infraclavicular lymph 
nodes. 
Status of the supra- and infraclavicular lymph nodes 
Age at onset of menopause 
Considered to 
contain growth Other Totals whole series Totals noticed data 
· < 45 years 6 
100.0 
11.5 
11.5 
109 6 
100.0 
11.5 
11.5 
45-55 years 33 
100.0 
63.5 
63.5 
33 
100.0 
63.5 
63.5 
> 55 years 1 
100.0 
1.9 
1.9 
36 1 
100.0 
1.9 
1.9 
N o menopause ¡2 
100.0 
23.1 
23.1 
213 225 12 
100.0 
23.1 
23.1 
Other 28 483 511 
Totals whole series 1337 80 
140 
Totals noticed data 52 
100.0 
100.0 
100.0 
906 52 
100.0 
100.0 
100.0 
TABLE fe 47 Age at onset of menopause versus Clinical stage (International TNM classification). 
Clinical stage (International T N M classification) 
Affc at oiuct 
menopause 
< 45 years 
45-55 yean 
> 55 years 
of 
No menopause 
Other 
Totals whole series 
Stage I 
34 
30.6 
11.5 
3.9 
168 
31.B 
56.9 
18.5 
13 
35.1 
4.4 
1.4 
SO 
35.7 
27.1 
8.9 
119 
414 
Stage II 
75 
13.5 
12.8 
1.7 
59 
11.2 
50.4 
6.5 
6 
16.2 
5.1 
0.7 
37 
16.5 
31.6 
4.1 
66 
183 
Stage III 
57 
51.4 
12.9 
6.4 
274 
51.8 
61.9 
30.2 
IS 
43.2 
3.6 
1.8 
96 
42.8 
21.6 
10.6 
300 
743 
Stage IV 
5 
4.5 
10.9 
0.7 
28 
5.3 
60.9 
3.1 
2 
5.4 
4.3 
0.2 
11 
5.0 
23.9 
1.2 
23 
69 
Other 
4 
-
-
1 
3 
8 
Totals 
whole series 
115 
529 
37 
225 
511 
1417 
Totals 
noticed data 
111 
100.0 
12.7 
12.7 
529 
100.0 
58.4 
58.4 
37 
100.0 
4.1 
4.1 
224 
100.0 
24.8 
24.8 
-
1409 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals noticed data 295 
32.7 
100.0 
32.7 
¡17 
13.0 
100.0 
13.0 
443 
49.0 
100.0 
49.0 
46 
5.2 
100.0 
5.2 
901 
100.0 
loo.o 
100.0 
TABLE fc 48 Age at onset of menopause versus Histology of the axillary lymph nodes. 
Age at onset of 
menopause 
Histology of the axillary lymph nodes 
Histologically 
negative 
Histologically 
positive Other 
Totals 
whole series 
Totals 
noticed data 
< 45 years 38 
45.2 
13.8 
5.5 
46 
54.8 
11.0 
6.6 
115 84 
100.0 
12.1 
12.1 
45-55 years 164 
41.2 
59.6 
23.6 
234 
58.Θ 
55.8 
33.7 
529 398 
100.0 
57.3 
57.3 
> 55 years 10 
32.3 
3.6 
1.4 
21 
67.7 
5.0 
3.0 
37 31 
100.0 
4.5 
4.5 
No menopause 63 
34.8 
22.9 
9.1 
118 
65.2 
28.2 
17.0 
44 225 181 
100.0 
26.1 
26.1 
Other 127 233 151 
Totals whole series 363 
Totals noticed data 275 
39.6 
100.0 
39.6 
419 
60.4 
100.0 
60.4 
906 694 
100.0 
100.0 
100.0 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed с 
TABLE fo 49 Cause of menopause versus Location of tumor. 
Location of tumor 
Cause of menopause 
Medial, 
subareolar, 
or whole breast lateral Other 
Totali 
whole series 
Spontaneous 
Surgical or radiological 
castration 
N o menopause 
Other 
Totals whole sen cs 
344 
58 5 
68 8 
4 0 0 
33 
52 4 
6 6 
3 8 
J23 
58 9 
24 6 
14 3 
234 
244 
41 5 
67 8 
28 4 
28 
30 
47 6 
83 
35 
86 
41 1 
23 9 
10 0 
241 32 
225 
82 1417 
Totals 
noticed data 
588 
100.0 
68 4 
68 4 
63 
100.0 
7 3 
7 3 
209 
100.0 
24 3 
24 3 
1335 
Totals noticed data 500 
58 1 
100.0 
58 1 
360 
4 1 9 
100.0 
4 1 9 
860 
100 0 
100.0 
100.0 
TABLE fe 50 Cause of menopause versus Size of tumor. 
Size of tumor 
Cause of menopause 
Spontaneous 
Surgical or radiological 
castration 
No menopause 
Other 
ISot more 
than 2 cm 
77 
132 
57 5 
8 9 
13 
19 7 
9 7 
1 5 
44 
20 4 
32 8 
5 1 
55 
2-5 cm 
291 
5 0 0 
69 1 
33 7 
32 
48 5 
7 6 
3 7 
98 
45 4 
23 3 
113 
170 
5-10 cm 
173 
29 7 
68 1 
20 0 
19 
28 8 
7 5 
2 2 
62 
28 7 
24 4 
7 2 
191 
More than 
10 cm 
41 
7 0 
74 5 
4 7 
2 
3 0 
3 6 
0 2 
12 
5 6 
21 В 
1 4 
45 
Other 
34 
3 
9 
35 
Totals 
whole series 
616 
69 
225 
507 
Totals 
noticed data 
582 
100 0 
67 4 
67 4 
55 
100.0 
7 6 
7 6 
216 
100.0 
25 0 
25 0 
-
Totab whole acnes 445 
Totals noticed data 134 
155 
100.0 
155 
421 
4 8 7 
100.0 
4 8 7 
254 
29 4 
100.0 
29 4 
55 
6 4 
100.0 
6 4 
910 864 
100 0 
100 0 
100.0 
142 
TABLE f
c
 51 Саше of menopause versus Fixation to skin 
l ixation to skin 
Cause of menopause 
Spontaneous 
Surgical or radiological 
castration 
\ o menopause 
Other 
Incomplete 
skin fixation 
188 
30 9 
77 4 
2 1 2 
17 
26 6 
7 0 
1 9 
38 
176 
15 6 
4 3 
106 
Complete 
skin fixation 
150 
24 7 
75 8 
16 9 
12 
18 8 
6 1 
1 4 
зе 
16 7 
18 2 
4 1 
не 
Skin fixation 
wide of tumor 
but not 
beyond 
breast area 
41 
6 7 
78 8 
4 6 
; 
1 6 
1 9 
0 1 
10 
4 6 
19 2 
1 1 
32 
Skin not 
involved 
229 
37 7 
58 0 
25 8 
34 
53 0 
9 0 
3 8 
132 
61 1 
32 9 
14 8 
186 
Other 
8 
5 
9 
37 
Totals 
whole scries 
616 
69 
225 
507 
Totals 
noticed data 
608 
100 0 
68 5 
68 5 
64 
100 0 
7 2 
7 2 
216 
100 0 
24 3 
24 3 
-
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole scries 59 
Totals noticed data 243 
27 4 
100 0 
27 4 
198 
22 3 
100 0 
22 3 
52 
5 9 
100 0 
5 9 
395 
4 4 4 
100 0 
4 4 4 
910 
100 0 
100 0 
100 0 
TABLE fc 52 Cause of menopause versus Nipple retraction. 
Nipple retraction 
Cause of menopause 
Spontaneous 
Surgical or radiological 
castration 
N o menopause 
Other 
Nipple 
retraction 
202 
33 4 
77 7 
22 9 
15 
22 7 
5 8 
17 
43 
20 1 
165 
4 9 
138 
No nipple 
retraction 
402 
6 6 6 
6 4 4 
45 5 
51 
77 3 
8 2 
5 8 
171 
79 9 
27 4 
19 3 
309 
Other 
12 
3 
11 
60 
Totab 
whole scries 
616 
69 
225 
507 
Totals 
noticed data 
604 
100 0 
68 3 
68 3 
66 
100 0 
7 5 
7 5 
214 
100 0 
24 2 
24 2 
-
Totals whole series 398 1417 
Totals noticed data 260 
29 4 
100 0 
29 4 
624 
70 6 
100 0 
70 6 
910 884 
100 0 
100 0 
100 0 
143 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fc 53 Cause of menopause versus Pectoral muscle fixation. 
Pectoral muscle fixation 
Cause of menopause No fixation 
Incomplete 
fixation 
Complete 
fixation Other 
Totals 
whole senes 
Spontaneous 
Surgical or radiological 
castration 
No menopause 
Other 
Totals whole series 
471 
78 6 
67 6 
53 7 
53 
8 0 3 
7 6 
6 0 
173 
81 6 
24 8 
19 7 
361 
¡OSS 
82 
13 7 
68 3 
9 4 
46 
7 7 
76 7 
5 2 
¡1 
16 7 
9 2 
1 3 
2 
3 0 
3 3 
0 2 
27 
12 7 
22 5 
3 1 
12 
5 7 
20 0 
1 4 
13 225 
48 32 66 507 
168 92 99 1417 
Totals 
noticed data 
599 
100.0 
68 3 
6 8 3 
66 
100.0 
7 5 
7 5 
212 
100.0 
24 2 
24 2 
Totals noticed data 697 
79 5 
100.0 
79 5 
120 
13 7 
100.0 
137 
60 
6 8 
100.0 
6 8 
877 
100.0 
100 0 
100.0 
TABLE fc 54 Cause of menopause versus Status of the homolateral axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Cause of menopause 
Spontaneous 
Surgical or radiological 
castration 
No menopause 
Other 
Single 
no 
18 2 
67 9 
12 3 
9 
136 
5 6 
1 0 
43 
19 5 
26 5 
4Θ 
80 
Multiple 
79 
13 1 
68 7 
8 9 
и 
16 7 
9 6 
1 2 
25 
11 3 
21 7 
2 8 
93 
Fixed to one 
another or to 
other structures 
52 
8 6 
78 8 
5 8 
5 
7 6 
7 6 
0 6 
9 
4 1 
136 
1 0 
27 
Considered 
to contain 
no growth 
363 
60 1 
6 6 2 
4 0 8 
41 
62 1 
7 5 
4 6 
144 
65.1 
26 3 
16 2 
285 
Other 
12 
3 
4 
22 
Totals 
whole scries 
616 
69 
225 
507 
Totals 
noticed data 
604 
100.0 
67 8 
67 8 
66 
100.0 
7 4 
7 4 
221 
100.0 
24 8 
24 8 
-
Totals whole series 242 208 93 833 41 1376 
Totals noticed data 162 
18 1 
100.0 
18 1 
115 
12 9 
100.0 
12 9 
66 
7 4 
100.0 
7 4 
548 
6 1 6 
100.0 
6 1 6 
891 
100.0 
100.0 
100.0 
144 
TABLE fe 55 Cause of menopause versus Status of the supra- and infraclavicular lymph nodes. ЯитЬ"* 
% Horizontal 
% Verlical 
% Totals noticed data 
Cause of menopause 
Spontaneous 
Surgical or radiological 
castration 
No menopause 
Other 
I otals whole scries 
Status of the supra and iniraclavicular lymph nodes 
Considered to 
contain growth Other Totals whole series Totals noticed data 
41 
100 0 
73 2 
73 2 
3 
1000 
5 4 
5 4 
12 
100 0 
2 1 4 
2 1 4 
24 
SO 
616 41 
100 0 
73 2 
73 2 
3 
100 0 
5 4 
5 4 
12 
100 0 
2 1 4 
21 4 
80 
Totals noticed data 56 
100 0 
100 0 
100 0 
910 56 
100 0 
100 0 
100 0 
TABI E f
e
 56 Cause of menopause versus Clinical stage (International TNM classification). 
Clinical stage (International l N M dassifìcation) 
Cause of menopause 
Spontaneous 
Surgical or radiological 
castration 
No menopause 
Other 
Totals whole scries 
Stage I 
¡90 
3 1 0 
6 4 6 
2 1 0 
23 
33 3 
7 8 
2 5 
81 
36 1 
27 6 
9 0 
120 
414 
Stage II 
73 
12 1 
6 1 9 
8 2 
9 
130 
7 6 
1 0 
36 
16 1 
30 5 
4 0 
65 
183 
Stage III 
321 
52 2 
7 1 5 
35 3 
32 
4 6 4 
7 1 
3 5 
96 
42 8 
2 1 4 
105 
294 
743 
Stage IV 
29 
4 7 
6 4 4 
3 2 
5 
7 2 
11 1 
0 5 
11 
5 0 
24 4 
12 
24 
69 
Other 
3 
-
I 
4 
8 
Totals 
whole series 
616 
69 
225 
507 
1417 
Totals 
noticed data 
613 
100 0 
67 7 
67 7 
69 
100 0 
7 6 
7 6 
224 
100 0 
24 7 
24 7 
-
1409 
Totab noticed data 294 
32 5 
100 0 
32 5 
118 
132 
100 0 
132 
449 
49 3 
100 0 
49 3 
45 
4 9 
100 0 
4 9 
910 906 
100 0 
100 0 
100 0 
145 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed с 
TABLE fc 57 Cause of menopause versus Histology of the axillary lymph nodes. 
Cause of menopause 
Spontaneous 
Surgical or ra diological 
castration 
N o menopause 
Other 
Totals whole series 
Histology of the axillary lymph nodes 
Histologically 
negative 
191 
4 1 2 
68 2 
27 3 
25 
4 6 3 
8 9 
3 6 
64 
35 4 
22 9 
9 2 
122 
402 
Histologically 
positive Other 
1 otals 
whole scries 
273 
58 8 
65 2 
39 1 
29 
53 7 
6 9 
4 1 
117 
6 4 6 
27 9 
16 7 
225 
233 507 
1417 
Totals 
noticed data 
464 
100.0 
66 4 
66 4 
54 
100.0 
7 7 
7 7 
Ш 
100.0 
25 9 
25 9 
1054 
Totals noticed data 280 
4 0 1 
100.0 
4 0 1 
419 
59 9 
100 0 
59 9 
910 699 
100.0 
100.0 
100 0 
TABLE f
c
 58 Location of tumor versus Size of tumor. 
Size of tumor 
Location of tumor 
Medial, subareolar or 
whole breast 
Lateral 
Other 
Not more 
than 2 cm 
91 
13 1 
50 6 
7 2 
89 
15 5 
49 4 
7 0 
20 
2-5 cm 
303 
43 5 
53 3 
23 9 
266 
4 6 3 
4 6 7 
20 9 
22 
5-10 cm 
222 
3 1 9 
52 7 
175 
199 
34 7 
47 3 
15 7 
24 
More than 
10 cm 
80 
115 
80 0 
6 3 
20 
3 5 
20 0 
1 6 
-
Other 
38 
27 
16 
Totals 
whole series 
734 
601 
82 
Totals 
noticed data 
696 
100.0 
54 8 
54 8 
574 
100.0 
45 2 
45 2 
-
Totals whole series 200 591 445 100 81 1417 1336 
Totals noticed data 180 
14 2 
100.0 
142 
569 
4 4 8 
100 0 
4 4 8 
421 
33 1 
100 0 
33 1 
100 
7 9 
100 0 
7 9 
1335 1270 
100.0 
100.0 
100.0 
146 
TABLE fe 59 Location of tumor versus Fixation to skin. 
Fixation to skin 
Locatioi 
Medial, 
ι of tumor 
subareolar or 
whole breast 
Lateral 
Other 
Incomplete 
skin fixation 
169 
23 6 
50 1 
13 1 
168 
29 1 
49 9 
1 3 0 
12 
Complete 
skin fixation 
200 
27 9 
59 3 
1 5 4 
137 
23 7 
4 0 7 
10 6 
7 
Skin fixation 
wide of tumor 
but not 
beyond 
breast area 
66 
9 2 
79 5 
5 1 
17 
2 9 
20 5 
1 3 
; 
Skin not 
involved 
2β2 
39 3 
55 5 
2 1 8 
256 
4 4 2 
4 4 5 
19 7 
43 
Other 
¡7 
23 
19 
Totals 
whole senes 
734 
601 
82 
Totals 
noticed data 
717 
100.0 
55 4 
55 4 
578 
100.0 
4 4 6 
4 4 6 
-
Numbert 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole series 349 344 84 59 1417 1358 
Totals noticed data 337 
26 0 
100.0 
26 0 
337 
26 0 
100.0 
26 0 
83 
6 4 
100 0 
6 4 
53S 
41 5 
100.0 
4 1 5 
1295 
100 0 
loo.o 
100 0 
TABLE fe 60 Location of tumor versus Nipple retraction. 
Nipple retraction 
Location of tumor 
Medial, subareolar or 
whole breast 
Lateral 
Nipple 
retraction 
276 
39 1 
72 1 
2 1 7 
107 
19 0 
27 9 
8 4 
No nipple 
retraction 
430 
60 9 
48 5 
33 9 
456 
8 1 0 
5 1 5 
35 9 
Other 
Totals 
whole series 
Totals 
noticed data 
734 706 
100.0 
55 6 
55 6 
563 
100.0 
444 
444 
15 82 
Totals whole senes 398 933 1331 
Totals noticed data 383 
30 2 
loo.o 
30 2 
886 
69 8 
100.0 
69 8 
1269 
100.0 
100 0 
100.0 
147 
Numbers 
% Horizontal 
% Vertical 
% 1 otals noticed data 
TABLE fc 61 Location of tumor versus Pectoral muscle fixation. 
Location of tumor No fixation 
Pectoral muscle fixation 
Incomplete 
fìxatiou 
Complete 
fixation Other 
1 otals 
whole series 
Total 
noticed data 
Medial, subareolar or 
whole breast 
S40 
77 0 
53 6 
43 0 
100 
14 3 
61 7 
8 0 
61 
8 7 
67 0 
4 9 
33 701 
loo.o 
55 8 
55 8 
Lateral 463 
83 4 
4 6 2 
36 9 
62 
112 
38 3 
4 9 
30 
54 
33 0 
24 
601 555 
100.0 
4 4 2 
4 4 2 
Other 55 20 82 
Totals whole series ¡058 168 99 1417 1318 
Totals noticed data 1003 
79 9 
100.0 
79 9 
162 
129 
100.0 
129 
91 
7 2 
100.0 
7 2 
1256 
100 0 
100.0 
100.0 
TABLE fc 62 Location of tumor versus Status of the homolateral axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Location of tumor 
Medial, subareolar or 
whole breast 
Lateral 
Other 
Totals whole series 
Single 
118 
16 4 
52 4 
9 1 
107 
183 
47 6 
8 2 
17 
242 
Multiple 
102 
14 2 
5 1 8 
7 8 
95 
162 
48 2 
7 3 
11 
208 
Fixed to one 
another or to 
other structures 
54 
7 5 
59 3 
4 1 
37 
6 3 
4 0 7 
2 8 
2 
93 
Considered 
to contain 
no growth 
444 
6 1 8 
5 6 2 
34 0 
346 
59 1 
43 8 
26 6 
43 
833 
Other 
16 
16 
9 
41 
Totals 
whole series 
734 
601 
82 
1417 
Totals 
noticed data 
718 
100.0 
55 1 
55 1 
585 
100.0 
4 4 9 
4 4 9 
-
1376 
Totals noticed data 225 
173 
100 0 
17 3 
197 
15 1 
100.0 
15 1 
91 
7 0 
100.0 
7 0 
790 
6 0 6 
100 0 
60 6 
1303 
100.0 
100 0 
100.0 
148 
TABLE fe 63 location of tumor versus Status of the supra- and infraclavicular lymph nodes. lumbers 
% Horizontal 
Status ofthc supra- and infraclavicular lymph nodes 
% lotalsnouced data 
Considered to 
Location of tumor contain growth Other Totals whole series Totals noticed data 
Medial, subareolar or 
whole breast 
Lateral 
Other 
Totals whole series 
Totals noticed data 
49 
1000 
63 6 
63 6 
28 
100 0 
36 4 
36 4 
3 
80 
77 
100 0 
100.0 
100 0 
685 
573 
79 
1337 
734 
601 
82 
1417 
1335 
49 
100.0 
63 6 
63 6 
28 
100.0 
36 4 
36 4 
-
80 
77 
100.0 
loo.o 
100.0 
TABLE fc 64 Location of tumor versus Clinical stage (International TNM classification). 
Clinical stage (International T N M classification) 
Totals Totals 
Location of tumor Stage I Stage II Stage III Stage IV Other whole series noticed data 
Medial, subareolar or 
whole breast 
Lateral 
Other 
Totals whole series 
Totals noticed data 
205 
28 1 
53 9 
1 5 4 
175 
29 3 
4 6 1 
13 1 
34 
414 
380 
28 6 
100.0 
28 6 
74 
9 8 
4 4 3 
5 5 
93 
156 
55 7 
7 0 
16 
183 
167 
12 6 
100.0 
126 
403 
55 0 
5 6 0 
30 2 
317 
53 0 
4 4 0 
23 9 
23 
743 
720 
53 9 
100.0 
53 9 
51 
7 1 
79 7 
3 8 
13 
2 2 
20 3 
1 0 
5 
69 
64 
4 9 
100.0 
4 9 
; 
3 
4 
8 
_ 
734 
601 
82 
1417 
1335 
733 
100.0 
55 0 
55 0 
598 
100.0 
45 0 
45 0 
-
1409 
1331 
100.0 
100.0 
100.0 
149 
lumbers T A B L E Γ0 6 5 Location of tumor versus Chnical stage (International T N M classification) 
/ъ onzonta Stage in is divided into two groups\ a: large tumor only, no other symptoms; b: also other 
% Totals noticed data SymptOMS. 
Clmiral 4tage (International T \ M classification) 
Stage III 
large tumor 
only, no Stage III 
Location of other also other Totals Totals 
tumor Stage I Stage II symptoms s>mptoms Stage IV Olher whole series noticed data 
Medial, 
subareolar or 
whole breast 
Lateral 
Other 
Totals whole series 
Totals noticed data 
205 
28 0 
53 9 
1 5 4 
175 
29 3 
4 6 1 
13 1 
34 
414 
380 
28 5 
100 0 
28 5 
74 
10 1 
4 4 3 
5 6 
93 
156 
55 7 
7 0 
16 
183 
167 
1 2 6 
100 0 
12 6 
81 
11 1 
4 6 3 
6 1 
94 
157 
53 7 
7 1 
9 
184 
175 
132 
100 0 
13 2 
322 
43 9 
59 1 
¿4 2 
223 
37 3 
4 0 9 
16 8 
14 
559 
545 
4 0 9 
100 0 
4 0 9 
51 
7 0 
79 7 
3 8 
13 
2 2 
20 3 
1 0 
5 
69 
64 
4 8 
100 0 
4 8 
1 
3 
4 
8 
_ 
734 
601 
82 
1417 
1335 
733 
100 0 
55 1 
55 1 
598 
100 0 
4 4 9 
4 4 9 
-
1409 
1331 
100 0 
100 0 
100 0 
TABLE fc 66 Location of tumor versus Histology of the axillary lymph nodes. 
Histology of the axillary lymph nodes 
Histologically Histologically Totals Totals 
location of tumor negative positive Other whole series noticed data 
Medial, subareolar or 
whole breast 
Lateral 
Other 
Totals whole series 
Totals noticed data 
194 
37 3 
51 1 
195 
186 
39 1 
48 9 
18 7 
22 
402 
380 
38 2 
100 0 
38 2 
326 
62 7 
52 9 
32 7 
290 
60 9 
47 1 
29 1 
36 
652 
616 
6 1 8 
100 0 
6 1 8 
214 
125 
24 
363 
734 
601 
82 
1417 
1335 
520 
100 0 
52 2 
52 2 
476 
100 0 
47 8 
47 8 
-
1054 
996 
100 0 
100 0 
100.0 
150 
TABLE fe 67 Size of tumor versus Fixation to skin. 
Fixation to ikm 
Size of tumor 
Not more 
2-5 cm 
5-10 cm 
More than 10 cm 
Other 
Incomplete 
skin fixation 
32 
17 1 
9 7 
2 5 
180 
3 1 7 
5 4 5 
139 
109 
25 2 
33 0 
8 4 
9 
9 2 
2 7 
0 7 
19 
Complete 
skin fixation 
18 
9 6 
5 5 
1 4 
115 
20 2 
35 3 
8 9 
155 
35 8 
47 5 
12 0 
38 
38 8 
1 1 7 
2 9 
18 
Skin fixation 
wide of tumor 
but not 
beyond 
breast area 
1 
0 5 
1 3 
0 1 
8 
1 4 
10 1 
0 6 
34 
7 9 
43 0 
2 6 
Зв 
3 6 7 
45 6 
2 8 
5 
Skin not 
involved 
138 
72 8 
24 7 
1 1 0 
265 
4 6 7 
4 8 1 
20 9 
135 
31 1 
24 5 
1 0 2 
15 
15 3 
2 7 
1 1 
30 
Other 
13 
23 
12 
2 
9 
Total. 
whole senes 
200 
591 
445 
100 
81 
Totali 
noticed data 
187 
100.0 
15 0 
15 0 
568 
100.0 
4 4 3 
4 4 3 
433 
100 0 
33 2 
33 2 
98 
100.0 
7 5 
7 5 
-
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole senes 344 59 1417 1358 
Totals noticed data 330 
25 5 
100 0 
25 5 
326 
25 3 
100.0 
25 3 
79 
6 1 
100.0 
6 1 
551 
43 1 
100.0 
43 1 
¡336 1286 
100 0 
100.0 
100 0 
TABLE fc 68 Size of tumor versus Nipple retraction. 
Nipple retraction 
Size of tumor 
Not more 
2-5 cm 
5-10 cm 
than 2 cm 
More than 10 cm 
Other 
Nipple 
retraction 
23 
1 2 4 
6 2 
1 8 
127 
22 6 
3 4 1 
10 1 
171 
4 0 8 
4 6 0 
136 
51 
53 1 
13 7 
4 0 
26 
No nipple 
retraction 
162 
87 6 
182 
12 8 
434 
77 4 
4 8 8 
3 4 4 
248 
59 2 
27 9 
19 7 
45 
4 6 9 
5 1 
3 6 
44 
Other 
15 
30 
26 
4 
11 
Totals 
whole sene» 
200 
591 
445 
100 
81 
Totals 
noticed data 
185 
100.0 
14 7 
14 7 
561 
100.0 
4 4 5 
4 4 5 
419 
100.0 
33 2 
33 2 
96 
100.0 
7 6 
7 6 
-
Totals whole series 398 933 86 1417 1331 
Totals noticed data 372 
29 5 
100 0 
29 5 
889 
70 5 
100 0 
70 5 
1336 1261 
100.0 
100 0 
100.0 151 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fc 69 Size of tumor versus Pectoral muscle fixation. 
Size of tumor 
Not more than 2 cm 
2-5 cm 
5-10 cm 
More than 10 cm 
Other 
Totals whole series 
Pectoral muscle fixation 
No fixation 
Incomplete 
fixation 
Complete 
fixation Other 
Totals 
whole series 
17β 
96.2 
17.9 
14.3 
45S 
81.6 
45.9 
36.5 
303 
75.1 
31.0 
24.7 
52 
54.7 
5.2 
4.2 
64 
5 
2.7 
3.0 
0.4 
2 
1.1 
2.2 
0.2 
84 
15.0 
50.9 
6.7 
19 
3.4 
21.1 
1.5 
63 
15.4 
38.2 
5.0 
39 
9.5 
43.3 
3.1 
35 
13 
13.7 
7.9 
1.0 
30 
31.6 
33.3 
2.4 
3 
445 
100 
ai 
Totals 
noticed data 
135 
100.0 
14.8 
14.8 
559 
100.0 
44.8 
44.8 
410 
100.0 
32.8 
32.8 
95 
100.0 
7.6 
7.6 
Totals noticed data 994 
79.6 
100.0 
79.6 
165 
13.2 
100.0 
13.2 
90 
7.2 
100.0 
7.2 
1336 1249 
100.0 
100.0 
100.0 
TABLE fc 70 Size of tumor versus Status of the homolateral axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Size of tumor 
Not more than 2 cm 
2-5 cm 
5-10 cm 
Other 
Totals whole series 
Single 
31 
16.0 
13.6 
2.4 
102 
17.6 
44.7 
7.8 
75 
17.5 
32.9 
5.8 
20 
20.4 
8.8 
1.5 
14 
242 
Multiple 
15 
7.7 
7.7 
1.2 
60 
10.4 
31.0 
4.6 
SP 
23.1 
51.0 
7.6 
20 
20.4 
10.3 
1.5 
14 
208 
Fixed to one 
another or to 
other structures 
4 
2.1 
4.6 
0.3 
26 
4.5 
29.9 
2.0 
32 
7.5 
36.8 
2.5 
25 
25.5 
28.7 
1.9 
6 
93 
Considered 
to contain 
no growth 
144 
74.2 
18.2 
11.1 
390 
67.4 
48.4 
30.0 
222 
51.9 
28.1 
17.0 
33 
33.7 
5.3 
2.7 
44 
833 
Other 
6 
13 
17 
2 
3 
41 
Totals 
whole series 
200 
591 
445 
100 
81 
1417 
Totals 
noticed data 
194 
100.0 
15.0 
15.0 
57« 
100.0 
44.4 
44.4 
428 
100.0 
32.9 
32.9 
se 
100.0 
7.6 
7.6 
-
1376 
Totals noticed data 
152 
228 
17.5 
100.0 
17.5 
194 
15.0 
100.0 
15.0 
87 
6.7 
100.0 
6.7 
789 
60.8 
100.0 
60.8 
¡336 1298 
100.0 
loo.o 
100.0 
TABLE fe 71 Size of tumor versus Status of the supra- and infraclavicular lymph nodes. 
Size of tumor 
Not more than 2 cm 
2-5 cm 
5-10 cm 
More than 10 cm 
Status of the supra- and infraclavicular lymph nodes 
Considered to 
contain growth Other Totals whole s Totals noticed data 
3 
100 0 
4 1 
4 1 
17 
100 0 
23 0 
23 0 
26 
100 0 
35 1 
35 1 
23 
100 0 
37 6 
37 8 
574 
419 
72 
200 
591 
445 
3 
100.0 
4 1 
4 1 
17 
100.0 
23 0 
23 0 
26 
100.0 
35 1 
35 1 
28 
100.0 
37 8 
37 8 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals whole senes 80 1337 1417 
Totals noticed data 74 
1000 
100.0 
100.0 
74 
100.0 
100 0 
looo 
TABLE fc 72 Size of tumor versus Clinical stage (International TNM classification). 
Size of tumor 
Clinical stage (International T N M classification) 
Stage I Stage II Stage III 
Totals Totals 
Stage I V Other whole senes noticed data 
Not more than 2 cm 132 
6 6 0 
34 9 
9 9 
42 
210 
26 0 
3 1 
23 
115 
3 2 
17 
3 
1 5 
4 5 
0 2 
200 200 
100 0 
15 0 
15 0 
2-5 cm 245 
41 5 
65 1 
18 3 
124 
2 1 0 
74 0 
9 3 
206 
35 0 
28 7 
15 6 
¡4 
2 5 
2 1 2 
1 0 
591 589 
100.0 
44 2 
4 4 2 
5-10 cm 418 
93 9 
57 2 
31 3 
27 
6 1 
4 0 9 
2 0 
445 
100.0 
33 3 
33 3 
More than 10 cm 78 
78 0 
10 9 
5 8 
22 
22 0 
33 3 
1 6 
100 
100 0 
7 5 
7 5 
Other 32 15 25 
Totals whole series 409 181 750 69 1409 
Totals noticed data 377 
28 2 
100.0 
28 2 
¡66 
12 5 
100 0 
12 5 
725 
544 
100 0 
544 
66 
49 
100 0 
49 
1336 1334 
100 0 
100 0 
100 0 
153 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fc 73 Size of tumor versus Histology of the axillary lymph nodes. 
Size of tumor 
Not more than 2 cm 
2-5 cm 
5-101 
More than 10 cm 
Totals whole series 
Histology of the axillary lymph nodes 
Histologically 
negative 
79 
52.0 
20.6 
7.9 
210 
45.0 
55.1 
20.9 
85 
26.2 
22.2 
8.5 
S 
14.0 
2.1 
0.8 
20 
402 
Histologically 
positive Other 
Totals 
whole series 
73 
48.0 
11.8 
7.3 
257 
55.0 
41.7 
25.6 
124 
240 
73.8 
38.6 
23.9 
¡20 
49 
86.0 
7.9 
4.9 
43 
33 28 
200 
445 
100 
81 
363 
Totals 
noticed data 
152 
100.0 
15.3 
15.3 
467 
100.0 
46.5 
46.5 
325 
100.0 
32.4 
32.4 
57 
100.0 
5.7 
5.7 
Totals noticed data 382 
38.1 
100.0 
38.1 
619 
61.9 
100.0 
61.9 
1336 1001 
100.0 
100.0 
100.0 
TABLE fc 74 Fixation to skin versus Nipple retraction. 
Nipple retraction 
Fixation to skin 
Incomplete skin fixation 
Complete skin fixation 
Skin fixation wide of tumor 
but not beyond breast area 
Skin not involved 
Other 
Nipple 
retraction 
107 
31.7 
27.2 
8.1 
147 
44.1 
37.4 
11.1 
46 
59.0 
11.7 
3.5 
93 
16.2 
23.6 
7.0 
5 
N o nipple 
retraction 
231 
68.3 
24.8 
17.5 
186 
55.9 
20.0 
14.1 
32 
41.0 
3.4 
2.4 
481 
83.8 
51.8 
36.4 
3 
Other 
11 
11 
6 
7 
51 
Totab 
whole series 
349 
344 
84 
581 
59 
Totals 
noticed data 
338 
100.0 
25.5 
25.5 
333 
100.0 
25.2 
25.2 
78 
100.0 
5.9 
5.9 
574 
100.0 
43.5 
43.5 
-
Totab whole series 398 933 86 ¡417 1331 
Totals noticed data 393 
29.7 
100.0 
29.7 
930 
70.3 
100.0 
70.3 
1323 
100.0 
100.0 
100.0 
154 
TABLE fe 75 Fixation to skin versus Pectoral muscle fixation. 
Pectoral muscle fixation 
Fixation to skin 
Incomplete skin fixation 
Complete skin fixation 
Skin fixation wide of 
tumor but not beyond 
breast area 
Skin not involved 
Other 
Totals whole series 
No fixation 
261 
77.7 
24.8 
19.9 
225 
69.4 
21.4 
17.2 
/ Í 
53.2 
3.9 
3.1 
526 
91.7 
49.9 
40.1 
5 
lose 
Incomplete 
fixation 
65 
19.3 
38.7 
5.0 
54 
16.7 
32.1 
4.1 
9 
11.7 
5.4 
0.7 
40 
7.5 
23.8 
3.1 
-
168 
Complete 
fixation 
10 
3.0 
11.1 
0.8 
45 
13.9 
50.0 
3.4 
27 
35.1 
30.0 
2.1 
β 
0.9 
8.8 
0.6 
2 
92 
O t h e r 
13 
20 
7 
7 
52 
99 
Totals 
whole series 
349 
344 
84 
581 
59 
1417 
Totals 
noticed d a t a 
336 
100.0 
25.6 
25.6 
324 
100.0 
24.7 
24.7 
77 
100.0 
5.9 
5.9 
574 
100.0 
43.8 
43.8 
-
1318 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
Totals noticed data 1053 
80.3 
100.0 
80.3 
168 
12.8 
100.0 
12.8 
90 
6.9 
100.0 
6.9 
1358 1311 
100.0 
100.0 
100.0 
TABLE fo 76 Fixation to skin versus Status of the homolateral axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Fixation to skin 
Incomplete skin 
fixation 
Complete skin 
fixation 
Skin fixation wide of 
tumor but not beyond 
breast area 
Skin not involved 
Other 
Totals whole series 
Single 
64 
18.5 
27.6 
4.8 
57 
17.0 
24.6 
4.3 
13 
16.5 
5.6 
1.0 
98 
17.1 
42.2 
7.3 
10 
242 
Multiple 
43 
12.4 
21.3 
3.2 
73 
21.8 
36.1 
5.5 
17 
21.5 
8.4 
1.3 
69 
12.0 
34.2 
5.1 
6 
208 
Fixed to one 
another or to 
other structures 
23 
6.6 
24.7 
1.7 
34 
10.1 
36.6 
2.5 
23 
29.1 
24.7 
1.7 
13 
2.3 
14.0 
1.1 
-
93 
Considered 
to contain 
no growth 
216 
62.5 
26.8 
16.2 
171 
51.1 
21.1 
12.8 
26 
32.9 
3.2 
1.9 
394 
68.6 
48.9 
29.6 
26 
833 
O t h e r 
3 
9 
5 
7 
17 
41 
Totals 
whole series 
349 
344 
84 
581 
59 
1417 
Totals 
noticed data 
346 
100.0 
25.9 
25.9 
335 
100.0 
25.1 
25.1 
79 
100.0 
5.9 
5.9 
574 
100.0 
43.1 
43.1 
-
1376 
Totals noticed data 232 
17.4 
100.0 
17.4 
202 
15.1 
100.0 
15.1 
93 
7.0 
100.0 
7.0 
807 
60.5 
100.0 
60.5 
¡334 
100.0 
100.0 
100.0 
155 
Numbers 
% Honzonta l 
% Vertical 
% Totals noticed da ta 
TABLE fc 77 Fixation to skin versus Status of the supra- and infraclavicular lymph nodes 
Fixation to skin 
Incomplete skin fixation 
Complete skin fixation 
Skin fixation wide of 
tumor but not beyond 
breast area 
Skin not involved 
Other 
Totals whole series 
Status of the supra- and infraclavicular lymph nodes 
Considered to 
contain Rrowth Other Totals whole series Totals noticed data 
16 
100 0 
20 3 
20 3 
30 
100 0 
3B0 
38 0 
22 
100 0 
27 8 
27 8 
¡1 
100 0 
14 0 
1 4 0 
333 
314 
62 
58 
349 
344 
84 
581 
1337 
16 
100 0 
20 3 
20 3 
30 
100 0 
38 0 
38 0 
22 
100 0 
27 8 
27 8 
// 
100 0 
1 4 0 
14 0 
Totals noticed data 79 
100 0 
100.0 
100 0 
1358 79 
100.0 
100.0 
100.0 
TABLE fc 78 Fixation to skin versus Clinical stage (International TNM classification). 
Cluneal stage (International T N M clasifìcation) 
Fixation to skin Stage I Stage I I Stage I I I 
Totals Totals 
Stage I V Other whole series noticed data 
Incomplete skin 
fixation 
118 
33 8 
30 6 
8 7 
54 
15 5 
3 1 6 
4 0 
167 
47 9 
22 9 
12 3 
10 
2 9 
15 4 
0 7 
349 349 
100.0 
25 7 
25 7 
Complete skin 
fixation 
314 
9 1 6 
42 9 
23 0 
29 
85 
4 4 6 
2 1 
343 
100.0 
25 3 
25 3 
Skin fixation wide of 
tumor but not beyond 
breast area 
66 
78 6 
9 1 
4 9 
18 
2 1 4 
27 7 
1 3 
84 
100.0 
62 
62 
Skin not involved 268 
4 6 4 
69 4 
19 9 
118 
20 5 
6 8 4 
8 8 
183 
31 7 
25 1 
1 3 5 
8 
1 4 
12 3 
0 6 
577 
100 0 
42 8 
42 8 
Other 28 10 14 
Totals whole senes 414 182 69 1417 1409 
Totals noticed data 386 
28 6 
100.0 
28 6 
172 
12 9 
100 0 
12 9 
730 
53 7 
100.0 
53 7 
65 
47 
100.0 
47 
1358 1353 
100 0 
100 0 
100 0 
156 
TABLE fe 79 Fixation to skin versus Clinical stage (International TNM classification). 
Stage in is divided into two groups, a: large tumor only, no other symptoms; b: also other 
symptoms. 
Clinical stage (International T N M classification) 
Fixation to skin 
Incomplete skin 
fixation 
Complete skin 
fixation 
Skin fixation wide 
of tumor but not 
beyond breast area 
Skin not involved 
Other 
S u g e I 
118 
33 8 
30 6 
8 7 
_ 
_ 
268 
4 8 0 
69 4 
19 8 
28 
Stage II 
54 
15 5 
3 1 6 
4 0 
_ 
-
118 
2 1 6 
6 8 4 
8 7 
10 
Stage III 
targe tumor 
only, no 
other 
symptoms 
70 
20 1 
4 0 0 
5 2 
-
-
105 
156 
60 0 
7 7 
9 
Stage III 
also other 
symptoms 
s; 
27 8 
17 5 
7 2 
314 
9 1 6 
5 6 5 
23 2 
66 
78 6 
119 
4 9 
78 
133 
14 1 
5 7 
5 
Stage IV 
10 
2 9 
1 5 4 
0 7 
29 
8 5 
4 4 6 
2 1 
18 
2 1 4 
27 7 
1 3 
8 
1 5 
12 3 
0 7 
4 
Other 
-
1 
-
4 
3 
Totals 
whole series 
349 
344 
84 
581 
59 
Totals 
noticed data 
349 
100 0 
25 8 
25 8 
343 
100 0 
25 4 
25 4 
84 
100.0 
6 2 
6 2 
577 
100 0 
42 6 
42 6 
-
Numbers 
% Horizontal 
% Vertical 
% Totab noticed data 
Totals whole series 414 69 1417 1409 
Totals noticed data 386 
28 5 
100 0 
28 5 
172 
12 8 
100.0 
12 8 
175 
12 9 
100 0 
12 9 
555 
4 0 9 
100 0 
4 0 9 
65 
4 8 
100 0 
4 8 
Ш З 
100 0 
100.0 
100.0 
TABLE fc 80 Fixation to skin versus Histology of the homolateral axillary lymph nodes. 
Histology of the homolateral axillary lymph nodes 
Fixation to skin 
Histologically 
negative 
Histologically 
positive Other 
Totals 
whole series 
Totals 
noticed data 
Incomplete skin fixation 108 
4 0 3 
28 0 
10 7 
160 
59 7 
25 5 
15 8 
349 268 
100 0 
26 5 
26 5 
Complete skin fixation 55 
23 4 
14 2 
5 4 
180 
76 6 
28 7 
178 
109 344 235 
100.0 
23 2 
23 2 
Skin fixation wide of tumor 
but not beyond breast area 
6 
1 4 0 
1 6 
0 6 
37 
8 6 0 
5 9 
3 7 
41 84 43 
100 0 
4 2 
4 2 
Skin not involved 217 
47 6 
5 6 3 
2 1 4 
250 
52 4 
39 8 
24 6 
467 
100.0 
4 6 1 
4 6 1 
Other 16 25 
Totals whole series 402 1417 1054 
Totab noticed data 386 
381 
100.0 
3 8 1 
627 
6 1 9 
100 0 
6 1 9 
1358 1013 
100.0 
100.0 
100.0 157 
Numbers 
% Horizontal 
% Vertical 
% Totali noticed data 
TABLE fc 81 Nipple retraction versus Pectoral muscle fixation. 
Nipple retraction 
Nipple retraction 
No nipple retraction 
Other 
Totals whole series 
Pectoral muscle fixation 
No fixation 
23S 
73.7 
27.1 
21.8 
769 
83.2 
72.9 
58.6 
Incomplete 
fixation 
53 
14.9 
34.9 
4.4 
103 
11.7 
65.1 
8.2 
Complete 
fixation 
44 
11.3 
48.4 
3.4 
47 
5.1 
51.6 
3.6 
Other 
Totali 
whole aeries 
1053 
10 393 
933 
SO 86 
Totals 
noticed data 
388 
100.0 
29.6 
29.6 
924 
100.0 
70.4 
70.4 
1318 
Totals noticed data 1055 
80.4 
100.0 
80.4 
¡66 
12.7 
100.0 
12.7 
Si 
6.9 
100.0 
6.9 
1331 1312 
100.0 
100.0 
100.0 
TABLE fc 82 Nipple retraction versus Status of the homolateral axillary lymph nodes. 
Status of the homolateral axillary lymph nodes 
Nipple retraction 
Nipple retraction 
No nipple retraction 
Other 
Totals whole seríes 
Single 
62 
15.8 
27.0 
4.7 
168 
18.3 
73.0 
12.8 
12 
242 
Multiple 
72 
18.3 
36.2 
5.5 
127 
13.8 
63.8 
9.7 
9 
208 
Fixed to one 
another or to 
other structures 
39 
9.9 
42.4 
3.0 
53 
5.8 
57.6 
4.0 
i 
93 
Considered 
to contain 
no growth 
220 
56.0 
27.8 
16.7 
571 
62.1 
72.2 
43.5 
42 
833 
Other 
5 
14 
22 
41 
Totals 
whole series 
398 
933 
86 
1417 
Totals 
noticed data 
393 
100.0 
30.0 
30.0 
919 
100.0 
70.0 
70.0 
-
1376 
Totals noticed data 230 
17.5 
100.0 
17.5 
199 
15.2 
100.0 
15.2 
92 
7.0 
100.0 
7.0 
791 
60.3 
100.0 
60.3 
1331 1312 
100.0 
100.0 
100.0 
158 
TABLE fc 83 Nipple retraction versus Status of the supra- and infraclavicular lymph nodes. ambers 
% Horizontal 
Status of the supra- and infraclavicular lymph nodes r I c a 
% Totals noticed data 
Considered to 
Nipple retraction contain growth Other Totals whole series Totals noticed data 
Nipple retraction 
N o nipple retraction 
Other 
Totals whole series 
Totals noticed data 
30 
100 0 
39 5 
39 5 
46 
100 0 
6 0 5 
6 0 5 
4 
80 
76 
100 0 
100.0 
1000 
368 
887 
B2 
1337 
398 
933 
86 
1417 
1331 
30 
100.0 
39 5 
39 5 
46 
100.0 
6 0 5 
6 0 5 
-
80 
76 
100.0 
100.0 
100 0 
TABLE fc 84 Nipple retraction versus Clinical stage (International TNM classification). 
Clinical stage (International T N M classification) 
Totals Totals 
Nipple retraction Stage I Stage II Stage III Stage IV Other whole series noticed data 
Nipple retraction 
No nipple retraction 
Other 
Totals whole scries 
Totals noticed data 
61 
15 3 
15 9 
4 6 
322 
34 6 
8 4 1 
24 3 
31 
414 
383 
28 9 
100.0 
28 9 
28 
7 0 
16 5 
2 1 
142 
153 
83.5 
10.7 
13 
183 
170 
12 8 
100.0 
12 8 
275 
69 1 
38 7 
20 7 
435 
4 6 8 
6 1 3 
32 8 
33 
743 
710 
53 5 
100.0 
53 5 
34 
8 5 
5 4 0 
2 6 
29 
3 2 
4 6 0 
2 2 
6 
69 
63 
4 7 
100.0 
4 7 
-
5 
3 
8 
_ 
398 
933 
86 
1417 
1331 
398 
100.0 
29 9 
29 9 
928 
100.0 
70 1 
70 1 
-
1409 
1326 
100.0 
100.0 
100.0 
159 
Numbers 
% Honzontal 
% Vertical 
% Total» noticed data Symptoms. 
TABLE fc 85 Nipple retraction versus Clinical stage (International TNM classification). 
Stage in is divided into two groups, a: large tumor only, no other symptoms ; b: also other 
Clinical stage (International T N M classification) 
Nipple retraction 
Nipple retraction 
No nipple 
retraction 
Other 
Stage I 
61 
15 3 
15 9 
4 6 
322 
34 7 
84 1 
24 3 
31 
Stage II 
28 
7 0 
16 5 
2 1 
¡42 
15 3 
83 5 
10 7 
13 
Stage III 
large tumor 
only, no 
other 
symptoms 
55 
13 8 
3 1 8 
4 1 
118 
12 7 
6 8 2 
8 9 
11 
Stage III 
also other 
symptoms 
220 
55 3 
4 1 0 
16 6 
317 
34 2 
59 0 
23 9 
22 
Stage I V 
34 
8 5 
5 4 0 
2 6 
29 
3 1 
4 6 0 
2 2 
e 
Other 
-
5 
3 
Totals 
whole series 
398 
933 
86 
Totals 
noticed data 
398 
100 0 
30 0 
30 0 
928 
100 0 
70 0 
70 0 
-
Totals whole series 414 В 1417 
Totals noticed data 383 
28 9 
100.0 
28 9 
no 
12 8 
100.0 
12 8 
173 
130 
100.0 
13 0 
537 
4 0 5 
100.0 
4 0 5 
63 
4 8 
100.0 
4 8 
1331 1326 
100 0 
100 0 
100.0 
TABLE fc 86 Nipple retraction versus Histology of the axillary lymph nodes. 
Nipple retraction 
Histology of the axillary lymph nodes 
Histologically 
negative 
70 
25 4 
18 4 
7 0 
311 
43 0 
8 1 6 
31 I 
Histologically 
positive 
206 
74 6 
33 3 
20 6 
412 
57 0 
6 6 7 
4 1 2 
Other 
Totals 
whole series 
Totals 
noticed data 
Nipple retraction 276 
100.0 
27 6 
27 6 
No nipple retraction 210 933 723 
100.0 
72 4 
72 4 
21 34 31 86 
Totals whole series 402 652 363 
Totals noticed data 381 
38 1 
100.0 
38 1 
618 
6 1 9 
100.0 
6 1 9 
1331 999 
100.0 
100.0 
100.0 
160 
TABLE fe 87 Pectoral muscle fixation versus Status of the homolateral axillary lymph nodes. Wwbers 
% H o n z o n t a l 
Status of the homolateral axillary lymph nodes ^ V e r t l c a l 
• % Totals noticed data 
Fixed to one Considered 
Pectoral muscle another or to to contain Totals Totals 
fixation Smgle Multiple other structures n o growth Other whole senes noticed data 
No fixation 
Incomplete fixation 
Complete fixation 
Other 
Totals whole senes 
Totals noticed data 
176 
16 8 
76 9 
1 3 6 
33 
19 9 
14 4 
2 5 
20 
22 2 
8 7 
1 5 
13 
242 
229 
1 7 6 
100.0 
1 7 6 
Ш 
1 4 0 
75 3 
112 
28 
16 9 
14 4 
2 2 
20 
22 2 
10 3 
1 5 
14 
208 
194 
149 
100.0 
14 9 
55 
5 2 
59 8 
4 2 
ie 
9.6 
17.4 
1 2 
21 
23 3 
22 8 
1 7 
/ 
93 
92 
7 1 
100.0 
7 1 
668 
6 4 0 
85 0 
51.3 
S9 
53 6 
11.2 
6 9 
29 
32.3 
3 8 
2 2 
47 
833 
786 
6 0 4 
100.0 
60 4 
13 
2 
2 
24 
41 
-
1058 
168 
92 
99 
1417 
1318 
1045 
100.0 
80.3 
80.3 
166 
100.0 
12 8 
12 8 
90 
100.0 
6 9 
6 9 
-
1376 
1301 
100.0 
100.0 
100.0 
TABLE fc 88 Pectoral muscL· fixation versus Status of the supra- and infraclavicular lymph 
nodes. 
Status of the supra- and infraclavicular lymph nodes 
Considered to 
Pectoral muscle fixation contain growth Other Totals whole series Totals noticed data 
No fixation 
Incomplete fixation 
Complete fixation 
Other 
Totals whole series 
Totals noticed data 
46 
looo 
59.7 
59 7 
12 
100 0 
15 6 
156 
19 
100 0 
24 7 
24 7 
3 
80 
77 
1000 
100 0 
looo 
1012 
156 
73 
96 
1337 
1058 
168 
92 
99 
1417 
1318 
46 
100.0 
59.7 
59 7 
12 
100.0 
15 6 
156 
19 
100.0 
24 7 
24 7 
-
80 
77 
100.0 
100.0 
100.0 
161 
TABLE fe 89 Pectoral muscle fixation versus Clinical stage (International TNM classification). 
Clinical stage (International TNM classification) 
Pectoral muscle Totals Totals 
fixation Stage I Stage II Stage III Stage IV Other whole series noticed data 
No fixation 
Incomplete fixation 
Complete fixation 
Other 
Totals whole senes 
Totals noticed data 
380 
3 6 0 
100 0 
28 9 
30 
410 
380 
28 9 
100.0 
28 9 
165 
15 7 
1000 
12 5 
14 
179 
165 
12.5 
100.0 
12.5 
478 
45 3 
67 4 
36 4 
157 
93 5 
22 0 
11.9 
74 
80.4 
10 6 
5.6 
42 
751 
709 
5 4 0 
100.0 
54 0 
32 
3 0 
52 5 
2 4 
11 
6.5 
18.0 
0 8 
18 
19 6 
29 5 
1.4 
8 
69 
61 
4 6 
100.0 
4 6 
3 
5 
8 
_ 
1058 
168 
92 
99 
1417 
1318 
1055 
100.0 
80 3 
80 3 
168 
100.0 
12 7 
12 7 
92 
100.0 
7 0 
7 0 
-
1409 
1315 
100.0 
100.0 
100.0 
TABLE fc 90 Pectoral muscle fixation versus Histology of the axillary lymph nodes. 
Histology of the axillary lymph nodes 
Histologically Histologically Totals Totals 
Pectoral muscle fixation negative positive Other whole series noticed data 
No fixation 322 490 246 1058 812 
39.7 60 3 100.0 
84 5 80 6 82.1 
32 6 49.5 82 1 
Incomplete fixation 
Complete fixation 
Other 
Totals whole senes 
Totals noticed data 
46 
37.1 
12.1 
4 7 
13 
24.5 
3 4 
1.3 
21 
402 
381 
3 8 5 
100.0 
38 5 
78 
62.9 
12 8 
7 9 
40 
75.5 
6.6 
4 0 
44 
652 
608 
61.5 
100.0 
61.5 
44 
39 
34 
363 
168 
92 
99 
1417 
1318 
124 
100.0 
125 
12.5 
S3 
100.0 
5.4 
5 4 
-
1054 
989 
100.0 
100.0 
100.0 
162 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
TABLE fe 91 Status of the homolateral axillary lymph nodes versus Status of the supra- and Numbers 
infraclavicular lymph nodes '{· "
е
0
г
™°"
Ы 
Statua of the supra- and infraclavicular lymph nodes % Totals noticed data 
Status of the homolateral Considered to 
axillary lymph nodes contain growth Other Totals whole senes Totals noticed data 
Single 13 229 242 
Multiple 
Fixed to one another or to 
other structures 
Considered to contain no growth 
¡  
100 0 
1 6 9 
169 
21 
1000 
27 3 
27 3 
23 
100 0 
29 9 
29 9 
20 
1000 
26 0 
26 0 
187 
813 
13 
looo 
16 9 
169 
21 
100 0 
27 3 
27 3 
23 
looo 
29 9 
29 9 
20 
100 0 
26 0 
26 0 
Totals whole series 80 1337 
Totals noticed data 77 
1000 
looo 
100 0 
77 
100 0 
100 0 
looo 
TABLE fc 92 Status of the homolateral axillary lymph nodes versus Clinical stage (International 
TNM classification). 
Clinical stage (International T N M classification) 
Status of the 
homolateral axillary 
.ymph nodes Stage I 
Totals Totals 
Stage II Stage III Stage IV Other whole series noticed data 
Single 98 
4 0 8 
5 1 6 
7 3 
127 
52 9 
176 
9 2 
15 
6 3 
23 1 
1 1 
242 240 
100 0 
176 
176 
Multiple 50 
24 0 
26 3 
3 6 
146 
70 2 
20 2 
10 6 
12 
5 8 
18 5 
0 9 
208 
100 0 
15 1 
15 1 
Fixed to one another or 
to other structures 
77 
82 9 
10 1 
5 5 
ie 
172 
24 6 
1 2 
93 
100 0 
6 8 
6 8 
no growth 
390 
47 0 
1000 
28 5 
42 
5 1 
22 1 
32 
57« 
45 3 
52 2 
27 4 
22 
2 7 
33 9 
1 5 
830 
100 0 
6 0 6 
6 0 6 
Other 10 21 41 
Totals whole series 400 193 747 1417 1409 
Totals noticed data 390 
28 5 
100.0 
28 5 
190 
14 1 
100 0 
14 1 
726 
52 7 
100.0 
52 7 
65 
4 7 
100.0 
47 
737/ 
100.0 
100.0 
100.0 163 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed 
TABLE fc 93 Status of the homolateral axillary lymph nodes versus Clinical stage (International 
TNM classification). 
data Stage in is divided into two groups, a: large tumor only, no other symptoms; b: also other 
symptoms. 
Clinical stage ^International T N M classification^ 
Status of the Stage III 
homolateral large tumor Stage III 
axillary only, no also other Totals Totals 
lymph nodes Stage I Stage II other symptoms symptoms Stage IV Other whole series noticed data 
Single 
Multiple 
Fixed to one 
another or to other 
structures 
Considered to 
contain no growth 
390 
47.0 
100.0 
28.5 
Other 10 
98 
40.8 
51.6 
7.3 
26 
10.8 
14.5 
2.0 
101 
42.1 
18.6 
7.2 
15 
6.3 
23.1 
1.1 
242 
50 
24.0 
26.3 
3.6 
40 
19.2 
22.3 
2.9 
106 
51.0 
19.5 
7.7 
12 
5.8 
18.5 
0.9 
208 
77 
B2.9 
13.4 
5.6 
16 
17.2 
24.6 
1.2 
93 
42 
5.1 
22.1 
3.2 
¡13 
14.7 
63.1 
8.2 
263 
30.6 
48.5 
19.1 
22 
2 .7 
33.9 
1.5 
16 
240 
100.0 
17.5 
17.5 
208 
100.0 
15.2 
15.2 
93 
100.0 
6.8 
6.8 
830 
100.0 
60.5 
60.5 
Totals whole series 400 193 184 69 ¡409 
Totals noticed data 390 
28.5 
100.0 
28.5 
190 
14.1 
100.0 
14.1 
779 
13.1 
100.0 
13.1 
547 
39.7 
100.0 
39.7 
55 
4.7 
100.0 
4.7 
137¡ 
100.0 
100.0 
loo.o 
TABLE fc 94 Status of the fomolateral axillary lymph nodes versus Histology of the axillary 
lymph nodes. 
Histology of the axillary lymph nodes 
Status of the homolateral Histologically Histologically Totals Totals 
axillary lymph nodes negative positive Other whole series noticed data 
Single 35 
18.1 
8.9 
3.4 
¡58 
81.9 
24.8 
15.4 
49 242 ¡93 
100.0 
18.8 
18.8 
Multiple 26 
15.1 
6.6 
2.5 
¡46 
84.9 
23.0 
14.2 
208 ¡72 
100.0 
16.7 
16.7 
Fixed to one another or to 
other structures 
1 
1.7 
0.3 
0.1 
58 
98.3 
9.1 
5.6 
34 93 59 
100.0 
5.7 
5.7 
Considered to contain 
no growth 
330 
54.6 
84.1 
32.1 
274 
45.4 
43.1 
26.6 
229 833 604 
100.0 
58.7 
58.7 
Other ¡0 16 15 4¡ 
Totals whole series 363 ¡417 
164 
Totals noticed data 392 
38.1 
100.0 
38.1 
636 
61.9 
100.0 
61.9 
¡376 ¡028 
100.0 
100.0 
100.0 
TABLE fc 95 Status of the supra- and infraclavicular lymph nodes versus Clinical stage 
(international TNM classification). 
Clinical stage (International T N M classiñcation) 
Status of the supra- and 
infraclavicular Totals Totals 
lymph nodes Stage I Stage I I Stage III Stage IV Other whole series noticed da ta 
Considered to contain 
Krowth 
Other 
Totals whole series 
T o t a b noticed data 
414 
414 
183 
183 
66 
82.5 
100.0 
82.S 
677 
743 
66 
82.5 
100.0 
82.5 
14 
17.5 
100.0 
17.5 
55 
69 
14 
17.5 
100.0 
17.5 
" 
8 
8 
80 
1337 
1417 
80 
80 
100.0 
100.0 
100.0 
-
1409 
80 
100.0 
100.0 
100.0 
TABLE fc 96 Status of the supra- and infraclavicular lymph nodes versus Clinical stage 
(International TNM classification). Stage in is divided into two groups, a : large tumor only, 
no other symptoms; b: also other symptoms. 
Clinical stage (International T N M classi ñcation) 
Stage III 
large tumor 
Status of the supra- only, no Stage III 
and infraclavicular other also other Totals Totals 
lymph nodes Stage I Stage I I symptoms symptoms Stage I V Other whole series noticed data 
Considered to 
contain growth 
Other 
Totals whole series 
Totals noticed data 
_ 
414 
414 
-
183 
183 
-
184 
184 
66 
82.5 
100.0 
82.5 
493 
559 
66 
82.5 
100.0 
82.5 
14 
17.5 
1000 
17.5 
J J 
69 
14 
17.5 
100.0 
17.5 
_ 
в 
8 
80 
П37 
1417 
80 
80 
100.0 
100.0 
100.0 
-
1409 
80 
100.0 
100.0 
100.0 
Numbers 
% Horizontal 
% Vertical 
% Totals noticed data 
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Ntmbtrs TABLE fe 97 Status of the supra- and infraclavicular lymph nodes versus Histology of the 
% « 3 Ы axillary lymph nodes 
% Totals noticed data 
Histology of the axillary lymph nodes 
Status of the supra- and 
infraclavicular Histologically Histologically Totals Totals 
lymph nodes negative positive Other whole series noticed data 
Considered to 
contain growth 
Other 
Totals whole senes 
Totals noticed data 
5 
1 1 6 
100 0 
116 
397 
402 
5 
1 1 6 
100 0 
116 
38 
8 8 4 
1000 
8 8 4 
614 
652 
38 
8 8 4 
100 0 
8 8 4 
37 
326 
363 
80 
1337 
1417 
80 
43 
100.0 
100 0 
100 0 
-
1054 
43 
100 0 
100 0 
100 0 
TABLE f
c
 98 Cltmcal stage (International TNM classification) versus Histology of the axillary 
lymph nodes 
Histology of the axillary lymph nodes 
Clinical stage 
(International T N M Histologically Histologically Totals Totals 
classification) negative positive Other whole scries noticed data 
Stage I 
Stage II 
Stage III 
Stage IV 
Other 
Totals whole senes 
Totals noticed data 
199 
63 0 
4 9 6 
19 0 
51 
31 3 
12 7 
4 8 
147 
27 0 
36 7 
1 3 9 
4 
15 4 
1 0 
0 4 
1 
402 
401 
38 1 
100.0 
38 1 
117 
37 0 
18 0 
112 
112 
6 8 7 
17 3 
10 7 
398 
73 0 
6 1 2 
37 9 
22 
8 4 6 
3 5 
2 1 
3 
652 
649 
6 1 9 
100 0 
6 1 9 
98 
20 
198 
43 
4 
363 
_ 
414 
183 
743 
69 
8 
1417 
1409 
316 
100.0 
3 0 1 
30 1 
¡63 
100.0 
156 
15 6 
545 
100 0 
5 1 8 
5 1 8 
26 
100.0 
2 5 
2 5 
-
1054 
1050 
100 0 
100.0 
100.0 
166 
TABLE fe 99 Clinical stage (International TNM classification). Stage m is divided into two ^w"**" 
groups
 г
 a: large tumor only у no other symptoms; b : abo other symptoms, versus Histology of the £ vertical 
axillary lymph nodes. %Totals noticed data 
Histology of the axillary lymph nodes 
Clinical stage 
(International TNM Histologically Histologically Totals Totals 
classification) negative positive Other whole series noticed data 
Stage I 
Stage II 
Stage III large tumor only, 
no other syraptonu 
Stage III also other 
symptoms 
Stage IV 
Other 
lotaU whole series 
Totab noticed data 
1S9 
63.0 
49.6 
19 0 
51 
31.3 
12.7 
4.9 
43 
30 1 
10 7 
4 1 
104 
25.9 
25 9 
9 9 
4 
15 4 
1 0 
0 4 
1 
402 
401 
38 2 
100 0 
38 2 
117 
37.0 
18 0 
11 1 
112 
68.7 
17 3 
10 7 
100 
69 9 
15 4 
9 5 
298 
74 1 
45 9 
28.4 
22 
8 4 6 
3 4 
2 1 
3 
652 
649 
6 1 8 
100 0 
6 1 8 
98 
20 
41 
157 
43 
4 
363 
_ 
414 
Ш 
¡84 
559 
69 
8 
1417 
1409 
316 
100.0 
30.1 
30.1 
163 
100.0 
15.5 
15.5 
143 
100.0 
13 6 
1 3 6 
402 
100 0 
38 3 
38.3 
26 
100 0 
2.5 
2 5 
-
1054 
1050 
100 0 
100 0 
100 0 
167 
PART II FIGURES TO BE USED IN COMPUTING THE CURATIVE 
OPERABILITY. TABLES 01-08 
Occurrence of local and/or regional recurrences and distant metastases, 5years follow up and 
10 years follow up (each clinical stage considered as 100 percent). 
T A B L E О 1 j years follow up. 
Clinical stage (International TNM classification) 
Stage I Stage II Stage III Stage IV· Totals 
I 
I I 
I 
minus I I 
I I I 
I V 
I I I 
minus I V 
V 
V I 
V 
minus VI 
V I I 
I + V I I 
Local/regional recurrence 
and/or distant metastases 
Local/regional recurrence 
without simultaneous 
distant metastases 
Distant 
metastases 
First signs of local/regional 
recurrence and/or distant 
metastases within 3 y e a n 
Local/regional recurrence 
without simultaneous distant 
metastases within 3 years 
First a igus o f d is tant 
m é t a s t a s e s wi th in 3 y e a r s 
(Cf table О 3) 
F i n t signs of local/regional 
recurrence and/or distant 
metastases after 4 y e a n or later 
Local/regional recurrence 
without simultaneous distant 
metastases after 4 y e a n or later 
Firet signs of distant metas­
tases after 4 years or later 
N o local/iegional recurrence 
and/or distant metastases 
Whole series 
5 y e a n follow u p 
N o 
% 
N o 
% 
N o 
7. 
N o 
% 
N o 
% 
N o 
% 
N o 
No 
% 
N o 
% 
N o 
% 
N o 
% 
120 
42 9 
12 
4 3 
ιοβ 
38 В 
74 
26 4 
в 
2 9 
se 
23.7 
46 
16 4 
4 
1 4 
4¿ 
15 1 
158 
57 1 
278 
100 0 
61 
4 8 8 
7 
5 6 
54 
42 9 
51 
4 0 8 
5 
4 0 
46 
36 5 
10 
8 0 
2 
1 6 
а 
6 3 
Í S 
5 1 2 
126 
100 0 
351 
6 6 6 
53 
10 3 
298 
5 6 3 
270 
5 1 2 
38 
7 2 
232 
4 3 9 
81 
15 4 
15 
2 8 
66 
12 5 
178 
33 4 
529 
100 0 
40 
85 1 
3 
6 2 
37 
78 7 
37 
78 7 
3 
6 2 
34 
72 3 
3 
6 2 
-
3 
6 2 
7 
1 4 9 
47 
100 0 
572 
58 4 
75 
7 7 
497 
50 7 
432 
4 4 1 
54 
5 5 
378 
3 8 6 
140 
1 4 3 
21 
2 1 
119 
12 1 
408 
4 1 6 
980 
100 0 
Stage IV occurrence of new signs of tumor growth 
For example 
Stage I 66 patients with firet signs of distant metastases within 3 yean This is 23 7% of 278 patients ш stage I of the 
whole scries 
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TABLE О 2 io years follow up. 
Оііптгаі stage (lotemattonal TNM dasaification) 
Stage I Stage II Suge III Stage IV· Touh 
I 
II 
I 
т ш щ II 
III 
IV 
III 
minus IV 
V 
VI 
V 
minus VI 
VII 
I + VII 
Local/regional recurrence 
and/or distant metastases 
Local/regional recurrence 
without simultaneous 
distant metastases 
Distant 
metastases 
First signs of local/regional 
recurrence and/or distant 
metastases within 3 yean 
Local/regional recurrence 
without simultaneous distant 
metastases within 3 years 
First e igne of d ie tant 
m é t a s t a s e s w i t h i n 3 y e a r s 
(Ci table О 4) 
First signs of local/regional 
recurrence and/or distant 
metastases after 4 years or later 
Local/regional recurrence 
without simultaneous distant 
metastases after 4 yean or later 
First signs of distant metas­
tases after 4 years or later 
No local/regional recurrence 
and/or distant metastases 
Whole series 
10 yeara follow up 
No. 
% 
No 
% 
No. 
% 
No. 
% 
No. 
% 
No 
7. 
No 
% 
No 
% 
No 
'/. 
No. 
% 
No 
% 
46 
50 5 
4 
4 4 
42 
4 6 2 
28 
30 8 
3 
3 3 
25 
27.5 
IS 
19.8 
1 
1.1 
17 
18 7 
45 
49 5 
91 
100.0 
21 
55.3 
2 
5 3 
19 
5 0 0 
17 
44.7 
2 
5.3 
15 
39.5 
4 
10.5 
— 
— 
4 
10 5 
17 
4 4 7 
38 
100.0 
157 
75.1 
29 
139 
128 
6 1 2 
115 
55 0 
17 
8.1 
98 
46.9 
42 
2 0 1 
12 
5 7 
30 
14 4 
52 
24 9 
209 
100.0 
18 
9 4 7 
1 
5.3 
17 
89 5 
17 
8 9 5 
i 
5.3 
16 
84.2 
/ 
5 3 
— 
— 
/ 
5 3 
1 
5 3 
19 
100.0 
242 
67 8 
36 
10 1 
206 
57 7 
177 
49 6 
23 
6 4 
154 
43.1 
« 
І .2 
13 
3.6 
52 
14 6 
115 
32 2 
357 
100.0 
Stage IV occurrence of new signs of tumor growth 
For example 
Stage 1. 25 patients with fint signs of distant metastases within 3 yean. This is 27.5% of 91 patients in stage I of the 
whole sene·. 
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Estimation of curative operability on the basis ofifirst signs of distant metastases within 3years 
after starting treatment' by stage (each clinical stage and combination of stages (International 
TNM clasnfication) considered as 100 percent). 
TABEL О 3 5 years follow up. 
Clinical Stage Distant* metastases 'Curative operability' ^ 
(International TNM dassifìeation) within 3 years % % 
Stage I 
Stage II 
Stage III 
Stage I + II 
Stage II + III 
Stage I + II τ III 
Whole series 
Including stage IV 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
X 
No. 
7. 
66 
23.7 
46 
36.5 
232 
43.9 
112 
27.7 
27« 
42.4 
344 
36.9 
378 
38.6 
76.3 
63.5 
56.1 
72.3 
57.6 
63.1 
61.4 
1.31 
1.57 
1.78 
1.38 
1.74 
1.58 
1.63 
For example : 
Stage I: 66 patients with distant metastases within 3 yeais. This is 23.7% of 278 patients in stage I of the whole series. 
This means 23.7 % 'curative inoperable' and 100.0-23.7 » 76.3 % 'curative operable'. 
100 100 
= 1.31 (Cf. Appendix ¡table ) 
76.3% V^ % 
TABLE О 4 10 years follow up. 
Clinical stage Distant* metastases 'Curative operability' 100 
(International TNM classification) within 3 years % % 
Stage I 
Stage II 
Suge III 
Stage I 4- II 
Stage II + III 
Stage I + II + III 
Whole series 
Including Stage IV 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
25 
27.5 
15 
39.5 
98 
46.9 
40 
31.0 
113 
45.7 
138 
40.8 
154 
43.1 
72.5 
60.5 
53.1 
69.0 
54.3 
59.2 
56.9 
1.38 
1.65 
1.88 
1.45 
1.84 
1.69 
1.76 
* local and/or regioaal recurrence without simultaneous distant metastases arc not considered. 
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Prognosis (in absolute and relative frequencies) by stage (each clinical stage considered as 
100 percent). 
TABLE О 5 J years follow up. 
Death from 
Clinical Stage Died of tumor Died of tumor cause other 
(International Alive without Alive with within Э years after 4 years than tumor 
TNM classification) signs of tumor signs of tumor (Cf table 07) or later or unknown Totals 
S u g e I 
Stage I I 
Stage I I I 
S u g e I V 
Whole senes 
5 years follow u p 
N o 
% 
No 
No 
No 
No 
% 
140 
5 0 4 
53 
42 1 
132 
25 0 
: 
325 
33 3 
10 
3 6 
J 
4 0 
в 
1 5 
-
23 
2 2 
59 
21.2 
40 
31.7 
22e 
42.7 
41 
87.2 
366 
37 3 
49 
1 7 6 
15 
1 1 9 
110 
20 8 
4 
8 5 
178 
182 
20 
7 2 
13 
10 3 
53 
10 0 
2 
4 3 
88 
9 0 
278 
100.0 
126 
100.0 
529 
100.0 
47 
100.0 
980 
100.0 
TABLE О б 10 years folhw up. 
Death from 
Clinical Stage Died of tumor Died of tumor cause other 
(International Alive without Alive with within 3 years after 4 years than tumor 
TNM classification) signs of tumor signs of tumor (Cf table OB) or later or unknown Totals 
Stage I 
S u g e I I 
S u g e III 
Stage I V 
N o 
N o 
7. 
No 
% 
N o 
% 
39 
42 9 
14 
36 В 
42 
20 1 
1 
5 3 
1 1 
2 
5 3 
-
-
24 
26.4 
14 
36.8 
97 
46.4 
17 
89.5 
21 
23 1 
4 
10 5 
54 
25 8 
1 
5 3 
6 
6 6 
4 
10 5 
16 
7 7 
_ 
91 
100.0 
38 
100.0 
209 
100 0 
19 
100.0 
Whole sene» No SS 3 152 80 26 357 
10 years follow up % 26 9 0 8 42 6 22 4 7 3 100.0 
Estimation of the curative operability on the bans of 'died of tumor within 3years after starting 
treatment' by stage (each clinical stage and combination of stages (International TNM 
classification) coruidered as 100percent). 
T A B E L О 7 5 years follow up. 
Сішісаі stage Died of tumor 'Curative operabüity· ^0( 
(International TNM classification) within 3 yean % % 
Stage I 
Stage II 
Stage III 
Stage I + II 
SUge II + III 
Stage I + II + III 
Whole вен» 
Including stage IV 
No. 
% 
No 
% 
No. 
% 
No 
% 
No. 
% 
No. 
% 
No. 
% 
59 
212 
40 
31.7 
226 
AZI 
99 
24 5 
266 
405 
325 
347 
366 
37 3 
78 8 
683 
57 3 
75 5 
59 5 
65 3 
62 7 
127 
146 
175 
132 
168 
153 
159 
For txamph · 
Stage I. 59 patients died of tumor within 3 yean. This is 21 2% of 278 patients in stage I of the whole series. 
This means 21 2% 'curative inoperable' and 100.0 — 21.2 = 78 8% 'curative operable'. 
100 100 
1 27 (Cf Append«· table ). 
T A B E L О 8 10 years follow up. 
amical stage Died of tumor 'Curative operability'« 100 
(International TNM classification) within 3 yean % % 
Stage I 
Stage II 
Stage III 
Stage I + II 
Stage II + III 
Stage I + II + III 
Whole senes 
Including stage IV 
No. 
% 
No. 
% 
No 
% 
No 
% 
No. 
% 
No. 
% 
No. 
24 
26 4 
¡4 
36.8 
97 
464 
за 
29 5 
111 
449 
135 
39.9 
152 
42 6 
73 6 
63 2 
53 6 
70 5 
55 1 
60.1 
57.4 
136 
158 
187 
142 
181 
166 
174 
• Cf Fig. III-l. 
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PART III FIGURES TO BE USED IN COMPUTING THE NUMBER OF 
MEMBERS OF THE GENERAL FEMALE POPULATION 
REQUIRED FOR A CLINICAL TRIAL 
TABLE Ρ OUT computation of factor Ρ on the basts of the annual number of deaths from malig­
nant disease of the breast infernales (modification from Segi, 1966). 
Country 
Canada 
Chile 
USA (white) 
USA (non-white) 
Israel 
Japan 
Germany (Federal republic) 
Austria 
Belgium 
Denmark 
Finland 
France 
Ireland 
Italy 
Norway 
The Netherlands 
Portugal 
England and Wales 
Scotland 
Northern Ireland 
Sweden 
Switzerland 
Australia 
New Zealand 
Female population 
9,361,600 
4,194,413 
84,538,000 
11,367,000 
1,043,061 
48,925,000 
30,361,700 
3,824,644 
4.757,001 
2,361,217 
2,351,061 
24,424,823 
1,414,674 
26,269,077 
1,839,649 
6,003,373 
4,735,900 
24,193,700 
2,705,200 
741,000 
3,810,352 
2,973,900 
5,409,783 
1,265,348 
Number of deaths Trom 
malignant disease of 
the breast 
2,353 
291 
21,985 
2,020 
258 
1,857 
8,389 
1,048 
1,576 
873 
351 
6,305 
399 
5,354 
495 
1,819 
662 
9,442 
975 
IBS 
1,179 
905 
1,278 
337 
Percentage of deaths 
from malignant disease 
of the breast 
0 025 
0 007 
0 026 
0 0 1 7 
0 025 
0 0038 
0 028 
0 027 
0 033 
0 037 
0 015 
0 026 
0 028 
0 020 
0 027 
0 030 
0 014 
0.040 
0 036 
0 025 
0 031 
0 030 
0 024 
0.027 
Factor Ρ 
r
1
,
0 0) 
4 0 χ 103 
14 2 χ 103 
3 9 χ 103 
5 9 χ 103 
4 0 χ 103 
26 χ 103 
3 6 χ 103 
3 7 χ 103 
3 0 χ 103 
2 7 χ 103 
0 67 χ 103 
3 9 χ 103 
3 6 χ 103 
5 0 χ 103 
3 7 χ 103 
3 3 χ 103 
7 1 χ 103 
2 5 χ 103 
2 8 χ 103 
4 0 χ 103 
3 2 χ 103 
3 3 χ 103 
4 2 χ 103 
3 7 χ 103 
PART IV AIDS TO THE CALCULATION OF THE MULTIPLICATION 
100 
FACTOR - — 
0 
1 
2 
3 
4 
5 
6 
7 
β 
9 
10 
11 
11 
13 
14 
15 
16 
IT 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
33 
36 
37 
3B 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
0 
100 00 
50 00 
33 33 
25 00 
20 00 
16 67 
14.29 
12 50 
11 11 
10 00 
909 
8 33 
7 69 
7 14 
6 67 
6 25 
588 
556 
5 26 
500 
4 76 
4 55 
4 35 
417 
400 
3 85 
3 70 
3 57 
3 45 
3 33 
3 23 
3 12 
3 03 
294 
286 
2 78 
2 70 
2 63 
256 
250 
244 
2 38 
2 33 
2 27 
2 22 
2 17 
2 13 
208 
204 
1 
1000 00 
90 91 
47 62 
32 26 
24 39 
19 61 
16 39 
14 08 
12 35 
10 99 
990 
9 01 
8 26 
7 63 
709 
6 62 
6 21 
585 
5 52 
5 24 
4 98 
4 74 
4 52 
4 33 
4 15 
3 98 
3 83 
3 69 
356 
344 
3 32 
3 22 
3 12 
302 
2 93 
2 85 
2 77 
2 70 
2 62 
256 
249 
2 43 
2 38 
2 32 
2 27 
2 22 
2 17 
2 12 
208 
204 
г 
500 00 
83 33 
45 45 
3125 
23 81 
19 23 
16 13 
13 89 
12 20 
10 87 
980 
8 93 
8 20 
7 58 
704 
658 
6 17 
5 81 
549 
521 
4 95 
4 72 
450 
4 31 
4 13 
3 97 
3 82 
368 
3 55 
3 42 
3 31 
321 
3 11 
3 01 
2 92 
284 
2 76 
2 69 
2 62 
2 55 
2 49 
2 43 
2 37 
2 31 
2 26 
2 21 
2 16 
2 12 
2 07 
2 03 
3 
333 33 
76 92 
43 48 
30 30 
23 26 
18 87 
15 87 
13 70 
12 05 
10 75 
9 71 
8 85 
8 13 
7 52 
699 
654 
6 13 
5 78 
546 
5 18 
4 93 
4 69 
448 
4 29 
4 12 
3 95 
380 
366 
3 53 
3 41 
330 
3 19 
3 10 
300 
2 92 
2 83 
2 75 
268 
2 61 
254 
248 
2 42 
2 36 
2 31 
2 26 
2 21 
2 16 
211 
2 07 
2 03 
4 
250 00 
7143 
41 67 
29 41 
22 73 
18 52 
15 62 
13 51 
1190 
10 64 
9 62 
8 77 
806 
746 
694 
6 49 
6 10 
5 75 
5 43 
5 15 
490 
4 67 
446 
4 27 
4 10 
394 
3 79 
365 
3 52 
340 
3 29 
3 18 
309 
299 
2 91 
2 82 
2 75 
2 67 
260 
254 
248 
2 42 
2 36 
2 30 
2 25 
2 20 
2 16 
211 
2 07 
2 02 
S 
200 00 
66 67 
40 00 
28 57 
22 22 
18 18 
15 38 
13 33 
1176 
10 53 
9 52 
8 70 
800 
7 41 
690 
6 45 
606 
5 71 
5 41 
5 13 
488 
4 65 
444 
4 26 
408 
3 92 
3 77 
364 
3 51 
3 39 
3 28 
3 17 
308 
299 
290 
2 82 
2 74 
2 67 
2 60 
2 53 
2 47 
2 41 
2 35 
2 30 
2 25 
2 20 
2 15 
211 
206 
2 02 
e 
166 67 
62 50 
38 46 
27 78 
21 74 
17 86 
15 15 
13 16 
1163 
1042 
9 43 
8 62 
794 
7 35 
685 
6 41 
602 
568 
538 
5 10 
4 85 
4 63 
4 42 
4 24 
4 07 
391 
3 76 
3 62 
3 50 
338 
3 27 
3 16 
3 07 
2 98 
2 89 
2 81 
2 73 
266 
2 59 
2 53 
246 
240 
2 35 
2 29 
2 24 
2 19 
2 15 
2 10 
206 
2 02 
7 
142 86 
58 82 
37 04 
27 03 
2128 
1754 
14 93 
12 99 
1149 
10 31 
9 35 
8 55 
7 87 
7 30 
6 80 
6 37 
599 
5 65 
5 35 
508 
4 83 
461 
4 41 
4 22 
4 05 
3 89 
3 75 
3 61 
348 
3 37 
3 26 
3 15 
306 
2 97 
288 
2 80 
2 72 
2 65 
2 58 
2 52 
246 
240 
2 34 
2 29 
2 24 
2 19 
2 14 
2 10 
2 05 
2 01 
В 
125 00 
55 56 
35 71 
26 32 
20 83 
17 24 
14 71 
12 82 
Il 36 
10 20 
9 26 
8 47 
7 81 
7 25 
6 76 
6 33 
5 95 
5 62 
5 32 
5 05 
481 
4 59 
4 39 
4 20 
4 03 
3 88 
3 73 
360 
3 47 
336 
3 25 
3 14 
3 05 
296 
2 87 
2 79 
2 72 
2 65 
258 
2 51 
2 45 
2 39 
2 34 
2 28 
2 23 
2 18 
2 14 
209 
2 05 
2 01 
9 
111 11 
52 63 
34 48 
25 64 
2041 
16 95 
14 49 
1266 
1124 
10 10 
9 17 
840 
7 75 
7 19 
6 71 
6 29 
5 92 
5 59 
5 29 
5 03 
4 78 
4 57 
4 37 
4 18 
4 02 
3 86 
3 72 
3 58 
346 
334 
3 24 
3 13 
304 
2 95 
2 87 
2 79 
2 71 
264 
2 57 
2 51 
244 
2 39 
2 33 
2 28 
2 23 
2 IB 
2 13 
209 
204 
200 
For example = 2 81 
35 6 
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P A R T V I N S E R T I O N ( M A M M A ) F O R M 
N o Clinical r e c o r d : Year: 
Clinic : 
Date of admission : Physician : 
Patient's marital state: unmarried/married/widowcd/divorced. 
N a m e of patient : 
(can be omitted provided N o . of clinical record is known) 
Date of birth : 
Profession of patient/husband : 
Residence: Family Doctor : 
male patient • 
H i s t o r y (Tick appropriate box) 
Duration of symptoms : 
First consultation of Family Doctor : 
Commencement of treatment : 
How was the tumor discovered : 
a) Accidentally by patient 
b) Deliberate self-examination 
e) By periodic medical examination 
d) Accidentally by physician 
e) With reference to breast complaints 
ƒ ) With reference to other complaints (e.g.mctastases) 
Surgeon : 
D 
α 
D 
π 
D 
D 
Symptoms: 
Tumor 
Pain 
Secretion 
Discoloration 
Swelling 
D 
D 
D 
D 
D 
Year of menarche 
Cycle d /irregular • disturbances: 
Year of marriage(s) ist 
Dates of confinements ist 
Duration of nursing ist 
Puerperal mastitis ist 
Dates of abortions ist 
Year menopause 
, 2nd 
, 2nd 
, 2nd 
, 2nd 
, 2nd 
castration • 
3rd 
3rd 
3rd 
3rd 
3rd 
operative • X-Ray D 
Mastopathia : none Π moderate • serious • 
Pregnant at t ime of discovery or t reatment of tumor • 
Nursing during discovery or treatment of tumor • 
Other diagnoses : 
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Clinical findings (draw in scheme) (Use of histological findings not allowed) 
Mammary tumor (Ύ) Occult tumor (TO) Π 
Tumor manifest • 
Right Π Left Π 
Location (supine position) medial half (170.1) • 
lateral half (170.2) Π 
subareolar (central) . (170.3) D 
other localizations . . (170.4) • 
not recorded . . . . (170.9) Π 
Size biggest diameter 2 cm or less (Ti) • 
2-5 cm (Та) Π 
5-IO cm (Тз) Π 
„ „ more than io cm (T4) • 
Consistency: soft • elastic • fluctuating • 
solid Π hard Π 
Boundaries: sharp • roonded • vague • 
Skin Skin not involved (Τι) Π 
Incomplete fixation (limited movement or wrinkling) (Та) • 
Complete fixation (infiltration, ulceration) or peau d'orange over tumor (T3) • 
Skin fixation wide of tumor but not beyond breast area (T4) • 
Paget's disease Limited to the nipple (Τι) Π 
Outside the nipple (Та) О 
Nipple retraction Nipple retraction (Та) • 
Pectoral muscle fixation No fixation (Ti) • 
Incomplete fixation (contraction reduces mobility of tumor) (Тза) • 
Complete fixation (contraction eliminates mobility of tumor) (ТзЬ) • 
Chest wall attachment No fixation (Ti) • 
Fixation (T4) • 
Regional lymphnodes (N) 
Homolateral lymphnodes Not palpable (N0) Π 
Palpable, still movable 
Considered to contain no growth (Nia) • 
Considered to contain growth (Nib) • 
Single (Nix) • 
Multiple (Niy) Π 
Fixed to one another (Naa) • 
Fixed to other structures (Nab) • 
Homolateral supra- or 
infraclavicular lymph nodes Movable or fixed (N3) • 
Arm edema Present (N3) Π 
Distant metastases (M) 
No distant metastases (MO) • 
Distant metastases : 
Skin wide from breast (M) • 
Heterolateral lymphnodes or breast (M) • 
Lungs, pleura (M) • 
Bony metastases (M) • 
Liver (M) • 
Other sites (M) • 
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Diameter cm 
Boundaries 
a) Sharp \J 
b) Diffuse 
' - ! • 
Relation to 
surroundings: 
Ulceration ^ ^ ^ 
Ingrowth ^ ^ ^ ^ _ _ 
Incomplete J ^ ^ 
fixation ' 
Staging 
Carcinoma mammae 
right 
left 
S : : : : : : } 
M J 
= Stage 
Stage I - Τ ι NO MO 
- Ta NO MO 
Stage II - T i N i MO 
- T 2 N 1 MO 
Stage III - T i N3 or N3 MO 
- Ta Na or N3 MO 
- T 3 NO, N1, N2 0 Γ Ν 3 MO 
- T4 NO, N1, N2 or N3 MO 
Stage IV - Any combination of 
Τ and N with M 
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PART VI SOME STATISTICAL METHODS SUITABLE FOR T H E ANA­
LYSIS OFCONTROLLED CLINICAL TRIALS IN THE TREAT­
M E N T OF MAMMARY CARCINOMA 
PH. VAN ELTEREN M.Sc. 
Head of the statistical department of the University computer center of the Catholic University 
of Nijmegen. 
1. Introduction 
The purpose of clinical trials is to compare two or more methods of treating the same 
disease. By observing the statistical rules for adequate experimental design and for 
analyzing the findings, one attempts to obtain justified conclusions regarding the 
methods of treatment compared. In this appendix we discuss in some detail certain 
methods of analysis used in the study of the treatment of mammary carcinoma, and the 
corresponding experimental designs. 
The decision as to which method of analysis is to be applied cannot be postponed 
until after the experiment, because the experimental design depends on the method of 
analysis employed. In this study we limit ourselves to methods of analyzing trials in 
which two treatments are compared, and which have the character of statistical tests. 
For every test there is a so-called 'Null Hypothesis' and a criterion on the basis of which 
the null hypothesis has to be rejected or accepted. In testing the results of a clinical trial, 
the null hypothesis is that the two methods of treatment are equivalent in a sense yet to 
be determined. T h e criterion consists of the comparison of a parameter to be calculated 
from the findings, the Statistic, with a so-called Critical Value. If the statistic is larger 
or smaller than the critical value, the null hypothesis is rejected and one concludes that 
the methods of treatment compared differ 'significantly'. In this study we shall always 
consider so-called Two-sided Tests which, if a significant difference is found between 
two methods of treatment, also offer the possibility of determining which was the better 
method of treatment. - T h e test criterion is selected in such a way that the probability 
of the decision that there is a difference between the therapies, if this decision is false, 
is below a previously determined limit, the level of significance a. As a rule, the tests 
are carried out with a level of significance α = 0.05 = 5%. 
If a difference exists between the therapies, there is a certain probability that this will 
be detected by the test on the basis of the results of the trial, in other words that the null 
hypothesis will be rejected. This probability is a function of certain parameters in which 
the difference between the therapies is expressed. This function is called the Power of 
the test. O n e generally demands that the power for differences of at least a certain 
extent must exceed e.g. 9 5 % . This can only be achieved when a certain minimum 
number of patients is used in the trial. 
I t is a condition of the validity of the conclusions of the statistical tests to be discussed 
that the methods of treatment are assigned to the patients at random. I n order to 
maximize the power of the test with a given number of patients, the groups treated by 
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the two methods must be equal in size. If the patients become available gradually, they 
might for instance be treated alternately by the first and the second method, in order of 
their admission. In that case, however, it must be postulated that the order of admission 
is random in regard to elements which, apart from the treatment, might influence the 
course of their disease. 
This assumption can be omitted if the order is determined in advance by drawing 
lots. This can be done as follows : if 400 patients are to be concerned in the trial, 200 will 
be treated by method A and 200 by method B. Two hundred numbers from the series 1, 
2 , . . . , 400 are drawn by lot, e.g. by taking 200 cards at random from a box containing 
400 numbered cards. T h e numbers drawn by lot then become the serial numbers of the 
patients to be treated by method A, while patients whose numbers arc left in the box 
will be treated by method B. Tables with random numbers or certain computer 
programs (so-called Random Number Generators) may replace the box of cards for 
this purpose. This drawing of lots should preferably be done by a central organization 
not involved in the treatment. T h e physicians involved only learn what method to 
apply at the moment the patient starts treatment. This Lot method offers the advantage 
over the alternating assignment method that it is unpredictable, which may, for in­
stance, prevent selection in accepting patients for treatment. For the sequential sign 
test discussed in Section 4 we need pairs of patients, one of whom is treated by method A 
and one by method B. We may compose these pairs of patients admitted immediately 
after one another, and we may by this experimental design also form pairs of patients 
similar in certain relevant elements, e.g. age. For every new patient we then check 
whether he 'fits' into an incomplete pair, if not, he becomes the first of a new pair. With 
both methods of pairing one must always determine by lot whether the patient 
admitted first is to be treated by method A or method B. 
T h e most important points necessary from a statistical point of view for planning a 
clinical trial are listed above. They determine the statistical design of the experiment. 
During the trial, however, complications may arise in view of which one concludes, 
rightly or wrongly, that the design can no longer be followed. It is vitally important not 
to deviate from this design without consultation with the statistician involved in the 
organization of the trial. In Sections 2,3 and 4 of this appendix we shall describe three 
tests applicable for the analysis of clinical trials in regard to mammary carcinoma. 
Special attention is given in this connection to the number of patients required. Since 
the supply of patients with mammary carcinoma per unit time is limited, and the effect 
of the treatment determined by the usual criteria (such as duration of survival) is not 
generally discovered until a considerable time later, the duration of the trial may be of 
greater importance in one's selection of method of analysis than the number of patients 
required. This aspect will be discussed further in Section 5. 
2. The χΐ test for a 2 X 2 table 
Let us suppose that we are interested in comparing two methods of treatment, A and 
B. For the χΐ test for a 2 X 2 table, the criterion of comparison can be described as 
follows. For every patient included in the trial we determine whether the treatment 
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applied has been 'successful'. I t is designated successful if, after a certain period, pre­
viously stated conditions have been fulfilled. For instance, the patient must not have 
died or exhibited a recurrence. O n e must also define an 'unsuccessful' result : for in­
stance if the patient has died from the mammary carcinoma during the period stated, 
or had a recurrence. I n addit ion, there will be a number of patients to whom the terms 
'successful' or 'unsuccessful' do not apply, for instance those who have died during 
the period in question due to accidents or other diseases. In our further discussion these 
'undecided cases' will not be taken into consideration. 
We now assume that we may logically speak of the probability Рд that 'success' will 
be obtained in a patient treated by method A. This is the case, for instance, when the 
patients included in the trial constitute a random sample of a population of patients of 
which a fraction Рд, after treatment by method A, will certainly be 'successful', or when 
every patient in such a population has a certain probability of'success' after treatment 
by method A and the average of these individual probabilities is P A . Similarly, we 
define P B as the probability of'success' of patients treated by method B. 
Using the χ2 test for a 2 X 2 table, we now test the null hypothesis P A — P B · For this 
test to be applied, the following parameters must be determined : 
S A = number of patients treated by method A (excepting undecided cases). 
ПА = number of patients in whom method A was successful. 
The terms S B and п в refer to method B. 
For the sake of efficiency we generally at tempt to have trials in which S A — S B , 
although 'drop-out' of patients may result in these numbers not being precisely the 
same at the end of the trial. If we further postulate that N = SA + S B and η = η A + 
η в, then: 
(1) 2
 { [ П А З В — H B S A I — i N } z N 
f
 S A S B M N — n) 
For the p a r t of the e q u a t i o n between the vertical lines, t h e absolute va lue must 
be used. 
W e c o m p a r e t h e statistic χ2 wi th t h e critical value χ1 (of the χ2 d i s t r ibut ion with 
1 degree of freedom) corresponding to t h e level of significance selected. 
S o m e critical values a r e : 
for α = 0.10 ( 1 0 % ) 
α = 0.05 ( 5 % ) 
α = 0.01 ( 1 % ) 
α = 0.001 ( l o / 0 0 ) 
Let us assume that we test with α = 5%. We thus reject the null hypothesis P A = 
P B if χ2 > χ$.05 = 3.84. We may then conclude that P A # P B , i.e that the result of the 
trial is significant. This conclusion may be specified further. 
The parameters : 
P A = П А / S A a n d P B = ПВ/SB 
У
2 
л 0 . 1 0 
л 0 . 0 5 
л 0 . 0 1 
У
2 
л 0 . 0 0 1 
= 
= 
= 
= 
2.71 
3.84 
6.63 
10.83 
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are, from the statistical point of view, 'estimates' of P A and Рв. Thus, if with χ2 > 3.84 
we also have P A > Р в (or п д З в > П В 8 А ) ) we conclude that P A > Р в or that treatment 
A was significantly better than treatment B. With χ2 > 3.84 and Рд < Рв (or H A S B < 
HBSA) , the conclusion is that P A < Р в , or that treatment В was significantly better than 
treatment A. 
O n the other hand, if we find that χ2 < /o.05 = 3.84, the hypothesis Рд = Р в mayjnot 
be rejected. We then conclude that the result of the trial was not statistically significant, 
or that the methods of treatment did not differ significantly. 
If we have selected some different value for a, we must apply the corresponding 
critical value. O u r formulation of the results may remain analogous in this case; it is 
advisable for the value of α chosen to be mentioned clearly by adding the qualification 
'at the level of significance a' to all statements including the term 'significant'. This 
term without qualification is usually interpreted as 'significant for α = 5%' . 
As a rule, in reporting the result of a test, the ρ value is also mentioned. This is the 
value that would have to be assigned to α for a just barely significant result. In the case 
considered here, the ρ value equals twice the probability that a random variable u * 
with a standard normal distribution exceeds χ (— д// 2 ) · T h e tables of normal 
distribution required for this purpose may be found in any statistical textbook or book 
of tables. If the ρ value is under 5%, the test result is significant for α = 5 % and vice 
versa. T h e more the ρ value deviates from the level of significance chosen, the greater 
the certainty with which the null hypothesis may be rejected or accepted. 
An example is given here to illustrate the test. 
A trial regarding mammary carcinoma was organized with 200 patients in group A 
and 200 in group B. In group A, 95 patients died of mammary carcinoma within 5 
years, and 67 in group B. In addition, 18 patients dropped out of group A and 25 out of 
group В due to other causes within these 5 years. 
T h e 2 x 2 table of the relevant data is then 
Therapy Treated 
A 
В 
Total 
consequently: 
SA = 
S B = 
N = 
182, 
175, 
357, 
2 0 0 -
2 0 0 -
ПА = 
Пв = 
η = 
-18 = 
-25 = 
87 
108 
195 
182 
175 
357 
Of which 
Successfully Unsuccessfully 
87 
108 
l is 
95 
67 
Тб2 
P A = 87/182 = 47.8% 
Р в = 108/175 = 61.7% 
N-n= 162 and: 
/2 = { | 87 x 175 - 108 χ 182 | - | χ 357 }2 χ 357 
182 χ 175 χ 195 χ 162 = 6.42 
* In the text of this appendix symbols for random variables will be underlined. 
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Since this value is higher than 3.84, the hypothesis of equivalence at α = 5 % may be 
rejected. Since P A < Рв> the conclusion is that treatment В was significantly better than 
treatment A. O n the other hand if we had chosen α = 1 % , the hypothesis of equivalence 
of the methods of treatment could not have been rejected, since 6.42 < 6.63. 
Further, χ = V 6.42 = 2.53. From a table of standard normal distribution we find 
as the value for ρ : 
ρ = 2 P [ u > 2.53] = 1 . 1 % 
Accordingly, 1% < ρ < 5%, which agrees with what we found by comparing 
critical values. 
T h e test described above is in fact an approximation to Fisher's exact rest for a 
2 x 2 table. This approximation is sufficiently reliable in practice when the values of 
SA) S B , η and N-n are not too small (e.g. all ^ 10). In clinical trials on mammary 
carcinoma this condition will generally be fulfilled. For exceptions, the reader is 
referred to the textbooks. 
T h e power of the test is determined by the values of P A and Ρ в. Eisenhart et al. ( 1947) 
present an approximation formula for this purpose based on the so-called arc sine 
transformation of the binominal distribution. This formula applies to the case S A = 
S B = S which, as mentioned in Section 1, is the most efficient distribution of 2S patients 
over the treatment groups. If we now require that the power must equal Ι-β, we find an 
equation for the necessary number of patients S (in each of the two treatment groups) 
in order that for the given values of P A and Р в rejection of the null hypothesis will be 
possible with a probability Ι-β if the test is carried out with a level of significance of a. 
This equation is : 
(u«/2 + V 2 
(2) S = — _ _ 
2 (arc sine ν P A — arc sine ν Ρ в ) 2 
in which : 
Ua/2 and u/f are the values by which a variable with a standard normal distribution 
is exceeded with a probability of a/2 or β ((ото. — β = 5%, (ua/2 + uß)2 = 13.0). 
Arc sine χ is the angle in radiais between — π/2 and π/2, the sine of which equals χ 
(e.g. arc sine 0.5 = π/6, because sine π/6 = sine 30° = 0.5). 
An example of the application of equation (2) would be as follows. T h e number of 
patients necessary with α = 5 % to obtain a significant result with 9 5 % certainty 
{β = 5%), if P A = 5 0 % and Рв = 2 5 % , is: 
(1.9600 + 1.6449)2 
2 (arc sine yO.SO - arc sine VO-25) 2 
Since arc sine VO.50 = arc sine £ V2 = 45° = π/4 (rad.) = 0.7854 
and arc sine VÖ~.25 = arc sine | = 30° = π/6 (rad) = 0.5236 
13.0 13.0
 = 9 4 _ 8 
2 χ 0.26182 0.1371 
Accordingly, at least 95 patients are necessary per treatment group. Equation (2) is 
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approximately valid if α and β are relatively small (e.g. both less than 20%) and 
probabilities P A and Р в do not differ too much. Naturally, it does not generally give a 
whole number for S. Since we need a minimum number to obtain a certain power of 
the test it is best to list the smallest whole number higher than the value of S found by 
equation (2). 
I n table SI (cf. Ch. I l l p . 17) the necessary value for S is listed for combinations of 
P A and Р в which are whole multiples of 10%, for α = β = 5%. O n the basis of the 
above condition for the reliability of the approximation, a number of extreme combi­
nations of P A and Ρ в have been omitted. 
T h e table shows a certain symmetry. If we exchange P A and Р в , or exchange P A 
and Р в for ( 1 - Рд) and ( 1 - Р в ) , we find the same number of patients is required. 
Further, we find that the number of patients necessary depends to a great and non­
linear extent on P A and Р в ; this renders interpolation between tabulated values im­
possible. For deviating values of Рд and Р в , equation (2) must be applied. T h e con­
stants Ua/2 and \ΐβ for a few values of α and β can be found in the following table : 
uo.io = 1.2816 
uo.05 = 1-6449 
U0.025 = 1.9600 
UQ.OI = 2.3263 
uo.005 = 2.5758 
A simple table of the arc sine function can be found in e.g. Documenta Geigy ( 1960), 
p . 69. 
Using equation (2) it is very easy to deduce a table from table SI for other values 
of α and β; we have only to multiply by a factor: 
(U + " J 2 (U . + U )2 
α /2 Ρ a/2 Ρ 
f ^ 
(Uo.025 + Uo.05)2 13.0 
for a = 1 %, β = 1 % this factor equals 1.849 
α = 1 % , / ? = 5 % „ „ „ 1.371 
α = 5%, β = 10% „ „ „ 0.809 
For α = 5 % and β = 10% this multiplication has been carried out (see table S2 
cf. Ch. I l l , p . 18). As for this purpose, the rounded-off values of table SI were used, 
direct calculation by equation (2) may reveal small deviations. Rümke (1968) 
published a table for the number of observations necessary for the one-sided χ2- test 
(see Section 1) with α = β = 5 % . This can also be used as a table for the two-sided test 
w i t h a = 10%, β = 5 %. O n verification we find that the values in this table are slight­
ly higher than those calculated by equation (2). A slightly different approximation of 
the power of the test may have been used. 
I t can be concluded from table S1 that the number of observations necessary does not 
only depend on the difference between Рд and Рв- T h e question arises what number 
would be sufficient for every pair of values Рд, Р в with a given difference A to be 
demonstrated with a probability of at least l-ß. We can find this number by sub-
stituting in equation (2) the values Рд = -\ (1 + J ) and Р в = i (1 — A). A few ex­
amples are listed in table A l . 
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J 
1 - β = 95% 
1 - β = 90% 
for S = 100 
S = 200 
S = 500 
5% 
2600 
2100 
13.6% 
23.0% 
48.8% 
10% 
640 
524 
28.2% 
50.0% 
87.1% 
15% 
287 
232 
56.7% 
85.4% 
99.7% 
20% 
161 
130 
81.3% 
98.1% 
100.0% 
25% 
102 
83 
94.7% 
99.9% 
100.0% 
TABLE Al . Power of the x2-testfor a 2 X 2 table: level of significance χ = 5%, equal sampel 
nzes S (number of patients in each therapy group). 
S j = minimum number of patients required to detect with a probability of at 
least l-ß the difference between P A and Р в if | P A — Р в | ~ Л 
l-ßj = minimum probability of detecting the difference between Р д and Р в and if 
the number of patients S is as indicated. 
Ι-βΑ 
Table Al allows one to specify the conclusion further if the hypothesis P A = Р в cannot 
be rejected on the basis of the test. Suppose each treatment group includes more than 287 
patients. According to table Al , the probability that the hypothesis Рд — Ρ в will be 
rejected if the actual difference between Рд and Р в amounts to 1 5 % is at least 9 5 % . 
Therefore if (for S ^ 287) Рд = Ρ в is not rejected, it may be concluded that the 
difference between Рд and Ρ в is not more than 15%. The probability of this conclu­
sion if it is incorrect is less than 5 % . - In table Al we have listed for a few values of S 
the least power that can be achieved if Рд and Р в differ by an amount J. This gives 
us some impression of the power of the test when a certain required number cannot be 
obtained. If 9 5 % certainty is required to demonstrate a difference of 1 0 % in the 
probability of success, 648 patients per treatment group are necessary according to 
table Al . However, table Al also shows that with only 200 patients per treatment 
group there is still a probability of at least 5 0 % of detecting a difference of 10%, and 
that a difference of 20 % will be established with almost complete certainty. 
In using tables SI, S2 and Al , we must clearly recognize the significance of the 
parameters Рд and Рв· They concern unknown probabilities of success in applying the 
methods of t reatment A and В to be compared, which must not be confused with the 
estimates of these probabilities Рд = пд/Зд and Р в = П В / S B which can be obtained 
from observations after completion of the trial. I t is quite possible that Рд and Р в will 
differ by less than 10% and that this difference will be significant according to the test, 
while the number of patients according to table Al was insufficient to detect a differ­
ence of 10% between probabilities Рд and Р в with a certainty of 9 5 % or 90%. I f t h e 
number did fulfill this condition, we may still, if the null hypothesis is rejected, not 
conclude that Рд and Р в differ by at least 10%. Rejection of the null hypothesis only 
means that Рд and Р в are (probably) not equal. - I n planning a trial it must also be 
kept in mind that the unknown probabilities P A and Р в depend on the following factors : 
1. criterion applied for 'success' of treatment. Instead of just establishing whether the 
patient has survived for a certain period since the start of treatment, one may also 
determine whether the patient had a recurrence during that period; 
2. duration of period mentioned under 1 ; and 
3. any selection applied to patients prior to their inclusion in the trial. 
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I n this connection the following remarks must be made. 
1. T h e criterion of 'success' must always be selected so that the treatment given to 
all patients fulfilling it may be considered more successful than that given to patients 
not fulfilling it. 
2. It is possible for the difference between the short-term effects of two methods of 
t reatment not to be the same as the difference between the long-term effects. This may 
be a reason for applying the test to e.g. the 5 year as well as the 10 year results. If we 
postulate an exponential distribution of durations of survival, we can calculate an 
optimal period as a function of the expected durations of survival per method of 
treatment. This aspect will not be further discussed here, the reader is referred to the 
example at the end of Section 3 of this appendix. 
3. Let M be the population of all patients with mammary carcinoma on whom a 
clinical trial is to be carried out to compare therapeutical methods A and B. We will 
assume that M consists of two portions, M Q and M i , and that the difference in effect of 
the treatments given to M i is greater than that to M Q . T h e question then arises whether 
a trial limited to the patients in M i might not be more efficient than a trial without this 
limitation. 
Let us suppose Si is the number of patients required per treatment for a trial limited 
to M i and that S is the number required for a trial within M. In this case Si will be less 
than S. If we further suppose that a fraction po of the patients in M belong to portion 
M Q and accordingly a fraction ( 1-po) belong to M j , it may be expected that among N 
patients of the entire population M there will be ( l - p o ) N patients of portion M p 
Consequently N — Si/(l-po) patients from M are needed in order that the ex­
pected number of patients from M i will be Sj . Now if this number N is less than S, 
we consider the trial within M] more efficient than a trial within M. In this respect, the 
following may be demonstrated (we refrain from giving the proof). 
If within the partial population MQ there is no difference in effect between methods of treatment 
A and В (i.e. if in MQ the probabilities of success of A and В are the same), it is more efficient to 
limit the trial to the partial population Mi. 
Example: Suppose that for the entire population M, P A = 0.6 and Рв = 0.5. 
According to table S1, the number of patients S necessary per treatment group is then 
642. T h e population consists of portions Mo and M ] containing fractions po = 0.2 and 
(1 — po) = 0.8 of all patients of M. In Mo the probabilities of success are : Рдо = Рво 
= 0.3. If Рді and Р щ are these probabilities for M i and P A and Р в the probabilities 
for the entire population, then P A = POPAO + (1 — Po) P A I · 
P A — POPAO 0.6 — 0.2 X 0.3 
from which follows that P A I = , - - = •— = 0.675, simi-
1 — p o 0.8 
larly, we find that P B I = 0.55. 
Equation (2) then gives for the number of patients necessary for a trial within M, 
(a = β = 0.05) : 
6 5 g ііі^ ßgo 5 
(arc sine yO.Slò — a rc sine \А)-55) 2 
T o attain an expected number of 392.5 patients from M i we need N = 392.5/0.8 = 491 
patients of M. If the trial were not limited to M i , 642 patients from M would have been 
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neccessary. Accordingly the trial within M j is in fact more efficient. In view of 
this it is advisable for all inoperable patients (a partial group M Q with PAO = Рво = 0) 
to be excluded from the trial or, if operability can only be established after application 
of treatment, to exclude them from the calculations. However, this only applies when 
the criterion of inoperability is strictly independent of the treatment. If all patients who 
die within a certain period after operation are regarded as inoperable, this condition 
need not be fulfilled. 
3. Wilcoxon's two sample test 
I n Wilcoxon's test the criterion of comparison is the period which elapses between 
commencement of treatment and occurrence of a certain eventuality, e.g. the patient's 
death or a recurrence. T o simplify the terminology we call this period the patient's 
'Survival Time ' . T h e survival time is regarded in this connection as a random variable 
dependent on the treatment applied, indicated as IA or ts- A random variable is a 
variable with a probability distribution. This means that for IA for every value of t ^ 0 
the probability 
F A W = Ρ [tA < t] 
exists that a patient treated by method A will have a survival time less than t. T h e 
corresponding probability for ta is expressed as : 
F B W = P [ t B < t ] . 
This assumption is realized for instance when the patients in the trial constitute a 
random sample from a population in which the cumulative frequency distribution of 
survival times (when all patients are treated by method A or B) is supplied by the 
function Р А ( І ) or Рв( і ) . T h e null hypothesis of Wilcoxon's test now implies that t\ 
and t s have the same probability distribution, in other words that for each value of t, 
(3) F A W = F B W 
applies. 
T h e null hypothesis of the χ2 test only requires that equation (3) applies to one 
particular value oft, the lime until the result of the treatment is determined. 
Wilcoxon's test is carried out as follows : wait until all patients have died and then 
arrange them according to increasing survival time. T h e result is expressed by a line of 
letters A and B, depending on whether the patient had been treated by method A or 
method B. In this line we then determine the number of times U where a letter A comes 
before (i.e. to the left of) a letter B. U then represents the number of pairs of one 
patient treated by method A and one by method B, in which the former had a 
shorter survival time than the latter. For S A patients treated by method A and S в 
treated by method B, we have: 
0 й U й S A S B , 
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because S A S B pairs of one A and one В can be formed. If the series includes such pairs 
with equal survival times, the contribution to the value U for each of these pairs equals -J. 
Subsequently, we calculate the variable 
. . . { I 2 U - S A S B I - 1 } V 3 
(4) u = • J 
VSASB (SA + SB + 1)" 
and reject the null hypothesis at the level of significance a, when u > Ua/2· If 2U > 
S A S B ) we can conclude that the survival time of patients treated by method A was 
significantly shorter than that of patients treated by method B, i.e. that treatment В 
was better than treatment A. However, if 2U < S A S B , we conclude that treatment A 
was significantly better than treatment B. If we find a value lower than u
a
/2, the null 
hypothesis cannot be rejected. In this case there is no significant difference between the 
survival times. T h e ρ value in Wilcoxon's test equals twice the probability that a 
variable with a standard normal distribution will exceed u. T h e procedure described 
above is an approximation of Wilcoxon's test, valid when the values of S A and S B are 
not too low and there are no excessively large ties, i.e. groups of patients with equal 
survival times. For the exact Wilcoxon's test and corrections for ties the reader is 
referred to textbooks on distribution free statistical methods. 
Example: 
Ten patients were treated by method A and 10 by method B. T h e survival times in 
years were: 
A 1.6 2.2 2.5 3.2 3.8 4.1 4.9 5.0 5.7 8.3 
В 0.4 0.6 1.1 1.2 1.7 2.2 2.4 2.5 3.1 4.0 
T h e line of letters corresponding to increasing survival time now becomes : 
B B B B A B A B В A B B A A B A A A A A 
'tie' ' t ie ' 
T h e number of letters A to the left of each letter В is now 
0; 0; 0; 0; 1; Ц; 2; 2*; 3; 5 
in which the letters A constituting a tie with a certain В as prescribed have been 
counted with this В as ^. U is the sum of the line of numbers obtained, hence U = 15. 
Further, S A = S B = 10; equation (4) now gives: 
u =
 {130 - loo ι - ι } у з
 =
 69 у з
 = 2 6 1 
VIOO x~W 1 0 ^ 2 1 
This value is higher than uo.01/2 = uo.oos = 2.5758, so that the null hypothesis can 
be rejected for α = 5 % and for α = 1 %. T h e ρ value is : 
ρ = 2P [ u > 2.61] = 0.009 = 0.9%. 
For calculating the number of patients required to achieve a certain power for the 
test, we once more start with equal numbers of patients per treatment group. S A = 
S B = S. Determination of this number is not as easy as for the χ2 test. For this purpose 
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we apply the theorem that Wilcoxon's statistic U for a large total S has an approxi­
mately normal distribution, with expectation 
(5) μ = S2PAB 
and variance 
(6)
 σ
2 = S2 {(PAAB + PBBA + 2PABPBA — 1 ) S + 1 — PAAB — PBBA — PABPBA} 
In this equiation, Рдв represents the probability that a patient treated by method A 
has a shorter survival time than one treated by method B, while PAAB represents the 
possibility that two patients treated by method A will both have shorter survival times 
than one patient treated by method B. The definitions for РВА = (1 — PAB) and PBBA 
are similar. 
This theorem was first proved by Lehmann (1951) : the formulae for μ and σ were 
deduced from ones supplied by van Dantzig ( 1951 ). If the null hypothesis (3) is correct, 
these can be expressed as : 
μο = ±S2 
a § = i - 2 S 2 ( 2 S + 1) 
Van Dantzig (1951) also indicates limits for— which are useful in the subse­
quent calculation: σ ο 
(7) (V3C + 1 -1)2<СІ<Щ. with С = 4PABPBA 
о 
From (5) and (6) we can deduce that the number of patients per treatment group S 
necessary ina Wilcoxon test with level of significance α for the null hypothesis to be rejec­
ted with a probability of ( 1 — β) can be found approximately by solving the equation : 
(8) S | P A B — P B A | л/З —ue/j V 2 S + 1 — u^ VaS + b = 0 
where a = 12 (PAAB + PBBA + 2PABPBA — 1) 
and b = 12 (1 — PAAB — PBBA — PABPBA). 
This equation has one positive root which in principle can be found by trial and error 
when variables PAB> PAAB and PBBA are known. The approximation to the number S 
required found in this way is reasonably reliable when α and β are not too large (e.g. 
both g 20%) and PAB is not too close to 0 or 1 ; in other words, for cases which do not 
give excessively low values for S. 
The inequality given under (7) allows for calculation of limits of the necessary 
number of observations depending on PAB ( = 1 — РВА) only. In combination with 
(8) this inequality leads to : 
(9) u
a / 2
 + U / V 3 C + 1 ~ 1) < 
S /3C 
< , I PAB - РВА | V3 < u + u 1/-=-
V2S + 1 a / 2 β * ¿ 
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F r o m this the limits of S can be deduced by solving two quadratic equations. I n 
fig. 1 these limits are plotted for α = β = 5 % against 
v = | P A B — Р В А I ~l 
Example. Suppose P A B = of 0.4; therefore Р В А = 0.6, i.e. the probability that the 
survival time of a patient treated by method A will exceed that of one treated by В 
equals 0.6. Thus | P A B — Р В А | _ 1 = 5. Fig. 1 shows that the limits of S then fall 
between about 210 and 260. Consequently we need at least 210 patients and at most 
260 per treatment group to demonstrate such a difference in survival times for α = 5%, 
with 9 5 % certainty. 
T h e number of observations required (S) can further be determined if the type of 
distribution of survival time is specified in more detail. We shall consider two relevant 
distribution types : * 
1. T h e survival times IA and t в are both distributed exponentially, i.e. : 
(10) F A ( t ) = Ρ [ u < t] - 1 — <Γνμ±; FB(t) = Ρ [tu < t] = 1 — e"^», 
where e = 2.718282, the base of the natural logarithmic system and μ A and μ-в are the 
mean survival times during the period considered. Variables Р д в — PBAJ a and b in 
equation (8) can all be expressed as in : 
βΑ + /¿в 1 ( И ) 
I M — ^ в | |Рлв — Ρ ΒΛ 
T h e solution of this equation for ct = ß= 5 % then yields values for S approximately 
the same as those according to the lower limit in fig. 1. 
2. T h e logarithms ( L A = log ÍA) and ( L B = log JB) of the survival times are both 
normally distributed with means of μ^ and μΒ respectively and the same standard 
deviation σ. Analogous to the exponential distribution, we can now solve equation (8), 
giving Р д в from : 
(12) P A B = P [ L A < L B ] = P [ U < ^ _ _ ! ^ | . 
T h e determination of PAAB and P B B A is more complicated. If we plot the solutions 
for α = β = 5 % against ν = | P A B — Р В А | _ 1 we again find a curve practically 
coinciding with the lower limit in fig. 1. 
Specification of distribution type also allows comparison with the χ2 test. Suppose 
that to is the period of reference after which the result of the treatment is evaluated by 
the χ2 test. T h e case with probabilities of success P A and Р в in the χ2 test then corres­
ponds to 
Ρ [tA < to] = 1 — P A ; Ρ [tB < to] = 1 — Рв-
This means, with survival times of the exponential type 
μΑ=— to/ e log P A and μΒ = — W 6 log Р в 
* For the sake of simplicity we ignore the fact that larger classes of distributions correspond to 
both types mentioned, equivalent in regard to the power of Wilcoxon's test. 
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Accordingly (see (11)) 
(13) v = b g Р л + log P B 
log P A — log P B 
and if we assume logarithmically normal distributions as indicated above under 2: 
( 14) i i ^ Ä = U P i - U n B . 
In this way the number of observations S required for Wilcoxon's test in both cases 
can be found as a function of PA and P B - Tables A2 and A3 list these values for α = β = 
5 % and for combinations of P B and P B which are whole multiples of 10%. Since the 
period of reference t 0 does not occur in formulae (13) and (14) these tables are valid for 
all values of IQ. 
If we compare tables A2 and A3 we see that the difference in assumption concerning 
the type of distribution gives rise to a considerable difference in the required number of 
observations as functions of P A and P B . Further, we find that both tables A3 and SI are 
symmetrical in regard to substitution of P A and P B by (1 — P A ) and (1 — P B ) . This 
is not so in table A2, where high values of P A and P B lead to considerably lower values 
of S than in the corresponding cases in table A3. 
The converse applies for low values for P A and P B - In both tables the number of 
patients required is lower than for the corresponding cases in table SI . Application of 
Wilcoxon's test therefore reduces the number of patients required, although to a total 
which still depends on the distribution type of the survival times. Once the distribution 
type of survival times is assumed to be known, we may attempt to improve the power of 
the χ1 test by a more favorable choice of period of reference to- T h e combination P A = 
0.6, and P B =• 0.4 according to table SI requires 161 patients per treatment group, but 
if we apply Wilcoxon's test with exponential distribution of survival time, only 104 
patients are necessary according to table A3. T h e combination mentioned gives the 
following parameters for the exponential distributions: 
to to j to to 
/Ά = - „, г, η =
 n
 r m o Q and/¿B = l o g 0.6 0.51083 ^ " «log 0.4 0.91629 
If we choose a term of reference 2.357 to, the probabilities P A and P B become: 
Ρ Α = e-2-357 x 0.51083 = 0.3 and Р 'в = e-2-357 У 0.91629 = 0.1154. 
If we now calculate S according to equation (2) with these values for Рл and P B , 
we find that S = 120. Consequently, if in calculating the number of patients for the 
χ
2
 test we also assume the distribution type to be known, this number can be reduced 
considerably. I n this respect the reduction in the number of patients required 
achieved by applying Wilcoxon's test as shown in tables A2 and A3 is presented as 
better than it actually is. 
* Here, up is the value of the standard normal distribution with ρ value P A (cf. definition of 
ищ/г and u^ under equation (2) ). 
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er of Wilcoxon's two sample test 
:1 of significance α = 5 % 
al sample sizes S 
idaries for the value of S required 
detect with a difference between 
= Ρ [t A < tu] and Р В А = Ρ [tA > tu] 
a probability of 9 5 % . 
boundaries are plotted as a function of 
1 
| P A B — P B A | 
upper boundary 
lower boundary 
[ P A B — РВА I 
TABLES A 2 AND A 3 
Power of Wilcoxon's two sample test: level of significance α = 5%, equal sample 
sizes S ( = number of patients per treatment group). Minimum value of S required to 
detect with a probability of 9 5 % the difference between probabilities of'success' Рд 
and P B after treatments A and В respectively. In this connection 'success' means a 
survival time of at least to years; the value of S is independent of to. 
TABLE A2 : The number S is calculated on the assumption that the survival times are exponentially 
distributed. 
A 
10 
20 
30 
40 
50 
60 
70 
80 
90 
PB 10 
272 
84 
43 
26 
18 
12 
* 
* 
20 
272 
413 
111 
51 
28 
18 
11 
* 
30 
84 
413 
467 
116 
49 
26 
14 
* 
40 
43 
111 
467 
447 
105 
41 
20 
10 
50 
26 
51 
116 
447 
374 
81 
29 
12 
60 
18 
28 
49 
104 
374 
271 
53 
16 
70 
12 
18 
26 
41 
81 
271 
160 
25 
80 
* 
11 
14 
20 
29 
53 
160 
64 
90% 
* 
* 
* 
10 
12 
16 
25 
64 
TABLE A3 : The number S is calculated on the assumption that the logarithms of the survival 
times are normally distributed with equal standard deviation a. 
A 
10 
20 
30 
40 
50 
60 
70 
80 
90 
PB 10 
141 
48 
26 
17 
12 
* 
* 
* 
20 
141 
270 
79 
39 
23 
15 
11 
* 
30 
48 
270 
371 
100 
46 
26 
15 
* 
40 
26 
79 
371 
426 
107 
46 
23 
12 
50 
17 
39 
100 
426 
426 
100 
39 
17 
60 
12 
23 
46 
107 
426 
371 
79 
26 
70 
* 
15 
26 
46 
100 
371 
270 
48 
80 
* 
11 
15 
23 
39 
79 
270 
141 
90% 
* 
* 
* 
12 
17 
26 
48 
141 
* Values less than 10 omitted, because of possible lack of accuracy of normal approximation for distribution of U. 
4. Sequential ngn tests 
Sequential tests are statistical procedures in which in principle one decides after each 
observation of an experiment whether more observations are to be made or whether the 
experiment may be terminated and a statistical conclusion drawn. T h e statistical 
conclusion is of the same character as described for the two previous tests; a certain null 
hypothesis is either accepted or rejected. T h e level of significance and the probability of 
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rejecting the null hypothesis, provided the actual situation includes at least some 
specified deviation from the null hypothesis, are established. 
T h e tests described in Sections 2 and 3 were based on the two sample design in which 
the methods of treatment A and В are assigned at random to patients admitted in 
succession. Textbooks such as that by A. Wald (1947), P. Armitage (1960) and G.B. 
Wetherill (1966) contain no descriptions of sequential two sample tests. We shall 
therefore confine ourselves to sequential tests for the scheme with paired observations 
described at the end of Section 1. T h e observations in this instance are carried out on 
pairs of patients of whom one is treated by method A and one by method B. T h e 
conclusions are based exclusively on comparison of observations of paired patients with 
each other. 
If this comparison is made at a certain interval of time after commencement of 
treatment, as with the χ2 test, there are four possibilities : 
1. both patients surviving; 
2. both patients dead ; 
3. patient treated by method A still alive and the one treated by method В dead, or 
4. patient treated by method В still alive and the one treated by method A dead. 
T h e method based on these results is called the Sequential Test for Two Proportions. 
This test offers the advantage over methods still to be dicussed that it requires no 
assumptions concerning the nature of distributions of survival times. Nevertheless this 
method is not taken into account here because when it is applied a considerable pro­
portion of pairs of patients (those who have both died or are both still alive) do not 
contribute to the decision, reducing the efficiency of the method. If we apply Student's 
sequential test, we determine for each pair of patients the difference in survival time 
between the patient treated by method A and the one treated by method B. This 
method presupposes that these differences or e.g. their logarithms are normally distrib­
uted, with the same standard deviation. Further, it has the disadvantage compared with 
the method discussed below that for each pair one has to wait until both patients are 
dead, which has an unfavorable effect on the duration of the experiment. 
For these reasons we prefer a more detailed discussion of the Sequential Sign Tests. 
These tests are primarily intended for the following situation. An experiment consists 
of a series of comparisons of two objects A and B. These comparisons lead to 'preference 
for A ' or 'preference for B'. For each comparison, the probability of a preference for A 
equals ρ and that of a preference for В equals (1 — p) . In this respect the sequential 
sign tests are tests for the null hypothesis ρ = •£. Other decisive elements of the procedure 
are the level of significance and the requirement that the probability of rejection of the 
null hypothesis when | p — -^ l > δ > 0 must be at least (1 — β). Thus the test is 
determined by the values of the parameters α, δ and β. 
I n principle, the procedures are carried out as follows. After each comparison, one 
plots on a graph along the horizontal axis (drawn through the center) the number η of 
the preferences decided already, and along the vertical axis the excess d of the number 
of preferences for A over those for B. This number is thus positive in the event of a 
predominance of preferences for A and negative in the event of a predominance of 
preferences for B. By connecting the successive points we obtain a broken line graphic­
ally representing the progress of the experiment. This line begins at the origin. Each 
time a preference for A is reported, we progress one step obliquely upward to the right, 
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because η and d both increase by 1. In the event of a preference for B, we proceed one 
step obliquely down to the right, because in this case η increases by 1 but d is decreased 
by 1. 
This line is called the Sample Path. The figure contains three more lines : the Upper 
Boundary U, the Lower Boundary L and the Middle Boundary M. If the sample path 
crosses the upper boundary, the experiment is terminated with the conclusion that there 
is a significant preference for A; if the sample path crosses the lower boundary, the 
experiment terminates with the conclusion that there is a significant preference for B, 
and if it crosses the middle boundary, the experiment ends in the conclusion that there 
is no significant difference in preferences. The length of the path projected onto the 
horizontal axis gives the number of comparisons of pairs necessary until the experiment 
could be terminated. This Required Number of Pairs is relatively low if there is a pre­
dominance of preferences in one direction. Prior to the experiment it is a random 
variable whose distribution is determined by the value of p. 
Figure 2: Open Sequential Sign Test 
Test for ρ = 0.5; level of significance α = 5% (two-sided) 
Power at least 1 — β = 95% for |p — 0.5 | ^ 0.15 
Sample path of experiment with ρ = 2/3 is drawn in the figure 
ρ = probability of a preference for A ( = РВА)· 
Co • 
-4° 
excess number of prelerenLes for A over В 
(pref. for A — pref. for B) 
End nfthe experiment: 
Conclusion significant preference for Л 
Figure 2 is a graph of an Open Sequential Sign Test. This test is an application of the 
principle for the construction of a two-sided sequential test described for a different 
case by M. Sobel and A. Wald (1949). It consists of the combination of two one-sided 
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(in this case, binominal) tests. T h e boundaries are straight lines given by the equations : 
(15) U : d = a 1 + bn M ! : d = — &z + bn (for d > o) 
L : d = — ai — bn M2 : d = &г — bn (for d < o) 
in which the coefficients a j , аг and b are calculated from the parameters α, β and δ. 
(16) a, = , _,_ ox a* = 
(17) b • 
η ι
 2
 (1 - ß) ο ι 2 - α 
2 log . _ 2 1 o g - ^ -
1 + 2δ Ά2 . 1 + 2δ 
l o g
 Γ^δ
 l o g
 Γ^-2δ 
- log (1 - 4¿2) 
, 1 + 2δ log 
1 - 2(5 
In Figure 2, these boundaries have been drawn for α = /? = 0.05 ( = 5%) and δ = 0.15. 
By substitution in equations (16) and (17) we get: 
l o g r ^ Í = log ¿4 = 0.26884 
1 9 1 95 2 1 o g w 21og-£r 
a i
 = 0.26884 = 1 1 · 7 5 a i ^ 0.26884 = 9 · 6 0 
- log 0.91_ 
D
 0.26884 U - 1 0 ¿ 
In this figure we have also plotted the path of an experiment where ρ = 2/3, obtained 
by casting a dice and counting throws 1, 2, 3 and 4 as preferences for A and throws 
5 and 6 as preferences for B. T h e experiment ended after 68 throws when the upper boun­
dary was crossed, leading to the conclusion that there was a significant preference for A. 
If the path successively crosses both extensions of the boundaries M i and M2, 
indicated by dotted lines, this is equivalent to crossing one of these boundaries itself. 
This also leads to termination of the experiment with the conclusion that there is no 
significant difference in preferences. It can be demonstrated that the procedure will 
certainly end, although the delimitation of the scheme is open to the right. T h e 
probability that the sample path continues indefinitely in one of the corridors between 
U and M i or between L and M2, equals 0. However, an objection to the open scheme 
is that it may be a long time before the experiment can be concluded, especially when 
the value of ρ is close to -J- (1 + b) or ·£ (1 — b). For this reason, so-called Closed 
Sequential Designs have been elaborated, with a closed delimitation, so that a maxi­
m u m can be indicated for the required number of preferences. 
Figure 3 is the graph of Armitage's closed sequential design* for the same parameter 
values as the design in Figure 2. T h e boundaires U and L coincide with those of the 
open design, at least for δ ^ 0.20; fthe middle boundary here in the first instance is a 
* See P. Armitage (1960), p. 34. In this connection he uses the term 'Restricted Designs', which 
we shall continue to use for his designs. 
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vertical line. Armitage has defined it in such a way that the requirements (the values 
of α, β and <5) are fulfilled. 
Figure 3: Restricted sequential sign test (Armitage) 
Test for ρ = 0.5; level of significance α = 5% (two-sided) 
Power at least 1 — β = 95% for | ρ — 0.5 | ^ 0.15 
Sample path of experiment with ρ = 0.4 is drawn in the figure. 
ρ = probability of a preference for A ( = РВА) 
6o 
40 
-40. 
excess number of preferences for A over В 
(pref. for A — pref. for B) 
End of the experiment 
Conclusion no significant 
difference 
This was done by approximating the probability distribution of the sample path with 
the aid of a diffusion process, not discussed in detail here. In table A4 we show the 
maximum number of preferences required for a few combinations of α, β and δ. 
TABLE A4: Maximum number jV of preferences required for Armilage's Restricted Sequential 
Sign Test, with level of significance α and minimum probability (1 — β) of detecting values of 
p with [p —0.5] ^ δ. (From P. Armitage (I960), p. 35). 
δ 
0.05 
0.10 
0.15 
0.20 
value of N for : 
« = β = 5% 
1778 
439 
191 
104 
α = = 1%;0 = 5% 
2290 
565 
244 
132 
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Subsequently this middle boundary may be replaced by two lines M i and M2 at an 
angle of 45° to the horizontal axis, as shown in Figure 3. Once one of these lines has 
been crossed it is impossible for the sample path to reach the upper or lower bounda­
ries, so the experiment may be terminated with the conclusion that no significant 
difference in preferences could be demonstrated. 
Figure 3 shows the sample path of an experiment where ρ = 0.4, obtained by 
sampling from a table with random numbers and interpreting numbers 0, 1, 2 and 3 
as preferences for A and numbers 5, 6, 7, 8, 9 as preferences for B. 
This is an experiment which does not fulfil the null hypothesis (p = 0.5). Never­
theless the conclusion based on the sequential test after 172 comparisons of pairs is 
that there is no significant difference in preference, corresponding to ρ = 0.5. This is 
not surprising, since the design only guarantees adequate certainty (95%) for 
rejection of the null hypothesis when | ρ — 0.5 | > 0.15, i.e. for ρ > 0.65 or ρ < 0.35, 
which was not so in this experiment. 
Besides Armitage's restricted design, there are other closed sequential designs, such 
as that of Bross (1952), also described in Armitage (1960), but they need not be dis­
cussed further. T h e sequential sign tests may be applied to the results of a clinical trial 
with pairs of patients of whom one is treated by method A and one by method B. A pair 
in which the patient treated by method A survives longer after commencement of 
treatment than the patient treated by method В is interpreted as a preference for A, 
and a pair with the opposite result as a preference for B. The probability ρ is then the 
probability Р В А = Р[ів < *А] introduced in Section 3. 
In this instance the survival time after commencement of treatment is considered. 
Suppose that in one pair the patient receiving method A started treatment first. Now if 
the patient treated by method В dies first, the result of the pair may immediately be 
interpreted as a preference for A, but if the patient treated by method A dies first, the 
result may only be regarded as a preference for В if the patient treated by method В 
survives longer than the period between the commencements of treatment of both 
patients. 
For a sequential sign test to be applied to the results of a clinical trial with pairs of 
patients, the distribution of the survival times t A and t a must fulfil a condition resulting 
from the fact that a considerable number of pairs of patients are involved simulta­
neously. In order for this situation to fit into the design for the sequential sign test, 
it is necessary that for every pair at any moment, i.e. irrespective of the length of time 
for which the pair has been included in the trial, the probability that the patient 
treated by method A has a longer survival time than the patient treated by method В 
remains constant. 
This condition is only fulfilled if to Г А ( І ) = Ρ [ t A < t ] andFA(t) = P [ t B < t ] applies: 
(18) 1 — F B ( t ) = { l — F A ( t ) } k 
for a certain positive value of к and all values oft. 
If condition (18) is fulfilled, к determines the value of p, for in this case we have: 
(19) p=PBA = P [ t B < t A ] - ^ q - ¡ -
The sequential sign tests are tests for the hypothesis ρ = -J-. If condition (18) is 
fulfilled, it follows from ρ = i that к = 1 or А(І) = Гв(і) for all positive values oft. 
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Consequently condition (18), which must be fulfilled if a sequential sign test is to be 
applied to the results of a pair trial, requires the null hypothesis that ÍA and t s have the 
same probability distribution. This is the same null hypothesis as in Wilcoxon's test, 
see (3). 
A particularly important case concerns exponentially distributed survival times: 
FA(t) = 1 — e-*"*; F B W = 1 - e " ^ 8 
because then : 
1 — F B W = e " 1 ' ^ = (e-*"'*) μ*Ιμ» = {1 — F A ( t ) } * 
with 
к = /u/^B-
From this it follows (see (19) ) that : 
(20) Р В А = 
/¿A + № 
For this particular case we have considered the numbers of patients required for the 
two sequential sign tests, indicated by OSST and A R S T compared with those for the 
χΐ test ( C T T T ) and Wilcoxon's test (WTST), see table A5. 
1. As mentioned in the sequential sign tests the number of patients required is a 
random variable dependent on ρ = Р В А · For the open test we have mentioned the 
average numbers of pairs of patients required for the cases ρ = 0.5 and | ρ — 0.5 | = 
<5, as well as the maximum value of this average. For this purpose, use was made of 
table 3.1 in Armitage's book (1960). T h e (approximative) method for calculation 
of these averages was devised by Wald (1947). For Armitage's restricted test, the 
maximum number of pairs of patients required is listed; no average values were 
available here. T h e average number required is undoubtedly higher with the 
restricted test for ρ = 0.5 than for the open test. With | ρ — 0.5 | = δ the difference 
will probably be slight. 
2. For the sequential tests, the numbers of pairs required are listed ; for the χ1 test and 
Wilcoxon's test, the numbers of patients per treatment group. In both the number 
of patients necessary for a trial is double. 
3. In the χ2 test, the number required also depends on the period of reference to (see 
also end of section 3). When μ A. and //в are given, the proportion of to and ~μ = 
i (/¿A + Цъ) is decisive. In the table, the numbers of patients necessary are listed 
forto//2 = 1.0, 1.5 and 2.0. 
Table A5 shows that the open sequential test requires fewer patients on average than 
the χ1 test and Wilcoxon's test if | ρ — £ | = δ, and a fortiori if | ρ — \\> δ. This is 
probably also true of Armitage's test. In general, therefore, the sequential tests would 
appear to be more efficient than tests with a fixed number of random samples if the 
methods of treatment diverge widely. It is only when the methods of treatment are 
more or less equivalent that tests with a fixed number of random samples appear to be 
preferable. This would constitute a strong argument in favor of using one of the 
sequential sign tests. If the methods of treatment differ only slightly, there is less ob­
jection to including a few more patients in the trial. If, on the other hand the methods 
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of treatment are markedly different, the presence of a large number of patients in the 
trial implies that, purely for the sake of the trial, large numbers of patients are being 
treated by an inferior method. 
TABLE A5 : Comparison between : 
ossT : Open Sequential Sign Test 
ARST : Armitage's Restricted Sequential Sign Test 
WTST: Wilcoxoris Two Sample Test 
CTTT: ^2 Test for 2x2 table 
with respect to number of patients required. 
Level of significance α = 5% ; required power for | p — 0.5 | ^ δ is ^ 95%. 
Survival times are assumed to be distributed exponentially. 
O S S T ARST WTST C T T T 
Maximum Number 
number required Number of patients 
Average number of pairs required of paira in each required in each treatment 
if at required group group if IQIμ = 
S p = 0 5 I ρ — 0 5 I - (5 maximum 1 0 1 5 2 0 
0 05 
0 10 
0 15 
0 20 
0 25 
870 
215 
95 
51 
31 
660 
160 
70 
40 
25 
1080 
270 
115 
63 
38 
1778 
439 
191 
104 
62 
861 
210 
91 
49 
30 
1108 
271 
116 
62 
37 
1001 
247 
107 
59 
36 
1036 
257 
113 
63 
40 
Ρ = Р В А = P[tA > t B ] 
to = reference period for the CTTT 
μ = ^ (μ\ h /¿в); the average of the expected values of survival times. 
There is, however, an important objection to this argument. For tests with a fixed 
number of samples, it is only necessary to collect patients until the previously fixed 
number is attained. With sequential tests, this number is not previously known and it 
is therefore necessary in principle to continue to include patients in the trial until it is 
concluded or at any rate until the large maximum number required for Armitage's 
test is reached. As a result, especially in trials with patients with long average survival 
times, large numbers of patients will be involved in the trials who do not contribute 
to the ultimate conclusion, and who are not taken into account in the calculations 
for table A5. 
We can reduce this number of'superfluous' patients by limiting the total included in 
the trial at the beginning to the number required on average in a favorable situation 
(e.g. : | ρ — 0.5 | = δ). More patients should only be included in the trial if it appears 
that the number required will be larger. This means a considerable delay in conclusion 
of the trial, since patient pairs introduced later will also yield their results later. 
T h e period in which a trial is completed is, however, an important aspect of the 
design. As long as the trial has not resulted in a conclusion concerning the choice 
between methods of treatment, numerous patients not included in the trial risk being 
treated by a method which the trial will eventually prove inferior. This number of 
patients might well be much larger than the number of extra patients treated by the 
inferior method in a trial completed earlier due to the inclusion of a larger number of 
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patients. This consideration has prompted us to pay more attention to the relation 
between duration of trial and choice of test. 
5. Duration of trial 
We base our considerations re. duration of the trial on the following assumptions. 
1. T h e survival times ί
Α
 and tß are distributed exponentially with averages μ A and μη 
respectively. 
2. T h e intake of patients is homogeneous: on average, m pairs of patients can be 
formed per year, i.e. m patients per year can be included in each of the patient 
groups. 
3. When tests with a fixed number of samples are applied, patients are included in the 
trial until the number required for the test has been attained. 
4. When one of the sequential sign tests is used, inclusion of new patients in the trial is 
continued until the trial is complete. 
An intake of patients is called 'homogeneous' if it neither increases nor decreases 
systematically with time. From the mathematical point of view the intake can follow a 
Poisson process in which the time intervals between successively admitted patients is 
distributed exponentially with a constant average. 
We base our discussion on equation 7.2 (p. 84) in Armitage's book (1960). O n the 
above assumptions 1, 2 and 4 it gives the expectation G of the number of pairs of which 
at least one patient has died when the trial has run for Τ years. 
(21) G =
 m
T J l - l - C - 2 l T ì 
2ДТ J 
in which 
T h e determination of T , when G and m are given from (21), would require the 
solution ofa transcendent equation. We therefore determine m as a function of G and 
T. We have done this for the open and the closed sequential sign tests and have sub­
stituted for G the maximum average number required and the maximum number of 
pairs of patients required respectively. Thus we find the number of pairs of patients m 
which must be available each year in order to obtain a number of results within a 
period Τ of the beginning of the trial sufficient on average (with the open sequential 
test) or sufficient (with the restricted test) for completion of the trial. T h e figures in 
question can be found in column O S S T and A R S T in table A6, where various cases 
are distinguished according to the value ofá = | Р В А — 0.5 | , in which Р В А = 
P[tB < ÍA] = / u / ( / U + Ив) = μΑΐ(2μ) (cf. (20) ). 
T h e length of time required for a trial analysed by the χ2 test for a 2 X 2 table is 
the sum of: 
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1. the time tj necessary to obtain the required number of patients S per treatment 
group, and 
2. the period of reference to. 
Once the last patient has been included in the trial (after period t i ) , we must wait for 
a further period to until the results are known for this patient. For an intake of m 
patients per treatment group per year, ti = S/m, so that for the χ2 test we find : 
(22) Τ = to + S/m. 
T h e number S under the assumptions 1 and 2 is a function of the relation between 
to and μ = $ (μ
Α
 + μκ). 
By substituting this value for S in equation (22), we can find m from (22) as a 
function of α, β, δ, ~ß, Τ and t^fß. This number m then represents the number of 
patients which must be available annually per treatment group in order to complete 
the trial within period Τ with application of the χ2 test for a 2 X 2 table with period of 
reference to. 
This number is presented in table A6 for to//¡ = 0.5, 0.75 and 1.0. Clearly, in the 
majority of the cases m reaches its minimum for a value of to ¡μ in this interval. 
Table Λ6 contains no data concerning Wilcoxon's test, because with this test, the 
trial for all cases considered will generally last longer than the defined period Τ as 
Wilcoxon's statistic can only be calculated when all the patients of at least one treat­
ment group have died. 
TABLE A6: Average intake m of patients f or each therapy per year required to complete a clinical 
trial within Τ years at the average. 
τ 
6 
6 
8 
β 
10 
10 
10 
10 
10 
10 
β 
3 
3 
3 
3 
3 
3 
4 
4 
5 
5 
δ 
01 
02 
Ol 
02 
01 
02 
01 
02 
01 
02 
OSSTi 
58 9 
133 
41 1 
9 3 
315 
72 
33 4 
76 
35 4 
8 0 
ARST2 
95 8 
219 
66 9 
15 4 
51 3 
11 9 
54 3 
12 5 
57 5 
13 I 
Value of m for 
4)/ï = 
0 5 
90 0 
19 8 
62 3 
13.7 
47 6 
105 
50 6 
11.1 
540 
119 
СТТТЗ 
0 75 
83 2 
18 9 
54 3 
123 
403 
92 
446 
10 1 
49 9 
114 
ι
θ//ί = 
10 
90 3 
20 7 
542 
12 4 
38 7 
8 9 
45 2 
10.3 
542 
12 4 
Level of significance α — 5%, required power 1 — β = 95% for P A B — ^ ¡> I = Ô Survival distributions assumed 
to be exponential which expected values ¿ід and μ^, μ = ^ (¿ід + μ^) 
1 OSST (Open Sequential Sign Test), m computed from (21) with G = the maximum of the average number of pairs of 
patients required 
2 ARST (Arm11age's Restricted Sequential Sign Test), m computed from (21) with G = the maximum number of pairs of 
patients required 
3 CTTT {χ2 Test for 2 Χ 2 Table), m computed from (22) with S = the number of patients required for each therapy group 
according to formula (2) 
IQ =• reference period for CTTT 
As far as duration of the trial is concerned, we shall further restrict ourselves to 
comparing the sequential tests and the / 2 test for a 2 X 2 table on the basis of table A6. 
O n this basis we are inclined to prefer the sequential method to the χ2 test. With the 
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open sequential test the maximum average intake of patients required per year is 
considerably less; with the restricted test the maximum intake required is only slightly 
higher than that required with the χ2 test. This means that when the conditions stated 
at the beginning of this section are observed, the sequential tests will, given a certain 
intake of patients, generally give a result earlier than the χ2 test. 
Some notes must be made in this connection. 
1. T h e methods are compared exclusively for the case of exponentially distributed 
survival times. 
2. T h e sequential methods considered are based on paired comparisons. If one of the 
patients in a pair drops out for any reason other than death from the disease studied, 
it will as a rule be useless to continue to keep the other one in the trial. This may cause 
a loss of efficiency in the sequential tests, which cannot occur with the χ1 test. 
3. Although the period required for the χ2 test is, on average, longer than for the 
sequential tests, it is more constant. Variation in duration can only be caused by 
variation in intake. With the sequential tests, especially the open test, the variation 
in length of time required is much greater. Consequently, they may take longer 
than the χ2 test. 
4. Obviously organizing a trial using the χ2 test, for which it is only necessary to 
determine the patient's condition a fixed time after starting the trial, is simpler than 
organizing a trial with a sequential sign test which requires that relevant changes in 
condition be registered immediately. 
In this discussion we may further consider the average total number of patients which 
must be included in the trial before a decision can be reached. For the sequential tests 
this total is T m (if m = required intake per year) ; for the χ2 test, (T — to)m. If we 
calculate these numbers for the open sequential test and for the χ2 test with to/μ =• 0.75 
and to/μ = 1.0, we always find that the values for the χ2 test compared with the 
sequential test are lower where to/μ = 0.75 and very much lower where to/μ = 1.0. 
Admittedly these results are not entirely comparable, since the value for the open test 
is the average number required in the most unfavorable circumstances, but it does 
nevertheless appear that in this respect the χ2 test is no less advantageous than the 
sequential test. 
O u r findings concerning the value of the χ2 test for a 2 X 2 table, Wilcoxon's test 
and the sequential sign test for the analysis of clinical trials based on survival times may 
be summarized as follows. 
1. T h e χ2 test calls for the simplest organization of a trial and may be applied without 
specification of type of distribution of survival times. Further, this test is not unfavorable 
as regards duration of trials analysed. However, if one only wishes to minimalize the 
number of patients, irrespective of duration of trial, the χ2 test is the least efficient 
method. 
2. Wilcoxon's test for two samples is much more demanding as regards organization 
of the trial; for calculating the number of patients required the type of distribution of 
survival times must in principle be specified, although the number does not appear to 
depend greatly on this specification. I n comparable cases, Wilcoxon's test requires 
considerably fewer patients than the χ2 test. However, where duration is concerned, 
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Wilcoxon's test is by far the least efficient. I n this respect preference may be given to 
variants of Wilcoxon's test, under which the trial may be discontinued after a fixed 
period Τ (see e.g. Efron, В. (1967) ). 
3. T h e sequential sign tests also require a more complicated organization of the trial 
than the /2 test. With these methods, not only the number of patients required but also 
the test criterion depends on the type of distribution of the survival times. For practical 
purposes, still more restricted schemes will have to be worked out. This might be worth­
while, since the sequential tests are particularly attractive if one wishes to restrict the 
trial as much as possible in regard to number of patients or duration, in case the methods 
of treatment compared should differ considerably from one another. 
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ERRATA 
On page Vi l i in Contents under Part VII '5. Duration of trial 194', read 
. . . 2 0 1 . 
On page 23 in fourth par., second rule: 'On page 55', read: On page 56. 
Ibidem in last rule of 6th par.: '(for a detailed calculation cf. Ch V § 2 p. 65)', 
read . . . 67 . 
On page 26 in second rule (above diagram): cf. Appendix table 04 ' , read: 
. . . table 0 8 . 
On page 32 beside the diagram: 'f Died of other cause than tumor', read: 
e Died etc. 
On page 57 - In note instead of en read and — . 
78.8 100 78.8 100 
On page 76 first rule: In Ch. I l l § 3 p. 14', read: . . . p. 15. 
On page 139 in table f
c
43 in third item ' < 5 5 years' read: > 5 5 years. 
On page 173 in last column of table Ρ instead of '0.67 Χ 103' read 6.7 X 10'. 

CONCISE REVIEW OF THE CALCULATION 
For statistical reason required 
number 
S (¿2 test for a 2 X 2 table, cf. table S1 
Ch. 3 p . 17) 
The number of therapies ~y+ t ( t = 2 is used) 
The percentage of incidence of the 
characteristic properties of patients 
which are considered of essential im-
portance for the assessment of the 
therapies 
f i % X f2% X f3% X fo% = Fn% 
From this, the multiplicationfactor 
100 
% 
can be calculated 
100 (cf. table -¡y Appendix Part IV) . 
/o 
For the planning of the extent of the registration (cf. Ch. I l l § 6) 
Xc(linical) t(rial) = S X t 
To determine the total number of patients suffering from the disease who must be 
available to make a particular trial possible (cf. Ch. I l l § 6) 
X m(aterial) = S X t X 
100 
In case of a fixed number of available patients, to calculate the minimal percentage 
of incidence of characteristic elements in the material as a whole that is necessary to 
make the trial possible (cf. Ch. I l l § 6) 
Fmln. = 
100 X t X S 
In order to determine the size of the entire female population necessary to make the 
trial possible (cf. Ch. I l l § 9) 
(Ж) 
100 v Ρ ' 
Xpíopulatlon) = Ь X t Χ -=ρ Χ 
F q 
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PART VII CONCISE REVIEW OF THE CALCULATION 
STELLINGEN. 
I. 
Alvorens men overgaat tot de organisatie van een 'controlled clinical trial', dient 
men zich te bezinnen op de vraag of het aantal patiënten, dat in het betreffende 
rayon binnen een afzienbare termijn beschikbaar komt, voldoende zal zijn voor de 
uitvoering van de 'trial'. 
II 
Onderzoekingen betreffende de behandeling van patiënten met mammacarcinoom 
zullen betere resultaten geven, indien men betere methoden ontwikkelt om de uit-
breiding van het ziekteproces exact te diagnostiseren. 
III 
Een goede samenwerking tussen statisticus en medicus onderling is van groot belang 
voor het kankeronderzoek. 
IV 
Op anatomische en physiologische gronden dient men, wanneer er een indicatie be-
staat voor een lumbale sympathectomie wegens een éénzijdige arteriële doorbloe-
dingsstoornis, deze ingreep dubbelzijdig te verrichten. 
V 
Arteriografisch röntgenonderzoek is slechts volledig, indien de serieopnamen in twee 
richtingen worden gemaakt. Slechts op deze wijze is het mogelijk de uitgebreidheid 
van subtotale afsluitingen van arteriën zuiver te beoordelen en eerst dan is een even-
tuele indicatie tot operatie exact te stellen. 
VI 
De éénzijdige everterende gastrointestinale anastomose is eenvoudig, veilig en doel-
treffend. 
Ravitch, M. Af. et al: Ann. Surg. 166:670, 1967. 
VII 
Bij anatomische repositie van een enkelfractuur, al dan niet met behulp van Osteo-
synthese, wordt het resultaat niet beïnvloed door een tevoren bestaande luxatie van 
de talus. 
VIII 
Bij behandeling van fracturen van het os zygomaticum is repositie alleen meestal een 
onvoldoende therapie. 
Aan de fixatie dient veel aandacht te worden besteed, waarbij de Osteosynthese in de 
laterale orbitarand en de steuntampon in de sinus maxillaris in overweging moeten 
worden genomen. 

IX 
Ook bij afwezigheid van de karakteristieke cutané laesies moet een gedissemineerde 
lupus erythematodes als diagnose overwogen worden in gevallen, die gelijken op een 
rheumatische endocarditis en gepaard gaan met verschijnselen van een glomerulo-
nephritis zonder hypertensie. 
X 
Longscanning draagt bij tot het vroeg stellen van de diagnose longembolie. 
Bovendien wordt hierdoor later een objectieve beoordeling van de mate van herstel 
van de circulatie mogelijk. 
Wagner, H. v.: Radiology Vol. 91 No. 6. 
XI 
Het verdient aanbeveling om instrumentarium dat met ethyleenoxyde is gesterili-
seerd, geruime tijd aan de lucht bloot te stellen, teneinde het eventuele toxische 
ethyleenoxyde te verwijderen. Over de duur van dit proces en over de hoeveelheid 
ethyleenoxyde die achterblijft in verschillende soorten materiaal zijn geen exacte 
gegevens bekend. 
The Medical Leiter on Drugs and Therapeutics 1967, vol. 9 No. 7. 
XII 
De leiding in de medische technologie dient te worden toevertrouwd aan technische 
medici en niet aan medische technici. 
XI I I 
Voor de verdere uitgroei en ontwikkeling van het ziekenhuiswezen in ons land is 
regionaal overleg en regionale samenwerking noodzakelijk. 
XIV 
De verwerking van kwik in tandheelkundig amalgaam kan mede milieuverontreini-
gend werken. 
XV 
Het in te stellen 'landelijk meetnet' voor het opsporen van luchtverontreiniging 
('Trouw', 23 oktober 1971), is een zinloze perfektie, die slechts zal leren wat men al 
enige tijd weet: dat onze lucht verontreinigd is. 
XVI 
Wenn man nicht weiss, wie, was, warum, 
dann gibt man immer valium. 
SteUingeii behorende by het proelächrift 'Controlled Clinical Trials* door H. P. J. M. Beerepoot. 
Nümegen, 17 december 1971. 


